These B-Premise
effects I-Premise
remained I-Premise
when I-Premise
statistically I-Premise
controlling I-Premise
for I-Premise
baseline I-Premise
levels I-Premise
of I-Premise
distress I-Premise
, I-Premise
immunity I-Premise
, I-Premise
and I-Premise
health I-Premise
as I-Premise
well I-Premise
as I-Premise
sociodemographic I-Premise
, I-Premise
disease I-Premise
, I-Premise
and I-Premise
cancer I-Premise
treatment I-Premise
variables I-Premise
. I-Premise

During B-Premise
the I-Premise
study I-Premise
, I-Premise
31.7 I-Premise
% I-Premise
of I-Premise
placebo-treated I-Premise
patients I-Premise
achieved I-Premise
a I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
g/dL I-Premise
HgB I-Premise
increase I-Premise
compared I-Premise
with I-Premise
72.7 I-Premise
% I-Premise
of I-Premise
epoetin-treated I-Premise
patients I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

The O
primary O
endpoint O
was O
biochemical O
relapse O
according O
to O
the O
modified O
1997-American O
Society O
for O
Therapeutic O
Radiology O
and O
Oncology O
and O
Phoenix O
definitions O
. O

A O
total O
of O
769 O
patients O
were O
randomized O
to O
EXE O
25 O
mg/d O
( O
n O
= O
366 O
) O
or O
MA O
( O
n O
= O
403 O
) O
40 O
mg O
four O
times O
daily O
. O

The B-Premise
survival I-Premise
benefit I-Premise
, I-Premise
adjusted I-Premise
for I-Premise
prognostic I-Premise
factors I-Premise
in I-Premise
a I-Premise
multivariate I-Premise
analysis I-Premise
, I-Premise
remained I-Premise
significant I-Premise
( I-Premise
p=0.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
advantage I-Premise
lasted I-Premise
for I-Premise
all I-Premise
the I-Premise
duration I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise

The B-Premise
surviving I-Premise
fraction I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
based I-Premise
on I-Premise
Kaplan-Meier I-Premise
analysis I-Premise
. I-Premise

Chemotherapy B-Claim
is I-Claim
moderately I-Claim
efficient I-Claim
as I-Claim
a I-Claim
treatment I-Claim
for I-Claim
pancreatic I-Claim
adenocarcinoma I-Claim
, I-Claim
but B-Claim
patient I-Claim
survival I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
has I-Claim
improved I-Claim
with I-Claim
this I-Claim
modality I-Claim
in I-Claim
some I-Claim
trials I-Claim
. I-Claim

After B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
23 I-Premise
months I-Premise
, I-Premise
both I-Premise
groups I-Premise
had I-Premise
similar I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
medians I-Premise
of I-Premise
15.0 I-Premise
months I-Premise
for I-Premise
docetaxel-carboplatin I-Premise
and I-Premise
14.8 I-Premise
months I-Premise
for I-Premise
paclitaxel-carboplatin I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
docetaxel-paclitaxel I-Premise
= I-Premise
0.97 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0.83 I-Premise
to I-Premise
1.13 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.707 I-Premise
) I-Premise
, I-Premise
overall I-Premise
survival I-Premise
rates I-Premise
at I-Premise
2 I-Premise
years I-Premise
( I-Premise
64.2 I-Premise
% I-Premise
and I-Premise
68.9 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
HR I-Premise
= I-Premise
1.13 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.92 I-Premise
to I-Premise
1.39 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.238 I-Premise
) I-Premise
, I-Premise
and I-Premise
objective I-Premise
tumor I-Premise
( I-Premise
58.7 I-Premise
% I-Premise
and I-Premise
59.5 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
difference I-Premise
between I-Premise
docetaxel I-Premise
and I-Premise
paclitaxel I-Premise
= I-Premise
-0.8 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-8.6 I-Premise
% I-Premise
to I-Premise
7.1 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.868 I-Premise
) I-Premise
and I-Premise
CA-125 I-Premise
( I-Premise
75.8 I-Premise
% I-Premise
and I-Premise
76.8 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
difference I-Premise
docetaxel-paclitaxel I-Premise
= I-Premise
-1.0 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-7.2 I-Premise
% I-Premise
to I-Premise
5.1 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.794 I-Premise
) I-Premise
response I-Premise
rates I-Premise
. I-Premise

To O
compare O
directly O
the O
effect O
of O
intensity-modulated O
radiotherapy O
( O
IMRT O
) O
vs. O
conventional O
radiotherapy O
( O
CRT O
) O
on O
salivary O
flow O
and O
quality O
of O
life O
( O
QoL O
) O
in O
patients O
with O
early-stage O
nasopharyngeal O
carcinoma O
( O
NPC O
) O
. O

They O
were O
stratified O
by O
radiotherapy O
( O
early O
, O
late O
, O
or O
none O
) O
, O
stage O
( O
extensive O
or O
limited O
) O
, O
response O
( O
complete O
or O
partial O
) O
, O
and O
cooperative O
group O
( O
National O
Cancer O
Institute O
of O
Canada-Clinical O
Trials O
Group O
or O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
) O
. O

The B-Premise
estimated I-Premise
treatment I-Premise
effects I-Premise
( I-Premise
intervention I-Premise
minus I-Premise
usual I-Premise
care I-Premise
) I-Premise
for I-Premise
all I-Premise
participants I-Premise
were I-Premise
a I-Premise
mean I-Premise
( I-Premise
SE I-Premise
) I-Premise
of I-Premise
4.6 I-Premise
( I-Premise
2 I-Premise
) I-Premise
for I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
-27.8 I-Premise
( I-Premise
15 I-Premise
) I-Premise
for I-Premise
symptom I-Premise
intensity I-Premise
( I-Premise
P I-Premise
= I-Premise
.06 I-Premise
) I-Premise
, I-Premise
and I-Premise
-1.8 I-Premise
( I-Premise
0.81 I-Premise
) I-Premise
for I-Premise
depressed I-Premise
mood I-Premise
( I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

Degarelix O
treatment O
evokes O
, O
however O
, O
significantly O
better O
relief O
of O
lower O
urinary O
tract O
symptoms O
in O
patients O
having O
moderate O
and O
severe O
voiding O
problems O
. O

Our O
primary O
sleep O
endpoint O
was O
global O
sleep O
quality O
assessed O
by O
the O
Pittsburgh O
Sleep O
Quality O
Index O
( O
PSQI O
) O
. O

An O
independent O
data O
review O
board O
recommended O
termination O
of O
recruitment O
because O
of O
insufficient O
differences O
between O
study O
arms O
. O

Coloplasty B-Claim
pouches I-Claim
resulted I-Claim
in I-Claim
more I-Claim
anastomotic I-Claim
leaks I-Claim
and I-Claim
minimal I-Claim
differences I-Claim
in I-Claim
bowel I-Claim
function I-Claim
. I-Claim

The B-Claim
addition I-Claim
of I-Claim
ASA404 I-Claim
to I-Claim
carboplatin I-Claim
and I-Claim
paclitaxel I-Claim
, I-Claim
although I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
, I-Claim
failed I-Claim
to I-Claim
improve I-Claim
frontline I-Claim
efficacy I-Claim
in I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

At B-Premise
3 I-Premise
months I-Premise
, I-Premise
the I-Premise
reduction I-Premise
of I-Premise
incidence/severity I-Premise
of I-Premise
grade I-Premise
1+2 I-Premise
anorexia I-Premise
, I-Premise
nausea/vomiting I-Premise
, I-Premise
xerostomia I-Premise
, I-Premise
and I-Premise
dysgeusia I-Premise
was I-Premise
different I-Premise
: I-Premise
90 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
improved I-Premise
in I-Premise
group I-Premise
1 I-Premise
versus I-Premise
67 I-Premise
% I-Premise
in I-Premise
group I-Premise
2 I-Premise
versus I-Premise
51 I-Premise
% I-Premise
in I-Premise
group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
effect O
of O
a O
SMART O
( O
Stress O
Management O
and O
Resiliency O
Training O
) O
program O
for O
increasing O
resiliency O
and O
for O
decreasing O
stress O
and O
anxiety O
among O
mentors O
who O
themselves O
were O
previously O
diagnosed O
with O
breast O
cancer O
. O

The B-Premise
overall I-Premise
QoL-scale I-Premise
QLQ-C30-HRQoL I-Premise
showed I-Premise
a I-Premise
significant I-Premise
time I-Premise
trend I-Premise
towards I-Premise
more I-Premise
favourable I-Premise
mean I-Premise
values I-Premise
during I-Premise
protocol I-Premise
treatment I-Premise
without I-Premise
differences I-Premise
between I-Premise
MP I-Premise
and I-Premise
MPT I-Premise
. I-Premise

Although B-Premise
there I-Premise
are I-Premise
no I-Premise
differences I-Premise
in I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
between I-Premise
the I-Premise
patients I-Premise
treated I-Premise
with I-Premise
and I-Premise
without I-Premise
radiotherapy I-Premise
, I-Premise
there I-Premise
are I-Premise
several I-Premise
dimensions I-Premise
that I-Premise
exhibit I-Premise
significant I-Premise
advantage I-Premise
to I-Premise
the I-Premise
omission I-Premise
of I-Premise
irradiation I-Premise
. I-Premise

Responders O
were O
separately O
compared O
with O
nonresponders O
( O
patients O
with O
SD O
( O
6m O
) O
or O
PD O
) O
and O
with O
patients O
with O
SD O
( O
6m O
) O
, O
and O
patients O
with O
clinical O
benefit O
were O
compared O
with O
patients O
with O
PD O
by O
analysis O
of O
covariance O
with O
adjustment O
for O
baseline O
scores O
. O

The B-Premise
rate I-Premise
of I-Premise
recurrence I-Premise
was I-Premise
9/74 I-Premise
( I-Premise
12.1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
and I-Premise
6/92 I-Premise
( I-Premise
6.5 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
.937 I-Premise
) I-Premise
. I-Premise

In O
the O
randomized O
, O
multinational O
phase O
II/III O
trial O
( O
V325 O
) O
of O
untreated O
advanced O
gastric O
cancer O
patients O
, O
the O
phase O
II O
part O
selected O
docetaxel O
, O
cisplatin O
, O
and O
fluorouracil O
( O
DCF O
) O
over O
docetaxel O
and O
cisplatin O
for O
comparison O
against O
cisplatin O
and O
fluorouracil O
( O
CF O
";" O
reference O
regimen O
) O
in O
the O
phase O
III O
part O
. O

HRQOL O
was O
assessed O
using O
EORTC O
QLQ-C30 O
and O
QLQ-BR23 O
questionnaires O
at O
baseline O
and O
every O
6 O
weeks O
thereafter O
until O
treatment O
discontinuation O
because O
of O
disease O
progression O
, O
toxicity O
, O
or O
consent O
withdrawal O
. O

ONJ B-Claim
is I-Claim
multifactorial I-Claim
and I-Claim
no I-Claim
single I-Claim
treatment I-Claim
modality I-Claim
is I-Claim
likely I-Claim
to I-Claim
reverse I-Claim
it I-Claim
";" I-Claim
however B-Claim
, I-Claim
it I-Claim
is I-Claim
treatable I-Claim
and I-Claim
even I-Claim
advanced I-Claim
presentations I-Claim
can I-Claim
improve I-Claim
with I-Claim
intensive I-Claim
multimodal I-Claim
therapy I-Claim
. I-Claim

Future O
trials O
should O
be O
designed O
so O
that O
the O
CR/PR O
and O
SD O
( O
6m O
) O
groups O
are O
investigated O
separately O
. O

There O
is O
dearth O
of O
evidence O
regarding O
the O
effects O
of O
LLLT O
on O
patient O
's O
subjective O
experience O
of O
OM O
and O
QOL O
. O

251 O
patients O
were O
randomly O
divided O
into O
pemetrexed O
combined O
with O
cisplatin O
group O
( O
PP O
group O
) O
with O
127 O
cases O
and O
gemcitabine O
combined O
with O
cisplatin O
group O
( O
GP O
group O
) O
with O
124 O
cases O
. O

Imatinib B-Claim
interruption I-Claim
results I-Claim
in I-Claim
rapid I-Claim
progression I-Claim
in I-Claim
most I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
GIST I-Claim
, I-Claim
and I-Claim
can I-Claim
not I-Claim
be I-Claim
recommended I-Claim
in I-Claim
routine I-Claim
practice I-Claim
unless I-Claim
patient I-Claim
experience I-Claim
significant I-Claim
toxicity I-Claim
. I-Claim

Unless B-Claim
additional I-Claim
follow-up I-Claim
data I-Claim
demonstrate I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
at I-Claim
higher I-Claim
doses I-Claim
, I-Claim
the I-Claim
160-mg/d I-Claim
dose I-Claim
is I-Claim
optimal I-Claim
, I-Claim
achieving I-Claim
maximal I-Claim
treatment I-Claim
effect I-Claim
with I-Claim
the I-Claim
fewest I-Claim
side I-Claim
effects I-Claim
and I-Claim
better I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

There O
were O
no O
differences O
in O
the O
two O
treatment O
groups O
at O
baseline O
. O

A O
further O
aim O
was O
to O
investigate O
the O
role O
of O
high-dose O
chemotherapy O
in O
young O
patients O
with O
parameningeal O
primary O
tumours O
. O

Patients O
assigned O
to O
delayed O
treatment O
continued O
masked O
CA125 O
measurements O
, O
with O
treatment O
commencing O
at O
clinical O
or O
symptomatic O
relapse O
. O

Median B-Premise
survival I-Premise
with I-Premise
GC I-Premise
and I-Premise
PE I-Premise
was I-Premise
8.0 I-Premise
and I-Premise
8.1 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

It O
is O
, O
however O
, O
unclear O
whether O
the O
size O
and O
location O
of O
incisions O
affect O
body O
image O
and O
QOL O
. O

Safe B-Claim
and I-Claim
effective I-Claim
interventions I-Claim
are I-Claim
needed I-Claim
to I-Claim
alleviate I-Claim
sexual I-Claim
dysfunction I-Claim
. I-Claim

Results B-Claim
showed I-Claim
a I-Claim
significant I-Claim
increase I-Claim
in I-Claim
pain I-Claim
knowledge I-Claim
in I-Claim
patients I-Claim
who I-Claim
received I-Claim
the I-Claim
Pain I-Claim
Education I-Claim
Program I-Claim
and I-Claim
a I-Claim
significant I-Claim
decrease I-Claim
in I-Claim
pain I-Claim
intensity I-Claim
. I-Claim

At O
baseline O
, O
15 O
% O
of O
patients O
were O
sexually O
active O
";" O
this O
increased O
significantly O
to O
39 O
% O
during O
the O
first O
year O
( O
P O
< O
.001 O
) O
. O

Based B-Premise
on I-Premise
serum I-Premise
rhTSH-stimulated I-Premise
Tg I-Premise
alone I-Premise
( I-Premise
Tg I-Premise
< I-Premise
0.8 I-Premise
microg/l I-Premise
, I-Premise
BRAHMS I-Premise
Tg I-Premise
Kryptor I-Premise
) I-Premise
, I-Premise
no I-Premise
difference I-Premise
in I-Premise
ablation I-Premise
success I-Premise
was I-Premise
observed I-Premise
between I-Premise
rhTSH I-Premise
and I-Premise
hypothyroidism I-Premise
groups I-Premise
, I-Premise
91.7 I-Premise
% I-Premise
and I-Premise
97.1 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

In B-Claim
conclusion I-Claim
, I-Claim
treatment I-Claim
with I-Claim
carboplatin I-Claim
and I-Claim
etoposide I-Claim
can I-Claim
improve I-Claim
both I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
the I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Tumor O
response O
, O
duration O
of O
tumor O
control O
, O
tumor-related O
signs O
and O
symptoms O
( O
TRSS O
) O
, O
quality O
of O
life O
( O
QOL O
) O
, O
survival O
, O
and O
tolerability O
were O
evaluated O
. O

On O
November O
18 O
, O
2004 O
, O
the O
FDA O
granted O
erlotinib O
regular O
approval O
for O
treatment O
of O
patients O
with O
locally O
advanced O
or O
metastatic O
NSCLC O
after O
failure O
of O
at O
least O
one O
prior O
chemotherapy O
regimen O
. O

Fulvestrant B-Claim
500 I-Claim
mg I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
statistically I-Claim
significant I-Claim
increase I-Claim
in I-Claim
PFS I-Claim
and I-Claim
not I-Claim
associated I-Claim
with I-Claim
increased I-Claim
toxicity I-Claim
, I-Claim
corresponding O
to O
a O
clinically O
meaningful O
improvement O
in O
benefit O
versus O
risk O
compared O
with O
fulvestrant O
250 O
mg O
. O

Patients O
were O
randomized O
to O
receive O
epoetin O
alfa O
40,000 O
U O
subcutaneously O
once O
weekly O
or O
placebo O
at O
the O
beginning O
of O
4 O
cycles O
of O
chemotherapy O
administered O
over O
12 O
weeks O
. O

The O
Steering O
Committee O
closed O
the O
trial O
. O

The B-Claim
hypothesised I-Claim
improvement I-Claim
in I-Claim
overall I-Claim
quality I-Claim
of I-Claim
life I-Claim
with I-Claim
the I-Claim
omission I-Claim
of I-Claim
radiotherapy I-Claim
was I-Claim
not I-Claim
seen I-Claim
in I-Claim
the I-Claim
EuroQol I-Claim
assessment I-Claim
or I-Claim
in I-Claim
the I-Claim
functionality I-Claim
and I-Claim
symptoms I-Claim
summary I-Claim
domains I-Claim
of I-Claim
the I-Claim
European I-Claim
Organisation I-Claim
for I-Claim
Research I-Claim
in I-Claim
the I-Claim
Treatment I-Claim
of I-Claim
Cancer I-Claim
( I-Claim
EORTC I-Claim
) I-Claim
scales I-Claim
. I-Claim

There O
was O
no O
difference O
of O
sex O
between O
two O
groups O
( O
IV O
arm O
: O
male/female O
= O
45/29 O
, O
oral O
arm O
: O
male/female O
= O
59/33 O
) O
. O

Symptom O
intensity O
was O
measured O
by O
the O
Edmonton O
Symptom O
Assessment O
Scale O
( O
score O
range O
, O
0-900 O
) O
. O

DC/CIK B-Claim
treatment I-Claim
is I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
method I-Claim
for I-Claim
maintenance I-Claim
therapy I-Claim
of I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
. I-Claim

No B-Premise
significant I-Premise
difference I-Premise
in I-Premise
any I-Premise
of I-Premise
these I-Premise
measures I-Premise
was I-Premise
noted I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
grade I-Premise
III/IV I-Premise
adverse I-Premise
events I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

The O
American O
College O
of O
Surgeons O
Oncology O
Group O
phase O
III O
Surgical O
Prostatectomy O
Versus O
Interstitial O
Radiation O
Intervention O
Trial O
comparing O
radical O
prostatectomy O
( O
RP O
) O
and O
brachytherapy O
( O
BT O
) O
closed O
after O
2 O
years O
due O
to O
poor O
accrual O
. O

QOL B-Premise
improved I-Premise
in I-Premise
the I-Premise
study I-Premise
group I-Premise
. I-Premise

Patients B-Premise
allocated I-Premise
to I-Premise
misoprostol I-Premise
did I-Premise
report I-Premise
slightly I-Premise
increased I-Premise
soreness I-Premise
( I-Premise
7.6 I-Premise
vs I-Premise
6.9 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
and I-Premise
a I-Premise
greater I-Premise
use I-Premise
of I-Premise
analgesics I-Premise
. I-Premise

In B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
who I-Claim
develop I-Claim
disease I-Claim
progression I-Claim
after I-Claim
treatment I-Claim
with I-Claim
nonsteroidal I-Claim
aromatase I-Claim
inhibitors I-Claim
, I-Claim
EVE I-Claim
+ I-Claim
EXE I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
longer I-Claim
TDD I-Claim
in I-Claim
global I-Claim
HRQOL I-Claim
versus I-Claim
PBO I-Claim
+ I-Claim
EXE I-Claim
. I-Claim

Gefitinib O
has O
shown O
high O
response O
rate O
and O
improved O
progression-free O
survival O
( O
PFS O
) O
in O
never-smokers O
with O
lung O
adenocarcinoma O
( O
NSLAs O
) O
. O

However B-Premise
, I-Premise
QOL I-Premise
scores I-Premise
gradually I-Premise
but I-Premise
definitely I-Premise
improved I-Premise
over I-Premise
time I-Premise
for I-Premise
most I-Premise
domains I-Premise
. I-Premise

We O
evaluated O
the O
role O
of O
glutathione-related O
genotypes O
on O
overall O
survival O
, O
time O
to O
progression O
, O
adverse O
events O
, O
and O
quality O
of O
life O
( O
QOL O
) O
in O
stage O
IIIB/IV O
non-small O
cell O
lung O
cancer O
patients O
who O
were O
stable O
or O
responding O
from O
initial O
treatment O
with O
platinum-based O
chemotherapy O
and O
subsequently O
randomized O
to O
receive O
daily O
oral O
carboxyaminoimidazole O
or O
a O
placebo O
. O

A B-Premise
decrease I-Premise
in I-Premise
the I-Premise
total I-Premise
lymphocyte I-Premise
count I-Premise
by I-Premise
559 I-Premise
cells/mul I-Premise
occurred I-Premise
with I-Premise
the I-Premise
fat-enriched I-Premise
diet I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

At B-Premise
radiotherapy I-Premise
completion I-Premise
, I-Premise
in I-Premise
G1 I-Premise
all I-Premise
QoL I-Premise
function I-Premise
scores I-Premise
improved I-Premise
proportionally I-Premise
to I-Premise
adequate I-Premise
intake I-Premise
or I-Premise
nutritional I-Premise
status I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
";" I-Premise
whereas I-Premise
in I-Premise
G2 I-Premise
only I-Premise
three I-Premise
of I-Premise
six I-Premise
function I-Premise
scores I-Premise
improved I-Premise
proportionally I-Premise
to I-Premise
protein I-Premise
intake I-Premise
( I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
, I-Premise
and I-Premise
in I-Premise
G3 I-Premise
all I-Premise
scores I-Premise
worsened I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

This O
double-blind O
randomized O
phase O
II O
trial O
examined O
whether O
vandetanib O
, O
an O
inhibitor O
of O
vascular O
endothelial O
and O
epidermal O
growth O
factor O
receptors O
, O
could O
prolong O
progression-free O
survival O
in O
responding O
patients O
with O
small-cell O
lung O
cancer O
. O

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
mean I-Premise
area I-Premise
under I-Premise
the I-Premise
mucositis I-Premise
curve I-Premise
( I-Premise
13.2 I-Premise
vs I-Premise
16.6 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.1 I-Premise
) I-Premise
. I-Premise

A O
total O
of O
72 O
NSCLC O
study O
subjects O
with O
MPE O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
. O

Consolidation B-Premise
chemotherapy I-Premise
was I-Premise
completed I-Premise
in I-Premise
75 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
. I-Premise

Vandetanib B-Claim
failed I-Claim
to I-Claim
demonstrate I-Claim
efficacy I-Claim
as I-Claim
maintenance I-Claim
therapy I-Claim
for I-Claim
small-cell I-Claim
lung I-Claim
cancer I-Claim
. I-Claim

The O
brief O
period O
of O
poorer O
QoL O
with O
standard O
treatment O
is O
a O
modest O
price O
to O
pay O
for O
a O
chance O
at O
improved O
survival O
. O

Eligible O
patients O
with O
complete O
response O
( O
CR O
) O
or O
partial O
response O
( O
PR O
) O
to O
combination O
chemotherapy O
( O
+/- O
thoracic O
or O
prophylactic O
cranial O
radiation O
) O
received O
oral O
vandetanib O
300 O
mg/d O
or O
matched O
placebo O
. O

For B-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
SFI I-Claim
can I-Claim
alleviate I-Claim
the I-Claim
bone I-Claim
marrow I-Claim
inhibition I-Claim
caused I-Claim
by I-Claim
chemotherapy I-Claim
, I-Claim
improve I-Claim
clinical I-Claim
symptoms I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
prolong I-Claim
the I-Claim
survival I-Claim
period I-Claim
by I-Claim
regulating I-Claim
cellular I-Claim
immune I-Claim
function I-Claim
of I-Claim
patients I-Claim
, I-Claim
so I-Claim
as I-Claim
to I-Claim
enhance I-Claim
the I-Claim
therapeutic I-Claim
effect I-Claim
of I-Claim
chemotherapy I-Claim
. I-Claim

Assessment O
of O
depression O
added O
to O
usual O
care O
probably O
had O
an O
effect O
because O
it O
is O
not O
normally O
a O
focus O
of O
hospice O
staff O
. O

Fifty O
patients O
were O
randomized O
";" O
30 O
patients O
received O
epoetin O
beta O
30,000 O
IU O
once O
weekly O
and O
20 O
received O
20,000 O
IU O
once O
weekly O
. O

The O
primary O
endpoint O
was O
increase O
in O
arm O
volume O
from O
baseline O
to O
the O
average O
of O
measurements O
at O
6 O
and O
12 O
months O
. O

However O
, O
loss O
of O
power O
was O
not O
an O
issue O
because O
of O
the O
planned O
large O
target O
sample O
size O
. O

Secondary O
endpoints O
were O
the O
PSQI O
component O
scores O
. O

Poor O
preoperative O
QOL O
as O
indicated O
by O
a O
rating O
scale O
of O
≤ O
50 O
was O
an O
independent O
predictor O
of O
poor O
QOL O
at O
2 O
months O
postoperatively O
. O

The B-Claim
results I-Claim
of I-Claim
this I-Claim
brief I-Claim
pilot I-Claim
counseling I-Claim
intervention I-Claim
demonstrated I-Claim
significant I-Claim
gains I-Claim
in I-Claim
sexual I-Claim
function I-Claim
and I-Claim
satisfaction I-Claim
and I-Claim
increased I-Claim
utilization I-Claim
of I-Claim
treatments I-Claim
for I-Claim
ED I-Claim
. I-Claim

Different B-Claim
analyses I-Claim
yielded I-Claim
slightly I-Claim
different I-Claim
conclusions I-Claim
but O
, O
in B-Claim
general I-Claim
, I-Claim
the I-Claim
QOL I-Claim
analyses I-Claim
were I-Claim
concordant I-Claim
and I-Claim
showed I-Claim
that I-Claim
patients I-Claim
on I-Claim
DOX I-Claim
alone I-Claim
had I-Claim
fewer I-Claim
disease I-Claim
and I-Claim
treatment I-Claim
related I-Claim
adverse I-Claim
events I-Claim
and I-Claim
better I-Claim
QOL I-Claim
. I-Claim

Administration O
amounts O
of O
nausea O
and O
pain O
medications O
were O
compared O
with O
a O
Two-Way O
ANOVA O
with O
One O
Repeated O
Measure O
resulting O
in O
no O
significant O
differences O
between O
groups O
and O
medications O
, O
F O
( O
1 O
, O
51 O
) O
= O
0.03 O
";" O
p O
> O
.05 O
. O

Hormone B-Claim
replacement I-Claim
therapy I-Claim
is I-Claim
often I-Claim
either I-Claim
undesirable I-Claim
or I-Claim
contraindicated I-Claim
. I-Claim

Interviews O
were O
conducted O
to O
explore O
women O
's O
experience O
of O
writing O
. O

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
13 I-Premise
months I-Premise
, I-Premise
the I-Premise
overall I-Premise
survival I-Premise
was I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
irinotecan I-Premise
group I-Premise
( I-Premise
p=0.0001 I-Premise
) I-Premise
, I-Premise
with I-Premise
36.2 I-Premise
% I-Premise
1-year I-Premise
survival I-Premise
in I-Premise
the I-Premise
irinotecan I-Premise
group I-Premise
versus I-Premise
13.8 I-Premise
% I-Premise
in I-Premise
the I-Premise
supportive-care I-Premise
group I-Premise
. I-Premise

The B-Claim
BT I-Claim
group I-Claim
, I-Claim
on I-Claim
average I-Claim
, I-Claim
experienced I-Claim
significant I-Claim
improvement I-Claim
on I-Claim
global I-Claim
sleep I-Claim
quality I-Claim
compared I-Claim
with I-Claim
the I-Claim
HEC I-Claim
group I-Claim
, I-Claim
but B-Claim
not I-Claim
on I-Claim
objective I-Claim
sleep I-Claim
or I-Claim
fatigue I-Claim
outcomes I-Claim
. I-Claim

From O
September O
1999 O
to O
April O
2002 O
, O
356 O
patients O
( O
178 O
participants O
received O
gemcitabine-carboplatin O
, O
178 O
received O
carboplatin O
only O
) O
were O
randomized O
to O
treatment O
. O

Treatment B-Premise
toxicity I-Premise
and I-Premise
the I-Premise
rate I-Premise
of I-Premise
adverse I-Premise
effects I-Premise
and I-Premise
intestinal I-Premise
adhesion I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
study I-Premise
groups I-Premise
. I-Premise

All O
patients O
were O
treated O
according O
to O
standard O
local O
practice O
. O

There B-Premise
were I-Premise
no I-Premise
group I-Premise
differences I-Premise
with I-Premise
respect I-Premise
to I-Premise
survival I-Premise
. I-Premise

Intrusive B-Claim
thoughts I-Claim
are I-Claim
associated I-Claim
with I-Claim
enduring I-Claim
elevations I-Claim
in I-Claim
behavioral I-Claim
symptoms I-Claim
and I-Claim
impaired I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
the I-Claim
year I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
and I-Claim
may I-Claim
be I-Claim
a I-Claim
risk I-Claim
factor I-Claim
for I-Claim
poor I-Claim
outcomes I-Claim
. I-Claim

TRUE B-Premise
acupuncture I-Premise
was I-Premise
associated I-Premise
with I-Premise
0.8 I-Premise
fewer I-Premise
hot I-Premise
flashes I-Premise
per I-Premise
day I-Premise
than I-Premise
sham I-Premise
at I-Premise
6 I-Premise
weeks I-Premise
, O
but B-Premise
the I-Premise
difference I-Premise
did I-Premise
not I-Premise
reach I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-0.7 I-Premise
to I-Premise
2.4 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.3 I-Premise
) I-Premise
. I-Premise

To O
evaluate O
the O
analgesic O
effect O
, O
safety O
, O
and O
cost-effectiveness O
of O
controlled-release O
oxycodone O
( O
CRO O
) O
to O
control O
postoperative O
pain O
in O
patients O
with O
liver O
cancer O
who O
are O
undergoing O
transarterial O
chemoembolization O
. O

Patients B-Premise
with I-Premise
dysuria I-Premise
had I-Premise
a I-Premise
statistically I-Premise
higher I-Premise
IPSS I-Premise
. I-Premise

The B-Premise
most I-Premise
common I-Premise
reason I-Premise
for I-Premise
dropout I-Premise
was I-Premise
patients I-Premise
feeling I-Premise
too I-Premise
ill I-Premise
. I-Premise

We B-Claim
conclude I-Claim
that I-Claim
TEC I-Claim
, I-Claim
compared I-Claim
with I-Claim
EUC I-Claim
, I-Claim
resulted I-Claim
in I-Claim
improved I-Claim
pain I-Claim
communication I-Claim
self-efficacy I-Claim
and I-Claim
temporary I-Claim
improvement I-Claim
in I-Claim
pain-related I-Claim
impairment I-Claim
, I-Claim
but I-Claim
no I-Claim
improvement I-Claim
in I-Claim
pain I-Claim
severity I-Claim
. I-Claim

At O
baseline O
, O
HRQoL O
measures O
were O
comparable O
between O
the O
two O
treatment O
groups O
. O

This O
study O
aimed O
to O
determine O
the O
effectiveness O
of O
a O
nurse-delivered O
telephone O
supportive O
intervention O
( O
the O
" O
CONNECT O
" O
intervention O
) O
. O

The B-Premise
RRs I-Premise
were I-Premise
identical I-Premise
in I-Premise
the I-Premise
2 I-Premise
arms I-Premise
( I-Premise
6.7 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
] I-Premise
, I-Premise
1.8-16.5 I-Premise
% I-Premise
) I-Premise
. I-Premise

Patients O
were O
followed O
up O
per-protocol O
";" O
there O
were O
no O
deaths O
, O
and O
five O
patients O
had O
a O
total O
of O
six O
complications O
. O

In B-Premise
contrast I-Premise
, I-Premise
the I-Premise
UC I-Premise
group I-Premise
experienced I-Premise
no I-Premise
change I-Premise
, I-Premise
or I-Premise
worsening I-Premise
QoL I-Premise
, I-Premise
fitness I-Premise
and I-Premise
fatigue I-Premise
, I-Premise
mid-intervention I-Premise
. I-Premise

Cognitive O
function O
was O
assessed O
by O
Executive O
Interview O
( O
EXIT25 O
) O
and O
Clock O
Drawing O
Tasks O
";" O
mood O
by O
Profile O
of O
Mood O
States O
";" O
anemia-related O
symptoms O
, O
including O
fatigue O
, O
by O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Anemia O
( O
FACT-An O
) O
subscale O
";" O
and O
QOL O
by O
Linear O
Analog O
Scale O
Assessment O
. O

A O
multicenter O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
was O
conducted O
. O

Patients O
with O
advanced O
NSCLC O
with O
no O
evidence O
of O
progression O
after O
four O
cycles O
of O
chemotherapy O
were O
randomized O
to O
receive O
erlotinib O
150 O
mg/day O
or O
placebo O
, O
until O
progressive O
disease O
or O
limiting O
toxicity O
. O

Results O
for O
functional O
outcome O
and O
quality O
of O
life O
are O
rarely O
reported O
beyond O
10 O
years O
and O
are O
lacking O
from O
randomised O
settings O
. O

Patients B-Premise
receiving I-Premise
the I-Premise
intervention I-Premise
demonstrated I-Premise
statistically I-Premise
significant I-Premise
improvement I-Premise
( I-Premise
P I-Premise
=.0004 I-Premise
) I-Premise
in I-Premise
menopausal I-Premise
symptoms I-Premise
but I-Premise
no I-Premise
significant I-Premise
change I-Premise
in I-Premise
vitality I-Premise
( I-Premise
P I-Premise
=.77 I-Premise
) I-Premise
. I-Premise

A O
total O
of O
74 O
patients O
were O
enrolled O
for O
the O
study O
. O

The B-Claim
magnitude I-Claim
of I-Claim
improvement I-Claim
obtained I-Claim
was I-Claim
similar I-Claim
whether I-Claim
on I-Claim
a I-Claim
self-declared-healer- I-Claim
or I-Claim
an I-Claim
actor-provided I-Claim
" I-Claim
treatment I-Claim
" I-Claim
. I-Claim

In B-Premise
grade I-Premise
IV I-Premise
the I-Premise
corresponding I-Premise
median I-Premise
survival I-Premise
time I-Premise
was I-Premise
12.3 I-Premise
( I-Premise
2.1-89.2 I-Premise
) I-Premise
and I-Premise
10.3 I-Premise
( I-Premise
0.3-91.7+ I-Premise
) I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

In O
one O
of O
these O
trials O
, O
HOVON49 O
, O
a O
prospective O
health-related O
quality-of-life O
( O
HRQoL O
) O
study O
was O
initiated O
in O
order O
to O
assess O
the O
impact O
of O
thalidomide O
on O
QoL O
. O

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
HRQoL I-Premise
between I-Premise
nurse-led I-Premise
telephone I-Premise
and I-Premise
hospital I-Premise
follow-up I-Premise
at I-Premise
12 I-Premise
months I-Premise
after I-Premise
treatment I-Premise
( I-Premise
p I-Premise
= I-Premise
0.42 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
for I-Premise
difference I-Premise
: I-Premise
-1.93-4.64 I-Premise
) I-Premise
and I-Premise
neither I-Premise
between I-Premise
follow-up I-Premise
with I-Premise
or I-Premise
without I-Premise
EGP I-Premise
( I-Premise
p I-Premise
= I-Premise
0.86 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
for I-Premise
difference I-Premise
: I-Premise
-3.59-3.00 I-Premise
) I-Premise
. I-Premise

The B-Premise
CCSP I-Premise
improved I-Premise
QOL I-Premise
for I-Premise
patients I-Premise
at I-Premise
1-year I-Premise
follow-up I-Premise
. I-Premise

Since O
elderly O
patients O
usually O
have O
several O
concomitant O
diseases O
and O
experience O
more O
treatment O
toxicity O
, O
an O
interim O
safety O
analysis O
was O
planned O
and O
performed O
after O
25 O
patients O
finished O
therapy O
to O
assess O
the O
tolerability O
of O
the O
treatment O
regimens O
. O

Chemoradiotherapy O
( O
CRT O
) O
-induced O
oral O
mucositis O
( O
OM O
) O
adversely O
affects O
a O
patient O
's O
oral O
functions O
and O
quality O
of O
life O
( O
QOL O
) O
. O

All O
statistical O
tests O
were O
two-sided O
. O

We O
evaluated O
QOL O
data O
from O
874 O
pre- O
and O
perimenopausal O
women O
with O
lymph O
node-negative O
breast O
cancer O
who O
were O
randomly O
assigned O
to O
receive O
six O
courses O
of O
classical O
cyclophosphamide O
, O
methotrexate O
, O
and O
fluorouracil O
( O
CMF O
) O
chemotherapy O
, O
ovarian O
suppression O
with O
goserelin O
for O
24 O
months O
, O
or O
six O
courses O
of O
classical O
CMF O
followed O
by O
18 O
months O
of O
goserelin O
. O

Patients O
given O
GC O
received O
more O
chemotherapy O
as O
outpatients O
( O
89 O
% O
GC O
vs O
66 O
% O
PE O
of O
treatment O
cycles O
) O
. O

Intervention O
patients O
had O
access O
for O
up O
to O
12 O
months O
to O
a O
depression O
care O
manager O
who O
was O
supervised O
by O
a O
psychiatrist O
and O
a O
primary O
care O
provider O
and O
who O
offered O
education O
, O
care O
management O
, O
support O
of O
antidepressant O
management O
, O
and O
brief O
, O
structured O
psychosocial O
interventions O
including O
behavioral O
activation O
and O
problem-solving O
treatment O
. O

Haemoglobin O
levels O
, O
transfusion O
need O
and O
QoL O
[ O
Functional O
Assessment O
of O
Cancer O
Therapy-fatigue O
( O
FACT-F O
) O
subscale O
score O
] O
were O
assessed O
at O
regular O
intervals O
. O

Conversely B-Premise
, I-Premise
the I-Premise
nocturnal I-Premise
group I-Premise
exhibited I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
muscle I-Premise
cramps I-Premise
in I-Premise
the I-Premise
legs I-Premise
( I-Premise
P I-Premise
= I-Premise
0.014 I-Premise
) I-Premise
and I-Premise
significantly I-Premise
improved I-Premise
Fisher I-Premise
's I-Premise
ratio I-Premise
after I-Premise
3 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

Design O
of O
the O
study O
was O
single-blind O
randomized O
clinical O
trial O
. O

The O
primary O
outcome O
was O
depression O
as O
assessed O
by O
the O
Centre O
for O
Epidemiologic O
Studies O
Depression O
scale O
( O
CES-D O
) O
";" O
the O
main O
secondary O
outcomes O
were O
: O
anxiety O
as O
assessed O
by O
Hospital O
Anxiety O
and O
Depression O
Scales O
( O
HADS-A O
) O
";" O
overall O
quality O
of O
life O
and O
fatigue O
as O
assessed O
by O
Functional O
Assessment O
of O
Cancer O
Therapy O
General O
and O
Fatigue O
scales O
( O
FACT-G O
and O
FACT-F O
, O
respectively O
) O
";" O
and O
clinicians O
' O
ratings O
of O
quality O
of O
life O
by O
use O
of O
Spizter O
's O
Quality O
of O
Life O
Index O
( O
SQLI O
) O
. O

A O
randomized O
Phase O
III O
trial O
for O
Stage O
IIIA O
( O
T1-T3N2M0 O
) O
non-small O
cell O
lung O
cancer O
was O
conducted O
by O
the O
Radiation O
Therapy O
Oncology O
Group O
( O
RTOG O
) O
and O
Eastern O
Cooperative O
Oncology O
Group O
between O
April O
1990 O
and O
April O
1994 O
. O

Somatostatin B-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
have I-Claim
antimitotic I-Claim
activity I-Claim
in I-Claim
endocrine I-Claim
as I-Claim
well I-Claim
as I-Claim
in I-Claim
a I-Claim
variety I-Claim
of I-Claim
nonendocrine I-Claim
tumors I-Claim
. I-Claim

GE O
does O
not O
warrant O
further O
investigation O
in O
unselected O
pancreatic O
cancer O
patients O
. O

To O
study O
the O
effects O
of O
Fuzheng O
Jianpi O
Decoction O
( O
FJD O
) O
combined O
chemotherapy O
on O
the O
quality O
of O
life O
( O
QOL O
) O
and O
the O
survival O
time O
of O
children O
with O
solid O
tumor O
. O

Bleomycin O
30 O
mg O
was O
administered O
on O
days O
1 O
, O
8 O
, O
and O
15 O
during O
cycles O
1 O
through O
3 O
. O

The O
primary O
end O
point O
was O
progression-free O
survival O
. O

Patients B-Premise
randomly I-Premise
assigned I-Premise
to I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
showed I-Premise
significant I-Premise
improvements I-Premise
on I-Premise
symptoms I-Premise
of I-Premise
depression I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
anxiety I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
health-related I-Premise
QOL I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
( I-Premise
i.e I-Premise
. I-Premise
better I-Premise
global I-Premise
health I-Premise
status I-Premise
, I-Premise
and I-Premise
physical I-Premise
and I-Premise
emotional I-Premise
functioning I-Premise
, I-Premise
and I-Premise
less I-Premise
insomnia I-Premise
) I-Premise
when I-Premise
compared I-Premise
with I-Premise
controls I-Premise
. I-Premise

The O
societal O
values O
of O
life O
expectancies O
were O
assessed O
with O
the O
EuroQol O
classification O
system O
( O
EQ-5D O
) O
questionnaire O
. O

A O
non-randomised O
cohort O
was O
also O
recruited O
, O
in O
order O
to O
complete O
a O
comprehensive O
cohort O
study O
. O

No B-Premise
differences I-Premise
in I-Premise
opioid I-Premise
doses I-Premise
during I-Premise
the I-Premise
period I-Premise
of I-Premise
study I-Premise
were I-Premise
found I-Premise
. I-Premise

Investigators O
were O
asked O
to O
provide O
the O
date O
of O
death O
or O
last O
follow-up O
for O
all O
participants O
who O
were O
alive O
in O
August O
2003 O
. O

Treatments B-Premise
were I-Premise
well I-Premise
tolerated I-Premise
in I-Premise
the I-Premise
3 I-Premise
groups I-Premise
. I-Premise

A O
total O
of O
111 O
colorectal O
cancer O
outpatients O
referred O
for O
radiotherapy O
, O
stratified O
by O
staging O
, O
were O
randomly O
assigned O
: O
group O
1 O
( O
G1 O
";" O
n O
= O
37 O
) O
, O
dietary O
counseling O
( O
regular O
foods O
) O
";" O
group O
2 O
( O
G2 O
";" O
n O
= O
37 O
) O
, O
protein O
supplements O
";" O
and O
group O
3 O
( O
G3 O
";" O
n O
= O
37 O
) O
, O
ad O
libitum O
intake O
. O

The B-Premise
ORRs I-Premise
were I-Premise
48.9 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
38.5 I-Premise
% I-Premise
-59.5 I-Premise
% I-Premise
) I-Premise
and I-Premise
58.7 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
47.9 I-Premise
% I-Premise
-68.9 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.117 I-Premise
) I-Premise
with I-Premise
PB I-Premise
and I-Premise
PB+G I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Overall B-Premise
survival I-Premise
was I-Premise
longer I-Premise
with I-Premise
DCF I-Premise
versus I-Premise
CF I-Premise
( I-Premise
23 I-Premise
% I-Premise
risk I-Premise
reduction I-Premise
";" I-Premise
log-rank I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

The B-Premise
hazard I-Premise
ratio I-Premise
for I-Premise
investigator-assessed I-Premise
PFS I-Premise
was I-Premise
0.82 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.65 I-Premise
to I-Premise
1.02 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.0775 I-Premise
";" I-Premise
median I-Premise
PFS I-Premise
, I-Premise
13.7 I-Premise
v I-Premise
16.5 I-Premise
months I-Premise
in I-Premise
the I-Premise
non-bevacizumab I-Premise
and I-Premise
bevacizumab I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
PFS I-Premise
events I-Premise
in I-Premise
72 I-Premise
% I-Premise
) I-Premise
. I-Premise

We O
used O
a O
randomized O
phase O
II O
design O
to O
evaluate O
and O
compare O
two O
such O
regimens O
. O

Hormone B-Claim
replacement I-Claim
therapy I-Claim
increases I-Claim
cardiovascular I-Claim
and I-Claim
thromboembolic I-Claim
risk I-Claim
when I-Claim
started I-Claim
many I-Claim
years I-Claim
after I-Claim
the I-Claim
menopause I-Claim
. I-Claim

This O
study O
was O
designed O
to O
evaluate O
the O
impact O
of O
laparoscopic O
rectal O
resection O
on O
short-term O
postoperative O
morbidity O
and O
costs O
. O

Patients O
with O
HER2-positive O
MBC O
whose O
disease O
progressed O
during O
prior O
trastuzumab-based O
therapies O
were O
randomly O
assigned O
to O
receive O
lapatinib O
monotherapy O
or O
lapatinib O
in O
combination O
with O
trastuzumab O
. O

The B-Premise
most I-Premise
frequent I-Premise
World I-Premise
Health I-Premise
Organization I-Premise
Grade I-Premise
3-4 I-Premise
toxic I-Premise
effects I-Premise
were I-Premise
gastrointestinal I-Premise
in I-Premise
Study I-Premise
A I-Premise
and I-Premise
hematologic I-Premise
in I-Premise
Study I-Premise
B I-Premise
. I-Premise

Although O
single- O
and O
multiple-fraction O
radiotherapy O
are O
thought O
to O
provide O
equal O
palliation O
, O
which O
treatment O
schedule O
provides O
better O
value O
for O
the O
money O
is O
unknown O
. O

Facial B-Claim
hirsutism I-Claim
is I-Claim
one I-Claim
of I-Claim
the I-Claim
characteristic I-Claim
features I-Claim
of I-Claim
polycystic I-Claim
ovary I-Claim
syndrome I-Claim
( I-Claim
PCOS I-Claim
) I-Claim
, I-Claim
and I-Claim
this I-Claim
can I-Claim
lead I-Claim
to I-Claim
high I-Claim
levels I-Claim
of I-Claim
depression I-Claim
and I-Claim
anxiety I-Claim
. I-Claim

We B-Claim
found I-Claim
a I-Claim
consistent I-Claim
pattern I-Claim
of I-Claim
better I-Claim
QOL I-Claim
outcomes I-Claim
at I-Claim
each I-Claim
follow-up I-Claim
assessment I-Claim
during I-Claim
the I-Claim
first I-Claim
6 I-Claim
months I-Claim
of I-Claim
treatment I-Claim
for I-Claim
orchiectomized I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
prostate I-Claim
cancer I-Claim
who I-Claim
received I-Claim
placebo I-Claim
versus I-Claim
flutamide I-Claim
. I-Claim

Stratification O
factors O
included O
chemotherapy O
cycle O
length O
, O
screening O
hemoglobin O
( O
< O
10 O
g/dL O
vs. O
≥10 O
g/dL O
) O
, O
and O
tumor O
type O
( O
lung/gynecological O
vs. O
other O
nonmyeloid O
malignancies O
) O
. O

A O
total O
of O
473 O
patients O
( O
234 O
to O
Sx O
+ O
Ax O
, O
239 O
to O
Sx O
) O
were O
randomly O
assigned O
. O

QOL O
variables O
were O
analyzed O
in O
449 O
randomized O
patients O
from O
the O
COST O
trial O
93-46-53 O
( O
INT O
146 O
) O
. O

Although B-Premise
toxicity I-Premise
was I-Premise
higher I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
FLOT I-Premise
, I-Premise
no B-Premise
negative I-Premise
impact I-Premise
of I-Premise
the I-Premise
addition I-Premise
of I-Premise
docetaxel I-Premise
on I-Premise
QOL I-Premise
parameters I-Premise
could I-Premise
be I-Premise
demonstrated I-Premise
. I-Premise

Although O
treatment O
allocation O
was O
random O
in O
only O
19 O
% O
, O
all O
patients O
received O
identical O
information O
in O
a O
multidisciplinary O
setting O
before O
selecting O
RP O
, O
BT O
, O
or O
random O
assignment O
. O

The B-Premise
dose-intensified I-Premise
arm I-Premise
was I-Premise
slightly I-Premise
more I-Premise
emetogenic I-Premise
and I-Premise
generated I-Premise
more I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
anemia I-Premise
but I-Premise
less I-Premise
febrile I-Premise
neutropenia I-Premise
episodes I-Premise
. I-Premise

Although B-Claim
it I-Claim
is I-Claim
premature I-Claim
to I-Claim
make I-Claim
any I-Claim
determination I-Claim
as I-Claim
to I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
the I-Claim
interventions I-Claim
tested I-Claim
in I-Claim
this I-Claim
feasibility I-Claim
study I-Claim
, I-Claim
these B-Claim
results I-Claim
indicate I-Claim
that I-Claim
pursuing I-Claim
the I-Claim
III I-Claim
+ I-Claim
ISG I-Claim
model I-Claim
, I-Claim
as I-Claim
well I-Claim
as I-Claim
standard I-Claim
IIIs I-Claim
, I-Claim
may I-Claim
be I-Claim
fruitful I-Claim
areas I-Claim
of I-Claim
future I-Claim
research I-Claim
. I-Claim

IMCP B-Claim
has I-Claim
clear I-Claim
short-term I-Claim
benefits I-Claim
for I-Claim
spiritual I-Claim
suffering I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
. I-Claim

Intention-to-treat B-Premise
analysis I-Premise
based I-Premise
on I-Premise
participants I-Premise
with I-Premise
follow-up I-Premise
data I-Premise
indicated I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
total I-Premise
exercise I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
recommendation-only I-Premise
group I-Premise
over I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
3.4 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
0.7-6.1 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
p I-Premise
= I-Premise
.011 I-Premise
) I-Premise
. I-Premise

Despite O
the O
uncertainty O
about O
undergoing O
a O
relatively O
new O
procedure O
and O
the O
possible O
need O
for O
further O
surgery O
, O
there B-Premise
was I-Premise
no I-Premise
evidence I-Premise
of I-Premise
increased I-Premise
anxiety I-Premise
amongst I-Premise
patients I-Premise
randomised I-Premise
to I-Premise
SNB I-Premise
( I-Premise
p I-Premise
> I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

A B-Premise
significant I-Premise
improvement I-Premise
in I-Premise
symptoms I-Premise
after I-Premise
treatment I-Premise
was I-Premise
found I-Premise
on I-Premise
day I-Premise
5 I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
on I-Premise
day I-Premise
10 I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0002 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
evidence I-Premise
that I-Premise
community I-Premise
treatment I-Premise
compromised I-Premise
patient I-Premise
safety I-Premise
and O
no B-Premise
significant I-Premise
difference I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
in I-Premise
terms I-Premise
of I-Premise
overall I-Premise
costs I-Premise
or I-Premise
Quality I-Premise
Adjusted I-Premise
Life I-Premise
Year I-Premise
. I-Premise

Complete B-Premise
remission I-Premise
was I-Premise
achieved I-Premise
in I-Premise
91 I-Premise
% I-Premise
( I-Premise
170/186 I-Premise
) I-Premise
of I-Premise
all I-Premise
patients I-Premise
. I-Premise

A B-Premise
7 I-Premise
% I-Premise
response I-Premise
rate I-Premise
was I-Premise
observed I-Premise
with I-Premise
topotecan I-Premise
( I-Premise
complete I-Premise
response I-Premise
, I-Premise
2 I-Premise
% I-Premise
";" I-Premise
partial I-Premise
response I-Premise
, I-Premise
5 I-Premise
% I-Premise
) I-Premise
. I-Premise

To O
prospectively O
evaluate O
and O
compare O
health-related O
quality-of-life O
( O
QOL O
) O
outcomes O
in O
patients O
with O
head-neck O
squamous O
cell O
carcinoma O
randomized O
to O
either O
intensity-modulated O
radiation O
therapy O
( O
IMRT O
) O
or O
three-dimensional O
conformal O
radiotherapy O
( O
3D-CRT O
) O
and O
assess O
serial O
longitudinal O
change O
in O
QOL O
over O
time O
. O

In B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
, I-Claim
GCa I-Claim
chemotherapy I-Claim
was I-Claim
shown I-Claim
to I-Claim
be I-Claim
a I-Claim
better-tolerated I-Claim
treatment I-Claim
that I-Claim
conferred I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
MIC I-Claim
. I-Claim

A O
specifically O
designed O
questionnaire O
was O
administered O
at O
three O
months O
to O
assess O
time O
from O
the O
operation O
until O
the O
patient O
was O
able O
to O
walk O
, O
return O
to O
daily O
activities O
, O
or O
sit O
without O
pain O
, O
time O
to O
return O
to O
work O
or O
school O
, O
and O
time O
to O
healing O
. O

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
mean I-Premise
dysphagia I-Premise
grade I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
6 I-Premise
weeks I-Premise
following I-Premise
treatment I-Premise
( I-Premise
P=0.046 I-Premise
) I-Premise
, I-Premise
with I-Premise
worse I-Premise
swallowing I-Premise
reported I-Premise
by I-Premise
rigid I-Premise
stent-treated I-Premise
patients I-Premise
( I-Premise
mean I-Premise
dysphagia I-Premise
score I-Premise
difference=-0.49 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
-0.10 I-Premise
to I-Premise
-0.89 I-Premise
, I-Premise
P=0.014 I-Premise
) I-Premise
. I-Premise

Lymphedema O
is O
an O
adverse O
effect O
of O
breast O
cancer O
surgery O
. O

Dose O
escalation O
was O
achieved O
in O
77 O
% O
of O
patients O
who O
had O
≥1 O
cycle O
. O

Vinorelbine-treated B-Premise
patients I-Premise
scored I-Premise
better I-Premise
than I-Premise
control I-Premise
patients I-Premise
on I-Premise
QoL I-Premise
functioning I-Premise
scales I-Premise
, I-Premise
and I-Premise
they I-Premise
reported I-Premise
fewer I-Premise
lung I-Premise
cancer-related I-Premise
symptoms I-Premise
but I-Premise
reported I-Premise
worse I-Premise
toxicity-related I-Premise
symptoms I-Premise
. I-Premise

At B-Premise
enrollment I-Premise
, I-Premise
mood I-Premise
and I-Premise
emotional I-Premise
functioning I-Premise
were I-Premise
similar I-Premise
among I-Premise
all I-Premise
patients I-Premise
, I-Premise
with I-Premise
no I-Premise
differences I-Premise
by I-Premise
type I-Premise
of I-Premise
treatment I-Premise
received I-Premise
. I-Premise

Immediate B-Premise
partial I-Premise
lung I-Premise
expansion I-Premise
was I-Premise
a I-Premise
frequent I-Premise
finding I-Premise
and I-Premise
was I-Premise
more I-Premise
frequent I-Premise
after I-Premise
TS I-Premise
. I-Premise

Health-Related O
Quality O
of O
Life O
[ O
RAND-36 O
and O
Rotterdam O
Symptom O
Check O
List O
( O
RSCL O
) O
] O
, O
exercise O
capacity O
( O
symptom O
limited O
bicycle O
ergometry O
) O
, O
muscle O
force O
( O
hand-held O
dynamometry O
) O
, O
and O
patient O
preferences O
. O

A O
total O
of O
322 O
participants O
with O
cancer O
of O
the O
gastrointestinal O
tract O
( O
41 O
% O
";" O
67 O
in O
the O
usual O
care O
group O
vs O
66 O
in O
the O
intervention O
group O
) O
, O
lung O
( O
36 O
% O
";" O
58 O
vs O
59 O
) O
, O
genitourinary O
tract O
( O
12 O
% O
";" O
20 O
vs O
19 O
) O
, O
and O
breast O
( O
10 O
% O
";" O
16 O
vs O
17 O
) O
were O
randomized O
. O

Fatigue B-Premise
and I-Premise
global I-Premise
health I-Premise
scores I-Premise
improved I-Premise
in I-Premise
both I-Premise
groups I-Premise
during I-Premise
the I-Premise
intervention I-Premise
( I-Premise
fatigue I-Premise
: I-Premise
training I-Premise
group I-Premise
21 I-Premise
% I-Premise
, I-Premise
relaxation I-Premise
group I-Premise
19 I-Premise
% I-Premise
";" I-Premise
global I-Premise
health I-Premise
of I-Premise
both I-Premise
groups I-Premise
19 I-Premise
% I-Premise
, I-Premise
p I-Premise
for I-Premise
all I-Premise
< I-Premise
or I-Premise
=0.01 I-Premise
) I-Premise
";" I-Premise
however B-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
changes I-Premise
in I-Premise
the I-Premise
scores I-Premise
of I-Premise
both I-Premise
groups I-Premise
( I-Premise
p=0.67 I-Premise
) I-Premise
. I-Premise

The B-Premise
total I-Premise
clinical I-Premise
effective I-Premise
rates I-Premise
in I-Premise
PP I-Premise
group I-Premise
and I-Premise
GP I-Premise
group I-Premise
were I-Premise
25.20 I-Premise
% I-Premise
and I-Premise
17.74 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Reported B-Premise
adverse I-Premise
events I-Premise
were I-Premise
similar I-Premise
between I-Premise
groups I-Premise
. I-Premise

All O
patients O
received O
etoposide O
and O
carboplatin O
every O
3 O
weeks O
for O
up O
to O
six O
cycles O
. O

In B-Claim
patients I-Claim
with I-Claim
cancer I-Claim
, I-Claim
a I-Claim
high-fat I-Claim
diet I-Claim
may I-Claim
possibly I-Claim
support I-Claim
the I-Claim
maintenance I-Claim
of I-Claim
both I-Claim
body I-Claim
weight I-Claim
and I-Claim
body I-Claim
cell I-Claim
mass I-Claim
. I-Claim

To O
determine O
whether O
an O
Internet-based B-Claim
tailored I-Claim
education I-Claim
program I-Claim
is I-Claim
effective I-Claim
for I-Claim
disease-free I-Claim
cancer I-Claim
survivors I-Claim
with I-Claim
cancer-related I-Claim
fatigue I-Claim
( I-Claim
CRF I-Claim
) I-Claim
. I-Claim

The O
secondary O
endpoints O
were O
also O
not O
significantly O
different O
between O
the O
arms O
. O

The O
World O
Health O
Organization O
( O
WHO O
) O
guidelines O
for O
the O
treatment O
of O
cancer O
pain O
recommend O
nonopioid O
analgesics O
as O
first-line O
therapy O
, O
so-called O
" O
weak O
" O
analgesics O
combined O
with O
nonopioid O
analgesics O
as O
second-line O
therapy O
, O
and O
so-called O
" O
strong O
" O
opioids O
( O
with O
nonopioid O
analgesics O
) O
only O
as O
third-line O
therapy O
. O

Also O
, O
the B-Premise
Kaplan-Meier I-Premise
survival I-Premise
curves I-Premise
of I-Premise
these I-Premise
two I-Premise
groups I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
by I-Premise
log-rank I-Premise
test I-Premise
( I-Premise
p=0.286 I-Premise
) I-Premise
. I-Premise

EW B-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
higher I-Claim
level I-Claim
of I-Claim
satisfaction I-Claim
with I-Claim
emotional I-Claim
support I-Claim
compared I-Claim
with I-Claim
controls I-Claim
. I-Claim

Breast B-Claim
IMRT I-Claim
significantly I-Claim
reduced I-Claim
the I-Claim
occurrence I-Claim
of I-Claim
moist I-Claim
desquamation I-Claim
compared I-Claim
with I-Claim
a I-Claim
standard I-Claim
wedged I-Claim
technique I-Claim
. I-Claim

The B-Premise
hazard I-Premise
ration I-Premise
( I-Premise
HR I-Premise
) I-Premise
for I-Premise
PFS I-Premise
was I-Premise
0.72 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.58 I-Premise
to I-Premise
0.90 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.0031 I-Premise
) I-Premise
. I-Premise

We O
conducted O
a O
randomized O
trial O
comparing O
uterine-artery O
embolization O
and O
surgery O
in O
women O
with O
symptomatic O
uterine O
fibroids O
. O

The O
content O
of O
consultation O
audio O
recordings O
between O
28 O
oncologists O
and O
198 O
patients O
over O
four O
consecutive O
visits O
( O
792 O
consultations O
) O
was O
analyzed O
. O

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
median I-Premise
overall I-Premise
survival I-Premise
time I-Premise
between I-Premise
the I-Premise
5-FU+low-dose I-Premise
CDDP I-Premise
arm I-Premise
and I-Premise
the I-Premise
5-FU I-Premise
arm I-Premise
( I-Premise
479 I-Premise
and I-Premise
491 I-Premise
days I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Eighty-eight O
patients O
were O
recruited O
from O
October O
1998 O
to O
April O
2000 O
. O

Regularly O
collecting O
patient-reported O
outcomes O
( O
PROs O
) O
of O
health-related O
quality O
of O
life O
with O
feedback O
to O
oncologists O
may O
assist O
in O
eliciting O
and O
monitoring O
patients O
' O
problems O
during O
cancer O
treatment O
. O

After O
medical O
treatment O
, O
they O
completed O
baseline O
measures O
and O
were O
randomly O
assigned O
to O
standard O
National O
Cancer O
Institute O
print O
material O
( O
CTL O
) O
";" O
standard O
print O
material O
and O
peer-modeling O
videotape O
( O
VID O
) O
";" O
or O
standard O
print O
material O
, O
videotape O
, O
two O
sessions O
with O
a O
trained O
cancer O
educator O
, O
and O
informational O
workbook O
( O
EDU O
) O
. O

Patients O
received O
traditional O
feeding O
scheme O
until O
resolution O
of O
postoperative O
ileus O
to O
start O
liquid O
diet O
. O

No B-Premise
other I-Premise
patient I-Premise
outcomes I-Premise
( I-Premise
symptom I-Premise
distress I-Premise
, I-Premise
spiritual I-Premise
needs I-Premise
) I-Premise
or I-Premise
caregiver I-Premise
outcomes I-Premise
( I-Premise
depression I-Premise
, I-Premise
support I-Premise
, I-Premise
spiritual I-Premise
needs I-Premise
) I-Premise
were I-Premise
significantly I-Premise
different I-Premise
. I-Premise

A O
multicomponent O
, O
psychoeducational O
intervention O
( O
Project O
ENABLE O
[ O
Educate O
, O
Nurture O
, O
Advise O
, O
Before O
Life O
Ends O
] O
) O
conducted O
by O
advanced O
practice O
nurses O
consisting O
of O
4 O
weekly O
educational O
sessions O
and O
monthly O
follow-up O
sessions O
until O
death O
or O
study O
completion O
( O
n O
= O
161 O
) O
vs O
usual O
care O
( O
n O
= O
161 O
) O
. O

Quality O
of O
life O
( O
QOL O
) O
was O
assessed O
. O

After B-Premise
a I-Premise
year I-Premise
of I-Premise
follow-up I-Premise
, I-Premise
the I-Premise
effect I-Premise
of I-Premise
CBT I-Premise
for I-Premise
fatigue I-Premise
was I-Premise
no I-Premise
longer I-Premise
observed I-Premise
, I-Premise
and I-Premise
the I-Premise
effect I-Premise
on I-Premise
fatigue I-Premise
seemed I-Premise
to I-Premise
be I-Premise
diminished I-Premise
7 I-Premise
months I-Premise
postintervention I-Premise
. I-Premise

Multiple O
measures O
were O
used O
for O
corroboration O
of O
the O
most O
important O
outcomes O
. O

The B-Premise
same I-Premise
pattern I-Premise
between I-Premise
intervention I-Premise
and I-Premise
control I-Premise
patients I-Premise
was I-Premise
observed I-Premise
for I-Premise
scores I-Premise
on I-Premise
the I-Premise
PSS-H I-Premise
& I-Premise
N I-Premise
. I-Premise

1442 O
patients O
were O
registered O
for O
the O
trial O
, O
of O
whom O
529 O
were O
randomly O
assigned O
to O
treatment O
groups O
and O
were O
included O
in O
our O
analysis O
( O
265 O
early O
, O
264 O
delayed O
) O
. O

In O
addition O
, O
folic O
acid O
, O
vitamin O
B12 O
, O
and O
dexamethasone O
were O
administered O
in O
both O
groups O
. O

Patients B-Premise
with I-Premise
a I-Premise
PS I-Premise
of I-Premise
0-1 I-Premise
and I-Premise
a I-Premise
resected I-Premise
tumor I-Premise
had I-Premise
the I-Premise
significantly I-Premise
longest I-Premise
survival I-Premise
both I-Premise
in I-Premise
EEP-L I-Premise
treated I-Premise
patients I-Premise
and I-Premise
in I-Premise
all I-Premise
evaluable I-Premise
patients I-Premise
in I-Premise
the I-Premise
two I-Premise
studies I-Premise
. I-Premise

Secondary O
end O
points O
included O
overall O
survival O
, O
response O
rate O
after O
reinitiation O
of O
imatinib O
, O
and O
quality O
of O
life O
. O

Convenience O
sample O
of O
38 O
women O
who O
were O
beginning O
outpatient O
chemotherapy O
. O

Slowly O
, O
recovery B-Premise
was I-Premise
found I-Premise
at I-Premise
both I-Premise
6 I-Premise
months I-Premise
and I-Premise
1 I-Premise
year I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

If O
the O
compounds O
work O
, O
they O
would O
offer O
a O
low-cost O
, O
readily O
available O
adjunctive O
treatment O
for O
the O
management O
of O
CINV O
. O

Bootstrap O
simulations O
( O
10,000 O
iterations O
) O
were O
conducted O
to O
account O
for O
uncertainty O
, O
and O
sensitivity O
analyses O
were O
conducted O
to O
establish O
robustness O
. O

Fatigue O
dimensions O
, O
fatigue O
NRS O
score O
, O
interference O
of O
fatigue O
with O
daily O
life O
, O
symptom O
burden O
, O
quality O
of O
life O
, O
anxiety O
, O
and O
depression O
were O
measured O
at O
baseline O
and O
after O
1 O
, O
2 O
, O
and O
3 O
months O
. O

Although B-Premise
our I-Premise
patient I-Premise
sample I-Premise
was I-Premise
small I-Premise
and I-Premise
patients I-Premise
who I-Premise
did I-Premise
not I-Premise
complete I-Premise
the I-Premise
follow-up I-Premise
survey I-Premise
were I-Premise
present I-Premise
, I-Premise
we B-Claim
could I-Claim
not I-Claim
identify I-Claim
any I-Claim
clinical I-Claim
difference I-Claim
between I-Claim
INT I-Claim
and I-Claim
RY I-Claim
after I-Claim
total I-Claim
gastrectomy I-Claim
60 I-Claim
months I-Claim
after I-Claim
surgery I-Claim
. I-Claim

Intensity O
of O
service O
was O
measured O
as O
the O
number O
of O
days O
in O
the O
hospital O
and O
in O
the O
intensive O
care O
unit O
( O
ICU O
) O
and O
the O
number O
of O
emergency O
department O
visits O
recorded O
in O
the O
electronic O
medical O
record O
. O

Two O
patients O
were O
excluded O
from O
the O
final O
analysis O
: O
One O
patient O
suspended O
ghrelin O
administration O
because O
of O
excessive O
diaphoresis O
, O
and O
another O
patient O
in O
the O
placebo O
group O
failed O
to O
monitor O
the O
self-questionnaire O
. O

The B-Premise
relative I-Premise
risks I-Premise
of I-Premise
any I-Premise
lymphedema I-Premise
and I-Premise
sensory I-Premise
loss I-Premise
for I-Premise
the I-Premise
sentinel I-Premise
lymph I-Premise
node I-Premise
biopsy I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
standard I-Premise
axillary I-Premise
treatment I-Premise
group I-Premise
at I-Premise
12 I-Premise
months I-Premise
were I-Premise
0.37 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0.23 I-Premise
to I-Premise
0.60 I-Premise
";" I-Premise
absolute I-Premise
rates I-Premise
: I-Premise
5 I-Premise
% I-Premise
versus I-Premise
13 I-Premise
% I-Premise
) I-Premise
and I-Premise
0.37 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.27 I-Premise
to I-Premise
0.50 I-Premise
";" I-Premise
absolute I-Premise
rates I-Premise
: I-Premise
11 I-Premise
% I-Premise
versus I-Premise
31 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

For B-Premise
TMZ-5 I-Premise
versus I-Premise
TMZ-21 I-Premise
, I-Premise
12-week I-Premise
PFS I-Premise
rates I-Premise
were I-Premise
similar I-Premise
( I-Premise
63.6 I-Premise
% I-Premise
and I-Premise
65.7 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
= I-Premise
.745 I-Premise
) I-Premise
, I-Premise
but B-Premise
TMZ-5 I-Premise
improved I-Premise
overall I-Premise
PFS I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.38 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.05 I-Premise
to I-Premise
1.82 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.023 I-Premise
) I-Premise
, I-Premise
survival I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.32 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.99 I-Premise
to I-Premise
1.75 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.056 I-Premise
) I-Premise
, I-Premise
and I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
49 I-Premise
% I-Premise
v I-Premise
19 I-Premise
% I-Premise
improved I-Premise
> I-Premise
10 I-Premise
points I-Premise
at I-Premise
6 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
= I-Premise
.005 I-Premise
) I-Premise
. I-Premise

Data O
were O
collected O
prior O
to O
intervention O
and O
post-intervention O
( O
3 O
and O
6 O
months O
from O
baseline O
) O
. O

The B-Claim
TAX I-Claim
326 I-Claim
study I-Claim
shows I-Claim
that I-Claim
docetaxel-platinum I-Claim
regimens I-Claim
relieve I-Claim
symptoms I-Claim
and I-Claim
improve I-Claim
QoL I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Intervention B-Premise
spouses I-Premise
reported I-Premise
higher I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
more I-Premise
self-efficacy I-Premise
, I-Premise
better I-Premise
communication I-Premise
, I-Premise
and I-Premise
less I-Premise
negative I-Premise
appraisal I-Premise
of I-Premise
caregiving I-Premise
, I-Premise
uncertainty I-Premise
, I-Premise
hopelessness I-Premise
, I-Premise
and I-Premise
symptom I-Premise
distress I-Premise
at I-Premise
4 I-Premise
months I-Premise
compared I-Premise
with I-Premise
controls I-Premise
, I-Premise
and I-Premise
some I-Premise
effects I-Premise
were I-Premise
sustained I-Premise
to I-Premise
8 I-Premise
months I-Premise
and I-Premise
12 I-Premise
months I-Premise
. I-Premise

The O
mean O
age O
of O
randomised O
women O
was O
62.8 O
( O
SD O
4.8 O
) O
years O
. O

However O
, O
when B-Premise
compared I-Premise
with I-Premise
sham I-Premise
acupuncture I-Premise
, I-Premise
the I-Premise
reduction I-Premise
by I-Premise
the I-Premise
acupuncture I-Premise
regimen I-Premise
as I-Premise
provided I-Premise
in I-Premise
the I-Premise
current I-Premise
study I-Premise
did I-Premise
not I-Premise
reach I-Premise
statistical I-Premise
significance I-Premise
. I-Premise

After O
16 O
wk O
both O
groups O
suspended O
duloxetine/placebo O
and O
continued O
rehabilitation O
. O

For B-Premise
the I-Premise
Pemetrexed I-Premise
group I-Premise
, I-Premise
objective I-Premise
response I-Premise
rate I-Premise
( I-Premise
ORR I-Premise
) I-Premise
was I-Premise
13.0 I-Premise
% I-Premise
( I-Premise
3/23 I-Premise
) I-Premise
, I-Premise
disease I-Premise
control I-Premise
rate I-Premise
( I-Premise
DCR I-Premise
) I-Premise
was I-Premise
30.4 I-Premise
% I-Premise
( I-Premise
7/23 I-Premise
) I-Premise
, I-Premise
and I-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
mPFS I-Premise
) I-Premise
was I-Premise
3.1 I-Premise
months I-Premise
. I-Premise

At B-Premise
6 I-Premise
months I-Premise
, I-Premise
in I-Premise
washout I-Premise
versus I-Premise
direct-switch I-Premise
patients I-Premise
, I-Premise
similar I-Premise
clinically I-Premise
meaningful I-Premise
improvements I-Premise
were I-Premise
seen I-Premise
in I-Premise
DAS28 I-Premise
( I-Premise
CRP I-Premise
) I-Premise
( I-Premise
> I-Premise
or I-Premise
=1.2 I-Premise
unit I-Premise
improvement I-Premise
, I-Premise
59.5 I-Premise
% I-Premise
vs I-Premise
53.6 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
low I-Premise
disease I-Premise
activity I-Premise
state I-Premise
, I-Premise
22.5 I-Premise
% I-Premise
vs I-Premise
22.3 I-Premise
% I-Premise
";" I-Premise
DAS28-defined I-Premise
remission I-Premise
, I-Premise
12.0 I-Premise
% I-Premise
vs I-Premise
13.7 I-Premise
% I-Premise
) I-Premise
, I-Premise
physical I-Premise
function I-Premise
( I-Premise
health I-Premise
assessment I-Premise
questionnaire I-Premise
disability I-Premise
index I-Premise
> I-Premise
or I-Premise
=0.22 I-Premise
improvement I-Premise
";" I-Premise
46.3 I-Premise
% I-Premise
vs I-Premise
47.1 I-Premise
% I-Premise
) I-Premise
and I-Premise
health-related I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
mean I-Premise
change I-Premise
in I-Premise
short-form I-Premise
36 I-Premise
scores I-Premise
: I-Premise
physical I-Premise
component I-Premise
summary I-Premise
, I-Premise
5.5 I-Premise
vs I-Premise
6.1 I-Premise
";" I-Premise
mental I-Premise
component I-Premise
summary I-Premise
, I-Premise
4.8 I-Premise
vs I-Premise
5.4 I-Premise
) I-Premise
. I-Premise

The O
management O
of O
cancer-related O
anorexia/cachexia O
syndrome O
( O
CACS O
) O
is O
a O
great O
challenge O
in O
clinical O
practice O
. O

The O
interventions O
offered O
dyads O
information O
and O
support O
. O

Patients O
were O
randomized O
to O
receive O
treatment O
over O
4 O
consecutive O
days O
or O
over O
11 O
days O
. O

Between O
March O
2007 O
and O
April O
2010 O
, O
151 O
( O
of O
the O
planned O
534 O
) O
patients O
were O
randomised O
( O
75 O
OSC O
+ O
WBRT O
, O
76 O
OSC O
) O
. O

SGN-15 B-Premise
was I-Premise
active I-Premise
against I-Premise
Le I-Premise
( I-Premise
y I-Premise
) I-Premise
-positive I-Premise
tumors I-Premise
in I-Premise
early I-Premise
phase I-Premise
clinical I-Premise
trials I-Premise
and I-Premise
was I-Premise
synergistic I-Premise
with I-Premise
docetaxel I-Premise
in I-Premise
preclinical I-Premise
experiments I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
either I-Premise
docetaxel I-Premise
regimen I-Premise
had I-Premise
more I-Premise
favorable I-Premise
changes I-Premise
in I-Premise
performance I-Premise
status I-Premise
( I-Premise
P=0.065 I-Premise
for I-Premise
DC I-Premise
and I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
for I-Premise
DCb I-Premise
versus I-Premise
VC I-Premise
) I-Premise
and I-Premise
mean I-Premise
weight I-Premise
loss I-Premise
( I-Premise
0.06 I-Premise
kg I-Premise
, I-Premise
gain I-Premise
of I-Premise
0.08 I-Premise
kg I-Premise
, I-Premise
and I-Premise
2.27 I-Premise
kg I-Premise
for I-Premise
DC I-Premise
, I-Premise
DCb I-Premise
, I-Premise
and I-Premise
VC I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
for I-Premise
both I-Premise
DC I-Premise
versus I-Premise
VC I-Premise
and I-Premise
DCb I-Premise
versus I-Premise
VC I-Premise
) I-Premise
. I-Premise

The O
results O
were O
statistically O
significant O
. O

The B-Premise
disease-related I-Premise
symptoms I-Premise
improved I-Premise
with I-Premise
time I-Premise
, I-Premise
and O
the B-Premise
benefits I-Premise
lasted I-Premise
for I-Premise
the I-Premise
entire I-Premise
treatment I-Premise
period I-Premise
. I-Premise

Moreover O
, O
the B-Premise
meta-analysis I-Premise
of I-Premise
two I-Premise
additional I-Premise
studies I-Premise
involving I-Premise
935 I-Premise
patients I-Premise
showed I-Premise
a I-Premise
significant I-Premise
survival I-Premise
benefit I-Premise
in I-Premise
favor I-Premise
of I-Premise
GEM-CAP I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.86 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.75 I-Premise
to I-Premise
0.98 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
with I-Premise
no I-Premise
intertrial I-Premise
heterogeneity I-Premise
. I-Premise

Uterine O
and O
quality-of-life O
data O
were O
analyzed O
using O
regression O
methods O
, O
and O
missing O
values O
were O
handled O
using O
multiple O
imputation O
. O

QoL O
was O
evaluated O
with O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
questionnaires O
QLQ-C30 O
and O
QLQ-LC13 O
, O
and O
the O
QoL O
data O
were O
analyzed O
by O
fitting O
a O
linear O
mixed O
model O
for O
each O
QoL O
scale O
. O

Results O
indicate O
no O
significant O
differences O
between O
groups O
for O
length O
of O
stay O
( O
t O
= O
.97 O
, O
df O
= O
25 O
, O
p O
> O
.05 O
) O
. O

A O
phase O
III O
study O
to O
definitively O
test O
this O
neoadjuvant-concurrent O
strategy O
is O
warranted O
. O

HDCT O
was O
repeated O
after O
6 O
weeks O
. O

Greater B-Premise
myelosuppression I-Premise
was I-Premise
reported I-Premise
in I-Premise
the I-Premise
combination I-Premise
arm I-Premise
. I-Premise

Sixty-eight O
eligible O
research O
volunteers O
with O
a O
minimum O
20 O
% O
increase O
in O
arm O
volume O
at O
a O
median O
15.5 O
years O
( O
range O
2-41 O
) O
after O
axillary/supraclavicular O
radiotherapy O
( O
plus O
axillary O
surgery O
in O
51/68 O
( O
75 O
% O
) O
cases O
) O
were O
randomised O
to O
active O
drugs O
or O
placebo O
. O

Exercise B-Claim
training I-Claim
during I-Claim
breast I-Claim
cancer I-Claim
chemotherapy I-Claim
may I-Claim
result I-Claim
in I-Claim
some I-Claim
longer-term I-Claim
and I-Claim
late I-Claim
effects I-Claim
for I-Claim
selected I-Claim
patient-rated I-Claim
outcomes I-Claim
. I-Claim

Patients B-Claim
treated I-Claim
with I-Claim
longer I-Claim
duration I-Claim
therapy I-Claim
( I-Claim
AC→T I-Claim
) I-Claim
had I-Claim
greater I-Claim
symptom I-Claim
severity I-Claim
and I-Claim
poorer I-Claim
QOL I-Claim
at I-Claim
6 I-Claim
months I-Claim
, I-Claim
but I-Claim
did I-Claim
not I-Claim
differ I-Claim
from I-Claim
shorter I-Claim
duration I-Claim
treatments I-Claim
at I-Claim
12 I-Claim
months I-Claim
. I-Claim

Three O
hundred O
three O
patients O
were O
randomized O
to O
DOX O
50 O
mg/m O
( O
2 O
) O
intravenously O
( O
IV O
) O
on O
day O
1 O
and O
VNB O
25 O
mg/m O
( O
2 O
) O
IV O
on O
days O
1 O
and O
8 O
( O
arm O
1 O
) O
or O
DOX O
70 O
mg/m O
( O
2 O
) O
IV O
on O
day O
1 O
( O
arm O
2 O
) O
. O

In B-Claim
the I-Claim
subset I-Claim
analysis I-Claim
, I-Claim
female I-Claim
patients I-Claim
, I-Claim
those I-Claim
that I-Claim
received I-Claim
high I-Claim
dose I-Claim
irradiation I-Claim
, I-Claim
and I-Claim
those I-Claim
that I-Claim
underwent I-Claim
adjuvant I-Claim
chemotherapy I-Claim
could I-Claim
benefit I-Claim
more I-Claim
from I-Claim
psychosocial I-Claim
intervention I-Claim
. I-Claim

Chemotherapy O
consisted O
of O
intravenous O
( O
i.v O
. O
) O

However B-Premise
, I-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
in I-Premise
the I-Premise
high-dose I-Premise
group I-Premise
( I-Premise
19 I-Premise
v I-Premise
14 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

The O
primary O
outcome O
was O
the O
adjusted O
mean O
difference O
in O
HFNS O
problem O
rating O
( O
1-10 O
) O
between O
CBT O
and O
usual O
care O
groups O
at O
9 O
weeks O
after O
randomisation O
. O

In B-Premise
patients I-Premise
with I-Premise
biopsies I-Premise
taken I-Premise
from I-Premise
liver I-Premise
lesions I-Premise
( I-Premise
n=91 I-Premise
) I-Premise
overall I-Premise
response I-Premise
to I-Premise
FOLFIRI I-Premise
and I-Premise
FUFA I-Premise
in I-Premise
TS I-Premise
high I-Premise
was I-Premise
53 I-Premise
% I-Premise
( I-Premise
9/17 I-Premise
) I-Premise
and I-Premise
18 I-Premise
% I-Premise
( I-Premise
3/17 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p=0.035 I-Premise
) I-Premise
. I-Premise

We O
evaluated O
safety O
and O
efficacy O
of O
IFNalpha O
and O
isotretinoin O
compared O
with O
IFNalpha O
alone O
as O
adjuvant O
treatment O
in O
patients O
with O
primary O
malignant O
melanoma O
stage O
IIA O
and O
IIB O
. O

Patients B-Premise
who I-Premise
had I-Premise
no I-Premise
preference I-Premise
had I-Premise
improved I-Premise
QoL I-Premise
when I-Premise
they I-Premise
were I-Premise
assigned I-Premise
to I-Premise
receive I-Premise
AET I-Premise
compared I-Premise
with I-Premise
RET I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
23 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
4.9-41 I-Premise
";" I-Premise
P= I-Premise
.014 I-Premise
) I-Premise
. I-Premise

Study O
patients O
included O
472 O
low-income O
, O
predominantly O
female O
Hispanic O
patients O
with O
cancer O
age O
> O
or= O
18 O
years O
with O
major O
depression O
( O
49 O
% O
) O
, O
dysthymia O
( O
5 O
% O
) O
, O
or O
both O
( O
46 O
% O
) O
. O

In B-Premise
the I-Premise
bevacizumab I-Premise
group I-Premise
, I-Premise
the I-Premise
levels I-Premise
of I-Premise
VEGF I-Premise
in I-Premise
the I-Premise
pleural I-Premise
fluid I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
compared I-Premise
to I-Premise
those I-Premise
of I-Premise
the I-Premise
cisplatin I-Premise
group I-Premise
after I-Premise
treatment I-Premise
, I-Premise
which I-Premise
showed I-Premise
greater I-Premise
efficacy I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

The O
purpose O
of O
this O
randomized O
study O
was O
to O
prospectively O
compare O
the O
efficacy O
and O
tolerability O
of O
strong O
opioids O
as O
first-line O
agents O
with O
the O
recommendations O
of O
the O
WHO O
in O
terminal O
cancer O
patients O
. O

In B-Claim
the I-Claim
watchful-waiting I-Claim
group I-Claim
, I-Claim
side-effects I-Claim
can I-Claim
be I-Claim
caused I-Claim
by I-Claim
tumour I-Claim
progression I-Claim
. I-Claim

During B-Premise
the I-Premise
last I-Premise
decade I-Premise
, I-Premise
survival I-Premise
rates I-Premise
for I-Premise
breast I-Premise
cancer I-Premise
have I-Premise
increased I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
earlier I-Premise
detection I-Premise
and I-Premise
increased I-Premise
use I-Premise
of I-Premise
adjuvant I-Premise
therapy I-Premise
. I-Premise

The B-Premise
average I-Premise
increase I-Premise
in I-Premise
arm I-Premise
volume I-Premise
was I-Premise
2.8 I-Premise
% I-Premise
in I-Premise
the I-Premise
SNBM I-Premise
group I-Premise
and I-Premise
4.2 I-Premise
% I-Premise
in I-Premise
the I-Premise
RAC I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
. I-Premise

The O
median O
follow-up O
was O
22.6 O
months O
. O

The B-Claim
addition I-Claim
of I-Claim
paclitaxel I-Claim
to I-Claim
best I-Claim
supportive I-Claim
care I-Claim
significantly I-Claim
improved I-Claim
survival I-Claim
and I-Claim
time I-Claim
to I-Claim
disease I-Claim
progression I-Claim
compared I-Claim
with I-Claim
best I-Claim
supportive I-Claim
care I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
and I-Claim
may I-Claim
improve I-Claim
some I-Claim
aspects I-Claim
of I-Claim
QOL I-Claim
. I-Claim

Corresponding B-Premise
median I-Premise
failure-free I-Premise
survival I-Premise
times I-Premise
were I-Premise
3.1 I-Premise
and I-Premise
1.7 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.20 I-Premise
) I-Premise
. I-Premise

For B-Premise
in-hospital I-Premise
mortality I-Premise
, I-Premise
one I-Premise
patient I-Premise
in I-Premise
the I-Premise
open I-Premise
oesophagectomy I-Premise
group I-Premise
died I-Premise
from I-Premise
anastomotic I-Premise
leakage I-Premise
and I-Premise
two I-Premise
in I-Premise
the I-Premise
minimally I-Premise
invasive I-Premise
group I-Premise
from I-Premise
aspiration I-Premise
and I-Premise
mediastinitis I-Premise
after I-Premise
anastomotic I-Premise
leakage I-Premise
. I-Premise

The B-Premise
mean I-Premise
hematocrit I-Premise
increased I-Premise
by I-Premise
6.0 I-Premise
percentage I-Premise
points I-Premise
in I-Premise
the I-Premise
r-HuEPO I-Premise
group I-Premise
versus I-Premise
1.3 I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

This B-Claim
study I-Claim
provides I-Claim
important I-Claim
information I-Claim
about I-Claim
the I-Claim
HRQOL I-Claim
of I-Claim
chemotherapy-treated I-Claim
MPM I-Claim
patients I-Claim
. I-Claim

HDCT B-Premise
was I-Premise
associated I-Premise
with I-Premise
significantly I-Premise
more I-Premise
myelosuppression I-Premise
, I-Premise
infection I-Premise
, I-Premise
diarrhea I-Premise
, I-Premise
stomatitis I-Premise
, I-Premise
and I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
, I-Premise
whereas I-Premise
patients I-Premise
treated I-Premise
with I-Premise
AT I-Premise
developed I-Premise
more I-Premise
neurotoxicity I-Premise
. I-Premise

Pain O
severity O
was O
assessed O
using O
the O
Brief O
Pain O
Inventory-Short O
Form O
" O
average O
pain O
" O
item O
with O
0 O
representing O
no O
pain O
and O
10 O
representing O
as O
bad O
as O
can O
be O
imagined O
. O

The B-Claim
timing I-Claim
of I-Claim
RT I-Claim
has I-Claim
minimal I-Claim
impact I-Claim
on I-Claim
the I-Claim
function I-Claim
of I-Claim
STS I-Claim
patients I-Claim
in I-Claim
the I-Claim
first I-Claim
year I-Claim
after I-Claim
surgery I-Claim
. O

These B-Claim
analyses I-Claim
confirm I-Claim
that I-Claim
EVE I-Claim
+ I-Claim
EXE I-Claim
provides I-Claim
clinical I-Claim
benefit I-Claim
without I-Claim
adversely I-Claim
impacting I-Claim
HRQOL I-Claim
in I-Claim
patients I-Claim
with I-Claim
HR I-Claim
( I-Claim
+ I-Claim
) I-Claim
ABC I-Claim
who I-Claim
recurred/progressed I-Claim
on I-Claim
prior I-Claim
NSAIs I-Claim
versus I-Claim
endocrine I-Claim
therapy I-Claim
alone I-Claim
. I-Claim

The B-Premise
median I-Premise
survival I-Premise
was I-Premise
22.7 I-Premise
weeks I-Premise
for I-Premise
regimen I-Premise
1 I-Premise
and I-Premise
28.3 I-Premise
weeks I-Premise
for I-Premise
regimen I-Premise
2 I-Premise
( I-Premise
P I-Premise
= I-Premise
0.197 I-Premise
) I-Premise
. I-Premise

However O
, O
few O
studies O
have O
assessed O
whether O
changes O
in O
depression O
symptoms O
are O
associated O
with O
survival O
. O

The B-Premise
combined I-Premise
anthracycline I-Premise
followed I-Premise
by I-Premise
taxane I-Premise
group I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
utility I-Premise
scores I-Premise
that I-Premise
the I-Premise
taxane-alone I-Premise
group I-Premise
, I-Premise
with I-Premise
no I-Premise
significant I-Premise
difference I-Premise
depending I-Premise
on I-Premise
the I-Premise
type I-Premise
of I-Premise
taxane I-Premise
. I-Premise

We O
have O
recently O
suggested O
that O
bolus O
5-fluorouracil O
( O
5-FU O
) O
may O
work O
via O
a O
RNA O
directed O
mechanism O
while O
continuous O
infusion O
5-FU O
may O
kill O
cells O
via O
a O
thymidylate O
synthase O
related O
pathway O
. O

Courses O
were O
repeated O
every O
two O
weeks O
in O
all O
arms O
of O
the O
trial O
. O

Those O
who O
received O
prednisone O
alone O
could O
have O
mitoxantrone O
added O
after O
6 O
weeks O
if O
there O
was O
no O
improvement O
in O
pain O
. O

Carry-over O
, O
period O
and O
treatment O
effects O
were O
analysed O
. O

Forty-two O
patients O
were O
randomized O
to O
receive O
misoprostol O
and O
41 O
to O
receive O
a O
placebo O
. O

Compared B-Claim
with I-Claim
IFN5 I-Claim
, I-Claim
IFN1 I-Claim
is I-Claim
neither I-Claim
more I-Claim
nor I-Claim
less I-Claim
effective I-Claim
but I-Claim
is I-Claim
less I-Claim
toxic I-Claim
, I-Claim
with I-Claim
a I-Claim
better I-Claim
reported I-Claim
QOL I-Claim
. I-Claim

In O
all O
, O
55 O
patients O
( O
27 O
on O
tamoxifen O
and O
28 O
on O
exemestane O
) O
completed O
the O
1-year O
study O
period O
. O

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
impact O
of O
pilates O
exercises O
on O
physical O
performance O
, O
flexibility O
, O
fatigue O
, O
depression O
and O
quality O
of O
life O
in O
women O
who O
had O
been O
treated O
for O
breast O
cancer O
. O

Our B-Claim
present I-Claim
study I-Claim
shows I-Claim
that I-Claim
glutamine-enriched I-Claim
TPN I-Claim
may I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
improving I-Claim
the I-Claim
inflammatory I-Claim
status I-Claim
and I-Claim
decreasing I-Claim
the I-Claim
infectious I-Claim
morbidity I-Claim
in I-Claim
postoperative I-Claim
GI I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Inclusion O
criteria O
were O
an O
age O
of O
18 O
years O
or O
older O
";" O
total O
thyroidectomy O
for O
differentiated O
thyroid O
carcinoma O
";" O
tumor-node-metastasis O
( O
TNM O
) O
stage O
, O
ascertained O
on O
pathological O
examination O
( O
p O
) O
of O
a O
surgical O
specimen O
, O
of O
pT1 O
( O
with O
tumor O
diameter O
≤1 O
cm O
) O
and O
N1 O
or O
Nx O
, O
pT1 O
( O
with O
tumor O
diameter O
> O
1 O
to O
2 O
cm O
) O
and O
any O
N O
stage O
, O
or O
pT2N0 O
";" O
absence O
of O
distant O
metastasis O
";" O
and O
no O
iodine O
contamination O
. O

A O
total O
of O
314 O
patients O
were O
included O
in O
the O
clinical O
trial O
. O

To O
determine O
the O
efficacy O
, O
impact O
on O
quality-of-life O
( O
QoL O
) O
and O
tolerability O
of O
two O
different O
irinotecan O
administration O
schedules O
in O
combination O
with O
capecitabine O
as O
first-line O
treatment O
of O
metastatic O
colorectal O
cancer O
. O

The B-Premise
inflammation I-Premise
and I-Premise
oxidative I-Premise
stress I-Premise
parameters I-Premise
IL-6 I-Premise
, I-Premise
TNF-α I-Premise
, I-Premise
CRP I-Premise
, I-Premise
and I-Premise
ROS I-Premise
decreased I-Premise
significantly I-Premise
in I-Premise
arm I-Premise
1 I-Premise
, I-Premise
while I-Premise
no I-Premise
significant I-Premise
change I-Premise
was I-Premise
observed I-Premise
in I-Premise
arm I-Premise
2 I-Premise
. I-Premise

This O
randomised O
multicentre O
trial O
was O
conducted O
to O
establish O
the O
optimal O
duration O
of O
palliative O
chemotherapy O
in O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

No B-Premise
significant I-Premise
differences I-Premise
were I-Premise
noted I-Premise
in I-Premise
the I-Premise
distress I-Premise
levels I-Premise
before I-Premise
and I-Premise
after I-Premise
completion I-Premise
of I-Premise
the I-Premise
study I-Premise
in I-Premise
the I-Premise
three I-Premise
groups I-Premise
. I-Premise

Patient B-Claim
preference I-Claim
, I-Claim
demographic I-Claim
variables I-Claim
, I-Claim
and I-Claim
medical I-Claim
variables I-Claim
moderated I-Claim
the I-Claim
effects I-Claim
of I-Claim
exercise I-Claim
training I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
who I-Claim
were I-Claim
receiving I-Claim
chemotherapy I-Claim
. I-Claim

At B-Premise
6 I-Premise
months I-Premise
, I-Premise
there I-Premise
was I-Premise
a I-Premise
clinically I-Premise
relevant I-Premise
, I-Premise
but I-Premise
nonsignificant I-Premise
reduction I-Premise
in I-Premise
presentations I-Premise
to I-Premise
emergency I-Premise
departments I-Premise
( I-Premise
21 I-Premise
% I-Premise
vs I-Premise
33 I-Premise
% I-Premise
";" I-Premise
χ1 I-Premise
= I-Premise
1.41 I-Premise
, I-Premise
P I-Premise
= I-Premise
.23 I-Premise
) I-Premise
and I-Premise
readmission I-Premise
to I-Premise
the I-Premise
hospital I-Premise
( I-Premise
37 I-Premise
% I-Premise
vs I-Premise
47 I-Premise
% I-Premise
";" I-Premise
χ1 I-Premise
= I-Premise
0.82 I-Premise
, I-Premise
P I-Premise
= I-Premise
.37 I-Premise
) I-Premise
among I-Premise
intervention I-Premise
compared I-Premise
with I-Premise
control I-Premise
group I-Premise
participants I-Premise
. I-Premise

There B-Premise
were I-Premise
three I-Premise
treatment-related I-Premise
deaths I-Premise
with I-Premise
CAF I-Premise
but B-Premise
none I-Premise
with I-Premise
the I-Premise
16-week I-Premise
regimen I-Premise
. I-Premise

The O
inflammation-related O
cytokines O
including O
interleukin-6 O
, O
interleukin-10 O
, O
and O
tumor O
necrosis O
factor-α O
were O
also O
determined O
. O

Of O
50 O
enrolled O
patients O
, O
25 O
patients O
were O
classified O
as O
the O
intervention O
group O
, O
and O
the O
control O
group O
also O
comprised O
25 O
patients O
. O

The O
scapula-oriented O
exercises O
were O
designed O
focusing O
on O
scapulothoracic O
movement O
. O

Between O
Nov O
26 O
, O
2007 O
, O
and O
Dec O
12 O
, O
2011 O
, O
we O
enrolled O
and O
randomly O
allocated O
218 O
patients O
to O
treatment O
: O
80 O
to O
the O
nurse O
group O
, O
70 O
to O
the O
gastroenterologist O
group O
, O
and O
68 O
to O
the O
booklet O
group O
( O
figure O
) O
. O

To O
determine O
whether O
a O
new O
agent O
, O
paclitaxel O
, O
would O
further O
improve O
survival O
in O
NSCLC O
, O
the O
Eastern O
Cooperative O
Oncology O
Group O
conducted O
a O
randomized O
trial O
comparing O
paclitaxel O
plus O
cisplatin O
to O
a O
standard O
chemotherapy O
regimen O
consisting O
of O
cisplatin O
and O
etoposide O
. O

We B-Premise
observed I-Premise
no I-Premise
significant I-Premise
changes I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Seventeen B-Premise
of I-Premise
25 I-Premise
HBO-treated I-Premise
patients I-Premise
( I-Premise
68 I-Premise
% I-Premise
) I-Premise
improved I-Premise
versus I-Premise
8 I-Premise
of I-Premise
21 I-Premise
controls I-Premise
( I-Premise
38.1 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.043 I-Premise
, I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
test I-Premise
) I-Premise
. I-Premise

An O
alpha-blocker O
was O
initiated O
either O
prophylactically O
2 O
weeks O
before O
implantation O
and O
continued O
at O
least O
until O
the O
International O
Prostate O
Symptom O
Score O
( O
IPSS O
) O
returned O
to O
normal O
, O
or O
withheld O
until O
the O
onset O
of O
significant O
brachytherapy-related O
urinary O
morbidity O
. O

In O
this O
part O
of O
our O
study O
, O
a O
blinded O
assessor O
collected O
subjective O
outcomes O
of O
the O
patient O
's O
reported O
measures O
of O
OM O
using O
Oral O
Mucositis O
Weekly O
Questionnaire-Head O
and O
Neck O
( O
OMWQ-HN O
) O
and O
QOL O
using O
Functional O
Assessment O
of O
Cancer O
Treatment-Head O
and O
Neck O
( O
FACT-HN O
) O
Questionnaire O
. O

This O
Phase O
II O
, O
open-label O
study O
was O
conducted O
to O
confirm O
the O
activity O
of O
SGN-15 O
plus O
docetaxel O
in O
previously O
treated O
NSCLC O
patients O
. O

Moreover O
, O
a B-Premise
significant I-Premise
lower I-Premise
serum I-Premise
C-reactive I-Premise
protein I-Premise
level I-Premise
was I-Premise
detected I-Premise
in I-Premise
glutamine-enriched I-Premise
TPN I-Premise
compared I-Premise
with I-Premise
standard I-Premise
TPN I-Premise
( I-Premise
P I-Premise
= I-Premise
0.013 I-Premise
) I-Premise
. I-Premise

Both O
interventions O
were O
carried O
out O
for O
3 O
weeks O
. O

No B-Premise
significant I-Premise
differences I-Premise
were I-Premise
noted I-Premise
between I-Premise
study I-Premise
arms I-Premise
for I-Premise
patients I-Premise
with I-Premise
mutated I-Premise
KRAS I-Premise
tumors I-Premise
. I-Premise

Following B-Premise
discontinuation I-Premise
of I-Premise
ccHRT I-Premise
, I-Premise
patient I-Premise
satisfaction I-Premise
was I-Premise
variable I-Premise
, I-Premise
with I-Premise
15 I-Premise
% I-Premise
electing I-Premise
to I-Premise
continue I-Premise
or I-Premise
restart I-Premise
HRT I-Premise
and I-Premise
7 I-Premise
% I-Premise
resuming I-Premise
at I-Premise
follow-up I-Premise
. I-Premise

There O
were O
70 O
female O
posttreatment O
anal O
or O
rectal O
cancer O
survivors O
assessed O
as O
part O
of O
the O
current O
study O
. O

Protein B-Premise
intake I-Premise
also I-Premise
increased I-Premise
in I-Premise
both I-Premise
groups I-Premise
1 I-Premise
and I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
.006 I-Premise
) I-Premise
. I-Premise

Sixteen O
advanced O
cancer O
patients O
with O
neuropathic O
pain O
on O
systemic O
morphine O
therapy O
, O
no O
longer O
receiving O
oncologic O
treatment O
, O
presenting O
moderate O
pain O
( O
about O
4 O
or O
more O
, O
but O
less O
than O
7 O
, O
on O
a O
numerical O
scale O
of O
0-10 O
) O
in O
the O
last O
week O
, O
and O
given O
a O
stable O
morphine O
dose O
in O
the O
last O
2 O
days O
were O
admitted O
to O
the O
study O
. O

V325 O
represents O
the O
largest O
trial O
with O
the O
longest O
prospectively O
controlled O
evaluations O
of O
QOL O
during O
protocol O
chemotherapy O
and O
follow-up O
in O
patients O
with O
advanced O
gastric O
or O
gastroesophageal O
junction O
cancer O
. O

Relatively O
small O
patient O
population O
. O

Toxicity B-Premise
was I-Premise
found I-Premise
to I-Premise
be I-Premise
relatively I-Premise
negligible I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

Among B-Premise
these I-Premise
32 I-Premise
patients I-Premise
, I-Premise
8 I-Premise
had I-Premise
a I-Premise
partial I-Premise
response I-Premise
( I-Premise
intent-to-treat I-Premise
response I-Premise
rate I-Premise
, I-Premise
20 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
10 I-Premise
( I-Premise
25 I-Premise
% I-Premise
) I-Premise
had I-Premise
stable I-Premise
disease I-Premise
. I-Premise

Grade B-Premise
4 I-Premise
neutropenia I-Premise
and I-Premise
thrombocytopenia I-Premise
occurred I-Premise
in I-Premise
50 I-Premise
% I-Premise
and I-Premise
3 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
of I-Premise
PE I-Premise
patients I-Premise
in I-Premise
step I-Premise
1 I-Premise
and I-Premise
60 I-Premise
% I-Premise
and I-Premise
13 I-Premise
% I-Premise
of I-Premise
topotecan I-Premise
patients I-Premise
in I-Premise
step I-Premise
2 I-Premise
. I-Premise

Functional O
outcome O
and O
health O
status O
of O
extremity O
STS O
patients O
randomized O
in O
a O
phase O
III O
trial O
comparing O
preoperative O
versus O
postoperative O
RT O
is O
described O
. O

Sentinel O
nodes O
were O
located O
using O
blue O
dye O
, O
alone O
or O
with O
technetium-labeled O
antimony O
sulfide O
colloid O
. O

Gynecomastia O
, O
breast O
pain O
, O
prostate O
specific O
antigen O
, O
QOL O
, O
sexual O
function O
and O
hormonal O
levels O
were O
assessed O
. O

The O
administration O
of O
the O
smallest O
possible O
amount O
of O
radioiodine O
would O
improve O
care O
. O

Participants O
with O
recurrent O
platinum-sensitive O
ovarian O
cancer O
were O
randomly O
assigned O
to O
receive O
either O
gemcitabine-carboplatin O
or O
carboplatin O
every O
21 O
days O
. O

Exemestane B-Premise
patients I-Premise
reported I-Premise
more I-Premise
bone/muscle I-Premise
aches I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
, I-Premise
vaginal I-Premise
dryness I-Premise
( I-Premise
P I-Premise
= I-Premise
.0004 I-Premise
) I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
sleeping I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
. I-Premise

Randomization O
totaled O
130 O
patients O
( O
GE O
= O
86 O
, O
G O
= O
44 O
) O
";" O
121 O
patients O
were O
treated O
( O
GE O
= O
82 O
, O
G O
= O
39 O
) O
. O

Hence O
, O
equivalence B-Claim
is I-Claim
claimed I-Claim
in I-Claim
this I-Claim
comparison I-Claim
also I-Claim
. I-Claim

Clinicians O
working O
with O
patients O
who O
have O
advanced O
cancer O
should O
consider O
IMCP O
as O
an O
approach O
to O
enhance O
quality O
of O
life O
and O
spiritual O
well-being O
. O

Analyses O
were O
performed O
on O
an O
intention-to-treat O
basis O
. O

The B-Premise
different I-Premise
schedules I-Premise
of I-Premise
vinorelbine I-Premise
in I-Premise
the I-Premise
two I-Premise
arms I-Premise
led I-Premise
to I-Premise
a I-Premise
greater I-Premise
survival I-Premise
in I-Premise
the I-Premise
NP I-Premise
arm I-Premise
without I-Premise
impairing I-Premise
the I-Premise
tolerance I-Premise
profile I-Premise
, I-Premise
although B-Premise
this I-Premise
is I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
. I-Premise

Paclitaxel O
and O
pegylated O
liposomal O
doxorubicin O
( O
PLD O
) O
are O
active O
cytotoxic O
agents O
for O
the O
treatment O
of O
human O
immunodeficiency O
virus O
( O
HIV O
) O
-associated O
Kaposi O
sarcoma O
( O
KS O
) O
. O

Larger B-Claim
studies I-Claim
are I-Claim
required I-Claim
to I-Claim
validate I-Claim
these I-Claim
results I-Claim
. I-Claim

These B-Premise
differences I-Premise
were I-Premise
not I-Premise
significant I-Premise
. I-Premise

573 O
patients O
with O
newly O
diagnosed O
glioblastoma O
were O
randomly O
allocated O
either O
radiotherapy O
alone O
or O
radiotherapy O
and O
temozolomide O
. O

Small O
improvements O
in O
pain O
and O
mood O
are O
observed O
despite O
progressive O
functional O
decline O
. O

Although O
initial O
pre-trial O
interviews O
revealed O
concerns O
among O
health-care O
professionals O
and O
some O
patients O
regarding O
community O
treatment O
, O
opinions O
were O
largely O
more O
favourable O
in O
post-trial O
interviews O
. O

Few O
randomized O
trials O
have O
compared O
the O
survival O
benefit O
of O
interferon-alfa O
over O
controls O
in O
metastatic O
renal O
cell O
carcinoma O
, O
and O
none O
has O
been O
performed O
using O
interleukin-2 O
. O

Replacement B-Claim
of I-Claim
most I-Claim
hospital I-Claim
follow-up I-Claim
visits I-Claim
in I-Claim
the I-Claim
first I-Claim
year I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
by I-Claim
nurse-led I-Claim
telephone I-Claim
follow-up I-Claim
does I-Claim
not I-Claim
impede I-Claim
patient I-Claim
outcomes I-Claim
. I-Claim

Grade B-Premise
3/4 I-Premise
anemia I-Premise
developed I-Premise
in I-Premise
22 I-Premise
% I-Premise
of I-Premise
patients I-Premise
who I-Premise
received I-Premise
topotecan I-Premise
. I-Premise

The B-Claim
regimen I-Claim
of I-Claim
once I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
significantly I-Claim
lower I-Claim
incidence I-Claim
of I-Claim
severe I-Claim
diarrhea I-Claim
. I-Claim

The O
current O
study O
evaluated O
the O
cost-effectiveness O
of O
the O
capecitabine/docetaxel O
combination O
versus O
docetaxel O
monotherapy O
, O
comparing O
the O
gain O
in O
quality-adjusted O
survival O
with O
associated O
health O
care O
costs O
. O

There B-Premise
were I-Premise
no I-Premise
other I-Premise
significant I-Premise
associations I-Premise
between I-Premise
attrition I-Premise
and I-Premise
any I-Premise
demographic I-Premise
, I-Premise
medical I-Premise
, I-Premise
psychiatric I-Premise
, I-Premise
or I-Premise
study-related I-Premise
variables I-Premise
. I-Premise

Chemonaive O
Taiwanese O
patients O
aged O
70 O
years O
or O
older O
who O
had O
advanced O
NSCLC O
were O
randomized O
to O
receive O
either O
oral O
erlotinib O
150 O
mg O
( O
E O
) O
daily O
or O
oral O
vinorelbine O
60 O
mg/m O
( O
V O
) O
on O
days O
1 O
and O
8 O
every O
3 O
weeks O
. O

Observational O
studies O
demonstrate O
an O
association O
between O
physical O
activity O
and O
improved O
outcomes O
in O
breast O
and O
colon O
cancer O
survivors O
. O

Factors O
from O
the O
EORTC O
QLQ-C30 O
were O
all O
function O
scales O
, O
fatigue O
, O
nausea/vomiting O
, O
pain O
, O
dyspnoea O
, O
insomnia O
, O
loss O
of O
appetite O
and O
global O
QL O
. O

Eligible O
patients O
were O
70 O
years O
of O
age O
or O
older O
, O
had O
stage O
IV O
or O
IIIB O
NSCLC O
that O
was O
ineligible O
for O
radiotherapy O
, O
and O
had O
a O
performance O
status O
of O
0-2 O
( O
a O
status O
of O
fully O
active O
to O
a O
status O
of O
capable O
of O
all O
self-care O
but O
unable O
to O
work O
) O
. O

Frequent B-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
toxicities I-Premise
for I-Premise
DCF I-Premise
v I-Premise
CF I-Premise
were I-Premise
: I-Premise
neutropenia I-Premise
( I-Premise
82 I-Premise
% I-Premise
v I-Premise
57 I-Premise
% I-Premise
) I-Premise
, I-Premise
stomatitis I-Premise
( I-Premise
21 I-Premise
% I-Premise
v I-Premise
27 I-Premise
% I-Premise
) I-Premise
, I-Premise
diarrhea I-Premise
( I-Premise
19 I-Premise
% I-Premise
v I-Premise
8 I-Premise
% I-Premise
) I-Premise
, I-Premise
lethargy I-Premise
( I-Premise
19 I-Premise
% I-Premise
v I-Premise
14 I-Premise
% I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
raw I-Premise
QOL I-Premise
scores I-Premise
were I-Premise
not I-Premise
different I-Premise
at I-Premise
these I-Premise
time-points I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

In O
addition O
, O
the O
data O
comparing O
their O
effects O
on O
the O
quality O
of O
life O
are O
lacking O
. O

The B-Premise
experimental-to-PC I-Premise
hazard I-Premise
ratios I-Premise
of I-Premise
death I-Premise
were I-Premise
1.15 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.79 I-Premise
to I-Premise
1.67 I-Premise
) I-Premise
for I-Premise
VC I-Premise
, I-Premise
1.32 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.91 I-Premise
to I-Premise
1.92 I-Premise
) I-Premise
for I-Premise
GC I-Premise
, I-Premise
and I-Premise
1.26 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.86 I-Premise
to I-Premise
1.82 I-Premise
) I-Premise
for I-Premise
TC I-Premise
. I-Premise

The B-Claim
oral I-Claim
regimen I-Claim
also I-Claim
can I-Claim
be I-Claim
safely I-Claim
given I-Claim
with I-Claim
appropriate I-Claim
toxicity I-Claim
and I-Claim
tolerability I-Claim
. I-Claim

Similarly B-Premise
, I-Premise
both I-Premise
groups I-Premise
showed I-Premise
a I-Premise
decline I-Premise
in I-Premise
physical I-Premise
and I-Premise
functional I-Premise
well I-Premise
being I-Premise
but I-Premise
recovered I-Premise
in I-Premise
the I-Premise
3 I-Premise
months I-Premise
posttreatment I-Premise
follow-up I-Premise
, I-Premise
with I-Premise
the I-Premise
rhDNase I-Premise
group I-Premise
exhibiting I-Premise
speedier I-Premise
recovery I-Premise
. I-Premise

Hospital B-Premise
stay I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
EOF I-Premise
( I-Premise
n=71 I-Premise
) I-Premise
was I-Premise
4.7 I-Premise
vs. I-Premise
5.8 I-Premise
days I-Premise
for I-Premise
the I-Premise
TOF I-Premise
group I-Premise
( I-Premise
n=72 I-Premise
) I-Premise
( I-Premise
P=0.006 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3/4 I-Premise
diarrhea I-Premise
occurred I-Premise
in I-Premise
36 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
weekly I-Premise
and I-Premise
in I-Premise
19 I-Premise
% I-Premise
of I-Premise
those I-Premise
treated I-Premise
once I-Premise
every I-Premise
3 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
=.002 I-Premise
) I-Premise
. I-Premise

Increased B-Premise
symptoms I-Premise
were I-Premise
reflected I-Premise
by I-Premise
the I-Premise
frequent I-Premise
use I-Premise
of I-Premise
incontinence I-Premise
materials I-Premise
after I-Premise
EBRT I-Premise
( I-Premise
day I-Premise
and I-Premise
night I-Premise
use I-Premise
, I-Premise
42.9 I-Premise
% I-Premise
v I-Premise
15.2 I-Premise
% I-Premise
for I-Premise
NAT I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

The O
purpose O
of O
this O
study O
is O
to O
compare O
the O
treatment O
and O
retention O
effects O
between O
standard O
decongestive O
lymphatic O
therapy O
( O
DLT O
) O
combined O
with O
pneumatic O
compression O
( O
PC O
) O
and O
modified O
DLT O
, O
in O
which O
the O
use O
of O
a O
short-stretch O
bandage O
is O
replaced O
with O
the O
use O
of O
Kinesio O
tape O
( O
K-tape O
) O
combined O
with O
PC O
. O

GHS B-Premise
change I-Premise
scores I-Premise
were I-Premise
-0.5 I-Premise
and I-Premise
-7.1 I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
and I-Premise
were I-Premise
-3.6 I-Premise
and I-Premise
-15.2 I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
at I-Premise
16 I-Premise
weeks I-Premise
for I-Premise
cetuximab I-Premise
and I-Premise
BSC I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Two O
hundred O
one O
( O
83.1 O
% O
) O
participants O
provided O
6-month O
follow-up O
data O
. O

Small B-Claim
effects I-Claim
were I-Claim
seen I-Claim
in I-Claim
some I-Claim
domains I-Claim
consistent I-Claim
with I-Claim
a I-Claim
minority I-Claim
of I-Claim
patients I-Claim
experiencing I-Claim
changes I-Claim
in I-Claim
QOL I-Claim
compatible I-Claim
with I-Claim
a I-Claim
reduction I-Claim
in I-Claim
estrogen I-Claim
synthesis I-Claim
. I-Claim

Seventy-two O
women O
were O
evaluable O
at O
the O
end O
of O
the O
study O
period O
. O

Embolization O
was O
performed O
in O
a O
standardized O
manner O
. O

Group B-Claim
CBT I-Claim
seems I-Claim
to I-Claim
be I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
treatment I-Claim
for I-Claim
women I-Claim
who I-Claim
have I-Claim
problematic I-Claim
HFNS I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
with I-Claim
additional I-Claim
benefits I-Claim
to I-Claim
mood I-Claim
, I-Claim
sleep I-Claim
, I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Avoiding B-Claim
axillary I-Claim
clearance I-Claim
for I-Claim
women I-Claim
> I-Claim
or I-Claim
= I-Claim
60 I-Claim
years I-Claim
old I-Claim
who I-Claim
have I-Claim
clinically I-Claim
node-negative I-Claim
disease I-Claim
and I-Claim
receive I-Claim
Tam I-Claim
for I-Claim
endocrine-responsive I-Claim
disease I-Claim
yields I-Claim
similar I-Claim
efficacy I-Claim
with I-Claim
better I-Claim
early I-Claim
QL I-Claim
. I-Claim

Adjuvant O
chemotherapy O
for O
early O
stage O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
is O
now O
the O
standard O
of O
care O
, O
but O
there O
is O
little O
information O
regarding O
its O
impact O
on O
quality O
of O
life O
( O
QOL O
) O
. O

This O
randomized O
trial O
demonstrates O
that O
ATP B-Claim
has I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
weight I-Claim
, I-Claim
muscle I-Claim
strength I-Claim
, I-Claim
and I-Claim
QOL I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Due O
to O
concerns O
of O
fragility O
fracture O
, O
exercise O
is O
a O
perceived O
contraindication O
for O
prostate O
cancer O
patients O
with O
bone O
metastases O
. O

Because O
neither O
clinical O
nor O
HRQOL O
outcomes O
differed O
based O
on O
the O
study O
arm O
, O
analyses O
were O
pooled O
. O

At O
six O
oncology O
clinics O
, O
physicians O
( O
N=22 O
) O
and O
nurses O
( O
N=23 O
) O
enrolled O
patients O
( O
N=93 O
) O
who O
were O
over O
18 O
years O
of O
age O
, O
with O
cancer O
diagnoses O
, O
pain O
, O
and O
a O
life O
expectancy O
of O
at O
least O
6 O
months O
. O

A B-Premise
significantly I-Premise
lower I-Premise
serum I-Premise
interleukin-6 I-Premise
level I-Premise
was I-Premise
found I-Premise
in I-Premise
comparing I-Premise
glutamine-enriched I-Premise
with I-Premise
standard I-Premise
TPN I-Premise
( I-Premise
P I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
but B-Premise
not I-Premise
in I-Premise
interleukin-10 I-Premise
( I-Premise
P I-Premise
= I-Premise
0.374 I-Premise
) I-Premise
and I-Premise
tumor I-Premise
necrosis I-Premise
factor-α I-Premise
levels I-Premise
( I-Premise
P I-Premise
= I-Premise
0.653 I-Premise
) I-Premise
. I-Premise

This B-Claim
study I-Claim
demonstrates I-Claim
the I-Claim
feasibility I-Claim
and I-Claim
effectiveness I-Claim
of I-Claim
a I-Claim
psycho-educational I-Claim
intervention I-Claim
, I-Claim
which I-Claim
can I-Claim
accelerate I-Claim
the I-Claim
reduction I-Claim
of I-Claim
those I-Claim
negative I-Claim
affects I-Claim
which I-Claim
are I-Claim
present I-Claim
at I-Claim
the I-Claim
end I-Claim
of I-Claim
treatment I-Claim
. I-Claim

Based O
on O
an O
intention O
to O
treat O
analysis O
, O
there O
was O
no O
statistically O
significant O
difference O
in O
the O
8-week O
lean O
body O
mass O
between O
the O
two O
arms O
. O

The O
program O
consisted O
of O
two O
90-minute O
group O
training O
sessions O
, O
a O
brief O
individual O
session O
, O
and O
3 O
follow-up O
telephone O
calls O
. O

Clinical O
examination O
and O
CA125 O
measurement O
were O
done O
every O
3 O
months O
. O

PVI B-Premise
5-FU I-Premise
+ I-Premise
MMC I-Premise
caused I-Premise
more I-Premise
overall I-Premise
haematological I-Premise
toxicity I-Premise
but I-Premise
CTC I-Premise
grades I-Premise
3/4 I-Premise
was I-Premise
increased I-Premise
only I-Premise
for I-Premise
thrombocytopaenia I-Premise
. I-Premise

The B-Premise
3-year I-Premise
overall I-Premise
survival I-Premise
for I-Premise
neoadjuvant I-Premise
versus I-Premise
control I-Premise
arm I-Premise
was I-Premise
94.1 I-Premise
% I-Premise
and I-Premise
67.7 I-Premise
% I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
= I-Premise
0.24 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.078 I-Premise
to I-Premise
0.73 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.012 I-Premise
) I-Premise
. I-Premise

Interestingly B-Claim
, I-Claim
the I-Claim
QOL I-Claim
response I-Claim
analysis I-Claim
also I-Claim
showed I-Claim
that I-Claim
aggressive I-Claim
premedication I-Claim
regimens I-Claim
appear I-Claim
to I-Claim
ameliorate I-Claim
potential I-Claim
negative I-Claim
effects I-Claim
of I-Claim
DPPE I-Claim
on I-Claim
emesis I-Claim
and I-Claim
nausea I-Claim
as I-Claim
measured I-Claim
by I-Claim
patient I-Claim
assessed I-Claim
QOL I-Claim
. I-Claim

The O
Wilcoxon O
rank O
sum O
test O
was O
used O
to O
compare O
summary O
scores O
between O
the O
two O
interventions O
. O

Two O
promising O
approaches O
to O
address O
this O
include O
dance/movement O
therapy O
and O
mindfulness O
. O

Thirty-one O
posttreatment O
cancer O
survivors O
were O
randomized O
in O
groups O
of O
seven O
to O
nine O
to O
either O
the O
8-week O
III O
+ O
ISG O
intervention O
or O
the O
8-week O
III O
condition O
. O

Intervention O
group O
patients O
received O
an O
individualized O
fatigue O
education O
and O
support O
program O
delivered O
in O
the O
clinic O
and O
by O
phone O
over O
three O
-10 O
to O
20-minute O
sessions O
1 O
week O
apart O
. O

Psychosocial O
stress O
was O
measured O
using O
the O
Symptoms O
Checklist-90-Revised O
, O
and O
quality O
of O
life O
was O
measured O
using O
the O
Medical O
Outcomes O
Study O
Short-Form O
Health O
Survey O
at O
baseline O
, O
immediately O
post-intervention O
, O
and O
at O
6 O
months O
. O

Methadone B-Claim
was I-Claim
significantly I-Claim
less I-Claim
expensive I-Claim
, I-Claim
but I-Claim
required I-Claim
more I-Claim
changes I-Claim
, I-Claim
up I-Claim
and I-Claim
down I-Claim
, I-Claim
of I-Claim
the I-Claim
doses I-Claim
, I-Claim
suggesting I-Claim
that I-Claim
dose I-Claim
titration I-Claim
of I-Claim
this I-Claim
drug I-Claim
requires I-Claim
major I-Claim
clinical I-Claim
expertise I-Claim
. I-Claim

Haemoglobin B-Premise
response I-Premise
( I-Premise
increase I-Premise
in I-Premise
Hb I-Premise
> I-Premise
or=2 I-Premise
g/dL I-Premise
from I-Premise
baseline I-Premise
) I-Premise
was I-Premise
observed I-Premise
in I-Premise
78.3 I-Premise
% I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
epoetin I-Premise
beta I-Premise
30,000 I-Premise
IU I-Premise
and I-Premise
66.7 I-Premise
% I-Premise
receiving I-Premise
epoetin I-Premise
beta I-Premise
20,000 I-Premise
IU I-Premise
. I-Premise

Complicated B-Premise
neutropenia I-Premise
was I-Premise
more I-Premise
frequent I-Premise
with I-Premise
DCF I-Premise
than I-Premise
CF I-Premise
( I-Premise
29 I-Premise
% I-Premise
v I-Premise
12 I-Premise
% I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3/4 I-Premise
neutropenia I-Premise
was I-Premise
frequent I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
although B-Premise
febrile I-Premise
neutropenia I-Premise
and I-Premise
infections I-Premise
were I-Premise
more I-Premise
frequent I-Premise
for I-Premise
patients I-Premise
taking I-Premise
AT I-Premise
( I-Premise
respectively I-Premise
, I-Premise
33 I-Premise
% I-Premise
v I-Premise
10 I-Premise
% I-Premise
, I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
8 I-Premise
% I-Premise
v I-Premise
2 I-Premise
% I-Premise
, I-Premise
P I-Premise
=.01 I-Premise
) I-Premise
. I-Premise

Limited O
data O
exist O
on O
the O
psychosocial O
aspects O
of O
the O
transitional O
period O
between O
the O
end O
of O
primary O
treatment O
and O
survivorship O
. O

Eighteen B-Premise
patients I-Premise
receiving I-Premise
IFN5 I-Premise
and I-Premise
4 I-Premise
patients I-Premise
receiving I-Premise
IFN1 I-Premise
had I-Premise
dose I-Premise
reductions I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

major O
cardiovascular O
disease O
, O
osteoporotic O
fractures O
, O
and O
breast O
cancer O
. O

Premenopausal O
women O
with O
breast O
cancer O
receiving O
adjuvant O
chemotherapy O
are O
at O
risk O
for O
amenorrhea O
. O

TCM B-Claim
therapy I-Claim
for I-Claim
removing I-Claim
toxic I-Claim
substance I-Claim
and I-Claim
unblocking I-Claim
meridians I-Claim
can I-Claim
improve I-Claim
the I-Claim
post-radiation I-Claim
QOL I-Claim
of I-Claim
patients I-Claim
with I-Claim
lung I-Claim
cancer I-Claim
to I-Claim
some I-Claim
extent I-Claim
. I-Claim

We O
studied O
the O
effect O
of O
a O
new O
bisphosphonate O
, O
zoledronic O
acid O
, O
which O
blocks O
bone O
destruction O
, O
on O
skeletal O
complications O
in O
prostate O
cancer O
patients O
with O
bone O
metastases O
. O

An O
historical O
control O
group O
( O
n O
= O
18 O
) O
without O
exercise O
was O
enrolled O
from O
breast O
cancer O
survivors O
. O

However B-Claim
, I-Claim
HRQoL I-Claim
is I-Claim
not I-Claim
compromised I-Claim
in I-Claim
the I-Claim
long I-Claim
term I-Claim
, I-Claim
recovering I-Claim
by I-Claim
the I-Claim
end-of-treatment I-Claim
visit I-Claim
to I-Claim
be I-Claim
comparable I-Claim
vs. I-Claim
MP I-Claim
. I-Claim

Subjects O
were O
randomized O
to O
receive O
either O
an O
individualized O
homeopathic O
single O
remedy O
, O
a O
homeopathic O
combination O
medicine O
, O
or O
placebo O
. O

Only B-Premise
the I-Premise
FACT-G I-Premise
social/family I-Premise
well-being I-Premise
subscale I-Premise
had I-Premise
no I-Premise
relationship I-Premise
with I-Premise
EQ-5D I-Premise
responses I-Premise
and I-Premise
utility I-Premise
scores I-Premise
. I-Premise

Ethics O
committee O
approval O
and O
informed O
consent O
were O
obtained O
for O
the O
Embolisation O
versus O
Hysterectomy O
Trial O
. O

The B-Claim
available I-Claim
data I-Claim
suggest I-Claim
a I-Claim
high I-Claim
probability I-Claim
of I-Claim
favourable I-Claim
cost-utility I-Claim
outcomes I-Claim
with I-Claim
epoetin-alfa I-Claim
treatment I-Claim
for I-Claim
anaemia I-Claim
in I-Claim
patients I-Claim
with I-Claim
stage I-Claim
IV I-Claim
breast I-Claim
cancer I-Claim
receiving I-Claim
nonplatinum-containing I-Claim
chemotherapy I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
vinorelbine I-Claim
plus I-Claim
gemcitabine I-Claim
is I-Claim
not I-Claim
more I-Claim
effective I-Claim
than I-Claim
single-agent I-Claim
vinorelbine I-Claim
or I-Claim
gemcitabine I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

To O
analyze O
the O
prospectively O
collected O
health-related O
quality-of-life O
( O
HRQOL O
) O
data O
from O
patients O
enrolled O
in O
two O
Radiation O
Therapy O
Oncology O
Group O
randomized O
Phase O
III O
head O
and O
neck O
cancer O
trials O
( O
90-03 O
and O
91-11 O
) O
to O
assess O
their O
value O
as O
an O
independent O
prognostic O
factor O
for O
locoregional O
control O
( O
LRC O
) O
and/or O
overall O
survival O
( O
OS O
) O
. O

Between O
1990 O
and O
1997 O
, O
714 O
patients O
with O
stage O
IC O
grade O
1 O
to O
2 O
or O
IB O
grade O
2 O
to O
3 O
EC O
were O
randomly O
allocated O
to O
pelvic O
external-beam O
radiotherapy O
( O
EBRT O
) O
or O
no O
additional O
treatment O
( O
NAT O
) O
. O

Further O
, O
cumulative B-Premise
survival I-Premise
rate I-Premise
was I-Premise
also I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
combined I-Premise
treatment I-Premise
group I-Premise
. I-Premise

Secondary O
end O
points O
included O
objective O
response O
rate O
, O
clinical O
benefit O
rate O
( O
CBR O
) O
, O
duration O
of O
clinical O
benefit O
( O
DoCB O
) O
, O
overall O
survival O
( O
OS O
) O
, O
and O
quality O
of O
life O
( O
QOL O
) O
. O

Improvements B-Premise
in I-Premise
absolute I-Premise
OS I-Premise
rates I-Premise
were I-Premise
10 I-Premise
% I-Premise
at I-Premise
6 I-Premise
months I-Premise
and I-Premise
15 I-Premise
% I-Premise
at I-Premise
12 I-Premise
months I-Premise
in I-Premise
the I-Premise
combination I-Premise
arm I-Premise
compared I-Premise
with I-Premise
the I-Premise
monotherapy I-Premise
arm I-Premise
. I-Premise

( O
600 O
mg/m O
( O
2 O
) O
day O
1-28 O
of O
a O
56-day O
cycle O
) O
for O
a O
maximum O
of O
12 O
cycles O
( O
i.v O
. O
) O

Le B-Claim
( I-Claim
y I-Claim
) I-Claim
is I-Claim
an I-Claim
attractive I-Claim
target I-Claim
since I-Claim
it I-Claim
is I-Claim
expressed I-Claim
by I-Claim
most I-Claim
NSCLC I-Claim
. I-Claim

Outcomes O
measured O
at O
baseline O
and O
weeks O
4 O
, O
27 O
, O
and O
52 O
included O
QOL O
( O
Linear O
Analogue O
Self-Assessment O
( O
LASA O
) O
, O
Functional O
Assessment O
of O
Cancer O
Therapy-General O
( O
FACT-G O
) O
) O
and O
mood O
( O
Profile O
of O
Mood O
States O
( O
POMS O
) O
) O
. O

The B-Premise
rate I-Premise
of I-Premise
endometrial I-Premise
cancer I-Premise
was I-Premise
increased I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
( I-Premise
risk I-Premise
ratio I-Premise
= I-Premise
2.53 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
= I-Premise
1.35-4.97 I-Premise
) I-Premise
";" I-Premise
this I-Premise
increased I-Premise
risk I-Premise
occurred I-Premise
predominantly I-Premise
in I-Premise
women I-Premise
aged I-Premise
50 I-Premise
years I-Premise
or I-Premise
older I-Premise
. I-Premise

Thirty-eight B-Premise
patients I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
and I-Premise
58 I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
, I-Premise
suffered I-Premise
breakthrough I-Premise
pain I-Premise
on I-Premise
day I-Premise
3 I-Premise
( I-Premise
P I-Premise
< I-Premise
0·001 I-Premise
) I-Premise
. I-Premise

Of O
1060 O
registered O
, O
the O
first O
300 O
consecutive O
patients O
were O
included O
in O
the O
current O
utility O
study O
. O

Wilcoxon O
test O
was O
used O
to O
analyse O
changes O
in O
IEF O
and O
in O
I-QoL O
score O
";" O
Fisher O
exact O
test O
was O
used O
to O
compare O
continent O
patients O
between O
the O
groups O
. O

Between O
May O
2003 O
and O
March O
2006 O
, O
107 O
patients O
were O
accrued O
";" O
46 O
had O
limited O
disease O
and O
61 O
extensive O
disease O
. O

We O
evaluated O
HRQOL O
with O
the O
EuroQol O
( O
EQ-5D™ O
) O
in O
patients O
with O
APC O
participating O
in O
Cancer O
and O
Leukemia O
Group O
B O
80303 O
, O
a O
multicenter O
, O
double-blind O
, O
randomized O
trial O
comparing O
overall O
survival O
( O
OS O
) O
between O
two O
treatment O
arms O
: O
gemcitabine O
with O
bevacizumab O
or O
gemcitabine O
with O
placebo O
. O

treosulfan O
for O
the O
treatment O
of O
relapsed O
ovarian O
carcinoma O
, O
women O
aged O
65 O
years O
or O
older O
were O
included O
in O
this O
prospective O
multicenter O
study O
. O

Although O
many O
drug O
combination O
therapies O
have O
been O
proposed O
, O
there B-Claim
is I-Claim
no I-Claim
standard I-Claim
therapy I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
carcinoma I-Claim
. I-Claim

All O
patients O
were O
given O
supportive O
treatment O
and O
were O
randomised O
to O
receive O
palliative O
thoracic O
radiotherapy O
either O
immediately O
or O
delayed O
until O
needed O
to O
treat O
symptoms O
. O

When B-Premise
evaluated I-Premise
with I-Premise
the I-Premise
EORTC I-Premise
questionnaire I-Premise
there I-Premise
was I-Premise
significantly I-Premise
less I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
( I-Premise
P=0.0001 I-Premise
) I-Premise
, I-Premise
appetite I-Premise
loss I-Premise
( I-Premise
P=0.01 I-Premise
) I-Premise
, I-Premise
insomnia I-Premise
( I-Premise
P=0.03 I-Premise
) I-Premise
, I-Premise
constipation I-Premise
( I-Premise
P=0.01 I-Premise
) I-Premise
and I-Premise
peripheral I-Premise
neuropathy I-Premise
( I-Premise
P=0.01 I-Premise
) I-Premise
in I-Premise
favour I-Premise
of I-Premise
MVC I-Premise
, I-Premise
and I-Premise
a I-Premise
trend I-Premise
for I-Premise
less I-Premise
hair I-Premise
loss I-Premise
( I-Premise
P=0.05 I-Premise
) I-Premise
. I-Premise

Time O
points O
were O
: O
baseline O
( O
prior O
to O
randomization O
) O
and O
prior O
to O
chemotherapy O
cycles O
2 O
, O
3 O
, O
and O
4 O
. O

At B-Premise
6 I-Premise
weeks I-Premise
, I-Premise
both I-Premise
groups I-Premise
showed I-Premise
improvement I-Premise
in I-Premise
several I-Premise
HQL I-Premise
domains I-Premise
, I-Premise
and O
only B-Premise
physical I-Premise
functioning I-Premise
and I-Premise
pain I-Premise
were I-Premise
better I-Premise
in I-Premise
the I-Premise
mitoxantrone-plus-prednisone I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
prednisone-alone I-Premise
group I-Premise
. I-Premise

All B-Premise
95 I-Premise
% I-Premise
confidence I-Premise
intervals I-Premise
for I-Premise
the I-Premise
differences I-Premise
were I-Premise
within I-Premise
±10 I-Premise
percentage I-Premise
points I-Premise
, I-Premise
indicating I-Premise
noninferiority I-Premise
. I-Premise

Patients O
completed O
the O
SWOG O
Quality O
of O
Life O
Questionnaire O
( O
emotional O
, O
physical O
, O
social O
, O
and O
role O
function O
";" O
general O
symptom O
status O
";" O
treatment/disease-specific O
symptoms O
";" O
and O
global O
HRQL O
[ O
GHRQL O
] O
) O
at O
baseline O
, O
6 O
weeks O
, O
6 O
months O
, O
and O
annually O
for O
5 O
years O
. O

Men B-Premise
with I-Premise
prostate I-Premise
cancer I-Premise
and I-Premise
their I-Premise
spouses I-Premise
reported I-Premise
positive I-Premise
outcomes I-Premise
from I-Premise
a I-Premise
family I-Premise
intervention I-Premise
that I-Premise
offered I-Premise
them I-Premise
information I-Premise
and I-Premise
support I-Premise
. I-Premise

Cosmetic B-Premise
results I-Premise
were I-Premise
better I-Premise
in I-Premise
those I-Premise
not I-Premise
receiving I-Premise
radiotherapy I-Premise
but B-Premise
this I-Premise
did I-Premise
not I-Premise
appear I-Premise
to I-Premise
be I-Premise
an I-Premise
important I-Premise
issue I-Premise
to I-Premise
the I-Premise
patients I-Premise
. I-Premise

Secondary O
end O
points O
were O
depressive O
symptoms O
and O
post-traumatic O
growth O
. O

Finally O
, O
change O
in O
self-efficacy O
for O
PA O
predicted O
PA O
at O
2-year O
follow-up O
. O

The O
two O
purposes O
of O
the O
study O
were O
to O
describe O
the O
effectiveness O
of O
the O
program O
and O
to O
obtain O
information O
about O
patient O
preferences O
for O
multi O
or O
mono O
dimensional O
rehabilitation O
programs O
. O

Conducted O
in O
small O
groups O
, O
intervention O
sessions O
were O
offered O
weekly O
for O
4 O
months O
and O
followed O
by O
monthly O
sessions O
for O
8 O
months O
. O

Overall O
response O
rate O
was O
34 O
% O
( O
95 O
% O
CL O
26-42 O
% O
) O
in O
the O
weekly O
VNR/CDDP O
arm O
, O
and O
32 O
% O
( O
95 O
% O
CL O
24-40 O
% O
) O
in O
patients O
treated O
with O
day O
1-8 O
VNR/CDDP O
without O
any O
statistically O
significant O
difference O
. O

However B-Claim
, I-Claim
the I-Claim
intervention I-Claim
was I-Claim
not I-Claim
found I-Claim
to I-Claim
reduce I-Claim
the I-Claim
risk I-Claim
of I-Claim
cancer I-Claim
recurrence I-Claim
and I-Claim
death I-Claim
. I-Claim

Patients O
with O
sentinel O
lymph O
node O
metastases O
proceeded O
to O
delayed O
axillary O
clearance O
or O
received O
axillary O
radiotherapy O
( O
depending O
on O
the O
protocol O
at O
the O
treating O
institution O
) O
. O

Treatment-induced O
arm O
lymphoedema O
is O
a O
common O
and O
distressing O
complication O
of O
curative O
surgery O
and O
radiotherapy O
for O
early O
breast O
cancer O
. O

Changes B-Premise
in I-Premise
resting I-Premise
energy I-Premise
expenditure I-Premise
and I-Premise
biochemical I-Premise
tests I-Premise
did I-Premise
not I-Premise
differ I-Premise
during I-Premise
follow-up I-Premise
among I-Premise
the I-Premise
groups I-Premise
. I-Premise

Compared B-Premise
with I-Premise
patients I-Premise
who I-Premise
were I-Premise
treated I-Premise
with I-Premise
standard I-Premise
chemotherapy I-Premise
, I-Premise
patients I-Premise
who I-Premise
were I-Premise
treated I-Premise
with I-Premise
capecitabine I-Premise
had I-Premise
significantly I-Premise
better I-Premise
QoL I-Premise
, I-Premise
role I-Premise
function I-Premise
, I-Premise
and I-Premise
social I-Premise
function I-Premise
, I-Premise
fewer I-Premise
systemic I-Premise
adverse I-Premise
effects I-Premise
, I-Premise
less I-Premise
psychological I-Premise
distress I-Premise
, I-Premise
and I-Premise
less I-Premise
fatigue I-Premise
during I-Premise
and I-Premise
at I-Premise
the I-Premise
completion I-Premise
of I-Premise
treatment I-Premise
( I-Premise
P I-Premise
≤ I-Premise
.005 I-Premise
) I-Premise
. I-Premise

Controls O
had O
no O
prophylactic O
exercises O
and O
were O
referred O
for O
swallowing O
treatment O
after O
completion O
of O
CRT O
if O
indicated O
. O

For O
NSCLC O
lung O
tumors O
≤ O
3 O
cm O
, O
a O
dose O
of O
48 O
Gy O
in O
4 O
fractions O
was O
used O
, O
otherwise O
52 O
Gy O
in O
4 O
fractions O
was O
delivered O
. O

At O
baseline O
and O
12 O
weeks O
, O
we O
used O
the O
Brief O
Fatigue O
Inventory O
( O
BFI O
) O
and O
Fatigue O
Severity O
Scale O
( O
FSS O
) O
as O
primary O
outcomes O
and O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
( O
HADS O
) O
and O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
for O
secondary O
outcomes O
. O

However O
, O
intraoperative B-Premise
blood I-Premise
loss I-Premise
and I-Premise
postoperative I-Premise
hospital I-Premise
stay I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
( I-Premise
Student I-Premise
t-test I-Premise
) I-Premise
. I-Premise

At B-Premise
first I-Premise
follow-up I-Premise
, I-Premise
groups I-Premise
differed I-Premise
only I-Premise
in I-Premise
social I-Premise
functioning I-Premise
, I-Premise
favouring I-Premise
the I-Premise
radiotherapy-only I-Premise
group I-Premise
( I-Premise
mean I-Premise
score I-Premise
79.0 I-Premise
[ I-Premise
SD I-Premise
3.2 I-Premise
] I-Premise
for I-Premise
patients I-Premise
assigned I-Premise
radiotherapy I-Premise
vs I-Premise
67.4 I-Premise
[ I-Premise
2.7 I-Premise
] I-Premise
for I-Premise
those I-Premise
assigned I-Premise
radiotherapy I-Premise
and I-Premise
temozolomide I-Premise
";" I-Premise
difference I-Premise
between I-Premise
groups I-Premise
11.6 I-Premise
points I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
3.5-19.7 I-Premise
] I-Premise
, I-Premise
p=0.0052 I-Premise
) I-Premise
. I-Premise

Patients O
with O
newly O
diagnosed O
early O
stage O
breast O
cancer O
were O
screened O
for O
depressive O
symptoms O
prior O
to O
the O
initiation O
of O
adjuvant O
therapy O
. O

Patients O
with O
lymphoma O
experience O
sleep O
problems O
that O
may O
be O
managed O
with O
aerobic O
exercise O
but O
no O
previous O
study O
has O
examined O
this O
issue O
. O

In B-Premise
response I-Premise
to I-Premise
training I-Premise
, I-Premise
QOL I-Premise
, I-Premise
VO2peak I-Premise
( I-Premise
mean I-Premise
3.9 I-Premise
ml/kg/min I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.93 I-Premise
, I-Premise
6.90 I-Premise
) I-Premise
performance I-Premise
in I-Premise
leg I-Premise
press I-Premise
( I-Premise
17.9 I-Premise
kg I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
12.8 I-Premise
, I-Premise
22.4 I-Premise
) I-Premise
and I-Premise
sit-stand I-Premise
test I-Premise
( I-Premise
- I-Premise
0.67 I-Premise
s I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
- I-Premise
0.52 I-Premise
, I-Premise
- I-Premise
1.2 I-Premise
) I-Premise
improved I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
survived I-Premise
longer I-Premise
than I-Premise
those I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
( I-Premise
1-year I-Premise
survival I-Premise
rate I-Premise
: I-Premise
40 I-Premise
% I-Premise
and I-Premise
29 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
median I-Premise
survival I-Premise
: I-Premise
10.5 I-Premise
and I-Premise
9.3 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
log-rank I-Premise
P I-Premise
=.0067 I-Premise
) I-Premise
. I-Premise

No B-Premise
difference I-Premise
in I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
detected I-Premise
( I-Premise
57 I-Premise
months I-Premise
for I-Premise
fludarabine I-Premise
v I-Premise
44 I-Premise
months I-Premise
for I-Premise
CVP I-Premise
";" I-Premise
P I-Premise
=.95 I-Premise
) I-Premise
. I-Premise

The B-Premise
embolization I-Premise
group I-Premise
had I-Premise
a I-Premise
shorter I-Premise
median I-Premise
duration I-Premise
of I-Premise
hospitalization I-Premise
than I-Premise
the I-Premise
surgical I-Premise
group I-Premise
( I-Premise
1 I-Premise
day I-Premise
vs. I-Premise
5 I-Premise
days I-Premise
, I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
a I-Premise
shorter I-Premise
time I-Premise
before I-Premise
returning I-Premise
to I-Premise
work I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

We O
performed O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
in O
2 O
tertiary O
referral O
centers O
. O

A O
response O
analysis O
compared O
the O
proportion O
of O
patients O
who O
demonstrated O
an O
important O
change O
in O
QOL O
. O

Letrozole B-Claim
did I-Claim
not I-Claim
have I-Claim
an I-Claim
adverse I-Claim
impact I-Claim
on I-Claim
overall I-Claim
QOL I-Claim
. I-Claim

Tertiary O
care O
, O
academic O
medical O
center O
. O

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
more I-Premise
than I-Premise
3 I-Premise
years I-Premise
, I-Premise
survival I-Premise
did I-Premise
not I-Premise
differ I-Premise
among I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
median I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
, I-Premise
11.1 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
10.2 I-Premise
to I-Premise
15.0 I-Premise
months I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
, I-Premise
13.0 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
10.4 I-Premise
to I-Premise
15.4 I-Premise
months I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
, I-Premise
13.7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
12.0 I-Premise
to I-Premise
16.4 I-Premise
months I-Premise
] I-Premise
";" I-Premise
P I-Premise
=.724 I-Premise
) I-Premise
. I-Premise

Pemetrexed O
maintenance O
therapy O
significantly O
improved O
overall O
survival O
and O
progression-free O
survival O
compared O
with O
placebo O
, O
and O
had O
a O
good O
safety O
profile O
in O
a O
phase O
3 O
placebo-controlled O
study O
in O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

One O
hundred O
twenty-six O
patients O
referred O
for O
resection O
of O
the O
esophagus O
( O
n O
= O
48 O
) O
, O
stomach O
( O
n O
= O
28 O
) O
, O
or O
pancreas O
( O
n O
= O
50 O
) O
were O
considered O
to O
be O
included O
before O
operation O
. O

The B-Claim
ADA I-Claim
MNT I-Claim
protocol I-Claim
for I-Claim
radiation I-Claim
oncology I-Claim
is I-Claim
a I-Claim
useful I-Claim
guide I-Claim
to I-Claim
the I-Claim
level I-Claim
of I-Claim
nutrition I-Claim
support I-Claim
required I-Claim
. I-Claim

To O
compare O
dose-volume O
histogram O
variables O
for O
the O
internal O
and O
external O
urinary O
sphincters O
( O
IUS/EUS O
) O
with O
urinary O
quality O
of O
life O
after O
prostate O
brachytherapy O
. O

Although B-Premise
the I-Premise
intervention I-Premise
simultaneously I-Premise
improved I-Premise
patients I-Premise
' I-Premise
T-cell I-Premise
blastogenesis I-Premise
in I-Premise
response I-Premise
to I-Premise
phytohemagglutinin I-Premise
( I-Premise
PHA I-Premise
) I-Premise
, I-Premise
the B-Premise
latter I-Premise
increases I-Premise
were I-Premise
unrelated I-Premise
to I-Premise
improved I-Premise
health I-Premise
. I-Premise

An B-Premise
objective I-Premise
response I-Premise
( I-Premise
complete I-Premise
[ I-Premise
CR I-Premise
] I-Premise
or I-Premise
partial I-Premise
[ I-Premise
PR I-Premise
] I-Premise
) I-Premise
was I-Premise
obtained I-Premise
in I-Premise
55 I-Premise
% I-Premise
, I-Premise
48 I-Premise
% I-Premise
, I-Premise
16 I-Premise
% I-Premise
, I-Premise
and I-Premise
7 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
CEF I-Premise
, I-Premise
E I-Premise
, I-Premise
M I-Premise
, I-Premise
and I-Premise
MV I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Menopausal B-Claim
symptoms I-Claim
( I-Claim
e.g. I-Claim
, I-Claim
hot I-Claim
flashes I-Claim
, I-Claim
vaginal I-Claim
dryness I-Claim
, I-Claim
and I-Claim
stress I-Claim
urinary I-Claim
incontinence I-Claim
) I-Claim
are I-Claim
very I-Claim
common I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
and I-Claim
can I-Claim
not I-Claim
be I-Claim
managed I-Claim
with I-Claim
standard I-Claim
estrogen I-Claim
replacement I-Claim
therapy I-Claim
( I-Claim
ERT I-Claim
) I-Claim
in I-Claim
these I-Claim
patients I-Claim
. I-Claim

Patients O
, O
and O
investigators O
undertaking O
interventions O
, O
assessing O
outcomes O
, O
and O
analysing O
data O
, O
were O
not O
masked O
to O
group O
assignment O
. O

Objective B-Premise
response I-Premise
rates I-Premise
were I-Premise
66.7 I-Premise
% I-Premise
for I-Premise
patients I-Premise
in I-Premise
the I-Premise
high-dose I-Premise
group I-Premise
and I-Premise
64.4 I-Premise
% I-Premise
for I-Premise
patients I-Premise
in I-Premise
the I-Premise
AT I-Premise
arm I-Premise
( I-Premise
P I-Premise
= I-Premise
.82 I-Premise
) I-Premise
. I-Premise

bolus O
( O
arm O
A O
) O
";" O
TOM O
, O
3 O
mg/m2 O
i.v O
. O

On B-Claim
the I-Claim
basis I-Claim
of I-Claim
these I-Claim
findings I-Claim
, I-Claim
the I-Claim
policy I-Claim
of I-Claim
EOF I-Claim
should I-Claim
be I-Claim
used I-Claim
after I-Claim
a I-Claim
complex I-Claim
gynecologic I-Claim
oncologic I-Claim
laparotomy I-Claim
. I-Claim

IMRT B-Claim
was I-Claim
significantly I-Claim
better I-Claim
than I-Claim
CRT I-Claim
in I-Claim
terms I-Claim
of I-Claim
parotid I-Claim
sparing I-Claim
and I-Claim
improved I-Claim
QoL I-Claim
for I-Claim
early-stage I-Claim
disease I-Claim
. I-Claim

The B-Claim
findings I-Claim
of I-Claim
this I-Claim
trial I-Claim
indicate I-Claim
that I-Claim
the I-Claim
negative I-Claim
effects I-Claim
of I-Claim
adjuvant I-Claim
chemotherapy I-Claim
on I-Claim
QOL I-Claim
appear I-Claim
to I-Claim
be I-Claim
temporary I-Claim
, I-Claim
and I-Claim
that I-Claim
improvements I-Claim
( I-Claim
with I-Claim
a I-Claim
return I-Claim
to I-Claim
baseline I-Claim
function I-Claim
) I-Claim
are I-Claim
likely I-Claim
in I-Claim
most I-Claim
patients I-Claim
. I-Claim

Between O
May O
2002 O
and O
January O
2005 O
, O
533 O
patients O
were O
randomly O
assigned O
to O
GEM O
( O
n O
= O
266 O
) O
and O
GEM-CAP O
( O
n O
= O
267 O
) O
arms O
. O

QOL B-Claim
was I-Claim
similar I-Claim
for I-Claim
both I-Claim
arms I-Claim
. I-Claim

The O
primary O
endpoints O
were O
the O
differences O
in O
double O
endometrial O
thickness O
and O
uterine O
volume O
after O
1 O
year O
. O

With B-Premise
regard I-Premise
to I-Premise
the I-Premise
long-term I-Premise
quality I-Premise
of I-Premise
life I-Premise
there I-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

Elbow B-Premise
flexor I-Premise
muscle I-Premise
strength I-Premise
declined I-Premise
by I-Premise
-5.5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-9.6 I-Premise
% I-Premise
to I-Premise
-1 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
per I-Premise
4 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
but I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0.0 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI= I-Premise
-1.4 I-Premise
% I-Premise
to I-Premise
+1.4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
( I-Premise
P I-Premise
=.01 I-Premise
) I-Premise
. I-Premise

Pain B-Premise
decreased I-Premise
faster I-Premise
for I-Premise
HBO-treated I-Premise
subjects I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
, I-Premise
linear I-Premise
regression I-Premise
) I-Premise
. I-Premise

No O
prospective O
comparison O
with O
nitrosourea-based O
chemotherapy O
exists O
. O

One O
hundred O
patients O
with O
mild-moderate O
pain O
were O
randomized O
to O
treatment O
according O
to O
WHO O
guidelines O
or O
to O
treatment O
with O
strong O
opioids O
. O

A O
randomised O
controlled O
clinical O
trial O
, O
using O
a O
method O
of O
minimisation O
balanced O
by O
centre O
, O
grade O
of O
cancer O
, O
age O
, O
lymphatic/vascular O
invasion O
and O
preoperative O
endocrine O
therapy O
, O
was O
performed O
. O

ALT B-Premise
had I-Premise
a I-Premise
positive I-Premise
, I-Premise
statistically I-Premise
and I-Premise
clinically I-Premise
significant I-Premise
immediate I-Premise
effect I-Premise
on I-Premise
limb I-Premise
volume I-Premise
but B-Premise
no I-Premise
long-term I-Premise
effect I-Premise
was I-Premise
noted I-Premise
. I-Premise

For B-Claim
men I-Claim
with I-Claim
localised I-Claim
prostate I-Claim
cancer I-Claim
, I-Claim
surgery I-Claim
provides I-Claim
a I-Claim
survival I-Claim
benefit I-Claim
compared I-Claim
with I-Claim
watchful I-Claim
waiting I-Claim
. I-Claim

Tamoxifen B-Premise
administration I-Premise
did I-Premise
not I-Premise
alter I-Premise
the I-Premise
average I-Premise
annual I-Premise
rate I-Premise
of I-Premise
ischemic I-Premise
heart I-Premise
disease I-Premise
";" I-Premise
however I-Premise
, I-Premise
a I-Premise
reduction I-Premise
in I-Premise
hip I-Premise
, I-Premise
radius I-Premise
( I-Premise
Colles I-Premise
' I-Premise
) I-Premise
, I-Premise
and I-Premise
spine I-Premise
fractures I-Premise
was I-Premise
observed I-Premise
. I-Premise

Women O
enrolled O
in O
the O
study O
intervention O
were O
on O
average O
55 O
years O
old O
, O
predominantly O
Caucasian O
( O
79 O
% O
) O
, O
married O
( O
57 O
% O
) O
, O
and O
a O
median O
of O
4 O
years O
postprimary O
treatment O
. O

After B-Premise
the I-Premise
first I-Premise
year I-Premise
of I-Premise
follow-up I-Premise
, I-Premise
14 I-Premise
women I-Premise
in I-Premise
the I-Premise
embolization I-Premise
group I-Premise
( I-Premise
13 I-Premise
% I-Premise
) I-Premise
required I-Premise
hospitalization I-Premise
, I-Premise
3 I-Premise
of I-Premise
them I-Premise
for I-Premise
major I-Premise
adverse I-Premise
events I-Premise
and I-Premise
11 I-Premise
for I-Premise
reintervention I-Premise
for I-Premise
treatment I-Premise
failure I-Premise
. I-Premise

Survival B-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
paclitaxel I-Premise
plus I-Premise
supportive I-Premise
care I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
supportive I-Premise
care I-Premise
alone I-Premise
arm I-Premise
( I-Premise
two-sided I-Premise
P I-Premise
=.037 I-Premise
) I-Premise
( I-Premise
median I-Premise
survival I-Premise
= I-Premise
6.8 I-Premise
months I-Premise
versus I-Premise
4.8 I-Premise
months I-Premise
) I-Premise
. I-Premise

Secondary O
end O
points O
included O
severity O
and O
duration O
of O
mucositis O
, O
pain O
measurement O
, O
radiation O
therapy O
interruption O
, O
and O
quality O
of O
life O
. O

The O
primary O
endpoint O
was O
survival O
, O
and O
HRQOL O
was O
a O
secondary O
endpoint O
. O

Furthermore B-Premise
, I-Premise
letrozole I-Premise
significantly I-Premise
improved I-Premise
distant I-Premise
DFS I-Premise
( I-Premise
HR=0.60 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.43 I-Premise
, I-Premise
0.84 I-Premise
";" I-Premise
P=0.002 I-Premise
) I-Premise
and I-Premise
, I-Premise
in I-Premise
women I-Premise
with I-Premise
node-positive I-Premise
tumors I-Premise
, I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HR=0.61 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.38 I-Premise
, I-Premise
0.98 I-Premise
";" I-Premise
P=0.04 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
had I-Premise
significant I-Premise
concerns I-Premise
about I-Premise
the I-Premise
delivery I-Premise
of I-Premise
radiotherapy I-Premise
services I-Premise
, I-Premise
such I-Premise
as I-Premise
transport I-Premise
, I-Premise
accommodation I-Premise
and I-Premise
travel I-Premise
costs I-Premise
associated I-Premise
with I-Premise
receiving I-Premise
radiotherapy I-Premise
. I-Premise

Group-wise O
randomization O
was O
implemented O
by O
assigning O
one O
half O
of O
the O
patients O
to O
the O
complete O
program O
while O
the O
other O
half O
were O
allowed O
to O
choose O
which O
program O
components O
they O
considered O
relevant O
. O

We O
designed O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
misoprostol O
in O
patients O
with O
head O
and O
neck O
cancer O
. O

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
more I-Premise
treatment I-Premise
cycles I-Premise
with I-Premise
docetaxel I-Premise
( I-Premise
TC I-Premise
, I-Premise
49 I-Premise
% I-Premise
";" I-Premise
TCF I-Premise
, I-Premise
57 I-Premise
% I-Premise
";" I-Premise
ECF I-Premise
, I-Premise
34 I-Premise
% I-Premise
) I-Premise
. I-Premise

This O
study O
included O
three O
groups O
of O
patients O
, O
enrolled O
consecutively O
. O

Results B-Premise
indicated I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
for I-Premise
4 I-Premise
of I-Premise
the I-Premise
6 I-Premise
quality I-Premise
of I-Premise
life I-Premise
measures I-Premise
: I-Premise
anxiety I-Premise
( I-Premise
p I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
perception I-Premise
of I-Premise
hospitalization I-Premise
( I-Premise
p I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
relaxation I-Premise
( I-Premise
p I-Premise
= I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
stress I-Premise
( I-Premise
p I-Premise
= I-Premise
.001 I-Premise
) I-Premise
. I-Premise

QoL O
was O
assessed O
in O
350 O
patients O
randomly O
assigned O
to O
either O
standard O
chemotherapy O
( O
cyclophosphamide O
, O
methotrexate O
, O
and O
fluorouracil O
[ O
CMF O
] O
or O
doxorubicin O
and O
cyclophosphamide O
[ O
AC O
] O
";" O
n O
= O
182 O
) O
or O
capecitabine O
( O
n O
= O
168 O
) O
. O

Symptom B-Premise
distress I-Premise
was I-Premise
significantly I-Premise
worse I-Premise
for I-Premise
the I-Premise
RP+RT I-Premise
arm I-Premise
compared I-Premise
with I-Premise
the I-Premise
RP I-Premise
alone I-Premise
arm I-Premise
, O
but B-Premise
the I-Premise
treatment I-Premise
arms I-Premise
did I-Premise
not I-Premise
differ I-Premise
with I-Premise
respect I-Premise
to I-Premise
other I-Premise
general I-Premise
measures I-Premise
of I-Premise
HRQL I-Premise
. I-Premise

This O
randomized O
, O
phase O
II O
trial O
compared O
bevacizumab O
plus O
fluorouracil O
and O
leucovorin O
( O
FU/LV O
) O
versus O
placebo O
plus O
FU/LV O
as O
first-line O
therapy O
in O
patients O
considered O
nonoptimal O
candidates O
for O
first-line O
irinotecan O
. O

A O
total O
of O
513 O
patients O
were O
enrolled O
when O
a O
planned O
interim O
analysis O
recommended O
early O
closure O
for O
futility O
. O

Thus B-Claim
, I-Claim
funds I-Claim
permitting I-Claim
, I-Claim
oral I-Claim
Etoposide I-Claim
is I-Claim
a I-Claim
pragmatic I-Claim
approach I-Claim
to I-Claim
treating I-Claim
EKS I-Claim
in I-Claim
an I-Claim
environment I-Claim
where I-Claim
antiretroviral I-Claim
drugs I-Claim
are I-Claim
not I-Claim
universally I-Claim
available I-Claim
. I-Claim

A O
total O
of O
724 O
patients O
( O
51 O
% O
with O
limited O
and O
49 O
% O
with O
extensive O
disease O
) O
were O
randomly O
assigned O
to O
receive O
placebo O
or O
thalidomide O
capsules O
, O
100-200 O
mg O
daily O
for O
up O
to O
2 O
years O
. O

However O
, O
it O
is O
unclear O
whether O
or O
not O
this O
administration O
method O
can O
improve O
the O
patients O
' O
quality O
of O
life O
( O
QOL O
) O
. O

Occurrence B-Premise
of I-Premise
grade I-Premise
3 I-Premise
and I-Premise
4 I-Premise
diarrhea I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
arm I-Premise
( I-Premise
22 I-Premise
% I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
FU24h I-Premise
( I-Premise
6 I-Premise
% I-Premise
) I-Premise
or I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
arms I-Premise
";" I-Premise
however B-Premise
, I-Premise
stomatitis I-Premise
( I-Premise
11 I-Premise
% I-Premise
in I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
v I-Premise
3 I-Premise
% I-Premise
in I-Premise
FU24h I-Premise
v I-Premise
5 I-Premise
% I-Premise
in I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
arms I-Premise
) I-Premise
and I-Premise
hematologic I-Premise
toxicity I-Premise
were I-Premise
higher I-Premise
in I-Premise
the I-Premise
bolus I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
arm I-Premise
. I-Premise

Data O
collection O
occurred O
at O
baseline O
before O
randomization O
and O
at O
4 O
months O
, O
8 O
months O
, O
and O
12 O
months O
. O

Treatment B-Claim
with I-Claim
MEV I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
demonstrated I-Claim
clinical I-Claim
activity I-Claim
in I-Claim
patients I-Claim
with I-Claim
CRPC I-Claim
. I-Claim

However B-Claim
, I-Claim
this I-Claim
combined I-Claim
treatment I-Claim
did I-Claim
not I-Claim
confer I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
treatment I-Claim
with I-Claim
continuous I-Claim
infusion I-Claim
of I-Claim
5-FU I-Claim
alone I-Claim
for I-Claim
patients I-Claim
with I-Claim
far-advanced I-Claim
CRC I-Claim
";" I-Claim
that I-Claim
might I-Claim
be I-Claim
attributable I-Claim
to I-Claim
the I-Claim
short I-Claim
CDDP I-Claim
administration I-Claim
setting I-Claim
of I-Claim
12 I-Claim
weeks I-Claim
. I-Claim

Patients B-Premise
in I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
reported I-Premise
better I-Premise
overall I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
symptom I-Premise
control I-Premise
compared I-Premise
with I-Premise
the I-Premise
supportive I-Premise
care I-Premise
group I-Premise
. I-Premise

55.6 B-Premise
% I-Premise
patients I-Premise
treated I-Premise
over I-Premise
4 I-Premise
days I-Premise
and I-Premise
33.3 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
over I-Premise
11 I-Premise
days I-Premise
experienced I-Premise
acute I-Premise
grade I-Premise
≥ I-Premise
2 I-Premise
toxicity I-Premise
( I-Premise
p=0.085 I-Premise
) I-Premise
. I-Premise

The B-Premise
response I-Premise
rates I-Premise
in I-Premise
the I-Premise
subgroup I-Premise
of I-Premise
patients I-Premise
with I-Premise
measurable I-Premise
disease I-Premise
were I-Premise
12 I-Premise
% I-Premise
, I-Premise
10 I-Premise
% I-Premise
, I-Premise
and I-Premise
17 I-Premise
% I-Premise
for I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
, I-Premise
FU24h I-Premise
, I-Premise
and I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
, I-Premise
respectively I-Premise
( I-Premise
not I-Premise
significant I-Premise
) I-Premise
. I-Premise

This O
double-blind O
phase O
III O
trial O
randomly O
assigned O
731 O
patients O
with O
NSCLC O
who O
had O
progressed O
after O
prior O
chemotherapy O
to O
erlotinib O
150 O
mg O
daily O
or O
placebo O
, O
with O
survival O
as O
the O
primary O
study O
outcome O
. O

Studies O
on O
quality O
of O
life O
( O
QOL O
) O
among O
women O
with O
endometrial O
cancer O
have O
shown O
that O
patients O
who O
undergo O
pelvic O
radiotherapy O
report O
lower O
role O
functioning O
and O
more O
diarrhea O
and O
fatigue O
. O

This O
study O
examined O
the O
characteristics O
of O
women O
enrolled O
in O
an O
intervention O
trial O
to O
treat O
sexual O
dysfunction O
, O
and O
explored O
the O
relationship O
between O
sexual O
functioning O
and O
psychological O
well-being O
. O

Patients O
were O
randomly O
assigned O
to O
intervention O
( O
regular O
completion O
of O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire-Core O
30 O
and O
Hospital O
Anxiety O
and O
Depression O
Scale O
with O
feedback O
to O
oncologists O
) O
, O
attention-control O
( O
completion O
of O
same O
questionnaires O
without O
feedback O
) O
, O
and O
control O
( O
standard O
care O
) O
arms O
. O

CBT B-Claim
and I-Claim
PE I-Claim
can I-Claim
have I-Claim
salutary I-Claim
effects I-Claim
on I-Claim
endocrine I-Claim
symptoms I-Claim
and I-Claim
, I-Claim
to I-Claim
a I-Claim
lesser I-Claim
degree I-Claim
, I-Claim
on I-Claim
sexuality I-Claim
and I-Claim
physical I-Claim
functioning I-Claim
of I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
experiencing I-Claim
treatment-induced I-Claim
menopause I-Claim
. I-Claim

The O
purpose O
of O
this O
article O
is O
to O
compare O
quality O
of O
life O
( O
QOL O
) O
and O
menopausal O
symptoms O
among O
premenopausal O
patients O
with O
lymph O
node-negative O
breast O
cancer O
receiving O
chemotherapy O
, O
goserelin O
, O
or O
their O
sequential O
combination O
, O
and O
to O
investigate O
differential O
effects O
by O
age O
. O

Vinorelbine B-Claim
prolongs I-Claim
survival I-Claim
and I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

Twenty-four O
mentors O
at O
Mayo O
Clinic O
in O
Rochester O
, O
Minnesota O
, O
were O
randomized O
in O
a O
single-blind O
, O
wait-list O
controlled O
clinical O
trial O
to O
either O
the O
SMART O
intervention O
or O
a O
control O
group O
for O
12 O
weeks O
. O

Postoperatively O
, O
body O
mass O
index O
( O
BMI O
) O
and O
nutritional O
conditions O
were O
measured O
serially O
, O
and O
QOL O
and O
postoperative O
squalor O
scores O
were O
evaluated O
at O
3 O
, O
12 O
, O
and O
60 O
months O
and O
compared O
between O
the O
2 O
groups O
. O

Based B-Premise
on I-Premise
the I-Premise
results I-Premise
of I-Premise
the I-Premise
area I-Premise
under I-Premise
the I-Premise
curve I-Premise
( I-Premise
AUC I-Premise
) I-Premise
analysis I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
HMB/Arg/Gln I-Premise
had I-Premise
a I-Premise
strong I-Premise
trend I-Premise
higher I-Premise
LBM I-Premise
throughout I-Premise
the I-Premise
study I-Premise
as I-Premise
measured I-Premise
by I-Premise
both I-Premise
bioimpedance I-Premise
( I-Premise
p I-Premise
= I-Premise
0.08 I-Premise
) I-Premise
and I-Premise
skin-fold I-Premise
measurements I-Premise
( I-Premise
p I-Premise
= I-Premise
0.08 I-Premise
) I-Premise
. I-Premise

Trends B-Premise
observed I-Premise
for I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
were I-Premise
similar I-Premise
. I-Premise

The B-Premise
change I-Premise
in I-Premise
physical I-Premise
function I-Premise
( I-Premise
muscle I-Premise
strength I-Premise
∼11 I-Premise
% I-Premise
";" I-Premise
submaximal I-Premise
aerobic I-Premise
exercise I-Premise
capacity I-Premise
∼5 I-Premise
% I-Premise
and I-Premise
ambulation I-Premise
∼12 I-Premise
% I-Premise
) I-Premise
, I-Premise
physical I-Premise
activity I-Premise
level I-Premise
( I-Premise
∼24 I-Premise
% I-Premise
) I-Premise
and I-Premise
lean I-Premise
mass I-Premise
( I-Premise
∼3 I-Premise
% I-Premise
) I-Premise
differed I-Premise
significantly I-Premise
between I-Premise
groups I-Premise
following I-Premise
the I-Premise
intervention I-Premise
, I-Premise
with I-Premise
favorable I-Premise
changes I-Premise
in I-Premise
the I-Premise
exercise I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
. I-Premise

Meta-analysis O
of O
published O
studies O
was O
also O
conducted O
. O

The B-Premise
intervention I-Premise
demonstrated I-Premise
a I-Premise
trend I-Premise
toward I-Premise
improved I-Premise
CRF I-Premise
, I-Premise
although B-Premise
this I-Premise
effect I-Premise
was I-Premise
reduced I-Premise
once I-Premise
confounders I-Premise
had I-Premise
been I-Premise
controlled I-Premise
statistically I-Premise
. I-Premise

The O
purpose O
of O
this O
analysis O
was O
to O
assess O
the O
impact O
of O
pretreatment O
factors O
on O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
locally O
advanced O
nonsmall O
cell O
lung O
cancer O
( O
NSCLC O
) O
. O

317 O
patients O
( O
218 O
from O
the O
abatacept O
and O
99 O
from O
the O
placebo O
group O
) O
entered O
and O
222 O
( O
70 O
% O
) O
completed O
18 O
months O
of O
long-term O
extension O
treatment O
. O

Patients O
14 O
to O
70 O
years O
of O
age O
with O
newly O
diagnosed O
GBM O
and O
Karnofsky O
Performance O
Scale O
( O
KPS O
) O
score O
> O
70 O
who O
were O
receiving O
initial O
treatment O
were O
enrolled O
and O
were O
randomized O
into O
2 O
groups O
during O
the O
5-year O
study O
period O
. O

Resilience O
, O
perceived O
stress O
, O
anxiety O
, O
and O
quality O
of O
life O
improved O
at O
12 O
weeks O
in O
the O
active O
but O
not O
the O
control O
arm O
. O

Response B-Premise
rates I-Premise
were I-Premise
55 I-Premise
% I-Premise
with I-Premise
gefitinib I-Premise
and I-Premise
46 I-Premise
% I-Premise
with I-Premise
GP I-Premise
( I-Premise
P I-Premise
= I-Premise
.101 I-Premise
) I-Premise
. I-Premise

This B-Claim
trial I-Claim
was I-Claim
unable I-Claim
to I-Claim
adequately I-Claim
test I-Claim
the I-Claim
ability I-Claim
of I-Claim
beta-hydroxy I-Claim
beta-methylbutyrate I-Claim
, I-Claim
glutamine I-Claim
, I-Claim
and I-Claim
arginine I-Claim
to I-Claim
reverse I-Claim
or I-Claim
prevent I-Claim
lean I-Claim
body I-Claim
mass I-Claim
wasting I-Claim
among I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Toxicity B-Premise
was I-Premise
mild I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

HEC O
participants O
received O
nutritional O
information O
and O
equal O
attention O
. O

Response B-Premise
rates I-Premise
were I-Premise
also I-Premise
significantly I-Premise
improved I-Premise
with I-Premise
docetaxel I-Premise
versus I-Premise
vinorelbine I-Premise
( I-Premise
22.7 I-Premise
% I-Premise
v I-Premise
9.9 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.019 I-Premise
) I-Premise
. I-Premise

The B-Claim
CLIP I-Claim
score I-Claim
seems I-Claim
to I-Claim
predict I-Claim
survival I-Claim
better I-Claim
than I-Claim
both I-Claim
Okuda I-Claim
and I-Claim
CTP I-Claim
score I-Claim
. I-Claim

The B-Premise
median I-Premise
OS I-Premise
for I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
was I-Premise
31.9 I-Premise
months I-Premise
and I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
was I-Premise
15.0 I-Premise
months I-Premise
( I-Premise
P I-Premise
< I-Premise
0.002 I-Premise
) I-Premise
. I-Premise

A O
randomized O
controlled O
trial O
previously O
conducted O
in O
radiation O
oncology O
patients O
demonstrated O
that O
nutrition O
intervention O
had O
a O
beneficial O
impact O
on O
body O
weight O
, O
nutritional O
status O
, O
and O
quality O
of O
life O
compared O
with O
standard O
practice O
, O
but O
it O
did O
not O
report O
on O
dietary O
intake O
data O
. O

No B-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
groups I-Premise
were I-Premise
evident I-Premise
with I-Premise
respect I-Premise
to I-Premise
quality I-Premise
of I-Premise
life I-Premise
according I-Premise
to I-Premise
the I-Premise
EORTC I-Premise
QLQ-protocol I-Premise
. I-Premise

At B-Claim
the I-Claim
end I-Claim
of I-Claim
primary I-Claim
treatment I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
women I-Claim
in I-Claim
all I-Claim
treatment I-Claim
groups I-Claim
report I-Claim
good I-Claim
emotional I-Claim
functioning I-Claim
but I-Claim
report I-Claim
decreased I-Claim
physical I-Claim
functioning I-Claim
, I-Claim
particularly I-Claim
among I-Claim
women I-Claim
who I-Claim
have I-Claim
a I-Claim
mastectomy I-Claim
or I-Claim
receive I-Claim
chemotherapy I-Claim
. I-Claim

Clinically B-Premise
relevant I-Premise
improvements I-Premise
in I-Premise
symptoms I-Premise
and I-Premise
mood I-Premise
disturbance I-Premise
were I-Premise
seen I-Premise
for I-Premise
both I-Premise
groups I-Premise
over I-Premise
the I-Premise
study I-Premise
period I-Premise
. I-Premise

When B-Premise
the I-Premise
two I-Premise
exercise I-Premise
groups I-Premise
were I-Premise
compared I-Premise
, I-Premise
there I-Premise
were I-Premise
significant I-Premise
differences I-Premise
in I-Premise
6MWT I-Premise
in I-Premise
pilates-exercise I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

The O
aim O
of O
this O
trial O
was O
to O
determine O
the O
value O
of O
thymidylate O
synthase O
( O
TS O
) O
, O
a O
key O
enzyme O
of O
DNA O
synthesis O
and O
target O
of O
5-FU O
, O
to O
predict O
response O
to O
chemotherapy O
of O
mCRC O
. O

Although O
capecitabine B-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
QoL I-Claim
during I-Claim
treatment I-Claim
, O
QoL B-Premise
was I-Premise
similar I-Premise
for I-Premise
both I-Premise
groups I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

These B-Claim
data I-Claim
suggest I-Claim
that I-Claim
epoetin I-Claim
alfa I-Claim
may I-Claim
have I-Claim
attenuated I-Claim
the I-Claim
cognitive I-Claim
impairment I-Claim
and I-Claim
fatigue I-Claim
that I-Claim
occurred I-Claim
during I-Claim
adjuvant I-Claim
breast I-Claim
cancer I-Claim
chemotherapy I-Claim
. I-Claim

The B-Premise
analysis I-Premise
of I-Premise
quality I-Premise
of I-Premise
live I-Premise
assessment I-Premise
showed I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
after I-Premise
treatment I-Premise
in I-Premise
patients I-Premise
with I-Premise
resectable I-Premise
pancreatic I-Premise
cancer I-Premise
and I-Premise
treated I-Premise
with I-Premise
radiotherapy I-Premise
and I-Premise
gemcitabine I-Premise
. I-Premise

Of O
260 O
eligible O
patients O
, O
104 O
( O
40 O
% O
) O
agreed O
to O
participate O
, O
and O
93 O
were O
randomised O
. O

After O
six O
cycles O
patients O
with O
limited O
disease O
in O
complete O
or O
partial O
remission O
and O
those O
with O
extensive O
disease O
in O
complete O
remission O
received O
irradiation O
to O
the O
primary O
( O
45 O
Gy O
) O
and O
the O
CNS O
( O
36 O
Gy O
) O
. O

Hormone O
replacement O
therapy O
is O
contraindicated O
in O
patients O
with O
breast O
cancer O
. O

Endpoints O
were O
overall O
survival O
, O
progression-free O
survival O
, O
tumor O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
QoL O
) O
. O

Using B-Claim
video I-Claim
and I-Claim
print I-Claim
materials I-Claim
, I-Claim
with I-Claim
brief I-Claim
individualized I-Claim
training I-Claim
, I-Claim
effectively I-Claim
improved I-Claim
pain I-Claim
management I-Claim
over I-Claim
time I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
of I-Claim
varying I-Claim
diagnostic I-Claim
and I-Claim
demographic I-Claim
groups I-Claim
. I-Claim

Toxicity B-Premise
profile I-Premise
was I-Premise
as I-Premise
follows I-Premise
: I-Premise
leukopenia I-Premise
( I-Premise
30/74 I-Premise
vs. I-Premise
17/92 I-Premise
) I-Premise
and I-Premise
alopecia I-Premise
( I-Premise
21/74 I-Premise
vs. I-Premise
13/92 I-Premise
) I-Premise
were I-Premise
statistically I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
. I-Premise

CP B-Premise
resulted I-Premise
in I-Premise
more I-Premise
anastomotic I-Premise
leaks I-Premise
. I-Premise

This B-Claim
research I-Claim
study I-Claim
indicates I-Claim
that I-Claim
live I-Claim
music I-Claim
therapy I-Claim
using I-Claim
patient-preferred I-Claim
music I-Claim
can I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
improving I-Claim
quality I-Claim
of I-Claim
life I-Claim
indicators I-Claim
such I-Claim
as I-Claim
anxiety I-Claim
, I-Claim
perception I-Claim
of I-Claim
the I-Claim
hospitalization I-Claim
or I-Claim
procedure I-Claim
, I-Claim
relaxation I-Claim
, I-Claim
and I-Claim
stress I-Claim
in I-Claim
patients I-Claim
undergoing I-Claim
surgical I-Claim
procedures I-Claim
of I-Claim
the I-Claim
brain I-Claim
. I-Claim

For B-Premise
men I-Premise
in I-Premise
SPCG-4 I-Premise
, I-Premise
negative I-Premise
side-effects I-Premise
were I-Premise
common I-Premise
and I-Premise
added I-Premise
more I-Premise
stress I-Premise
than I-Premise
was I-Premise
reported I-Premise
in I-Premise
the I-Premise
control I-Premise
population I-Premise
. I-Premise

These B-Premise
benefits I-Premise
were I-Premise
seen I-Premise
with I-Premise
no I-Premise
increase I-Premise
in I-Premise
anxiety I-Premise
levels I-Premise
in I-Premise
the I-Premise
sentinel I-Premise
lymph I-Premise
node I-Premise
biopsy I-Premise
group I-Premise
( I-Premise
P I-Premise
> I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Inclusion O
criteria O
were O
inoperable O
, O
disease O
too O
advanced O
for O
curative O
radiotherapy O
, O
and O
chest O
symptoms O
or O
central O
tumor O
threatening O
the O
airways O
. O

High B-Premise
self-assessed I-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
reported I-Premise
by I-Premise
62 I-Premise
( I-Premise
35 I-Premise
% I-Premise
) I-Premise
of I-Premise
179 I-Premise
men I-Premise
allocated I-Premise
radical I-Premise
prostatectomy I-Premise
, I-Premise
55 I-Premise
( I-Premise
34 I-Premise
% I-Premise
) I-Premise
of I-Premise
160 I-Premise
men I-Premise
assigned I-Premise
to I-Premise
watchful I-Premise
waiting I-Premise
, I-Premise
and I-Premise
93 I-Premise
( I-Premise
45 I-Premise
% I-Premise
) I-Premise
of I-Premise
208 I-Premise
men I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Symptomatic B-Premise
response I-Premise
during I-Premise
the I-Premise
first I-Premise
four I-Premise
weeks I-Premise
was I-Premise
seen I-Premise
after I-Premise
pamidronate I-Premise
, I-Premise
but I-Premise
not I-Premise
with I-Premise
placebo I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

A O
number O
of O
studies O
testing O
alpha-tocopherol O
( O
vitamin O
E O
) O
and O
pentoxifylline O
suggest O
evidence O
of O
clinical O
regression O
of O
superficial O
radiation-induced O
fibrosis O
but O
there O
is O
only O
very O
limited O
evidence O
from O
randomised O
trials O
. O

Other B-Premise
analyzed I-Premise
QOL I-Premise
parameters I-Premise
favored I-Premise
the I-Premise
group I-Premise
receiving I-Premise
placebo I-Premise
but B-Premise
were I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
after I-Premise
adjustment I-Premise
for I-Premise
multiple I-Premise
testing I-Premise
. I-Premise

Breast O
cancer O
patients O
were O
registered O
within O
6 O
weeks O
after O
surgery O
. O

To O
determine O
whether O
the O
impact O
of O
" O
laying O
on O
of O
hands O
" O
on O
the O
well-being O
of O
patients O
with O
advanced O
cancer O
is O
more O
efficient O
when O
performed O
by O
a O
person O
with O
self-declared O
" O
healing O
powers O
" O
as O
compared O
to O
an O
actor O
mimicking O
the O
healer O
in O
close O
detail O
. O

Baseline O
global O
health O
status O
scores O
were O
found O
to O
be O
similar O
between O
treatment O
groups O
( O
64.7 O
vs O
65.3 O
) O
. O

The B-Claim
combination I-Claim
of I-Claim
VNR I-Claim
on I-Claim
day I-Claim
1-8 I-Claim
plus I-Claim
CDDP I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
may I-Claim
be I-Claim
considered I-Claim
as I-Claim
a I-Claim
reference I-Claim
regimen I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
disease I-Claim
and I-Claim
those I-Claim
who I-Claim
deserve I-Claim
a I-Claim
postoperative I-Claim
therapy I-Claim
, I-Claim
and I-Claim
for I-Claim
future I-Claim
studies I-Claim
. I-Claim

No B-Premise
significant I-Premise
difference I-Premise
in I-Premise
survival I-Premise
among I-Premise
arms I-Premise
A I-Premise
, I-Premise
B I-Premise
, I-Premise
and I-Premise
C I-Premise
was I-Premise
found I-Premise
, I-Premise
with I-Premise
median I-Premise
survival I-Premise
8.2 I-Premise
, I-Premise
7.0 I-Premise
, I-Premise
and I-Premise
6.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

At B-Premise
enrollment I-Premise
, I-Premise
symptoms I-Premise
, I-Premise
including I-Premise
muscle I-Premise
stiffness I-Premise
, I-Premise
breast I-Premise
sensitivity I-Premise
, I-Premise
aches I-Premise
and I-Premise
pains I-Premise
, I-Premise
tendency I-Premise
to I-Premise
take I-Premise
naps I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
concentrating I-Premise
, I-Premise
were I-Premise
common I-Premise
among I-Premise
patients I-Premise
in I-Premise
all I-Premise
groups I-Premise
and I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
poor I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
emotional I-Premise
well-being I-Premise
. I-Premise

The O
benefits O
of O
sertraline O
compared O
with O
placebo O
are O
expressed O
on O
a O
range O
from O
100 O
( O
ie O
, O
maximum O
benefit O
) O
to O
-100 O
( O
ie O
, O
maximum O
harm O
) O
";" O
a O
difference O
of O
10 O
was O
deemed O
clinically O
significant O
. O

Rehabilitation O
aims O
to O
address O
these O
needs O
, O
maximize O
psychological O
and O
physical O
function O
, O
and O
enable O
minimum O
dependency O
regardless O
of O
life O
expectancy O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
pamidronate O
for O
bone O
pain O
in O
a O
randomised O
double-blind O
trial O
and O
to O
evaluate O
the O
contribution O
of O
new O
markers O
of O
bone O
resorption O
in O
patients O
with O
bone O
metastases O
. O

Since B-Claim
the I-Claim
cost I-Claim
difference I-Claim
between I-Claim
the I-Claim
two I-Claim
treatments I-Claim
was I-Claim
only I-Claim
small I-Claim
, I-Claim
cost B-Claim
should I-Claim
not I-Claim
play I-Claim
a I-Claim
predominant I-Claim
role I-Claim
when I-Claim
deciding I-Claim
on I-Claim
the I-Claim
type I-Claim
of I-Claim
treatment I-Claim
assigned I-Claim
to I-Claim
patients I-Claim
with I-Claim
malignant I-Claim
GOO I-Claim
. I-Claim

According O
to O
the O
1997-American O
Society O
for O
Therapeutic O
Radiology O
and O
Oncology O
definition O
, O
the O
5-year O
biochemical O
relapse O
rate O
was O
39 O
% O
and O
28 O
% O
in O
the O
-70 O
and O
80-Gy O
arms O
, O
respectively O
( O
p O
= O
.036 O
) O
. O

Best B-Premise
response I-Premise
to I-Premise
induction I-Premise
therapy I-Premise
was I-Premise
complete I-Premise
remission I-Premise
for I-Premise
176 I-Premise
patients I-Premise
( I-Premise
33 I-Premise
% I-Premise
) I-Premise
, I-Premise
partial I-Premise
remission I-Premise
for I-Premise
341 I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
15 I-Premise
patients I-Premise
( I-Premise
3 I-Premise
% I-Premise
) I-Premise
had I-Premise
undergone I-Premise
surgical I-Premise
resection I-Premise
. I-Premise

In B-Claim
conclusion I-Claim
, I-Claim
Tomudex I-Claim
is I-Claim
more I-Claim
toxic I-Claim
and I-Claim
yields I-Claim
shorter I-Claim
PFS I-Claim
than I-Claim
infusional I-Claim
5FU I-Claim
. I-Claim

Although O
many O
of O
the O
adverse O
effects O
associated O
with O
exemestane O
and O
tamoxifen O
have O
been O
analysed O
, O
there O
are O
no O
comparative O
data O
concerning O
body O
weight O
and O
body O
composition O
. O

Randomisation O
was O
done O
by O
use O
of O
a O
central O
, O
computerised O
minimisation O
system O
. O

For O
this O
three-arm O
randomised O
controlled O
trial O
we O
recruited O
patients O
( O
aged O
≥18 O
years O
) O
from O
clinics O
in O
London O
, O
UK O
, O
with O
new-onset O
gastrointestinal O
symptoms O
persisting O
6 O
months O
after O
pelvic O
radiotherapy O
. O

Estramustine O
was O
given O
orally O
, O
280 O
mg O
twice O
daily O
, O
as O
soon O
as O
the O
diagnosis O
was O
established O
, O
during O
and O
after O
the O
radiotherapy O
for O
a O
period O
of O
in O
total O
3 O
months O
. O

On B-Premise
the I-Premise
response I-Premise
analysis I-Premise
, I-Premise
a I-Premise
significant I-Premise
difference I-Premise
was I-Premise
seen I-Premise
between I-Premise
groups I-Premise
for I-Premise
the I-Premise
bodily I-Premise
pain I-Premise
domain I-Premise
( I-Premise
percentage I-Premise
of I-Premise
patients I-Premise
reporting I-Premise
a I-Premise
worsening I-Premise
of I-Premise
QOL I-Premise
, I-Premise
47 I-Premise
% I-Premise
placebo I-Premise
v I-Premise
51 I-Premise
% I-Premise
letrozole I-Premise
";" I-Premise
P I-Premise
= I-Premise
.009 I-Premise
) I-Premise
and I-Premise
the I-Premise
vasomotor I-Premise
domain I-Premise
( I-Premise
22 I-Premise
% I-Premise
placebo I-Premise
v I-Premise
29 I-Premise
% I-Premise
letrozole I-Premise
";" I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Randomized O
controlled O
trial O
conducted O
from O
November O
2003 O
through O
May O
2008 O
of O
322 O
patients O
with O
advanced O
cancer O
in O
a O
rural O
, O
National O
Cancer O
Institute-designated O
comprehensive O
cancer O
center O
in O
New O
Hampshire O
and O
affiliated O
outreach O
clinics O
and O
a O
VA O
medical O
center O
in O
Vermont O
. O

IFNalpha2a O
was O
given O
daily O
subcutaneously O
, O
starting O
at O
a O
dose O
of O
3 O
million O
units O
( O
MU O
) O
. O

The B-Premise
unadjusted I-Premise
significance I-Premise
level I-Premise
for I-Premise
group I-Premise
differences I-Premise
was I-Premise
P I-Premise
= I-Premise
.0006 I-Premise
for I-Premise
survival I-Premise
to I-Premise
10 I-Premise
years I-Premise
. I-Premise

Median B-Premise
length I-Premise
of I-Premise
stay I-Premise
was I-Premise
4 I-Premise
( I-Premise
range I-Premise
2-35 I-Premise
, I-Premise
interquartile I-Premise
range I-Premise
3-5 I-Premise
) I-Premise
days I-Premise
. I-Premise

Eligible O
patients O
who O
had O
previously O
completed O
four O
cycles O
of O
platinum-based O
chemotherapy O
were O
randomised O
1:1 O
to O
receive O
erlotinib O
150 O
mg/day O
or O
placebo O
until O
disease O
progression O
, O
unacceptable O
toxicity O
or O
death O
. O

Behavioral O
symptoms O
are O
common O
in O
breast O
cancer O
survivors O
, O
including O
disturbances O
in O
energy O
, O
sleep O
, O
and O
mood O
, O
though O
few O
risk O
factors O
for O
these O
negative O
outcomes O
have O
been O
identified O
. O

Cox B-Premise
multivariate I-Premise
analysis I-Premise
showed I-Premise
paclitaxel I-Premise
plus I-Premise
supportive I-Premise
care I-Premise
to I-Premise
be I-Premise
statistically I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
improved I-Premise
survival I-Premise
( I-Premise
two-sided I-Premise
P I-Premise
=.048 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
was I-Premise
7.8 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
4-11.6 I-Premise
months I-Premise
) I-Premise
. I-Premise

This O
difference O
( O
7.4 O
) O
was O
clinically O
relevant O
. O

End O
points O
included O
progression-free O
survival O
( O
PFS O
) O
, O
response O
rate O
( O
RR O
) O
, O
and O
response O
duration O
( O
RD O
) O
, O
quality O
of O
life O
( O
QOL O
) O
, O
toxicity O
, O
and O
overall O
survival O
( O
OS O
) O
. O

Swallowing O
AUC O
analyses O
were O
calculated O
from O
patient O
diaries O
and O
PDLs O
. O

This O
phase O
III O
, O
double-blind O
, O
randomized O
, O
multicenter O
study O
evaluated O
the O
efficacy O
, O
pharmacodynamics O
, O
and O
safety O
of O
the O
oral O
aromatase O
inactivator O
exemestane O
( O
EXE O
) O
versus O
megestrol O
acetate O
( O
MA O
) O
in O
postmenopausal O
women O
with O
progressive O
advanced O
breast O
cancer O
who O
experienced O
failure O
of O
tamoxifen O
. O

Patients B-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
had I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
higher I-Premise
frequency I-Premise
of I-Premise
combined I-Premise
complete I-Premise
plus I-Premise
partial I-Premise
responses I-Premise
compared I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
( I-Premise
21 I-Premise
% I-Premise
plus I-Premise
55 I-Premise
% I-Premise
versus I-Premise
13 I-Premise
% I-Premise
plus I-Premise
48 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
=.02 I-Premise
for I-Premise
difference I-Premise
in I-Premise
combined I-Premise
objective I-Premise
responses I-Premise
) I-Premise
. I-Premise

The O
majority O
of O
the O
patient O
loss O
was O
because O
of O
patient O
preference O
( O
45 O
% O
of O
enrolled O
patients O
) O
. O

The B-Premise
proportions I-Premise
of I-Premise
patients I-Premise
with I-Premise
adverse I-Premise
events I-Premise
were I-Premise
21 I-Premise
% I-Premise
in I-Premise
the I-Premise
low-dose I-Premise
group I-Premise
versus I-Premise
33 I-Premise
% I-Premise
in I-Premise
the I-Premise
high-dose I-Premise
group I-Premise
( I-Premise
P=0.007 I-Premise
) I-Premise
and I-Premise
23 I-Premise
% I-Premise
in I-Premise
the I-Premise
thyrotropin I-Premise
alfa I-Premise
group I-Premise
versus I-Premise
30 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
undergoing I-Premise
thyroid I-Premise
hormone I-Premise
withdrawal I-Premise
( I-Premise
P=0.11 I-Premise
) I-Premise
. I-Premise

In O
addition O
, O
at B-Premise
6 I-Premise
months I-Premise
follow-up I-Premise
, I-Premise
participants I-Premise
attending I-Premise
five I-Premise
or I-Premise
more I-Premise
sessions I-Premise
trended I-Premise
toward I-Premise
retaining I-Premise
treatment I-Premise
effects I-Premise
better I-Premise
in I-Premise
the I-Premise
MBAT I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Standardized O
questionnaires O
at O
baseline O
, O
posttreatment O
, O
and O
at O
3-month O
and O
6-month O
follow-up O
assessed O
sexual O
function O
, O
marital O
adjustment O
, O
psychologic O
distress O
, O
and O
utilization O
of O
treatments O
for O
ED O
. O

Maintenance O
therapy O
can O
delay O
progression O
and O
prolong O
survival O
in O
metastatic O
non-small-cell O
lung O
cancer O
( O
mNSCLC O
) O
. O

CD-DP O
was O
given O
intravenously O
at O
a O
dose O
of O
3 O
mg/m O
( O
2 O
) O
on O
days O
1-5 O
and O
days O
8-12 O
, O
and O
then O
at O
a O
dose O
of O
7 O
mg/m O
( O
2 O
) O
twice O
a O
week O
. O

Clinical O
data O
were O
collected O
prospectively O
, O
and O
follow-up O
was O
performed O
regularly O
. O

Most O
of O
these O
effects O
were O
observed O
at O
both O
the O
12-week O
and O
6-month O
follow-ups O
. O

Ten O
years O
of O
treatment O
planned O
. O

The O
primary O
outcome O
was O
self-reported O
total O
exercise O
( O
in O
metabolic O
equivalent O
[ O
MET O
] O
hours O
per O
week O
) O
at O
5 O
weeks O
postconsultation O
. O

As O
health O
economic O
aspects O
have O
only O
been O
studied O
in O
general O
terms O
, O
we O
estimated O
the O
cost O
of O
GJJ O
and O
that O
of O
stent O
placement O
in O
such O
patients O
. O

Exercise O
has O
been O
found O
to O
effectively O
decrease O
fatigue O
levels O
and O
improve O
physical O
functioning O
in O
cancer O
patients O
. O

Stage O
was O
limited O
for O
279 O
patients O
( O
52 O
% O
) O
and O
extensive O
for O
253 O
( O
48 O
% O
) O
. O

The B-Premise
median I-Premise
survival I-Premise
of I-Premise
all I-Premise
406 I-Premise
eligible I-Premise
patients I-Premise
was I-Premise
346 I-Premise
days I-Premise
with I-Premise
15 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
alive I-Premise
at I-Premise
two I-Premise
years I-Premise
. I-Premise

The B-Premise
final I-Premise
multivariate I-Premise
model I-Premise
predicted I-Premise
poor I-Premise
survival I-Premise
with I-Premise
multiple I-Premise
sites I-Premise
of I-Premise
visceral I-Premise
disease I-Premise
( I-Premise
P=0.003 I-Premise
) I-Premise
, I-Premise
DFI I-Premise
< I-Premise
/=2 I-Premise
years I-Premise
( I-Premise
P=0.026 I-Premise
) I-Premise
and I-Premise
pain I-Premise
( I-Premise
P=0.003 I-Premise
) I-Premise
. I-Premise

To O
explore O
the O
preference O
and O
compliance O
of O
elderly O
patients O
regarding O
p.o O
. O

After O
catheter O
removal O
, O
112 O
patients O
were O
randomized O
to O
receive O
rehabilitation O
and O
duloxetine O
( O
group O
A O
) O
or O
rehabilitation O
alone O
( O
group O
B O
) O
, O
for O
16 O
wk O
. O

Erlotinib B-Claim
was I-Claim
effective I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
in I-Claim
Asian I-Claim
patients I-Claim
, I-Claim
producing I-Claim
benefits I-Claim
consistent I-Claim
with I-Claim
those I-Claim
observed I-Claim
in I-Claim
the I-Claim
overall I-Claim
SATURN I-Claim
population I-Claim
. I-Claim

We B-Premise
found I-Premise
no I-Premise
difference I-Premise
in I-Premise
severe I-Premise
ARSR I-Premise
between I-Premise
the I-Premise
groups I-Premise
at I-Premise
any I-Premise
point I-Premise
of I-Premise
assessment I-Premise
. I-Premise

Fifty-one O
of O
84 O
couples O
randomized O
to O
treatment O
completed O
the O
intervention O
( O
61 O
% O
) O
. O

Missing O
data O
at O
baseline O
and O
during O
follow-up O
was O
equally O
distributed O
between O
groups O
. O

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
average I-Premise
score I-Premise
values I-Premise
between I-Premise
the I-Premise
" I-Premise
healer I-Premise
" I-Premise
and I-Premise
the I-Premise
actor I-Premise
with I-Premise
regard I-Premise
to I-Premise
the I-Premise
primary I-Premise
( I-Premise
p I-Premise
= I-Premise
0.34 I-Premise
) I-Premise
or I-Premise
the I-Premise
secondary I-Premise
endpoint I-Premise
( I-Premise
p I-Premise
= I-Premise
0.94 I-Premise
) I-Premise
, I-Premise
but B-Premise
the I-Premise
comparison I-Premise
was I-Premise
limited I-Premise
due I-Premise
to I-Premise
major I-Premise
protocol I-Premise
violations I-Premise
by I-Premise
the I-Premise
" I-Premise
healer I-Premise
" I-Premise
who I-Premise
unblinded I-Premise
his I-Premise
status I-Premise
after I-Premise
the I-Premise
first I-Premise
run I-Premise
and I-Premise
quit I-Premise
the I-Premise
study I-Premise
. I-Premise

As B-Premise
for I-Premise
the I-Premise
secondary I-Premise
efficacy I-Premise
endpoints I-Premise
, I-Premise
patient I-Premise
appetite I-Premise
increased I-Premise
, I-Premise
and I-Premise
ECOG I-Premise
PS I-Premise
decreased I-Premise
significantly I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

The B-Premise
final I-Premise
multivariate I-Premise
model I-Premise
for I-Premise
response I-Premise
selected I-Premise
DFI I-Premise
( I-Premise
P=0.009 I-Premise
) I-Premise
, I-Premise
multiple I-Premise
sites I-Premise
of I-Premise
visceral I-Premise
disease I-Premise
( I-Premise
P=0.037 I-Premise
) I-Premise
and I-Premise
dyspnoea I-Premise
( I-Premise
P= I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
using I-Premise
forward I-Premise
selection I-Premise
, I-Premise
but B-Premise
model I-Premise
instability I-Premise
was I-Premise
indicated I-Premise
by I-Premise
the I-Premise
inclusion I-Premise
of I-Premise
fatigue I-Premise
and I-Premise
emotional I-Premise
function I-Premise
in I-Premise
the I-Premise
final I-Premise
model I-Premise
when I-Premise
backward I-Premise
selection I-Premise
was I-Premise
used I-Premise
. I-Premise

Neoadjuvant B-Claim
docetaxel-cisplatin I-Claim
followed I-Claim
by I-Claim
CRT I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
with I-Claim
a I-Claim
manageable I-Claim
toxicity I-Claim
profile I-Claim
that I-Claim
allowed I-Claim
subsequent I-Claim
delivery I-Claim
of I-Claim
full-dose I-Claim
CRT I-Claim
. I-Claim

AM B-Claim
did I-Claim
not I-Claim
significantly I-Claim
reduce I-Claim
esophagitis I-Claim
> I-Claim
/= I-Claim
grade I-Claim
3 I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
hyperfractionated I-Claim
radiation I-Claim
and I-Claim
chemotherapy I-Claim
. I-Claim

However B-Claim
, I-Claim
it I-Claim
is I-Claim
not I-Claim
clear I-Claim
whether I-Claim
psychological I-Claim
improvements I-Claim
are I-Claim
, I-Claim
in I-Claim
turn I-Claim
, I-Claim
related I-Claim
to I-Claim
improved I-Claim
health I-Claim
. I-Claim

157 O
patients O
in O
the O
90 O
mg O
group O
and O
156 O
in O
the O
30 O
mg O
group O
were O
included O
in O
the O
primary O
analysis O
. O

The B-Premise
survival I-Premise
benefit I-Premise
of I-Premise
D3P I-Premise
compared I-Premise
with I-Premise
MP I-Premise
has I-Premise
persisted I-Premise
with I-Premise
extended I-Premise
follow-up I-Premise
( I-Premise
P I-Premise
= I-Premise
.004 I-Premise
) I-Premise
. I-Premise

Data O
were O
analysed O
up O
to O
6 O
months O
. O

One O
hundred O
and O
two O
candidates O
with O
CACS O
were O
randomly O
assigned O
to O
two O
treatment O
groups O
( O
trial O
group O
and O
control O
group O
) O
: O
the O
trial O
group O
received O
MA O
( O
160 O
mg O
po O
, O
bid O
) O
plus O
thalidomide O
( O
50 O
mg O
po O
, O
bid O
) O
, O
while O
the O
control O
group O
received O
MA O
( O
160 O
mg O
po O
, O
bid O
) O
alone O
. O

Bone B-Claim
metastases I-Claim
are I-Claim
a I-Claim
common I-Claim
cause I-Claim
of I-Claim
morbidity I-Claim
in I-Claim
patients I-Claim
with I-Claim
prostate I-Claim
carcinoma I-Claim
. I-Claim

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
treatments I-Premise
in I-Premise
hematological I-Premise
and I-Premise
nonhematological I-Premise
toxic I-Premise
effects I-Premise
, I-Premise
except B-Premise
more I-Premise
patients I-Premise
in I-Premise
the I-Premise
thalidomide I-Premise
group I-Premise
had I-Premise
rash I-Premise
, I-Premise
constipation I-Premise
, I-Premise
or I-Premise
neuropathy I-Premise
. I-Premise

There O
were O
752 O
patients O
enrolled O
between O
2007 O
and O
2010 O
";" O
92 O
% O
had O
papillary O
cancer O
. O

This O
study O
is O
registered O
, O
ISRCTN87786644 O
. O

Patients B-Claim
with I-Claim
poor I-Claim
preoperative I-Claim
QOL I-Claim
appear I-Claim
to I-Claim
be I-Claim
at I-Claim
higher I-Claim
risk I-Claim
for I-Claim
difficult I-Claim
postoperative I-Claim
courses I-Claim
, I-Claim
and I-Claim
may I-Claim
be I-Claim
candidates I-Claim
for I-Claim
enhanced I-Claim
ancillary I-Claim
services I-Claim
to I-Claim
address I-Claim
their I-Claim
particular I-Claim
needs I-Claim
. I-Claim

Thirty O
three O
patients O
( O
16 O
control O
, O
17 O
thalidomide O
) O
were O
evaluated O
at O
four O
weeks O
, O
and O
20 O
patients O
( O
eight O
control O
, O
12 O
thalidomide O
) O
at O
eight O
weeks O
. O

Qualitative B-Claim
interviews I-Claim
suggested I-Claim
that I-Claim
patients I-Claim
found I-Claim
participation I-Claim
in I-Claim
the I-Claim
trial I-Claim
acceptable I-Claim
and I-Claim
that I-Claim
they I-Claim
would I-Claim
consider I-Claim
participating I-Claim
in I-Claim
a I-Claim
future I-Claim
trial I-Claim
. I-Claim

The O
primary O
end O
point O
of O
this O
study O
was O
the O
objective O
response O
rate O
and O
based O
on O
the O
statistical O
design O
of O
the O
trial O
, O
the O
3-weekly O
irinotecan O
schedule O
was O
selected O
over O
weekly O
irinotecan O
administration O
. O

Outcome O
parameters O
were O
: O
postoperative O
morbidity O
, O
length O
of O
hospital O
stay O
, O
quality O
of O
life O
, O
long-term O
survival O
, O
and O
local O
recurrences O
. O

Treosulfan O
, O
an O
alkylating O
agent O
, O
has O
demonstrated O
activity O
in O
recurrent O
ovarian O
carcinoma O
. O

The O
intervention O
was O
delivered O
on O
an O
individual O
basis O
on O
3 O
occasions O
over O
a O
period O
from O
9 O
weeks O
to O
12 O
weeks O
, O
and O
the O
objective O
of O
the O
intervention O
was O
to O
alter O
fatigue-related O
thoughts O
and O
behavior O
. O

To O
assess O
the O
efficacy O
of O
monthly O
degarelix O
treatment O
for O
reduction O
of O
total O
prostate O
volume O
( O
TPV O
) O
, O
relief O
of O
lower O
urinary O
tract O
symptoms O
( O
LUTS O
) O
and O
improvement O
of O
quality O
of O
life O
( O
QoL O
) O
in O
patients O
with O
prostate O
cancer O
( O
PCa O
) O
using O
monthly O
goserelin O
as O
active O
control O
. O

To O
assess O
the O
safety O
and O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
of O
continuous O
combined O
hormone O
replacement O
therapy O
( O
ccHRT O
) O
with O
estradiol O
valerate/medroxyprogesterone O
acetate O
( O
E O
( O
2 O
) O
V/MPA O
) O
over O
nine O
years O
and O
at O
follow-up O
one O
year O
after O
discontinuation O
. O

In B-Claim
vivo I-Claim
data I-Claim
have I-Claim
shown I-Claim
a I-Claim
more I-Claim
potent I-Claim
antiangiogenic I-Claim
effect I-Claim
and I-Claim
a I-Claim
higher I-Claim
antitumor I-Claim
activity I-Claim
of I-Claim
low-dose I-Claim
interferon I-Claim
( I-Claim
IFN I-Claim
) I-Claim
given I-Claim
twice I-Claim
daily I-Claim
. I-Claim

Radiother O
Oncol O
104:349-354 O
, O
2012 O
) O
. O

Primary O
endpoint O
was O
overall O
survival O
";" O
secondary O
endpoints O
were O
disease-free O
survival O
, O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

Participants B-Premise
completing I-Premise
the I-Premise
intervention I-Premise
demonstrated I-Premise
improvement I-Premise
in I-Premise
male I-Premise
overall I-Premise
distress I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
male I-Premise
global I-Premise
sexual I-Premise
function I-Premise
( I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
, I-Premise
and I-Premise
female I-Premise
global I-Premise
sexual I-Premise
function I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
at I-Premise
3-month I-Premise
follow-up I-Premise
, I-Premise
but B-Premise
regression I-Premise
toward I-Premise
baseline I-Premise
was I-Premise
noted I-Premise
at I-Premise
6-month I-Premise
follow-up I-Premise
. I-Premise

Patients B-Premise
on I-Premise
marimastat I-Premise
had I-Premise
significantly I-Premise
poorer I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
3 I-Premise
and I-Premise
6 I-Premise
months I-Premise
. I-Premise

Compliance O
to O
HRQOL O
assessments O
was O
97 O
% O
at O
baseline O
, O
but O
dropped O
to O
54 O
% O
by O
6 O
months O
. O

Pain O
and O
physical O
disabilities O
related O
to O
upper O
limb O
dysfunction O
, O
quality O
of O
life O
and O
depression O
were O
used O
as O
subjective O
outcomes O
. O

Rash B-Premise
( I-Premise
75 I-Premise
% I-Premise
versus I-Premise
17 I-Premise
% I-Premise
) I-Premise
and I-Premise
diarrhea I-Premise
( I-Premise
54 I-Premise
% I-Premise
versus I-Premise
18 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
erlotnib I-Premise
and I-Premise
placebo I-Premise
group I-Premise
respectively I-Premise
were I-Premise
the I-Premise
most I-Premise
common I-Premise
adverse I-Premise
events I-Premise
. I-Premise

Here O
, O
we O
report O
an O
updated O
analysis O
of O
survival O
. O

In O
addition O
, O
the O
long-term O
effectiveness O
was O
investigated O
. O

Due O
to O
the O
various O
inter-individual O
differences O
in O
the O
biological O
characteristics O
of O
tumor O
cells O
, O
as O
well O
as O
issues O
on O
the O
efficacy O
, O
adverse O
reactions O
, O
and O
defects O
of O
existing O
drugs O
, O
we O
compared O
the O
clinical O
efficacy O
and O
toxicity O
of O
pemetrexed O
and O
gemcitabine O
combined O
with O
cisplatin O
for O
the O
treatment O
of O
previously O
untreated O
advanced O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
. O

To O
test O
the O
equivalence O
of O
three O
versus O
four O
cycles O
of O
bleomycin O
, O
etoposide O
, O
and O
cisplatin O
( O
BEP O
) O
and O
of O
the O
5-day O
schedule O
versus O
3 O
days O
per O
cycle O
in O
good-prognosis O
germ O
cell O
cancer O
. O

IFNalpha O
was O
administered O
three O
times O
a O
week O
at O
a O
dose O
of O
3 O
million O
units O
subcutaneously O
for O
24 O
months O
. O

Ongoing O
studies O
are O
exploring O
alternate O
schedules O
to O
maximize O
synergy O
between O
these O
agents O
. O

" B-Claim
Laying I-Claim
on I-Claim
of I-Claim
hands I-Claim
" I-Claim
resulted I-Claim
in I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
of I-Claim
cancer- I-Claim
or I-Claim
cancer-therapy-associated I-Claim
symptoms I-Claim
. I-Claim

Median B-Premise
PFS I-Premise
was I-Premise
5.5 I-Premise
months I-Premise
in I-Premise
both I-Premise
arms I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.04 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.727 I-Premise
) I-Premise
, I-Premise
while I-Premise
ORR I-Premise
was I-Premise
25 I-Premise
% I-Premise
in I-Premise
both I-Premise
arms I-Premise
( I-Premise
P I-Premise
= I-Premise
1.0 I-Premise
) I-Premise
. I-Premise

A B-Premise
decrease I-Premise
in I-Premise
transfusion I-Premise
requirement I-Premise
did I-Premise
not I-Premise
reach I-Premise
significance I-Premise
over I-Premise
all I-Premise
3 I-Premise
months I-Premise
, I-Premise
but I-Premise
there I-Premise
was I-Premise
a I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
the I-Premise
percentage I-Premise
of I-Premise
patients I-Premise
transfused I-Premise
in I-Premise
the I-Premise
second I-Premise
and I-Premise
third I-Premise
months I-Premise
( I-Premise
27 I-Premise
% I-Premise
r-HuEPO I-Premise
vs. I-Premise
56 I-Premise
% I-Premise
placebo I-Premise
) I-Premise
and I-Premise
a I-Premise
trend I-Premise
toward I-Premise
reduction I-Premise
in I-Premise
the I-Premise
mean I-Premise
total I-Premise
number I-Premise
of I-Premise
units I-Premise
transfused I-Premise
( I-Premise
1.20 I-Premise
units I-Premise
r-HuEPO I-Premise
vs. I-Premise
2.02 I-Premise
units I-Premise
placebo I-Premise
) I-Premise
, I-Premise
suggesting I-Premise
a I-Premise
lag I-Premise
of I-Premise
1 I-Premise
month I-Premise
before I-Premise
r-HuEPO I-Premise
can I-Premise
affect I-Premise
the I-Premise
transfusion I-Premise
requirement I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
RBC I-Premise
transfusion I-Premise
for I-Premise
placebo I-Premise
and I-Premise
epoetin I-Premise
treatment I-Premise
arms I-Premise
was I-Premise
39.6 I-Premise
% I-Premise
and I-Premise
25.3 I-Premise
% I-Premise
( I-Premise
P I-Premise
= I-Premise
.005 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

This O
phase O
III O
trial O
was O
conducted O
to O
test O
whether O
the O
novel O
vascular O
disrupting O
agent O
ASA404 O
( O
vadimezan O
) O
, O
when O
combined O
with O
first-line O
platinum-based O
chemotherapy O
, O
improves O
survival O
in O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
versus O
chemotherapy O
alone O
. O

A O
total O
of O
75 O
patients O
were O
registered O
";" O
71 O
are O
included O
in O
the O
analysis O
. O

A O
planned O
interim O
analysis O
failed O
to O
detect O
an O
RR O
difference O
more O
than O
5 O
% O
. O

Patients B-Claim
treated I-Claim
with I-Claim
single-agent I-Claim
E I-Claim
followed I-Claim
by I-Claim
single-agent I-Claim
M I-Claim
had I-Claim
similar I-Claim
survival I-Claim
, I-Claim
but I-Claim
less I-Claim
treatment-related I-Claim
toxicity I-Claim
and I-Claim
better I-Claim
QOL I-Claim
as I-Claim
compared I-Claim
with I-Claim
those I-Claim
treated I-Claim
with I-Claim
CEF I-Claim
followed I-Claim
by I-Claim
MV I-Claim
. I-Claim

The B-Claim
behaviorally I-Claim
oriented I-Claim
intervention I-Claim
brought I-Claim
about I-Claim
significant I-Claim
improvements I-Claim
in I-Claim
physical I-Claim
functioning I-Claim
, I-Claim
indicated I-Claim
a I-Claim
trend I-Claim
toward I-Claim
improved I-Claim
CRF I-Claim
, I-Claim
but I-Claim
detected I-Claim
no I-Claim
effect I-Claim
for I-Claim
fatigue-related I-Claim
distress I-Claim
. I-Claim

After B-Premise
6 I-Premise
weeks I-Premise
, I-Premise
patients I-Premise
taking I-Premise
prednisone I-Premise
showed I-Premise
no I-Premise
improvement I-Premise
in I-Premise
HQL I-Premise
scores I-Premise
, I-Premise
whereas I-Premise
those I-Premise
taking I-Premise
mitoxantrone I-Premise
plus I-Premise
prednisone I-Premise
showed I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
=.009 I-Premise
) I-Premise
, I-Premise
four I-Premise
functioning I-Premise
domains I-Premise
, I-Premise
and I-Premise
nine I-Premise
symptoms I-Premise
( I-Premise
.001 I-Premise
< I-Premise
P I-Premise
< I-Premise
. I-Premise
1 I-Premise
) I-Premise
, I-Premise
and O
the B-Premise
improvement I-Premise
( I-Premise
> I-Premise
10 I-Premise
units I-Premise
on I-Premise
a I-Premise
scale I-Premise
of I-Premise
0 I-Premise
to100 I-Premise
) I-Premise
lasted I-Premise
longer I-Premise
than I-Premise
in I-Premise
the I-Premise
prednisone-alone I-Premise
group I-Premise
( I-Premise
.004 I-Premise
< I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

The B-Premise
overall I-Premise
remission I-Premise
rate I-Premise
, I-Premise
the I-Premise
rate I-Premise
of I-Premise
complete I-Premise
remission I-Premise
, I-Premise
the I-Premise
median I-Premise
survival I-Premise
and I-Premise
the I-Premise
rate I-Premise
of I-Premise
long-term I-Premise
survival I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
in I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

This O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
prospective O
clinical O
study O
received O
institutional O
review O
board O
approval O
. O

Patients O
with O
advanced O
stage O
IIIB O
or O
IV O
NSCLC O
, O
stratified O
by O
sex O
and O
tumor O
histology O
, O
were O
randomly O
assigned O
1:1 O
to O
paclitaxel O
( O
200 O
mg/m O
( O
2 O
) O
) O
and O
carboplatin O
( O
area O
under O
the O
curve O
, O
6.0 O
) O
with O
or O
without O
ASA404 O
( O
1,800 O
mg O
m O
( O
2 O
) O
) O
, O
given O
intravenously O
once O
every O
3 O
weeks O
for O
six O
cycles O
followed O
by O
maintenance O
ASA404 O
or O
placebo O
. O

GE/G B-Premise
Grade I-Premise
3-4 I-Premise
toxicities I-Premise
included I-Premise
: I-Premise
neutropenia I-Premise
( I-Premise
18.3 I-Premise
% I-Premise
/28.2 I-Premise
% I-Premise
) I-Premise
";" I-Premise
thrombocytopenia I-Premise
( I-Premise
14.6 I-Premise
% I-Premise
/25.6 I-Premise
% I-Premise
) I-Premise
";" I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
11.0 I-Premise
% I-Premise
/7.7 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
response I-Premise
rate I-Premise
in I-Premise
the I-Premise
5-FU+low-dose I-Premise
CDDP I-Premise
arm I-Premise
( I-Premise
n=75 I-Premise
) I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
in I-Premise
the I-Premise
5-FU I-Premise
arm I-Premise
( I-Premise
n=77 I-Premise
) I-Premise
( I-Premise
25.3 I-Premise
% I-Premise
vs. I-Premise
11.7 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.037 I-Premise
) I-Premise
. I-Premise

Both B-Premise
treatments I-Premise
led I-Premise
to I-Premise
an I-Premise
improvement I-Premise
, I-Premise
over I-Premise
time I-Premise
, I-Premise
in I-Premise
dyspnoea I-Premise
. I-Premise

One O
hundred O
fifty-five O
patients O
with O
far-advanced O
CRC O
including O
at O
least O
one O
measurable O
lesion O
were O
enrolled O
in O
a O
prospective O
randomized O
clinical O
trial O
funded O
by O
the O
Japanese O
Foundation O
for O
Multidisciplinary O
Treatment O
of O
Cancer O
. O

AET B-Claim
did I-Claim
not I-Claim
significantly I-Claim
improve I-Claim
sleep I-Claim
quality I-Claim
in I-Claim
this I-Claim
heterogeneous I-Claim
sample I-Claim
of I-Claim
patients I-Claim
with I-Claim
lymphoma I-Claim
";" I-Claim
however B-Claim
, I-Claim
clinically I-Claim
identifiable I-Claim
subgroups I-Claim
appeared I-Claim
to I-Claim
benefit I-Claim
. I-Claim

Few O
intervention O
programs O
assist O
patients O
and O
their O
family O
caregivers O
to O
manage O
advanced O
cancer O
and O
maintain O
their O
quality O
of O
life O
( O
QOL O
) O
. O

As B-Premise
of I-Premise
October I-Premise
15 I-Premise
, I-Premise
2005 I-Premise
, I-Premise
eight I-Premise
of I-Premise
26 I-Premise
patients I-Premise
in I-Premise
the I-Premise
CONT I-Premise
group I-Premise
and I-Premise
26 I-Premise
of I-Premise
32 I-Premise
patients I-Premise
in I-Premise
the I-Premise
INT I-Premise
group I-Premise
had I-Premise
documented I-Premise
disease I-Premise
progression I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

Response B-Premise
rates I-Premise
were I-Premise
similar I-Premise
in I-Premise
the I-Premise
-24 I-Premise
and I-Premise
3-hour I-Premise
groups I-Premise
( I-Premise
19 I-Premise
% I-Premise
and I-Premise
16 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
= I-Premise
.6 I-Premise
) I-Premise
. I-Premise

All O
participants O
underwent O
assessment O
of O
physical O
activity O
, O
fitness O
, O
physical O
functioning O
, O
fatigue O
and O
exercise O
self-efficacy O
at O
baseline O
and O
after O
the O
16-week O
intervention O
. O

Nonetheless O
, O
no B-Claim
correlation I-Claim
between I-Claim
immediate I-Claim
lung I-Claim
expansion I-Claim
and I-Claim
clinical I-Claim
outcome I-Claim
was I-Claim
found I-Claim
in I-Claim
this I-Claim
study I-Claim
. I-Claim

A O
multi-site O
randomized O
study O
was O
conducted O
to O
evaluate O
the O
effects O
of O
a O
psycho-educational O
group O
intervention O
in O
this O
population O
. O

To O
test O
this O
hypothesis O
, O
the O
National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
initiated O
the O
Breast O
Cancer O
Prevention O
Trial O
( O
P-1 O
) O
in O
1992 O
. O

There B-Premise
were I-Premise
significant I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
interaction I-Premise
effects I-Premise
on I-Premise
QoL I-Premise
, I-Premise
fitness I-Premise
and I-Premise
fatigue I-Premise
with I-Premise
differences I-Premise
being I-Premise
observed I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
and I-Premise
the I-Premise
UC I-Premise
group I-Premise
. I-Premise

Overall O
, O
88 O
% O
( O
557 O
of O
634 O
) O
of O
expected O
QL O
forms O
were O
received O
. O

The B-Premise
major I-Premise
World I-Premise
Health I-Premise
Organization I-Premise
grade I-Premise
3-4 I-Premise
toxicities I-Premise
for I-Premise
NP I-Premise
and I-Premise
NIP I-Premise
, I-Premise
respectively I-Premise
, I-Premise
were I-Premise
: I-Premise
neutropenia I-Premise
( I-Premise
20.3 I-Premise
% I-Premise
compared I-Premise
with I-Premise
9 I-Premise
% I-Premise
of I-Premise
cycles I-Premise
) I-Premise
, I-Premise
anaemia I-Premise
( I-Premise
4.1 I-Premise
% I-Premise
compared I-Premise
with I-Premise
5 I-Premise
% I-Premise
of I-Premise
cycles I-Premise
) I-Premise
, I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
( I-Premise
22.2 I-Premise
% I-Premise
compared I-Premise
with I-Premise
19.4 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
and I-Premise
alopecia I-Premise
( I-Premise
5.6 I-Premise
% I-Premise
compared I-Premise
with I-Premise
29.8 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
. I-Premise

Seventy-two O
women O
with O
breast O
cancer O
experiencing O
three O
or O
more O
hot O
flashes O
per O
day O
were O
randomly O
assigned O
to O
receive O
either O
TRUE O
or O
sham O
acupuncture O
. O

Palliation O
was O
defined O
as O
an O
improvement O
of O
one O
point O
or O
more O
in O
the O
categorical O
scale O
. O

Post-surgery O
, O
227 O
breast O
cancer O
patients O
were O
randomized O
to O
intervention O
or O
assessment O
only O
Study O
Arms O
. O

The O
control O
group O
received O
no O
advice O
about O
exercise O
. O

If B-Premise
offered I-Premise
a I-Premise
choice I-Premise
, I-Premise
80 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
prior I-Premise
to I-Premise
start I-Premise
and I-Premise
58 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
after I-Premise
completion I-Premise
of I-Premise
the I-Premise
program I-Premise
indicated I-Premise
that I-Premise
they I-Premise
preferred I-Premise
the I-Premise
entire I-Premise
multidimensional I-Premise
program I-Premise
. I-Premise

Sixty O
female O
breast O
cancer O
survivors O
with O
hot O
flashes O
were O
randomly O
assigned O
to O
receive O
hypnosis O
intervention O
( O
five O
weekly O
sessions O
) O
or O
no O
treatment O
. O

An B-Claim
Internet-based I-Claim
education I-Claim
program I-Claim
based I-Claim
on I-Claim
NCCN I-Claim
guidelines I-Claim
and I-Claim
TTM I-Claim
may I-Claim
help I-Claim
patients I-Claim
manage I-Claim
CRF I-Claim
. I-Claim

No B-Premise
relevant I-Premise
differences I-Premise
in I-Premise
adverse I-Premise
effects I-Premise
were I-Premise
observed I-Premise
among I-Premise
the I-Premise
groups I-Premise
during I-Premise
either I-Premise
the I-Premise
titration I-Premise
phase I-Premise
and I-Premise
chronic I-Premise
treatment I-Premise
. I-Premise

The B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
almost I-Premise
the I-Premise
same I-Premise
between I-Premise
the I-Premise
arms I-Premise
. O

In O
a O
randomized O
Phase O
II O
trial O
, O
the O
authors O
tested O
the O
hypothesis O
that O
twice-daily O
low-dose O
IFN O
is O
more O
effective O
than O
daily O
intermediate-dose O
IFN O
in O
patients O
with O
metastatic O
renal O
cell O
cancer O
( O
MRCC O
) O
. O

Significantly B-Premise
greater I-Premise
improvements I-Premise
for I-Premise
IMCP I-Premise
patients I-Premise
were I-Premise
also I-Premise
observed I-Premise
for I-Premise
the I-Premise
secondary I-Premise
outcomes I-Premise
of I-Premise
symptom I-Premise
burden I-Premise
( I-Premise
b I-Premise
= I-Premise
-6.56 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
symptom-related I-Premise
distress I-Premise
( I-Premise
b I-Premise
= I-Premise
-0.47 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
but I-Premise
not I-Premise
for I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
or I-Premise
hopelessness I-Premise
. I-Premise

Those O
in O
the O
treatment O
group O
additionally O
took O
FJD O
, O
50 O
-100 O
mL O
each O
time O
, O
twice O
daily O
. O

Assessments O
were O
made O
on O
4 O
occasions O
: O
at O
baseline O
( O
T0 O
) O
, O
at O
the O
end O
of O
chemotherapy O
( O
T1 O
) O
, O
1 O
month O
after O
chemotherapy O
( O
T2 O
) O
, O
and O
9 O
months O
after O
recruitment O
( O
T3 O
) O
. O

The O
success O
of O
blinding O
was O
assessed O
using O
a O
mixed-methods O
approach O
. O

The O
aim O
of O
this O
prospective O
controlled O
study O
was O
to O
assess O
the O
efficacy O
of O
two O
different O
combination O
treatment O
modalities O
of O
lymphedema O
( O
LE O
) O
. O

After B-Premise
the I-Premise
rehabilitation I-Premise
program I-Premise
, I-Premise
cancer I-Premise
survivors I-Premise
( I-Premise
n=63 I-Premise
) I-Premise
displayed I-Premise
statistically I-Premise
significant I-Premise
improvements I-Premise
on I-Premise
health-related I-Premise
quality I-Premise
of I-Premise
life I-Premise
with I-Premise
effect I-Premise
sizes I-Premise
( I-Premise
ES I-Premise
) I-Premise
varying I-Premise
from I-Premise
0.38 I-Premise
to I-Premise
0.99 I-Premise
( I-Premise
RAND-36 I-Premise
) I-Premise
and I-Premise
from I-Premise
-0.34 I-Premise
to I-Premise
-0.57 I-Premise
( I-Premise
RSCL I-Premise
) I-Premise
, I-Premise
most I-Premise
persistent I-Premise
at I-Premise
3-month I-Premise
follow-up I-Premise
. I-Premise

Anxiety B-Premise
scores I-Premise
yielded I-Premise
a I-Premise
quadratic I-Premise
interaction I-Premise
comparing I-Premise
UCO I-Premise
and I-Premise
SMEX I-Premise
( I-Premise
p I-Premise
= I-Premise
0.049 I-Premise
) I-Premise
, I-Premise
with I-Premise
trends I-Premise
for I-Premise
changes I-Premise
in I-Premise
SMEX I-Premise
but I-Premise
not I-Premise
UCO I-Premise
. I-Premise

Randomisation O
was O
stratified O
by O
centre O
. O

Thus B-Claim
, I-Claim
docetaxel-carboplatin I-Claim
represents I-Claim
an I-Claim
alternative I-Claim
first-line I-Claim
chemotherapy I-Claim
regimen I-Claim
for I-Claim
patients I-Claim
with I-Claim
newly I-Claim
diagnosed I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

Compliance O
was O
excellent O
, O
with O
7,286 O
questionnaires O
analyzed O
. O

Three O
patients O
were O
excluded O
from O
the O
trial O
. O

other O
cancers O
, O
death O
from O
all O
causes O
, O
venous O
thromboembolism O
, O
cerebrovascular O
disease O
, O
dementia O
, O
and O
quality O
of O
life O
. O

A O
longitudinal O
QoL O
study O
on O
a O
subset O
of O
ESPAC-1 O
patients O
who O
prospectively O
completed O
the O
EORTC O
QLQ O
C-30 O
questionnaire O
during O
treatment O
and O
follow-up O
. O

In B-Premise
the I-Premise
pamidronate I-Premise
group I-Premise
, I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
hypercalcemia I-Premise
, I-Premise
severe I-Premise
bone I-Premise
pain I-Premise
, I-Premise
and I-Premise
symptomatic I-Premise
impending I-Premise
fractures I-Premise
decreased I-Premise
by I-Premise
65 I-Premise
% I-Premise
, I-Premise
30 I-Premise
% I-Premise
, I-Premise
and I-Premise
50 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
event-rates I-Premise
of I-Premise
systemic I-Premise
treatment I-Premise
and I-Premise
radiotherapy I-Premise
decreased I-Premise
by I-Premise
35 I-Premise
% I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

Laser B-Claim
treatment I-Claim
appeared I-Claim
to I-Claim
reduce I-Claim
the I-Claim
severity I-Claim
of I-Claim
facial I-Claim
hair I-Claim
and I-Claim
time I-Claim
spent I-Claim
on I-Claim
hair I-Claim
removal I-Claim
as I-Claim
well I-Claim
as I-Claim
alleviating I-Claim
depression I-Claim
and I-Claim
anxiety I-Claim
in I-Claim
women I-Claim
with I-Claim
PCOS I-Claim
. I-Claim

The O
purpose O
of O
this O
pilot O
study O
was O
to O
examine O
the O
effects O
of O
a O
combined O
cardiorespiratory O
and O
resistance O
exercise O
training O
program O
of O
short O
duration O
on O
the O
cardiorespiratory O
fitness O
, O
strength O
endurance O
, O
task O
specific O
functional O
muscle O
capacity O
, O
body O
composition O
and O
quality O
of O
life O
( O
QOL O
) O
in O
women O
breast O
cancer O
survivors O
. O

Enzastaurin O
( O
E O
) O
inhibits O
PKCβ O
and O
PI3K/AKT O
signaling O
pathways O
with O
a O
dose-dependent O
effect O
on O
growth O
of O
pancreatic O
carcinoma O
xenografts O
. O

To O
determine O
the O
incremental O
cost O
utility O
of O
epoetin-alfa O
versus O
placebo O
in O
anaemic O
patients O
with O
stage O
IV O
breast O
cancer O
from O
a O
UK O
National O
Health O
Service O
perspective O
. O

The B-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
for I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
was I-Premise
8.5 I-Premise
months I-Premise
, I-Premise
and I-Premise
8.0 I-Premise
months I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.075 I-Premise
) I-Premise
. I-Premise

Hypnosis B-Claim
appears I-Claim
to I-Claim
reduce I-Claim
perceived I-Claim
hot I-Claim
flashes I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
and I-Claim
may I-Claim
have I-Claim
additional I-Claim
benefits I-Claim
such I-Claim
as I-Claim
reduced I-Claim
anxiety I-Claim
and I-Claim
depression I-Claim
, I-Claim
and I-Claim
improved I-Claim
sleep I-Claim
. I-Claim

Using O
hierarchical O
cluster O
analysis O
, O
3 O
mutually O
exclusive O
symptom O
groupings O
were O
identified O
in O
the O
cohort O
. O

The B-Premise
mean I-Premise
changes I-Premise
in I-Premise
the I-Premise
endpoints I-Premise
from I-Premise
baseline I-Premise
in I-Premise
the I-Premise
trial I-Premise
group I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
: I-Premise
in I-Premise
the I-Premise
primary I-Premise
endpoints I-Premise
, I-Premise
body I-Premise
weight I-Premise
( I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
fatigue I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
in I-Premise
the I-Premise
secondary I-Premise
endpoints I-Premise
, I-Premise
grip I-Premise
strength I-Premise
( I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
Glasgow I-Premise
Prognostic I-Premise
Score I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
Eastern I-Premise
Cooperative I-Premise
Oncology I-Premise
Group I-Premise
performance I-Premise
status I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
IL-6 I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
and I-Premise
tumor I-Premise
necrosis I-Premise
factor-α I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Data O
were O
analyzed O
with O
use O
of O
t O
tests O
, O
the O
Mann-Whitney O
U O
test O
, O
and O
chi2 O
tests O
as O
appropriate O
. O

Although B-Premise
mean I-Premise
EQ-5D I-Premise
QL I-Premise
values I-Premise
differed I-Premise
between I-Premise
the I-Premise
treatments I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
this I-Premise
difference I-Premise
dissipated I-Premise
following I-Premise
generation I-Premise
of I-Premise
quality-adjusted I-Premise
life I-Premise
year I-Premise
values I-Premise
. I-Premise

Hot B-Claim
flash I-Claim
frequency I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
was I-Claim
reduced I-Claim
following I-Claim
acupuncture I-Claim
. I-Claim

Acupuncture B-Claim
appears I-Claim
to I-Claim
be I-Claim
equivalent I-Claim
to I-Claim
drug I-Claim
therapy I-Claim
in I-Claim
these I-Claim
patients I-Claim
. I-Claim

Intensive B-Claim
nutrition I-Claim
intervention I-Claim
following I-Claim
the I-Claim
ADA I-Claim
MNT I-Claim
protocol I-Claim
results I-Claim
in I-Claim
improved I-Claim
dietary I-Claim
intake I-Claim
compared I-Claim
with I-Claim
standard I-Claim
practice I-Claim
and I-Claim
seems I-Claim
to I-Claim
beneficially I-Claim
impact I-Claim
nutrition-related I-Claim
outcomes I-Claim
previously I-Claim
observed I-Claim
in I-Claim
oncology I-Claim
outpatients I-Claim
receiving I-Claim
radiotherapy I-Claim
. I-Claim

Progression-free O
survival O
, O
survival O
, O
response O
rate O
, O
safety O
, O
and O
HRQOL O
. O

In B-Premise
contrast I-Premise
, I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
endpoints I-Premise
with I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
from I-Premise
baseline I-Premise
included I-Premise
body I-Premise
weight I-Premise
( I-Premise
p I-Premise
< I-Premise
0.02 I-Premise
) I-Premise
and I-Premise
appetite I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

Bone O
resorption O
markers O
measured O
included O
urinary O
calcium O
( O
uCa O
) O
, O
hydroxyproline O
( O
Hyp O
) O
, O
and O
the O
collagen O
breakdown O
products O
: O
NTx O
, O
Crosslaps O
and O
Free O
Dpd O
. O

The B-Premise
clinical I-Premise
results I-Premise
found I-Premise
raltitrexed I-Premise
and I-Premise
cisplatin I-Premise
to I-Premise
be I-Premise
superior I-Premise
to I-Premise
cisplatin I-Premise
with I-Premise
regard I-Premise
to I-Premise
overall I-Premise
survival I-Premise
( I-Premise
P I-Premise
= I-Premise
.048 I-Premise
) I-Premise
. I-Premise

Further B-Claim
investigation I-Claim
to I-Claim
define I-Claim
and I-Claim
measure I-Claim
the I-Claim
effects I-Claim
of I-Claim
these I-Claim
genes I-Claim
in I-Claim
chemotherapeutic I-Claim
regimens I-Claim
, I-Claim
drug I-Claim
toxicities I-Claim
, I-Claim
disease I-Claim
progression I-Claim
, I-Claim
and I-Claim
QOL I-Claim
are I-Claim
critical I-Claim
. I-Claim

The B-Premise
median I-Premise
overall I-Premise
survival I-Premise
( I-Premise
OS I-Premise
) I-Premise
was I-Premise
34.1 I-Premise
and I-Premise
30.7 I-Premise
months I-Premise
in I-Premise
Arms I-Premise
A I-Premise
and I-Premise
B I-Premise
, I-Premise
respectively I-Premise
( I-Premise
HR I-Premise
0.98 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.81-1.18 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.82 I-Premise
) I-Premise
. I-Premise

On B-Claim
the I-Claim
basis I-Claim
of I-Claim
HRQOL I-Claim
results I-Claim
, I-Claim
the I-Claim
authors I-Claim
determined I-Claim
that I-Claim
UAE I-Claim
is I-Claim
a I-Claim
good I-Claim
alternative I-Claim
to I-Claim
hysterectomy I-Claim
. I-Claim

Compared B-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
, I-Premise
patients I-Premise
in I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
had I-Premise
more I-Premise
grade I-Premise
3-4 I-Premise
hematologic I-Premise
toxic I-Premise
effects I-Premise
( I-Premise
requiring I-Premise
more I-Premise
supportive I-Premise
care I-Premise
) I-Premise
and I-Premise
more I-Premise
grade I-Premise
3-4 I-Premise
infections I-Premise
( I-Premise
5.1 I-Premise
% I-Premise
versus I-Premise
2.7 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.034 I-Premise
) I-Premise
but I-Premise
did I-Premise
not I-Premise
have I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
increase I-Premise
in I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
3.3 I-Premise
% I-Premise
versus I-Premise
3.1 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.80 I-Premise
) I-Premise
. I-Premise

The O
purpose O
of O
this O
blinded O
, O
randomized O
clinical O
trial O
was O
to O
compare O
two O
topical O
agents O
( O
Calendula O
Weleda O
cream O
vs. O
Essex O
cream O
) O
in O
reducing O
the O
risk O
of O
severe O
acute O
radiation O
skin O
reactions O
( O
ARSR O
) O
in O
relation O
to O
adjuvant O
radiotherapy O
( O
RT O
) O
for O
breast O
cancer O
. O

Data O
come O
from O
the O
Moving O
Beyond O
Cancer O
psychoeducational O
intervention O
trial O
, O
aimed O
at O
easing O
the O
transition O
from O
patient O
to O
survivor O
. O

However O
, O
these O
guidelines O
can O
be O
questioned O
with O
regard O
to O
the O
extent O
of O
efficacy O
as O
well O
as O
the O
rationale O
for O
not O
using O
strong O
opioids O
as O
first-line O
treatment O
, O
especially O
in O
terminal O
cancer O
patients O
. O

The O
Medical O
Outcomes O
Trust O
Short-Form O
36 O
Survey O
was O
used O
to O
measure O
quality O
of O
life O
before O
and O
after O
the O
intervention O
. O

No B-Premise
significant I-Premise
difference I-Premise
was I-Premise
observed I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
and I-Premise
adverse I-Premise
events I-Premise
between I-Premise
the I-Premise
treated I-Premise
groups I-Premise
and I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

Chemotherapy B-Claim
provided I-Claim
on I-Claim
average I-Claim
an I-Claim
additional I-Claim
1.0 I-Claim
quality-adjusted I-Claim
life I-Claim
months I-Claim
within I-Claim
a I-Claim
restricted I-Claim
2-year I-Claim
time I-Claim
period I-Claim
from I-Claim
the I-Claim
time I-Claim
of I-Claim
resection I-Claim
. I-Claim

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
survival I-Premise
advantage I-Premise
for I-Premise
GCa I-Premise
compared I-Premise
with I-Premise
MIC I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.76 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.61 I-Premise
to I-Premise
0 I-Premise
. I-Premise
93 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
. I-Premise

The B-Premise
ICUR I-Premise
for I-Premise
epoetin-alfa I-Premise
treatment I-Premise
was I-Premise
pounds I-Premise
8,851 I-Premise
per I-Premise
QALY I-Premise
, I-Premise
with I-Premise
a I-Premise
99 I-Premise
% I-Premise
probability I-Premise
of I-Premise
a I-Premise
positive I-Premise
net I-Premise
benefit I-Premise
in I-Premise
QALYs I-Premise
( I-Premise
net I-Premise
benefit I-Premise
= I-Premise
0.4805 I-Premise
years I-Premise
of I-Premise
perfect I-Premise
life I-Premise
) I-Premise
and I-Premise
a I-Premise
94 I-Premise
% I-Premise
probability I-Premise
of I-Premise
being I-Premise
acceptable I-Premise
using I-Premise
a I-Premise
threshold I-Premise
ICUR I-Premise
of I-Premise
pounds I-Premise
30,000/QALY I-Premise
. I-Premise

Twenty-eight O
patients O
were O
allocated O
to O
receive O
ATP O
treatment O
and O
30 O
received O
no O
ATP O
. O

37 B-Premise
( I-Premise
11 I-Premise
% I-Premise
) I-Premise
of I-Premise
350 I-Premise
in I-Premise
the I-Premise
combined I-Premise
group I-Premise
and I-Premise
23 I-Premise
( I-Premise
7 I-Premise
% I-Premise
) I-Premise
of I-Premise
35 I-Premise
in I-Premise
the I-Premise
endocrine-only I-Premise
group I-Premise
had I-Premise
overall I-Premise
bother I-Premise
from I-Premise
all I-Premise
bowel I-Premise
symptoms I-Premise
( I-Premise
p=0.022 I-Premise
) I-Premise
. I-Premise

Findings B-Claim
suggest I-Claim
that I-Claim
self-efficacy I-Claim
may I-Claim
influence I-Claim
long-term I-Claim
maintenance I-Claim
of I-Claim
healthy I-Claim
lifestyle I-Claim
practices I-Claim
among I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

However O
, O
the O
early B-Claim
postoperative I-Claim
outcome I-Claim
does I-Claim
not I-Claim
give I-Claim
a I-Claim
complete I-Claim
answer I-Claim
and O
the B-Claim
eventual I-Claim
cost-effectiveness I-Claim
will I-Claim
only I-Claim
become I-Claim
clear I-Claim
after I-Claim
long-term I-Claim
follow-up I-Claim
. I-Claim

Subjects O
were O
asked O
to O
document O
the O
frequency O
, O
duration O
, O
and O
intensity O
of O
all O
exercise O
participation O
on O
monthly O
calendars O
. O

Assess O
toxicity O
and O
efficacy O
of O
cisplatin O
( O
Cis O
) O
doublet O
combinations O
in O
advanced O
and O
recurrent O
cervical O
carcinoma O
. O

In O
this O
large O
randomized O
trial O
, O
thalidomide B-Claim
in I-Claim
combination I-Claim
with I-Claim
chemotherapy I-Claim
did I-Claim
not I-Claim
improve I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
SCLC I-Claim
but I-Claim
was I-Claim
associated I-Claim
with I-Claim
an I-Claim
increased I-Claim
risk I-Claim
of I-Claim
thrombotic I-Claim
events I-Claim
. I-Claim

At O
the O
beginning O
and O
the O
end O
of O
the O
study O
, O
we O
evaluated O
physical O
, O
cognitive O
and O
emotional O
status O
and O
somatic O
complaints O
with O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
Core O
Module O
( O
EORTC-QLQ-30 O
) O
questionnaire O
, O
and O
maximal O
physical O
performance O
with O
an O
ergometric O
stress O
test O
. O

The B-Premise
daytime I-Premise
group I-Premise
showed I-Premise
a I-Premise
significant I-Premise
effect I-Premise
on I-Premise
general I-Premise
health I-Premise
, I-Premise
vitality I-Premise
, I-Premise
social I-Premise
functioning I-Premise
, I-Premise
mental I-Premise
health I-Premise
, I-Premise
and I-Premise
role I-Premise
emotional I-Premise
as I-Premise
revealed I-Premise
on I-Premise
the I-Premise
SF-8 I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
anorectal I-Premise
manometry I-Premise
and I-Premise
endoanal I-Premise
ultrasound I-Premise
findings I-Premise
. I-Premise

Between O
May O
2003 O
and O
April O
2004 O
, O
98 O
patients O
in O
response O
or O
stable O
disease O
under O
imatinib O
reached O
more O
than O
1 O
year O
of O
follow-up O
. O

Survival O
curves O
were O
plotted O
and O
were O
compared O
with O
the O
Mantel-Haenszel O
test O
. O

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
effects I-Premise
of I-Premise
the I-Premise
intervention I-Premise
on I-Premise
mood I-Premise
, I-Premise
QOL I-Premise
or I-Premise
healthcare I-Premise
utilisation I-Premise
. I-Premise

SATURN O
( O
Sequential O
Tarceva O
in O
Unresectable O
NSCLC O
) O
was O
a O
randomised O
, O
double-blind O
, O
placebo-controlled O
, O
multicentre O
study O
investigating O
the O
impact O
of O
erlotinib O
maintenance O
therapy O
on O
HRQoL O
in O
patients O
with O
locally O
advanced O
or O
recurrent O
NSCLC O
. O

The B-Claim
implication I-Claim
is I-Claim
that I-Claim
CBT I-Claim
for I-Claim
fatigue I-Claim
should I-Claim
be I-Claim
offered I-Claim
to I-Claim
patients I-Claim
with I-Claim
cancer I-Claim
with I-Claim
the I-Claim
highest I-Claim
chance I-Claim
to I-Claim
benefit I-Claim
. I-Claim

Patients O
with O
polycystic O
liver O
( O
n O
= O
54 O
) O
were O
randomly O
assigned O
to O
groups O
given O
lanreotide O
( O
120 O
mg O
) O
or O
placebo O
, O
administered O
every O
28 O
days O
for O
24 O
weeks O
. O

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
randomised I-Premise
groups I-Premise
in I-Premise
terms I-Premise
of I-Premise
secondary I-Premise
endpoints I-Premise
, I-Premise
including I-Premise
tissue I-Premise
induration I-Premise
( I-Premise
fibrosis I-Premise
) I-Premise
in I-Premise
the I-Premise
irradiated I-Premise
breast I-Premise
or I-Premise
chest I-Premise
wall I-Premise
, I-Premise
pectoral I-Premise
fold I-Premise
or I-Premise
supraclavicular I-Premise
fossa I-Premise
, I-Premise
change I-Premise
in I-Premise
photographic I-Premise
breast/chest I-Premise
wall I-Premise
appearance I-Premise
or I-Premise
patient I-Premise
self-assessment I-Premise
of I-Premise
function I-Premise
and I-Premise
Quality I-Premise
of I-Premise
Life I-Premise
at I-Premise
either I-Premise
6 I-Premise
or I-Premise
12 I-Premise
months I-Premise
. I-Premise

We B-Claim
conclude I-Claim
that I-Claim
a I-Claim
structured I-Claim
aerobic I-Claim
training I-Claim
programme I-Claim
improves I-Claim
the I-Claim
physical I-Claim
performance I-Claim
of I-Claim
patients I-Claim
recovering I-Claim
from I-Claim
surgery I-Claim
for I-Claim
solid I-Claim
tumours I-Claim
. I-Claim

Randomised O
controlled O
trial O
. O

We O
randomized O
122 O
patients O
with O
lymphoma O
to O
usual O
care O
( O
n O
= O
62 O
) O
or O
12 O
weeks O
of O
supervised O
aerobic O
exercise O
training O
( O
AET O
";" O
n O
= O
60 O
) O
. O

The B-Premise
most I-Premise
common I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
toxicities I-Premise
were I-Premise
neutropenia I-Premise
( I-Premise
82.9 I-Premise
% I-Premise
for I-Premise
docetaxel I-Premise
";" I-Premise
69.2 I-Premise
% I-Premise
for I-Premise
vinorelbine I-Premise
";" I-Premise
P I-Premise
= I-Premise
.031 I-Premise
) I-Premise
and I-Premise
leukopenia I-Premise
( I-Premise
58.0 I-Premise
% I-Premise
for I-Premise
docetaxel I-Premise
";" I-Premise
51.7 I-Premise
% I-Premise
for I-Premise
vinorelbine I-Premise
) I-Premise
. I-Premise

Among B-Premise
the I-Premise
54 I-Premise
patients I-Premise
who I-Premise
exhibited I-Premise
isolated I-Premise
local I-Premise
relapse I-Premise
, I-Premise
35 I-Premise
% I-Premise
( I-Premise
19/54 I-Premise
) I-Premise
survived I-Premise
in I-Premise
further I-Premise
remission I-Premise
longer I-Premise
than I-Premise
2 I-Premise
years I-Premise
after I-Premise
retreatment I-Premise
, I-Premise
including I-Premise
local I-Premise
therapy I-Premise
( I-Premise
surgery I-Premise
+/- I-Premise
radiotherapy I-Premise
) I-Premise
. I-Premise

This O
prospective O
, O
randomized O
, O
multicentric O
phase O
III O
study O
was O
designed O
to O
compare O
continuous O
( O
CONT O
) O
compared O
with O
interrupted O
( O
INT O
) O
imatinib O
beyond O
1 O
year O
of O
treatment O
in O
patients O
with O
advanced O
GIST O
. O

In O
the O
Post O
Operative O
Radiation O
Therapy O
in O
Endometrial O
Cancer O
( O
PORTEC O
) O
trial O
, O
patients O
with O
endometrial O
carcinoma O
were O
randomly O
assigned O
to O
receive O
external-beam O
radiotherapy O
( O
EBRT O
) O
or O
vaginal O
brachytherapy O
( O
VBT O
) O
. O

There O
are O
no O
known O
effective O
treatments O
for O
painful O
chemotherapy-induced O
peripheral O
neuropathy O
. O

In B-Premise
an I-Premise
intent-to-treat I-Premise
analysis I-Premise
, I-Premise
the I-Premise
2-year I-Premise
OS I-Premise
rates I-Premise
were I-Premise
65.7 I-Premise
% I-Premise
for I-Premise
CIS I-Premise
and I-Premise
66.2 I-Premise
% I-Premise
for I-Premise
TPZ/CIS I-Premise
( I-Premise
TPZ/CIS I-Premise
-- I-Premise
CIS I-Premise
: I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-5.9 I-Premise
% I-Premise
to I-Premise
6.9 I-Premise
% I-Premise
) I-Premise
. I-Premise

To O
determine O
whether O
drug O
intensification O
improves O
survival O
of O
patients O
with O
extensive O
SCLC O
, O
we O
compared O
this O
treatment O
with O
a O
four-drug O
regimen O
containing O
EP O
plus O
cyclophosphamide O
and O
4'-epidoxorubicin O
( O
PCDE O
) O
. O

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
granulocytopenia I-Premise
was I-Premise
equivalent I-Premise
in I-Premise
both I-Premise
arms I-Premise
but I-Premise
more I-Premise
grade I-Premise
3/4 I-Premise
neurotoxicity I-Premise
, I-Premise
mild I-Premise
venous I-Premise
toxicity I-Premise
, I-Premise
and I-Premise
FN I-Premise
were I-Premise
seen I-Premise
on I-Premise
arm I-Premise
1 I-Premise
. I-Premise

However O
, O
previous O
studies O
of O
coping O
skills O
training O
( O
CST O
) O
interventions O
have O
not O
been O
tested O
in O
patients O
with O
lung O
cancer O
nor O
have O
systematically O
included O
caregivers O
. O

Median B-Premise
survival I-Premise
time I-Premise
for I-Premise
all I-Premise
patients I-Premise
was I-Premise
15 I-Premise
months I-Premise
, I-Premise
with I-Premise
no I-Premise
difference I-Premise
in I-Premise
survival I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
P I-Premise
=.26 I-Premise
) I-Premise
. I-Premise

The O
regimens O
were O
compared O
with O
regard O
to O
effects O
on O
survival O
, O
response O
rates O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

However O
, O
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
of I-Premise
QOL I-Premise
scores I-Premise
and I-Premise
postoperative I-Premise
complication I-Premise
scores I-Premise
between I-Premise
the I-Premise
2 I-Premise
reconstruction I-Premise
groups I-Premise
. I-Premise

During B-Premise
thalidomide I-Premise
maintenance I-Premise
, I-Premise
the I-Premise
scores I-Premise
for I-Premise
the I-Premise
QLQ-MY24 I-Premise
paraesthesia I-Premise
became I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
MPT I-Premise
arm I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
684 I-Premise
patients I-Premise
with I-Premise
data I-Premise
that I-Premise
could I-Premise
be I-Premise
evaluated I-Premise
, I-Premise
ultrasonography I-Premise
of I-Premise
the I-Premise
neck I-Premise
was I-Premise
normal I-Premise
in I-Premise
652 I-Premise
( I-Premise
95 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
stimulated I-Premise
thyroglobulin I-Premise
level I-Premise
was I-Premise
1.0 I-Premise
ng I-Premise
per I-Premise
milliliter I-Premise
or I-Premise
less I-Premise
in I-Premise
621 I-Premise
of I-Premise
the I-Premise
652 I-Premise
patients I-Premise
( I-Premise
95 I-Premise
% I-Premise
) I-Premise
without I-Premise
detectable I-Premise
thyroglobulin I-Premise
antibodies I-Premise
. I-Premise

Care O
closer O
to O
home O
is O
being O
explored O
as O
a O
means O
of O
improving O
patient O
experience O
as O
well O
as O
efficiency O
in O
terms O
of O
cost O
savings O
. O

Consented O
participants O
were O
randomized O
to O
an O
experimental O
group O
( O
EG O
) O
( O
12 O
weekly O
MMP O
sessions O
) O
or O
a O
control O
group O
( O
no O
sessions O
) O
. O

The O
aim O
of O
this O
feasibility O
trial O
was O
to O
determine O
the O
safety O
and O
efficacy O
of O
resistance O
exercise O
by O
prostate O
cancer O
survivors O
with O
bone O
metastatic O
disease O
. O

Median B-Premise
survival I-Premise
from I-Premise
randomisation I-Premise
was I-Premise
25·7 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
23·0-27·9 I-Premise
) I-Premise
for I-Premise
patients I-Premise
on I-Premise
early I-Premise
treatment I-Premise
and I-Premise
27·1 I-Premise
months I-Premise
( I-Premise
22·8-30·9 I-Premise
) I-Premise
for I-Premise
those I-Premise
on I-Premise
delayed I-Premise
treatment I-Premise
. I-Premise

Response O
rate O
( O
RR O
) O
was O
evaluated O
after O
every O
four O
courses O
. O

The O
combination O
of O
cisplatin O
and O
etoposide O
( O
PE O
) O
has O
been O
a O
standard O
treatment O
for O
patients O
with O
poor-prognosis O
small O
cell O
lung O
cancer O
( O
SCLC O
) O
. O

Key O
trial O
variables O
monitored O
monthly O
were O
TPV O
( O
primary O
endpoint O
) O
, O
serum O
testosterone O
, O
prostate-specific O
antigen O
( O
PSA O
) O
, O
the O
International O
Prostate O
Symptom O
Score O
( O
IPSS O
) O
and O
the O
Benign O
Prostate O
Hyperplasia O
Impact O
Index O
. O

The B-Premise
total I-Premise
short-term I-Premise
remission I-Premise
rate I-Premise
, I-Premise
the I-Premise
improvement I-Premise
rate I-Premise
of I-Premise
clinical I-Premise
syndrome I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
50.0 I-Premise
% I-Premise
, I-Premise
70.0 I-Premise
% I-Premise
and I-Premise
76.7 I-Premise
% I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
and I-Premise
43.3 I-Premise
% I-Premise
, I-Premise
46.7 I-Premise
% I-Premise
and I-Premise
50.0 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
respectively I-Premise
, I-Premise
showing I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
( I-Premise
all I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

For B-Premise
survival I-Premise
, I-Premise
multiple I-Premise
sites I-Premise
of I-Premise
visceral I-Premise
disease I-Premise
, I-Premise
pain I-Premise
, I-Premise
global I-Premise
QL I-Premise
and I-Premise
fatigue I-Premise
were I-Premise
significant I-Premise
prognostic I-Premise
factors I-Premise
in I-Premise
the I-Premise
univariate I-Premise
analysis I-Premise
. I-Premise

Adherence O
was O
assessed O
by O
a O
self-reported O
diary O
, O
limb O
volume O
by O
a O
water O
displacement O
device O
, O
quality O
of O
life O
by O
the O
Upper O
Limb O
Lymphedema O
Questionnaire O
( O
ULL27 O
) O
, O
prior O
to O
, O
and O
after O
the O
intervention O
period O
. O

For B-Premise
19 I-Premise
'per I-Premise
protocol I-Premise
' I-Premise
patients I-Premise
, I-Premise
2/10 I-Premise
in I-Premise
the I-Premise
RS I-Premise
+ I-Premise
WBRT I-Premise
arm I-Premise
had I-Premise
distant I-Premise
intracranial I-Premise
failure I-Premise
( I-Premise
one I-Premise
also I-Premise
had I-Premise
local I-Premise
failure I-Premise
) I-Premise
and I-Premise
3/9 I-Premise
S I-Premise
+ I-Premise
WBRT I-Premise
patients I-Premise
had I-Premise
distant I-Premise
intracranial I-Premise
failure I-Premise
( I-Premise
no I-Premise
local I-Premise
failures I-Premise
) I-Premise
. I-Premise

The B-Premise
operation I-Premise
time I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
, I-Premise
and I-Premise
the I-Premise
leakage I-Premise
rate I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
transthoracic I-Premise
group I-Premise
( I-Premise
Student I-Premise
's I-Premise
t-test I-Premise
and I-Premise
Fischer I-Premise
's I-Premise
exact I-Premise
test I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Dignity B-Premise
therapy I-Premise
was I-Premise
significantly I-Premise
better I-Premise
than I-Premise
client-centred I-Premise
care I-Premise
in I-Premise
improving I-Premise
spiritual I-Premise
wellbeing I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=10·35 I-Premise
";" I-Premise
p=0·006 I-Premise
) I-Premise
, I-Premise
and I-Premise
was I-Premise
significantly I-Premise
better I-Premise
than I-Premise
standard I-Premise
palliative I-Premise
care I-Premise
in I-Premise
terms I-Premise
of I-Premise
lessening I-Premise
sadness I-Premise
or I-Premise
depression I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=9·38 I-Premise
";" I-Premise
p=0·009 I-Premise
) I-Premise
";" I-Premise
significantly B-Premise
more I-Premise
patients I-Premise
who I-Premise
had I-Premise
received I-Premise
dignity I-Premise
therapy I-Premise
reported I-Premise
that I-Premise
the I-Premise
study I-Premise
group I-Premise
had I-Premise
been I-Premise
satisfactory I-Premise
, I-Premise
compared I-Premise
with I-Premise
those I-Premise
who I-Premise
received I-Premise
standard I-Premise
palliative I-Premise
care I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=29·58 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0·0001 I-Premise
) I-Premise
. I-Premise

The B-Premise
HR I-Premise
for I-Premise
overall I-Premise
survival I-Premise
was I-Premise
0.96 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.75 I-Premise
to1.23 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.7349 I-Premise
) I-Premise
. I-Premise

To O
prospectively O
evaluate O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
outcomes O
for O
uterine O
artery O
embolization O
( O
UAE O
) O
and O
hysterectomy O
up O
to O
24 O
months O
after O
the O
intervention O
in O
terms O
of O
mental O
and O
physical O
health O
, O
urinary O
and O
defecatory O
function O
, O
and O
overall O
patient O
satisfaction O
. O

Opioids O
, O
on O
their O
own O
, O
do O
not O
control O
this O
type O
of O
pain O
well O
enough O
, O
and O
co-analgesics O
are O
necessary O
. O

Self-reported B-Premise
severity I-Premise
of I-Premise
facial I-Premise
hair I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
51 I-Premise
) I-Premise
fell I-Premise
from I-Premise
7.3 I-Premise
to I-Premise
3.6 I-Premise
over I-Premise
the I-Premise
6-month I-Premise
study I-Premise
period I-Premise
";" I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
37 I-Premise
) I-Premise
the I-Premise
corresponding I-Premise
scores I-Premise
were I-Premise
7.1 I-Premise
and I-Premise
6.1 I-Premise
. I-Premise

Over O
the O
next O
24 O
months O
, O
oral O
lesion O
size O
and O
number O
, O
pain O
, O
and O
quality O
of O
life O
were O
assessed O
. O

Only O
34 O
% O
( O
39/116 O
) O
received O
intensive O
local O
therapy O
defined O
as O
radical O
wide O
field O
radiotherapy O
or O
radical O
surgery O
or O
both O
. O

Clinical B-Premise
benefits I-Premise
, I-Premise
including I-Premise
an I-Premise
overall I-Premise
survival I-Premise
advantage I-Premise
, I-Premise
were I-Premise
also I-Premise
seen I-Premise
in I-Premise
women I-Premise
who I-Premise
crossed I-Premise
over I-Premise
from I-Premise
placebo I-Premise
to I-Premise
letrozole I-Premise
after I-Premise
unblinding I-Premise
, I-Premise
indicating I-Premise
that I-Premise
tumors I-Premise
remain I-Premise
sensitive I-Premise
to I-Premise
hormone I-Premise
therapy I-Premise
despite I-Premise
a I-Premise
prolonged I-Premise
period I-Premise
since I-Premise
discontinuation I-Premise
of I-Premise
tamoxifen I-Premise
. I-Premise

Patients O
randomly O
received O
docetaxel O
60 O
mg/m2 O
( O
day O
1 O
) O
or O
vinorelbine O
25 O
mg/m2 O
( O
days O
1 O
and O
8 O
) O
every O
21 O
days O
for O
four O
cycles O
. O

Median B-Premise
duration I-Premise
of I-Premise
response I-Premise
( I-Premise
complete I-Premise
and I-Premise
partial I-Premise
combined I-Premise
) I-Premise
in I-Premise
the I-Premise
group I-Premise
treated I-Premise
with I-Premise
the I-Premise
combination I-Premise
was I-Premise
33 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
9 I-Premise
to I-Premise
50 I-Premise
months I-Premise
) I-Premise
, I-Premise
versus I-Premise
22 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
5 I-Premise
to I-Premise
38 I-Premise
months I-Premise
) I-Premise
for I-Premise
the I-Premise
second I-Premise
group I-Premise
( I-Premise
P I-Premise
=.03 I-Premise
) I-Premise
. I-Premise

In O
view O
of O
the O
improvements O
in O
overall O
and O
progression-free O
survival O
noted O
with O
pemetrexed O
maintenance O
therapy O
, O
such B-Claim
treatment I-Claim
is I-Claim
an I-Claim
option I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-squamous I-Claim
NSCLC I-Claim
who I-Claim
have I-Claim
not I-Claim
progressed I-Claim
after I-Claim
platinum-based I-Claim
induction I-Claim
therapy I-Claim
. I-Claim

Two O
hundred O
thirty-three O
lung O
cancer O
patients O
and O
their O
caregivers O
were O
randomly O
assigned O
to O
receive O
14 O
telephone-based O
sessions O
of O
either O
caregiver-assisted O
CST O
or O
education/support O
involving O
the O
caregiver O
. O

Results B-Claim
of I-Claim
previous I-Claim
phase I-Claim
3 I-Claim
trials I-Claim
in I-Claim
inoperable I-Claim
HCC I-Claim
have I-Claim
been I-Claim
conflicting I-Claim
and I-Claim
inconclusive I-Claim
. I-Claim

The O
primary O
outcome O
, O
Fatigue O
score O
( O
CRF O
) O
, O
was O
evaluated O
by O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Anaemia O
Questionnaire O
( O
FACT-An- O
) O
( O
FACT-G O
score O
& O
FACT-An O
Anemia O
subscale O
) O
. O

Mixed-effects O
models O
and O
multivariate O
regressions O
were O
used O
to O
examine O
the O
longitudinal O
impact O
of O
the O
intervention O
on O
patient-physician O
communication O
, O
dynamics O
of O
patient-physician O
interaction O
, O
and O
the O
association O
between O
PROs O
and O
the O
content O
of O
clinic O
discussion O
. O

The B-Premise
addition I-Premise
of I-Premise
mitoxantrone I-Premise
to I-Premise
prednisone I-Premise
after I-Premise
failure I-Premise
of I-Premise
prednisone I-Premise
alone I-Premise
was I-Premise
associated I-Premise
with I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
, I-Premise
pain I-Premise
impact I-Premise
, I-Premise
pain I-Premise
relief I-Premise
, I-Premise
insomnia I-Premise
, I-Premise
and I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
.001 I-Premise
< I-Premise
P I-Premise
< I-Premise
.003 I-Premise
) I-Premise
. I-Premise

By B-Claim
patient-reported I-Claim
questionnaire I-Claim
, I-Claim
78 I-Claim
Gy I-Claim
produced I-Claim
an I-Claim
increase I-Claim
in I-Claim
bowel I-Claim
movement I-Claim
frequency I-Claim
and I-Claim
no I-Claim
increase I-Claim
in I-Claim
bladder I-Claim
or I-Claim
sexual I-Claim
side I-Claim
effects I-Claim
at I-Claim
3 I-Claim
years I-Claim
compared I-Claim
with I-Claim
70 I-Claim
Gy I-Claim
. I-Claim

The B-Claim
two I-Claim
schedules I-Claim
are I-Claim
equivalent I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
response I-Claim
rate I-Claim
, I-Claim
median I-Claim
time-to-progression I-Claim
and I-Claim
overall I-Claim
survival I-Claim
. I-Claim

We O
aimed O
to O
assess O
quality O
of O
life O
in O
men O
with O
locally O
advanced O
prostate O
cancer O
in O
an O
open-label O
phase O
III O
randomised O
comparison O
between O
lifelong O
endocrine O
treatment O
with O
and O
without O
radiotherapy O
. O

Tumor B-Premise
response I-Premise
rates I-Premise
were I-Premise
comparable I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
10.2 I-Premise
% I-Premise
v I-Premise
8.2 I-Premise
% I-Premise
) I-Premise
. I-Premise

At O
disease O
progression O
, O
temozolomide O
salvage O
treatment O
was O
given O
to O
161 O
of O
282 O
patients O
( O
57 O
% O
) O
in O
the O
radiotherapy O
alone O
arm O
, O
and O
to O
62 O
of O
277 O
patients O
( O
22 O
% O
) O
in O
the O
temozolomide O
+ O
radiotherapy O
arm O
. O

The B-Premise
Grade I-Premise
2 I-Premise
or I-Premise
greater I-Premise
urinary I-Premise
toxicity I-Premise
was I-Premise
10 I-Premise
% I-Premise
at I-Premise
70 I-Premise
Gy I-Premise
and I-Premise
17.5 I-Premise
% I-Premise
at I-Premise
80 I-Premise
Gy I-Premise
( I-Premise
p I-Premise
= I-Premise
.046 I-Premise
) I-Premise
. I-Premise

The O
Active O
After O
Cancer O
Trial O
( O
AACT O
) O
was O
a O
multicenter O
pilot O
study O
evaluating O
the O
feasibility O
of O
a O
telephone-based O
exercise O
intervention O
in O
a O
cooperative O
group O
setting O
. O

The O
treatment O
could O
be O
incorporated O
into O
breast O
cancer O
survivorship O
programmes O
and O
delivered O
by O
trained O
breast O
cancer O
nurses O
. O

The O
16-week O
regimen O
features O
greater O
doxorubicin O
and O
5-FU O
dose-intensity O
than O
CAF O
and O
improved O
scheduling O
of O
antimetabolites O
with O
sequential O
methotrexate O
and O
5-FU O
, O
as O
well O
as O
infusion O
5-FU O
. O

Analyses B-Claim
by I-Claim
bortezomib I-Claim
dose I-Claim
intensity I-Claim
indicated I-Claim
better I-Claim
HRQoL I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
lower I-Claim
dose I-Claim
intensity I-Claim
. I-Claim

After O
demonstrating O
the O
efficacy O
of O
chemotherapy O
combined O
with O
tamoxifen O
for O
postmenopausal O
patients O
with O
lymph O
node-positive O
disease O
, O
the O
International O
Breast O
Cancer O
Study O
Group O
launched O
a O
randomized O
trial O
( O
Trial O
IX O
) O
to O
evaluate O
the O
role O
of O
adjuvant O
chemotherapy O
preceding O
treatment O
with O
tamoxifen O
for O
patients O
with O
lymph O
node-negative O
disease O
. O

The O
mean O
age O
of O
the O
participants O
was O
58.8 O
years O
";" O
181 O
( O
65 O
% O
) O
were O
men O
and O
98 O
( O
35 O
% O
) O
were O
women O
. O

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
pain I-Premise
severity I-Premise
, I-Premise
other I-Premise
postprocedural I-Premise
symptoms I-Premise
, I-Premise
or I-Premise
medication I-Premise
use I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

269 O
patients O
with O
cancer O
";" O
73 O
men O
, O
196 O
women O
, O
mean O
age O
47 O
years O
( O
range O
20-65 O
) O
representing O
21 O
diagnoses O
. O

It B-Claim
represents I-Claim
an I-Claim
excellent I-Claim
complement I-Claim
or I-Claim
an I-Claim
alternative I-Claim
to I-Claim
individual I-Claim
psycho-oncologic I-Claim
therapeutic I-Claim
support I-Claim
, I-Claim
widely O
proposed O
in O
France O
, O
and O
should O
now O
be O
tested O
in O
groups O
with O
other O
types O
of O
cancer O
and O
at O
other O
disease O
phases O
. O

With O
100 O
patients O
and O
77 O
events O
, O
the O
study O
had O
80 O
% O
power O
to O
detect O
an O
improvement O
in O
median O
progression-free O
survival O
from O
4 O
to O
6.5 O
months O
( O
one-sided O
, O
10 O
% O
-level O
test O
) O
. O

To O
examine O
the O
effects O
of O
a O
seated O
exercise O
program O
on O
fatigue O
and O
quality O
of O
life O
( O
QOL O
) O
in O
women O
with O
metastatic O
breast O
cancer O
. O

Few O
RCT O
exercise O
intervention O
studies O
have O
included O
cancer O
patients O
undergoing O
chemotherapy O
. O

The O
CCSP O
intervention O
was O
taught O
2 O
week O
before O
hospital O
admission O
with O
reinforcement O
at O
specified O
times O
during O
treatment O
and O
3 O
months O
after O
discharge O
. O

No B-Premise
acute I-Premise
Grade I-Premise
4 I-Premise
radiation I-Premise
toxicity I-Premise
developed I-Premise
. I-Premise

To O
evaluate O
the O
impact O
of O
laser O
treatment O
on O
the O
severity O
of O
facial O
hirsutism O
and O
on O
psychological O
morbidity O
in O
women O
with O
PCOS O
. O

Patients B-Premise
reported I-Premise
increased I-Premise
leakage I-Premise
with I-Premise
a I-Premise
full I-Premise
bladder I-Premise
( I-Premise
urge I-Premise
incontinence I-Premise
) I-Premise
between I-Premise
the I-Premise
2 I-Premise
and I-Premise
3-year I-Premise
questionnaires I-Premise
( I-Premise
42 I-Premise
% I-Premise
versus I-Premise
50 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
. I-Premise

Statistically B-Premise
significantly I-Premise
higher I-Premise
global I-Premise
QOL I-Premise
scores I-Premise
were I-Premise
found I-Premise
in I-Premise
PLD-treated I-Premise
patients I-Premise
at I-Premise
the I-Premise
first I-Premise
and I-Premise
second I-Premise
postbaseline I-Premise
QOL I-Premise
assessments I-Premise
. I-Premise

With B-Premise
median I-Premise
follow-up I-Premise
of I-Premise
15.8 I-Premise
months I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
1-year I-Premise
survival I-Premise
( I-Premise
46 I-Premise
% I-Premise
v I-Premise
41 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
=.42 I-Premise
) I-Premise
, I-Premise
median I-Premise
survival I-Premise
( I-Premise
9.9 I-Premise
v I-Premise
9.9 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
=.43 I-Premise
) I-Premise
, I-Premise
or I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
( I-Premise
4.0 I-Premise
v I-Premise
3.0 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
=.54 I-Premise
) I-Premise
between I-Premise
the I-Premise
two I-Premise
regimens I-Premise
. I-Premise

By B-Premise
cycle I-Premise
4 I-Premise
, I-Premise
mean I-Premise
differences I-Premise
were I-Premise
clinically I-Premise
meaningful I-Premise
for I-Premise
most I-Premise
domains I-Premise
, I-Premise
indicating I-Premise
poorer I-Premise
health I-Premise
status I-Premise
with I-Premise
VMP I-Premise
. I-Premise

They O
were O
randomized O
to O
receive O
marimastat O
10 O
mg O
or O
placebo O
orally O
bid O
for O
up O
to O
2 O
years O
. O

The O
planned O
sample O
size O
was O
850 O
, O
estimated O
to O
result O
in O
334 O
deaths O
, O
which O
would O
provide O
90 O
% O
power O
to O
detect O
a O
difference O
in O
2-year O
survival O
rates O
of O
60 O
% O
v O
70 O
% O
for O
CIS O
versus O
TPZ/CIS O
, O
respectively O
( O
hazard O
ratio O
= O
0.69 O
) O
. O

AT B-Claim
represents I-Claim
a I-Claim
valid I-Claim
option I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
MBC I-Claim
. I-Claim

MRI O
scans O
at O
baseline O
, O
6 O
months O
, O
and O
5 O
years O
were O
independently O
interpreted O
by O
two O
radiologists O
. O

The B-Claim
use I-Claim
of I-Claim
the I-Claim
Pain I-Claim
Education I-Claim
Program I-Claim
by I-Claim
nurses I-Claim
should I-Claim
be I-Claim
seriously I-Claim
considered I-Claim
on I-Claim
oncology I-Claim
units I-Claim
. I-Claim

The B-Premise
dysuria I-Premise
resolved I-Premise
faster I-Premise
in I-Premise
patients I-Premise
implanted I-Premise
with I-Premise
103Pd I-Premise
but B-Premise
was I-Premise
unaffected I-Premise
by I-Premise
the I-Premise
use I-Premise
of I-Premise
supplemental I-Premise
radiotherapy I-Premise
and/or I-Premise
androgen I-Premise
deprivation I-Premise
therapy I-Premise
. I-Premise

Taken B-Premise
together I-Premise
with I-Premise
the I-Premise
broader I-Premise
literature I-Premise
in I-Premise
this I-Premise
area I-Premise
, I-Premise
results B-Claim
from I-Claim
this I-Claim
study I-Claim
suggest I-Claim
that I-Claim
psychosocial I-Claim
interventions I-Claim
can I-Claim
lead I-Claim
to I-Claim
improvements I-Claim
in I-Claim
a I-Claim
range I-Claim
of I-Claim
outcomes I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Gemcitabine B-Claim
plus I-Claim
carboplatin I-Claim
significantly I-Claim
improves I-Claim
PFS I-Claim
and I-Claim
response I-Claim
rate I-Claim
without I-Claim
worsening I-Claim
quality I-Claim
of I-Claim
life I-Claim
for I-Claim
patients I-Claim
with I-Claim
platinum-sensitive I-Claim
recurrent I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

We O
conducted O
a O
multicenter O
randomized O
trial O
to O
compare O
quality-of-life O
outcomes O
between O
patients O
with O
clinically O
node-negative O
invasive O
breast O
cancer O
who O
received O
sentinel O
lymph O
node O
biopsy O
and O
patients O
who O
received O
standard O
axillary O
treatment O
. O

This O
study O
compares O
the O
clinical O
effectiveness O
and O
cost-effectiveness O
of O
self-expanding O
metal O
stents O
( O
SEMSs O
) O
with O
other O
palliative O
therapies O
to O
aid O
clinicians O
in O
making O
an O
evidence-based O
treatment O
choice O
. O

Despite B-Claim
the I-Claim
early I-Claim
closure I-Claim
of I-Claim
the I-Claim
study I-Claim
and I-Claim
the I-Claim
lack I-Claim
of I-Claim
power I-Claim
of I-Claim
the I-Claim
comparison I-Claim
, I-Claim
it I-Claim
seems I-Claim
that I-Claim
ldLV5FU2 I-Claim
could I-Claim
be I-Claim
considered I-Claim
as I-Claim
an I-Claim
active I-Claim
, I-Claim
easier I-Claim
and I-Claim
less I-Claim
expensive I-Claim
option I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
metastatic I-Claim
colorectal I-Claim
cancer I-Claim
compared I-Claim
to I-Claim
classic I-Claim
LV5FU2 I-Claim
or I-Claim
weekly I-Claim
HD-FU I-Claim
. I-Claim

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
8 I-Premise
years I-Premise
, I-Premise
the I-Premise
5-year I-Premise
overall I-Premise
survival I-Premise
was I-Premise
68 I-Premise
% I-Premise
( I-Premise
+/- I-Premise
3 I-Premise
% I-Premise
standard I-Premise
error I-Premise
of I-Premise
the I-Premise
mean I-Premise
( I-Premise
SEM I-Premise
) I-Premise
and I-Premise
the I-Premise
5-year I-Premise
event-free I-Premise
survival I-Premise
53 I-Premise
% I-Premise
( I-Premise
+/- I-Premise
4 I-Premise
% I-Premise
SEM I-Premise
) I-Premise
. I-Premise

There B-Claim
were I-Claim
significant I-Claim
differences I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
favouring I-Claim
the I-Claim
SNB I-Claim
group I-Claim
throughout I-Claim
the I-Claim
18 I-Claim
months I-Claim
assessment I-Claim
. I-Claim

Breast B-Premise
symptoms I-Premise
increased I-Premise
for I-Premise
both I-Premise
groups I-Premise
during I-Premise
radiotherapy I-Premise
, I-Premise
without I-Premise
loss I-Premise
of I-Premise
strength I-Premise
or I-Premise
range I-Premise
of I-Premise
movement I-Premise
. I-Premise

Twelve O
patients O
received O
induction O
chemotherapy O
but O
were O
not O
randomized O
to O
RT O
or O
surgery O
thereafter O
. O

Cannabinoid-related O
toxicity O
was O
assessed O
every O
2 O
weeks O
. O

Using O
a O
two-group O
, O
randomized O
controlled O
design O
, O
we O
assigned O
76 O
postmenopausal O
breast O
cancer O
survivors O
with O
at O
least O
one O
severe O
target O
symptom O
either O
to O
the O
intervention O
group O
or O
to O
a O
usual-care O
group O
. O

OS O
and O
LRC O
were O
the O
outcome O
measures O
analyzed O
using O
a O
multivariate O
Cox O
proportional O
hazard O
model O
. O

Pretreatment B-Premise
serum I-Premise
erythropoietin I-Premise
levels I-Premise
were I-Premise
lower I-Premise
in I-Premise
responders I-Premise
than I-Premise
in I-Premise
nonresponders I-Premise
( I-Premise
73.5 I-Premise
IU/L I-Premise
and I-Premise
86.3 I-Premise
IU/L I-Premise
means I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Differences B-Premise
were I-Premise
significant I-Premise
between I-Premise
groups I-Premise
1 I-Premise
and I-Premise
2 I-Premise
( I-Premise
OR I-Premise
0.12 I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
groups I-Premise
1 I-Premise
and I-Premise
3 I-Premise
( I-Premise
OR I-Premise
0.52 I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Tumor O
treatment O
was O
unrestricted O
. O

Women O
( O
n O
= O
558 O
) O
completed O
psychosocial O
questionnaires O
within O
4 O
weeks O
posttreatment O
and O
again O
2 O
, O
6 O
, O
and O
12 O
months O
later O
. O

The O
secondary O
endpoints O
were O
also O
not O
significantly O
different O
between O
the O
arms O
. O

For B-Claim
patients I-Claim
with I-Claim
anthracycline-pretreated I-Claim
metastatic I-Claim
breast I-Claim
carcinoma I-Claim
, I-Claim
capecitabine I-Claim
plus I-Claim
docetaxel I-Claim
significantly I-Claim
increased I-Claim
overall I-Claim
survival I-Claim
compared I-Claim
with I-Claim
docetaxel I-Claim
alone I-Claim
. I-Claim

This B-Claim
study I-Claim
demonstrated I-Claim
no I-Claim
advantage I-Claim
in I-Claim
RR I-Claim
, I-Claim
RD I-Claim
, I-Claim
or I-Claim
PFS I-Claim
but I-Claim
significantly I-Claim
superior I-Claim
OS I-Claim
for I-Claim
DPPE I-Claim
plus I-Claim
DOX I-Claim
. I-Claim

Results B-Premise
showed I-Premise
improved I-Premise
patient I-Premise
depression I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
the I-Premise
intervention I-Premise
and I-Premise
improvement I-Premise
in I-Premise
both I-Premise
groups I-Premise
in I-Premise
patients I-Premise
' I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

We O
compared O
the O
effect O
on O
QoL O
of O
two O
docetaxel-platinum O
regimens O
with O
vinorelbine-cisplatin O
. O

Compared B-Premise
with I-Premise
their I-Premise
controls I-Premise
, I-Premise
in I-Premise
pamidronate I-Premise
HD/LD I-Premise
patients I-Premise
, I-Premise
events I-Premise
occurred I-Premise
60 I-Premise
% I-Premise
to I-Premise
90 I-Premise
% I-Premise
less I-Premise
frequently I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
.03 I-Premise
) I-Premise
and I-Premise
the I-Premise
EFP I-Premise
was I-Premise
prolonged I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

To O
test O
the O
hypothesis O
that O
modulation O
of O
Bcl-2 O
with O
13-cis O
retinoic O
acid O
( O
CRA O
) O
/interferon-alpha2b O
( O
IFN O
) O
with O
paclitaxel O
( O
TAX O
) O
, O
or O
mitoxantrone O
, O
estramustine O
and O
vinorelbine O
( O
MEV O
) O
will O
have O
clinical O
activity O
in O
men O
with O
metastatic O
castrate-resistant O
prostate O
cancer O
( O
CRPC O
) O
. O

We O
randomly O
assigned O
1077 O
patients O
to O
receive O
docetaxel O
at O
75 O
mg/m2 O
of O
body O
surface O
area O
( O
1-hour O
intravenous O
infusion O
) O
or O
paclitaxel O
at O
175 O
mg/m2 O
( O
3-hour O
intravenous O
infusion O
) O
. O

Patients O
with O
cytologically O
proven O
, O
symptomatic O
lung O
cancer O
not O
amenable O
to O
curative O
therapy O
, O
with O
performance O
status O
0-3 O
, O
were O
randomised O
to O
receive O
either O
30 O
Gy O
in O
10 O
fractions O
or O
a O
10 O
Gy O
single O
fraction O
. O

However O
, O
overall B-Premise
survival I-Premise
from I-Premise
date I-Premise
of I-Premise
randomization I-Premise
on I-Premise
step I-Premise
2 I-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
observation I-Premise
and I-Premise
topotecan I-Premise
arms I-Premise
( I-Premise
8.9 I-Premise
months I-Premise
v I-Premise
9.3 I-Premise
months I-Premise
";" I-Premise
P I-Premise
=.43 I-Premise
) I-Premise
. I-Premise

Pilates O
exercise O
sessions O
were O
performed O
three O
times O
a O
week O
for O
a O
period O
of O
eight O
weeks O
in O
the O
rehabilitation O
unit O
. O

A O
multicenter O
trial O
was O
conducted O
to O
determine O
the O
efficacy O
and O
toxicity O
of O
escalating O
dosages O
of O
liposomal O
tretinoin O
( O
all-trans-retinoic O
acid O
) O
administered O
once O
or O
three O
times O
weekly O
in O
patients O
with O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
-associated O
Kaposi O
sarcoma O
. O

Primary O
objective O
was O
overall O
survival O
( O
OS O
) O
";" O
secondary O
objectives O
assessed O
progression-free O
survival O
( O
PFS O
) O
, O
response O
rate O
( O
RR O
) O
, O
quality O
of O
life O
( O
QOL O
) O
, O
toxicity O
, O
and O
relationships O
between O
biomarker O
expression O
and O
clinical O
outcomes O
. O

It B-Claim
is I-Claim
a I-Claim
safe I-Claim
, I-Claim
effective I-Claim
and I-Claim
durable I-Claim
treatment I-Claim
for I-Claim
vasomotor I-Claim
symptoms I-Claim
secondary I-Claim
to I-Claim
long-term I-Claim
antiestrogen I-Claim
hormone I-Claim
use I-Claim
in I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Gefitinib B-Premise
did I-Premise
not I-Premise
show I-Premise
better I-Premise
OS I-Premise
compared I-Premise
with I-Premise
GP I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.932 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.716 I-Premise
to I-Premise
1.213 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.604 I-Premise
";" I-Premise
median I-Premise
OS I-Premise
, I-Premise
22.3 I-Premise
v I-Premise
22.9 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
VBT I-Premise
group I-Premise
reported I-Premise
better I-Premise
social I-Premise
functioning I-Premise
( I-Premise
P I-Premise
< I-Premise
.002 I-Premise
) I-Premise
and I-Premise
lower I-Premise
symptom I-Premise
scores I-Premise
for I-Premise
diarrhea I-Premise
, I-Premise
fecal I-Premise
leakage I-Premise
, I-Premise
the I-Premise
need I-Premise
to I-Premise
stay I-Premise
close I-Premise
to I-Premise
the I-Premise
toilet I-Premise
, I-Premise
and I-Premise
limitation I-Premise
in I-Premise
daily I-Premise
activities I-Premise
because I-Premise
of I-Premise
bowel I-Premise
symptoms I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
pad I-Premise
use I-Premise
in I-Premise
group I-Premise
A I-Premise
. I-Premise

Patient B-Premise
diaries I-Premise
demonstrated I-Premise
lower I-Premise
swallowing I-Premise
dysfunction I-Premise
AUC I-Premise
with I-Premise
amifostine I-Premise
( I-Premise
z I-Premise
test I-Premise
P I-Premise
= I-Premise
.025 I-Premise
) I-Premise
. I-Premise

Toxicity O
was O
graded O
using O
the O
Radiation O
Therapy O
Oncology O
Group O
1991 O
criteria O
and O
the O
late O
effects O
on O
normal O
tissues-subjective O
, O
objective O
, O
management O
, O
analytic O
scales O
( O
LENT-SOMA O
) O
scales O
. O

One- B-Premise
and I-Premise
2-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
25 I-Premise
and I-Premise
9 I-Premise
% I-Premise
vs I-Premise
25 I-Premise
and I-Premise
5 I-Premise
% I-Premise
in I-Premise
the I-Premise
C3 I-Premise
and I-Premise
C6 I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Patients O
completed O
questionnaires O
before O
and O
after O
the O
visit O
and O
were O
interviewed O
by O
telephone O
at O
2 O
, O
6 O
, O
and O
12 O
weeks O
. O

In B-Premise
addition I-Premise
, I-Premise
combination I-Premise
therapy I-Premise
showed I-Premise
greater I-Premise
efficacy I-Premise
in I-Premise
the I-Premise
patients I-Premise
with I-Premise
high I-Premise
levels I-Premise
of I-Premise
VEGF I-Premise
expression I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Androgen O
treatment O
for O
prostate O
cancer O
can O
adversely O
affect O
functional O
domains O
of O
quality O
of O
life O
. O

The O
primary O
end O
point O
of O
the O
study O
was O
survival O
. O

Resorption B-Premise
markers I-Premise
did I-Premise
not I-Premise
decrease I-Premise
after I-Premise
placebo I-Premise
, I-Premise
but B-Premise
NTx I-Premise
and I-Premise
Crosslaps I-Premise
both I-Premise
decreased I-Premise
by I-Premise
70 I-Premise
% I-Premise
after I-Premise
pamidronate I-Premise
( I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

For B-Claim
those I-Claim
patients I-Claim
who I-Claim
recur I-Claim
at I-Claim
least I-Claim
6 I-Claim
months I-Claim
after I-Claim
initial I-Claim
therapy I-Claim
, I-Claim
paclitaxel I-Claim
platinum I-Claim
has I-Claim
shown I-Claim
a I-Claim
modest I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
platinum I-Claim
without I-Claim
paclitaxel I-Claim
";" I-Claim
however B-Premise
, I-Premise
many I-Premise
patients I-Premise
develop I-Premise
clinically I-Premise
relevant I-Premise
neurotoxicity I-Premise
, I-Premise
frequently I-Premise
resulting I-Premise
in I-Premise
treatment I-Premise
discontinuation I-Premise
. O

Physician O
and O
nurse O
ratings O
were O
closer O
to O
patients O
' O
ratings O
of O
pain O
for O
trained O
versus O
nutrition O
groups O
( O
P=.04 O
and O
< O
.001 O
, O
respectively O
) O
. O

Baseline O
neutrophils O
over-ride O
nadir O
counts O
in O
prognostic O
significance O
. O

However O
, O
patients B-Premise
with I-Premise
low I-Premise
expression I-Premise
of I-Premise
cytoplasmic I-Premise
pGSK-3β I-Premise
trended I-Premise
toward I-Premise
greater I-Premise
OS I-Premise
with I-Premise
GE I-Premise
treatment I-Premise
. I-Premise

Capecitabine/docetaxel B-Premise
increased I-Premise
the I-Premise
median I-Premise
overall I-Premise
survival I-Premise
by I-Premise
3 I-Premise
months I-Premise
compared I-Premise
with I-Premise
docetaxel I-Premise
alone I-Premise
( I-Premise
14.5 I-Premise
vs. I-Premise
11.5 I-Premise
months I-Premise
) I-Premise
. I-Premise

The O
study O
was O
carried O
out O
by O
a O
multi-institutional O
cooperative O
group O
in O
chemotherapy-naive O
stage O
IIIB O
to O
IV O
NSCLC O
patients O
randomized O
to O
receive O
paclitaxel O
plus O
cisplatin O
or O
etoposide O
plus O
cisplatin O
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
quality O
of O
life O
( O
QOL O
) O
of O
high-risk O
breast O
cancer O
patients O
included O
in O
a O
randomized O
clinical O
trial O
( O
PEGASE O
1 O
) O
comparing O
conventional O
chemotherapy O
versus O
adding O
an O
additional O
high-dose O
chemotherapy O
( O
HDC O
) O
cycle O
with O
blood O
stem O
cell O
support O
. O

Patients O
were O
randomized O
in O
a O
2-by-2 O
factorial O
design O
to O
medroxyprogesterone O
acetate O
200 O
mg O
daily O
, O
interferon-alfa O
9 O
million O
IU O
3 O
times O
a O
week O
, O
subcutaneous O
interleukin-2 O
9 O
million O
IU O
daily O
, O
or O
a O
combination O
of O
both O
cytokines O
. O

The B-Claim
observation I-Claim
that I-Claim
longer I-Claim
infusion I-Claim
produces I-Claim
more I-Claim
myelosuppression I-Claim
but I-Claim
does I-Claim
not I-Claim
yield I-Claim
higher I-Claim
response I-Claim
rates I-Claim
should I-Claim
lead I-Claim
to I-Claim
further I-Claim
studies I-Claim
to I-Claim
determine I-Claim
the I-Claim
optimal I-Claim
dose I-Claim
and I-Claim
schedule I-Claim
of I-Claim
this I-Claim
interesting I-Claim
new I-Claim
agent I-Claim
. I-Claim

Hematologic B-Premise
toxicity I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
( I-Premise
22 I-Premise
% I-Premise
with I-Premise
documented I-Premise
infections I-Premise
compared I-Premise
with I-Premise
8 I-Premise
% I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
";" I-Premise
P I-Premise
=.0038 I-Premise
) I-Premise
, I-Premise
and O
the B-Premise
toxicity-related I-Premise
death I-Premise
rate I-Premise
was I-Premise
9 I-Premise
% I-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
versus I-Premise
5.5 I-Premise
% I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
( I-Premise
P I-Premise
=.22 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
recommendation-plus-referral I-Premise
group I-Premise
and I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
1.5 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-1.0 I-Premise
to I-Premise
4.0 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
p I-Premise
= I-Premise
.244 I-Premise
) I-Premise
. I-Premise

AT B-Claim
significantly I-Claim
improves I-Claim
TTP I-Claim
and I-Claim
ORR I-Claim
compared I-Claim
with I-Claim
AC I-Claim
in I-Claim
patients I-Claim
with I-Claim
MBC I-Claim
, I-Claim
but B-Claim
there I-Claim
is I-Claim
no I-Claim
difference I-Claim
in I-Claim
OS I-Claim
. I-Claim

This O
phase O
III O
study O
was O
performed O
to O
determine O
the O
superiority O
of O
doxorubicin O
( O
DOX O
) O
and O
vinorelbine O
( O
VNB O
) O
( O
arm O
1 O
) O
versus O
DOX O
alone O
( O
arm O
2 O
) O
in O
metastatic O
breast O
cancer O
( O
MBC O
) O
for O
overall O
survival O
( O
OS O
) O
, O
time O
to O
treatment O
failure O
( O
TTF O
) O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
QOL O
) O
. O

In B-Premise
planned I-Premise
subgroup I-Premise
analyses I-Premise
, I-Premise
statistically I-Premise
significant I-Premise
or I-Premise
borderline I-Premise
significant I-Premise
interactions I-Premise
were I-Premise
identified I-Premise
for I-Premise
type I-Premise
of I-Premise
lymphoma I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.006 I-Premise
) I-Premise
, I-Premise
current I-Premise
treatment I-Premise
status I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.036 I-Premise
) I-Premise
, I-Premise
time I-Premise
since I-Premise
diagnosis I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.010 I-Premise
) I-Premise
, I-Premise
body I-Premise
mass I-Premise
index I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.075 I-Premise
) I-Premise
, I-Premise
and I-Premise
baseline I-Premise
sleep I-Premise
quality I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.041 I-Premise
) I-Premise
. I-Premise

The B-Premise
hazard I-Premise
ratio I-Premise
of I-Premise
death I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
the I-Premise
combination I-Premise
treatment I-Premise
was I-Premise
1.17 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0.95 I-Premise
to I-Premise
1.44 I-Premise
) I-Premise
that I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
vinorelbine I-Premise
and I-Premise
1.06 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.86 I-Premise
to I-Premise
1.29 I-Premise
) I-Premise
that I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
gemcitabine I-Premise
. I-Premise

Patients O
were O
randomized O
to O
undergo O
10 O
sessions O
of O
manual O
lymphatic O
drainage O
followed O
by O
10 O
sessions O
of O
low-frequency O
low-intensity O
electrotherapy O
or O
to O
undergo O
first O
low-frequency O
low-intensity O
electrotherapy O
followed O
by O
manual O
lymphatic O
drainage O
. O

A B-Claim
carboplatin I-Claim
containing I-Claim
regimen I-Claim
with I-Claim
better I-Claim
toxicity I-Claim
profile I-Claim
and I-Claim
a I-Claim
similar I-Claim
potentiality I-Claim
for I-Claim
symptoms I-Claim
control I-Claim
offers I-Claim
an I-Claim
option I-Claim
in I-Claim
comparison I-Claim
to I-Claim
similar I-Claim
cisplatin I-Claim
containing I-Claim
combinations I-Claim
in I-Claim
the I-Claim
palliative I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

In O
this O
international O
, O
6-month O
, O
open-label O
trial O
, O
patients O
had O
active O
RA O
, O
an O
inadequate O
response O
to O
anti-TNF O
therapy O
for O
3 O
months O
or O
longer O
and O
a O
disease O
activity O
score O
in O
28 O
joints O
( O
DAS28 O
( O
C-reactive O
protein O
";" O
CRP O
) O
of O
5.1 O
or O
greater O
. O

A O
regression O
analysis O
with O
interactions O
was O
performed O
to O
determine O
if O
domains O
of O
quality O
of O
life O
( O
EORTC-QLQ-C30 O
) O
functioning O
( O
Health O
Survey O
Short O
Form-36 O
) O
or O
psychological O
distress O
( O
Symptom O
Checklist-90 O
) O
moderated O
the O
effect O
of O
CBT O
on O
fatigue O
. O

Ninety-nine O
patients O
who O
had O
UAE O
and O
eight O
patients O
who O
had O
myomectomy O
were O
analyzed O
. O

The O
median O
dose O
intensity O
delivered O
for O
C O
and O
E O
reached O
, O
respectively O
, O
85 O
% O
and O
87 O
% O
of O
that O
planned O
in O
the O
CEF O
arm O
and O
96 O
% O
and O
95 O
% O
of O
that O
planned O
in O
the O
EC O
arm O
. O

However B-Claim
, I-Claim
further I-Claim
research I-Claim
is I-Claim
needed I-Claim
to I-Claim
identify I-Claim
ways I-Claim
to I-Claim
improve I-Claim
the I-Claim
potency I-Claim
and I-Claim
sustainability I-Claim
of I-Claim
psychoeducational I-Claim
interventions I-Claim
for I-Claim
managing I-Claim
cancer-related I-Claim
fatigue I-Claim
. I-Claim

There B-Premise
were I-Premise
no I-Premise
opportunistic I-Premise
infections I-Premise
. I-Premise

From O
January O
2000 O
to O
July O
2004 O
, O
492 O
patients O
were O
enrolled O
. O

QOL B-Premise
, I-Premise
except I-Premise
for I-Premise
symptoms I-Premise
of I-Premise
sensory I-Premise
neuropathy I-Premise
and I-Premise
hearing I-Premise
loss I-Premise
, I-Premise
in I-Premise
those I-Premise
treated I-Premise
with I-Premise
chemotherapy I-Premise
returned I-Premise
to I-Premise
baseline I-Premise
by I-Premise
9 I-Premise
months I-Premise
. I-Premise

A B-Premise
response I-Premise
to I-Premise
CEF I-Premise
tended I-Premise
to I-Premise
last I-Premise
longer I-Premise
than I-Premise
a I-Premise
response I-Premise
to I-Premise
E I-Premise
( I-Premise
median I-Premise
, I-Premise
12 I-Premise
v I-Premise
10.5 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.07 I-Premise
) I-Premise
. I-Premise

Although B-Claim
addition I-Claim
of I-Claim
radiotherapy I-Claim
to I-Claim
endocrine I-Claim
treatment I-Claim
significantly I-Claim
increased I-Claim
some I-Claim
treatment-related I-Claim
symptoms I-Claim
, I-Claim
none I-Claim
were I-Claim
serious I-Claim
. I-Claim

HDC B-Claim
has I-Claim
a I-Claim
negative I-Claim
impact I-Claim
on I-Claim
QOL I-Claim
even I-Claim
after I-Claim
treatment I-Claim
phase I-Claim
. I-Claim

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
17 I-Premise
months I-Premise
, I-Premise
median I-Premise
PFS I-Premise
was I-Premise
8.6 I-Premise
months I-Premise
for I-Premise
gemcitabine-carboplatin I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
7.9-9.7 I-Premise
months I-Premise
) I-Premise
and I-Premise
5.8 I-Premise
months I-Premise
for I-Premise
carboplatin I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
5.2-7.1 I-Premise
months I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
0.72 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.58-0.90 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.0032 I-Premise
] I-Premise
) I-Premise
. I-Premise

Repeated-measures O
analysis O
of O
variance O
done O
on O
an O
intention O
to O
treat O
basis O
. O

Also B-Premise
, I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
superior I-Premise
for I-Premise
patients I-Premise
treated I-Premise
in I-Premise
the I-Premise
GemCis I-Premise
arm I-Premise
as I-Premise
compared I-Premise
with I-Premise
the I-Premise
Gem I-Premise
arm I-Premise
( I-Premise
7.5 I-Premise
v I-Premise
6.0 I-Premise
months I-Premise
) I-Premise
, I-Premise
an B-Premise
advantage I-Premise
which I-Premise
did I-Premise
not I-Premise
, I-Premise
however I-Premise
, I-Premise
reach I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
HR I-Premise
= I-Premise
0.80 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.15 I-Premise
) I-Premise
. I-Premise

Anemia B-Claim
, I-Claim
highly I-Claim
common I-Claim
among I-Claim
cancer I-Claim
patients I-Claim
, I-Claim
is I-Claim
often I-Claim
an I-Claim
underlying I-Claim
cause I-Claim
of I-Claim
cancer-related I-Claim
fatigue I-Claim
and I-Claim
other I-Claim
quality-of-life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
deficits I-Claim
. I-Claim

The O
2-year O
risk O
of O
progression O
was O
calculated O
for O
baseline O
PSA O
, O
'fast O
' O
and O
'slow O
' O
PSA O
decline O
to O
< O
4 O
ng/ml O
( O
60 O
days O
cut-off O
) O
, O
PSA O
nadir O
, O
performance O
status O
and O
pain O
. O

However B-Premise
, I-Premise
at I-Premise
the I-Premise
final I-Premise
analysis I-Premise
in I-Premise
July I-Premise
2006 I-Premise
of I-Premise
all I-Premise
patients I-Premise
( I-Premise
n=189 I-Premise
) I-Premise
and I-Premise
with I-Premise
longer I-Premise
follow-up I-Premise
, I-Premise
survival I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
unadjusted I-Premise
hazard I-Premise
ratio I-Premise
1.35 I-Premise
[ I-Premise
0.95-1.91 I-Premise
] I-Premise
, I-Premise
log-rank I-Premise
p=0.09 I-Premise
";" I-Premise
adjusted I-Premise
hazard I-Premise
ratio I-Premise
1.27 I-Premise
[ I-Premise
0.87-1.84 I-Premise
] I-Premise
, I-Premise
Cox I-Premise
model I-Premise
p=0.20 I-Premise
) I-Premise
. I-Premise

At B-Premise
postintervention I-Premise
, I-Premise
AET I-Premise
was I-Premise
superior I-Premise
to I-Premise
UC I-Premise
for I-Premise
patient-rated I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
mean I-Premise
group I-Premise
difference I-Premise
, I-Premise
+9.0 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.0 I-Premise
to I-Premise
16.0 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.012 I-Premise
) I-Premise
, I-Premise
overall I-Premise
QoL I-Premise
( I-Premise
P I-Premise
= I-Premise
.021 I-Premise
) I-Premise
, I-Premise
fatigue I-Premise
( I-Premise
P I-Premise
= I-Premise
.013 I-Premise
) I-Premise
, I-Premise
happiness I-Premise
( I-Premise
P I-Premise
= I-Premise
.004 I-Premise
) I-Premise
, I-Premise
depression I-Premise
( I-Premise
P I-Premise
= I-Premise
.005 I-Premise
) I-Premise
, I-Premise
general I-Premise
health I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
cardiovascular I-Premise
fitness I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
lean I-Premise
body I-Premise
mass I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
. I-Premise

These B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
ways I-Claim
of I-Claim
making I-Claim
this I-Claim
method I-Claim
of I-Claim
hair I-Claim
removal I-Claim
more I-Claim
widely I-Claim
available I-Claim
to I-Claim
women I-Claim
with I-Claim
facial I-Claim
hirsutism I-Claim
should I-Claim
be I-Claim
considered I-Claim
. I-Claim

These B-Claim
findings I-Claim
provide I-Claim
evidence I-Claim
for I-Claim
the I-Claim
short-term I-Claim
benefits I-Claim
of I-Claim
minimally I-Claim
invasive I-Claim
oesophagectomy I-Claim
for I-Claim
patients I-Claim
with I-Claim
resectable I-Claim
oesophageal I-Claim
cancer I-Claim
. I-Claim

After O
discharge O
, O
symptom O
severity O
, O
temperature O
, O
and O
medications O
used O
were O
recorded O
daily O
for O
1 O
week O
and O
symptom O
levels O
were O
measured O
for O
weeks O
2-4 O
. O

Lean O
body O
mass O
was O
estimated O
by O
bioimpedance O
and O
skin-fold O
measurements O
. O

Women O
with O
a O
history O
of O
breast O
cancer O
who O
had O
completed O
all O
surgery O
, O
chemotherapy O
, O
and O
radiation O
treatment O
and O
who O
had O
an O
average O
of O
at O
least O
three O
hot O
flashes O
per O
day O
for O
the O
previous O
month O
. O

From B-Premise
cycle I-Premise
5 I-Premise
onwards I-Premise
, I-Premise
improvements I-Premise
relative I-Premise
to I-Premise
baseline/MP I-Premise
were I-Premise
observed I-Premise
for I-Premise
all I-Premise
domains I-Premise
with I-Premise
VMP I-Premise
. I-Premise

The O
documented O
administration O
of O
postoperative O
pain O
medications O
";" O
the O
frequency O
, O
dosage O
, O
type O
, O
and O
how O
it O
was O
given O
was O
also O
compared O
between O
groups O
. O

No B-Premise
survival I-Premise
differences I-Premise
were I-Premise
noted I-Premise
. I-Premise

Topical O
photodynamic O
therapy O
( O
PDT O
) O
with O
aminolevulinic O
acid O
( O
ALA O
) O
and O
5 O
% O
imiquimod O
cream O
are O
effective O
therapies O
for O
the O
treatment O
of O
actinic O
keratoses O
( O
AKs O
) O
, O
but O
no O
split-face O
studies O
directly O
comparing O
these O
treatment O
options O
are O
available O
in O
the O
literature O
. O

Histology O
, O
marker O
values O
, O
and O
disease O
extent O
are O
well O
balanced O
in O
the O
treatment O
arms O
of O
the O
two O
comparisons O
. O

Future B-Claim
trial I-Claim
design I-Claim
must I-Claim
ensure I-Claim
adequate I-Claim
power I-Claim
to I-Claim
account I-Claim
for I-Claim
the I-Claim
nonspecific I-Claim
impact I-Claim
of I-Claim
such I-Claim
complex I-Claim
individualized I-Claim
interventions I-Claim
while I-Claim
pragmatic I-Claim
designs I-Claim
may I-Claim
more I-Claim
readily I-Claim
answer I-Claim
questions I-Claim
of I-Claim
clinical I-Claim
and I-Claim
cost I-Claim
effectiveness I-Claim
. O

The B-Premise
change I-Premise
was I-Premise
significantly I-Premise
greater I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
[ I-Premise
ancova I-Premise
F I-Premise
( I-Premise
( I-Premise
1,83 I-Premise
) I-Premise
) I-Premise
= I-Premise
24.5 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
] I-Premise
. I-Premise

Among B-Premise
the I-Premise
subset I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
concurrent I-Premise
chemotherapy I-Premise
, I-Premise
there I-Premise
were I-Premise
again I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
the I-Premise
endpoints I-Premise
. I-Premise

A O
recent O
randomized O
trial O
to O
compare O
external O
beam O
radiation O
therapy O
( O
EBRT O
) O
to O
cryoablation O
for O
localized O
disease O
showed O
cryoablation O
to O
be O
noninferior O
to O
external O
beam O
EBRT O
in O
disease O
progression O
and O
overall O
and O
disease-specific O
survival O
. O

Our B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
an I-Claim
oncologist I-Claim
recommendation I-Claim
may I-Claim
increase I-Claim
exercise I-Claim
behavior I-Claim
in I-Claim
newly I-Claim
diagnosed I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
, I-Claim
particularly I-Claim
if I-Claim
it I-Claim
is I-Claim
recalled I-Claim
1 I-Claim
week I-Claim
after I-Claim
the I-Claim
recommendation I-Claim
. I-Claim

In B-Claim
endocrine I-Claim
therapy I-Claim
trials I-Claim
in I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
patients I-Claim
with I-Claim
response I-Claim
( I-Claim
complete I-Claim
response/partial I-Claim
response I-Claim
[ I-Claim
CR/PR I-Claim
] I-Claim
) I-Claim
and I-Claim
patients I-Claim
with I-Claim
stable I-Claim
disease I-Claim
for I-Claim
at I-Claim
least I-Claim
6 I-Claim
months I-Claim
( I-Claim
SD I-Claim
( I-Claim
6m I-Claim
) I-Claim
) I-Claim
have I-Claim
shown I-Claim
similar I-Claim
survival I-Claim
and I-Claim
therefore I-Claim
are I-Claim
often I-Claim
defined I-Claim
as I-Claim
a I-Claim
population I-Claim
with I-Claim
clinical I-Claim
benefit I-Claim
( I-Claim
patients I-Claim
with I-Claim
CR/PR I-Claim
or I-Claim
SD I-Claim
( I-Claim
6m I-Claim
) I-Claim
) I-Claim
. I-Claim

Docetaxel B-Claim
monotherapy I-Claim
may I-Claim
be I-Claim
considered I-Claim
as I-Claim
an I-Claim
option I-Claim
in I-Claim
the I-Claim
standard I-Claim
treatment I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Sertraline B-Premise
was I-Premise
discontinued I-Premise
more I-Premise
often I-Premise
and I-Premise
earlier I-Premise
than I-Premise
was I-Premise
placebo I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
1.46 I-Premise
[ I-Premise
1.03-2.06 I-Premise
] I-Premise
, I-Premise
p=0.03 I-Premise
) I-Premise
. I-Premise

Combined B-Claim
with I-Claim
QOL I-Claim
results I-Claim
, I-Claim
the I-Claim
significant I-Claim
increase I-Claim
in I-Claim
response I-Claim
and I-Claim
PFS I-Claim
in I-Claim
the I-Claim
CP I-Claim
arm I-Claim
and I-Claim
the I-Claim
higher I-Claim
drop-out I-Claim
rate I-Claim
in I-Claim
the I-Claim
C I-Claim
arm I-Claim
suggest I-Claim
a I-Claim
better I-Claim
outcome I-Claim
for I-Claim
the I-Claim
combination I-Claim
regimen I-Claim
despite I-Claim
its I-Claim
increased I-Claim
myelosuppression I-Claim
. I-Claim

Approximately O
30 O
% O
of O
lung O
cancer O
cases O
are O
diagnosed O
in O
patients O
> O
70 O
years O
of O
age O
. O

This O
randomized O
, O
multicenter O
, O
phase O
III O
study O
compared O
doxorubicin O
and O
docetaxel O
( O
AT O
) O
with O
doxorubicin O
and O
cyclophosphamide O
( O
AC O
) O
as O
first-line O
chemotherapy O
( O
CT O
) O
in O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O

Instruments O
administered O
at O
baseline O
included O
the O
following O
: O
Quality O
of O
Life O
Index-Cancer O
Version O
( O
QOLI-CV O
) O
, O
State-Trait O
Anxiety O
Inventory O
, O
Beck O
Depression O
Inventory O
, O
and O
Coping O
Strategies O
Questionnaire O
. O

Eligible O
patients O
had O
measurable O
or O
assessable O
disease O
and O
an O
ECOG O
performance O
status O
of O
0 O
to O
2 O
";" O
stable O
brain O
metastases O
were O
allowed O
. O

Toxicity B-Premise
profiles I-Premise
were I-Premise
similar I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
of I-Premise
the I-Premise
study I-Premise
. I-Premise

We O
performed O
a O
randomized O
, O
double-blind O
, O
28-day O
trial O
of O
melatonin O
20 O
mg O
versus O
placebo O
in O
patients O
with O
advanced O
lung O
or O
GI O
cancer O
, O
appetite O
scores O
≥ O
4 O
on O
a O
0 O
to O
10 O
scale O
( O
10 O
= O
worst O
appetite O
) O
, O
and O
history O
of O
weight O
loss O
≥ O
5 O
% O
. O

The O
initial O
treatment O
consisted O
of O
taking O
1 O
capsule O
daily O
of O
either O
30 O
mg O
of O
duloxetine O
or O
placebo O
for O
the O
first O
week O
and O
2 O
capsules O
of O
either O
30 O
mg O
of O
duloxetine O
or O
placebo O
daily O
for O
4 O
additional O
weeks O
. O

Exercise O
therapies O
were O
performed O
for O
one O
session O
per O
week O
for O
eight O
weeks O
. O

However O
, O
in B-Claim
this I-Claim
group I-Claim
of I-Claim
patients I-Claim
treated I-Claim
with I-Claim
conventional I-Claim
radiotherapy I-Claim
, I-Claim
the I-Claim
lozenge I-Claim
did I-Claim
not I-Claim
impact I-Claim
significantly I-Claim
on I-Claim
the I-Claim
severity I-Claim
of I-Claim
mucositis I-Claim
. I-Claim

The O
majority O
of O
patients O
received O
the O
intended O
four O
cycles O
( O
GCa O
, O
64 O
% O
";" O
MIC O
, O
61 O
% O
) O
. O

Paclitaxel O
was O
administered O
as O
a O
3-hour O
intravenous O
infusion O
every O
3 O
weeks O
. O

In O
conclusion O
, O
TMX B-Claim
does I-Claim
not I-Claim
prolong I-Claim
survival I-Claim
in I-Claim
patients I-Claim
with I-Claim
inoperable I-Claim
HCC I-Claim
and I-Claim
has I-Claim
an I-Claim
increasingly I-Claim
negative I-Claim
impact I-Claim
with I-Claim
increasing I-Claim
dose I-Claim
. I-Claim

The O
subgroup O
analysis O
showed O
a O
better O
biochemical O
outcome O
for O
the O
higher O
dose O
group O
with O
an O
initial O
prostate-specific O
antigen O
level O
> O
15 O
ng/mL O
. O

Outcome O
data O
were O
collected O
at O
3 O
months O
after O
embolization O
, O
including O
assessment O
of O
clinical O
symptoms O
, O
scores O
from O
a O
fibroid O
tumor-specific O
symptom O
and O
quality O
of O
life O
( O
QOL O
) O
questionnaire O
, O
and O
findings O
on O
contrast O
material-enhanced O
magnetic O
resonance O
( O
MR O
) O
imaging O
, O
including O
the O
degree O
of O
tumor O
infarction O
and O
volume O
reduction O
. O

We B-Premise
found I-Premise
no I-Premise
difference I-Premise
in I-Premise
follow-up I-Premise
costs I-Premise
. I-Premise

The B-Premise
3-year I-Premise
progression-free I-Premise
survival I-Premise
for I-Premise
neoadjuvant I-Premise
versus I-Premise
control I-Premise
arm I-Premise
was I-Premise
88.2 I-Premise
% I-Premise
and I-Premise
59.5 I-Premise
% I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
= I-Premise
0.49 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.20 I-Premise
to I-Premise
1.19 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.12 I-Premise
) I-Premise
. I-Premise

For O
patients O
undergoing O
oncologic O
surgery O
, O
the O
quality O
of O
life O
( O
QoL O
) O
is O
generally O
accepted O
as O
an O
important O
outcome O
parameter O
in O
addition O
to O
long-term O
survival O
, O
mortality O
and O
complication O
rates O
. O

In O
a O
retrospective O
analysis O
, O
eight B-Premise
patients I-Premise
in I-Premise
the I-Premise
pamidronate I-Premise
90 I-Premise
mg I-Premise
group I-Premise
developed I-Premise
osteonecrosis I-Premise
of I-Premise
the I-Premise
jaw I-Premise
compared I-Premise
with I-Premise
two I-Premise
patients I-Premise
in I-Premise
the I-Premise
30 I-Premise
mg I-Premise
group I-Premise
. I-Premise

Participants O
had O
significant O
disease O
load O
with O
65 O
% O
of O
participants O
presenting O
with O
two O
or O
more O
regions O
affected O
by O
bone O
metastases O
and O
an O
average O
Gleason O
score O
of O
8.2±0.9 O
. O

Treatment B-Premise
arms I-Premise
did I-Premise
not I-Premise
differ I-Premise
regarding I-Premise
withdrawal I-Premise
rate I-Premise
and I-Premise
the I-Premise
experience I-Premise
of I-Premise
( I-Premise
serious I-Premise
) I-Premise
adverse I-Premise
events I-Premise
. I-Premise

The O
present O
study O
is O
an O
open O
randomized O
clinical O
trial O
comparing O
estramustine O
phosphate O
( O
Estracyt O
) O
in O
addition O
to O
radiotherapy O
with O
radiotherapy O
alone O
as O
first O
line O
treatment O
of O
astrocytoma O
grade O
III O
and O
IV O
. O

ALT B-Claim
was I-Claim
found I-Claim
to I-Claim
be I-Claim
a I-Claim
safe I-Claim
method I-Claim
, I-Claim
with I-Claim
high I-Claim
adherence I-Claim
, I-Claim
in I-Claim
treating I-Claim
women I-Claim
who I-Claim
suffer I-Claim
from I-Claim
mild I-Claim
to I-Claim
moderate I-Claim
lymphedema I-Claim
. I-Claim

In B-Claim
cachectic I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
, I-Claim
oral I-Claim
melatonin I-Claim
20 I-Claim
mg I-Claim
at I-Claim
night I-Claim
did I-Claim
not I-Claim
improve I-Claim
appetite I-Claim
, I-Claim
weight I-Claim
, I-Claim
or I-Claim
quality I-Claim
of I-Claim
life I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
. I-Claim

Planned O
subgroup O
analyses O
were O
also O
conducted O
. O

Patients O
with O
prior O
cytotoxic O
therapy O
for O
MBC O
were O
ineligible O
. O

Postoperative O
pain O
was O
assessed O
with O
a O
visual O
analog O
scale O
and O
the O
McGill O
Pain O
Questionnaire O
. O

Opioid O
consumption O
, O
pain O
intensity O
, O
symptoms O
and O
adverse O
effects O
, O
mood O
, O
sleep O
, O
patient O
's O
preference O
, O
quality O
of O
life O
before O
starting O
the O
study O
, O
the O
first O
week O
after O
and O
the O
second O
week O
after O
were O
recorded O
. O

Short-term O
, O
in-hospital O
medication O
use O
and O
pain O
levels O
were O
recorded O
. O

It B-Claim
is I-Claim
not I-Claim
known I-Claim
whether I-Claim
imatinib I-Claim
may I-Claim
be I-Claim
stopped I-Claim
in I-Claim
patients I-Claim
in I-Claim
whom I-Claim
disease I-Claim
is I-Claim
controlled I-Claim
. I-Claim

Tumor O
response O
was O
evaluated O
at O
Week O
12 O
and O
Month O
6 O
";" O
progression-free O
patients O
received O
further O
identical O
treatment O
for O
a O
maximum O
of O
3 O
additional O
months O
. O

One O
hundred O
two O
patients O
with O
resected O
PPC O
consented O
to O
participate O
in O
this O
study O
and O
were O
randomized O
to O
either O
an O
intervention O
group O
( O
IG O
) O
or O
a O
usual O
care O
group O
( O
UCG O
) O
. O

Lifestyle B-Claim
intervention I-Claim
research I-Claim
is I-Claim
feasible I-Claim
in I-Claim
a I-Claim
cooperative I-Claim
group I-Claim
setting I-Claim
. I-Claim

Three-hundred O
forty-eight O
patients O
( O
81 O
% O
) O
were O
evaluable O
for O
QOL O
. O

Euthyroid B-Premise
patients I-Premise
had I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
one I-Premise
third I-Premise
lower I-Premise
radiation I-Premise
dose I-Premise
to I-Premise
the I-Premise
blood I-Premise
, I-Premise
compared I-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
hypothyroid I-Premise
group I-Premise
. I-Premise

The O
significance O
of O
, O
and O
proportions O
of O
patients O
with O
, O
improved O
HRQOL O
scores O
-- O
defined O
as O
a O
change O
of O
10 O
points O
or O
more O
-- O
were O
recorded O
. O

Treatment B-Premise
with I-Premise
docetaxel-carboplatin I-Premise
was I-Premise
associated I-Premise
with I-Premise
statistically I-Premise
significantly I-Premise
more I-Premise
grade I-Premise
3-4 I-Premise
neutropenia I-Premise
( I-Premise
94 I-Premise
% I-Premise
versus I-Premise
84 I-Premise
% I-Premise
, I-Premise
difference I-Premise
= I-Premise
11 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
7 I-Premise
% I-Premise
to I-Premise
14 I-Premise
% I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
neutropenic I-Premise
complications I-Premise
than I-Premise
treatment I-Premise
with I-Premise
paclitaxel-carboplatin I-Premise
, I-Premise
although B-Premise
myelosuppression I-Premise
did I-Premise
not I-Premise
influence I-Premise
dose I-Premise
delivery I-Premise
or I-Premise
patient I-Premise
safety I-Premise
. I-Premise

Based O
on O
pattern-mixture O
models O
, O
patients O
who O
dropped O
out O
early O
had O
worse O
QL2 O
decline O
on O
both O
treatments O
. O

Multivariate O
analyses O
were O
performed O
for O
both O
OS O
and O
LRC O
. O

The O
randomized O
, O
controlled O
BOLERO-2 O
( O
Breast O
Cancer O
Trials O
of O
Oral O
Everolimus O
) O
trial O
demonstrated O
significantly O
improved O
progression-free O
survival O
with O
the O
use O
of O
everolimus O
plus O
exemestane O
( O
EVE O
+ O
EXE O
) O
versus O
placebo O
plus O
exemestane O
( O
PBO O
+ O
EXE O
) O
in O
patients O
with O
advanced O
breast O
cancer O
who O
developed O
disease O
progression O
after O
treatment O
with O
nonsteroidal O
aromatase O
inhibitors O
. O

Exploratory O
end O
points O
included O
association O
of O
efficacy O
with O
epidermal O
growth O
factor O
receptor O
gene O
copy O
number O
and O
other O
biomarkers O
. O

The B-Premise
rates I-Premise
of I-Premise
stroke I-Premise
, I-Premise
pulmonary I-Premise
embolism I-Premise
, I-Premise
and I-Premise
deep-vein I-Premise
thrombosis I-Premise
were I-Premise
elevated I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
";" I-Premise
these I-Premise
events I-Premise
occurred I-Premise
more I-Premise
frequently I-Premise
in I-Premise
women I-Premise
aged I-Premise
50 I-Premise
years I-Premise
or I-Premise
older I-Premise
. I-Premise

Among O
all O
participants O
, O
the O
mean O
number O
of O
logins O
over O
8 O
weeks O
was O
20.8 O
± O
17.7 O
logins O
for O
the O
III O
+ O
ISG O
compared O
with O
12.5 O
± O
12.5 O
in O
III-only O
( O
p O
= O
0.15 O
) O
. O

r-HuEPO B-Claim
is I-Claim
safe I-Claim
and I-Claim
can I-Claim
cause I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
the I-Claim
hematocrit I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
of I-Claim
anemic I-Claim
cancer I-Claim
patients I-Claim
receiving I-Claim
myelosuppressive I-Claim
, I-Claim
cisplatin-based I-Claim
chemotherapy I-Claim
. I-Claim

Two O
million O
people O
across O
the O
U.K. O
are O
living O
with O
cancer O
, O
often O
experienced O
as O
a O
long-term O
condition O
. O

These B-Claim
data I-Claim
demonstrated I-Claim
a I-Claim
significant I-Claim
4.5-month I-Claim
median I-Claim
OS I-Claim
advantage I-Claim
with I-Claim
the I-Claim
lapatinib I-Claim
and I-Claim
trastuzumab I-Claim
combination I-Claim
and I-Claim
support I-Claim
dual I-Claim
HER2 I-Claim
blockade I-Claim
in I-Claim
patients I-Claim
with I-Claim
heavily I-Claim
pretreated I-Claim
HER2-positive I-Claim
MBC I-Claim
. I-Claim

Gross-total B-Premise
removal I-Premise
( I-Premise
GTR I-Premise
) I-Premise
was I-Premise
achieved I-Premise
in I-Premise
five I-Premise
patients I-Premise
who I-Premise
underwent I-Premise
SS I-Premise
and I-Premise
in I-Premise
three I-Premise
who I-Premise
underwent I-Premise
SN I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
vaginal I-Premise
bleeding I-Premise
, I-Premise
mood I-Premise
alteration I-Premise
, I-Premise
or I-Premise
low I-Premise
energy I-Premise
. I-Premise

Frequencies B-Premise
of I-Premise
hematologic I-Premise
and I-Premise
nonhematologic I-Premise
toxicities I-Premise
were I-Premise
essentially I-Premise
similar I-Premise
. I-Premise

Two O
hundred O
eighty-four O
patients O
were O
randomized O
to O
treatment O
with O
IFNalpha2a O
plus O
13-CRA O
or O
treatment O
with O
IFNalpha2a O
alone O
. O

Participants B-Premise
randomized I-Premise
to I-Premise
the I-Premise
exercise I-Premise
group I-Premise
increased I-Premise
physical I-Premise
activity I-Premise
by I-Premise
more I-Premise
than I-Premise
100 I-Premise
versus I-Premise
22 I-Premise
% I-Premise
in I-Premise
controls I-Premise
( I-Premise
54.5 I-Premise
vs. I-Premise
14.6 I-Premise
min I-Premise
, I-Premise
P I-Premise
= I-Premise
0.13 I-Premise
) I-Premise
, I-Premise
and I-Premise
experienced I-Premise
significant I-Premise
increases I-Premise
in I-Premise
fitness I-Premise
( I-Premise
increased I-Premise
6-min I-Premise
walk I-Premise
test I-Premise
distance I-Premise
by I-Premise
186.9 I-Premise
vs. I-Premise
81.9 I-Premise
feet I-Premise
, I-Premise
P I-Premise
= I-Premise
0.006 I-Premise
) I-Premise
and I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
7.1 I-Premise
vs. I-Premise
2.6 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
as I-Premise
compared I-Premise
to I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Patients O
were O
randomly O
assigned O
to O
the O
8-week O
MBSR O
program O
or O
standard O
care O
. O

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
56·9 I-Premise
months I-Premise
( I-Premise
IQR I-Premise
37·4-81·8 I-Premise
) I-Premise
from I-Premise
randomisation I-Premise
and I-Premise
370 I-Premise
deaths I-Premise
( I-Premise
186 I-Premise
early I-Premise
, I-Premise
184 I-Premise
delayed I-Premise
) I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
in I-Premise
overall I-Premise
survival I-Premise
between I-Premise
early I-Premise
and I-Premise
delayed I-Premise
treatment I-Premise
( I-Premise
HR I-Premise
0·98 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·80-1·20 I-Premise
, I-Premise
p=0·85 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
at I-Premise
3 I-Premise
years I-Premise
after I-Premise
random I-Premise
assignment I-Premise
according I-Premise
to I-Premise
treatment I-Premise
except I-Premise
for I-Premise
hot I-Premise
flashes I-Premise
. I-Premise

The B-Claim
findings I-Claim
support I-Claim
the I-Claim
case I-Claim
for I-Claim
assessment I-Claim
of I-Claim
health-related I-Claim
QoL I-Claim
in I-Claim
relation I-Claim
to I-Claim
head-and-neck I-Claim
cancer I-Claim
using I-Claim
a I-Claim
site-specific I-Claim
approach I-Claim
. O

Treatment B-Claim
with I-Claim
mitoxantrone I-Claim
plus I-Claim
prednisone I-Claim
was I-Claim
associated I-Claim
with I-Claim
greater I-Claim
and I-Claim
longer-lasting I-Claim
improvement I-Claim
in I-Claim
several I-Claim
HQL I-Claim
domains I-Claim
and I-Claim
symptoms I-Claim
than I-Claim
treatment I-Claim
with I-Claim
prednisone I-Claim
alone I-Claim
. I-Claim

As B-Premise
reflected I-Premise
in I-Premise
the I-Premise
hot I-Premise
flashes I-Premise
scores I-Premise
, I-Premise
patients I-Premise
in I-Premise
all I-Premise
three I-Premise
treatment I-Premise
groups I-Premise
experienced I-Premise
induced I-Premise
amenorrhea I-Premise
, I-Premise
but B-Premise
the I-Premise
onset I-Premise
of I-Premise
ovarian I-Premise
function I-Premise
suppression I-Premise
was I-Premise
slightly I-Premise
delayed I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
chemotherapy I-Premise
. I-Premise

The O
CMA O
intervention O
, O
delivered O
by O
a O
nurse O
practitioner O
, O
focused O
on O
symptom O
assessment O
, O
education O
, O
counseling O
and O
, O
as O
appropriate O
, O
specific O
pharmacologic O
and O
behavioral O
interventions O
for O
each O
of O
the O
three O
target O
symptoms O
. O

Eighty-nine O
chemotherapy-naïve O
patients O
were O
randomized O
either O
to O
gemcitabine O
( O
1,000 O
mg/m2 O
, O
30-min O
infusion O
on O
days O
1 O
, O
8 O
and O
15 O
) O
and O
oral O
etoposide O
( O
50 O
mg O
, O
days O
1-14 O
";" O
GE O
group O
) O
or O
gemcitabine O
at O
the O
same O
schedule O
and O
cisplatin O
( O
75 O
mg/m2 O
on O
day O
15 O
";" O
GP O
group O
) O
. O

Dose-intensified B-Claim
EC I-Claim
does I-Claim
not I-Claim
provide I-Claim
a I-Claim
measurable I-Claim
therapeutic I-Claim
benefit I-Claim
over I-Claim
CEF I-Claim
as I-Claim
neoadjuvant I-Claim
chemotherapy I-Claim
for I-Claim
unselected I-Claim
locally I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

213 O
cancer O
patients O
with O
different O
diagnoses O
were O
randomised O
into O
an O
intervention O
group O
or O
wait-list O
control O
group O
. O

Serum O
CA125 O
concentration O
often O
rises O
several O
months O
before O
clinical O
or O
symptomatic O
relapse O
in O
women O
with O
ovarian O
cancer O
. O

This B-Claim
is I-Claim
the I-Claim
first I-Claim
prospective I-Claim
, I-Claim
randomized I-Claim
controlled I-Claim
trial I-Claim
to I-Claim
report I-Claim
that I-Claim
participation I-Claim
in I-Claim
a I-Claim
home I-Claim
walking I-Claim
program I-Claim
confers I-Claim
a I-Claim
significant I-Claim
benefit I-Claim
in I-Claim
resected I-Claim
PPC I-Claim
patients I-Claim
with I-Claim
regard I-Claim
to I-Claim
fatigue I-Claim
levels I-Claim
, I-Claim
physical I-Claim
functioning I-Claim
, I-Claim
and I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Thalidomide B-Premise
was I-Premise
associated I-Premise
with I-Premise
an I-Premise
increased I-Premise
risk I-Premise
of I-Premise
having I-Premise
a I-Premise
thrombotic I-Premise
event I-Premise
, I-Premise
mainly I-Premise
pulmonary I-Premise
embolus I-Premise
and I-Premise
deep I-Premise
vein I-Premise
thrombosis I-Premise
( I-Premise
19 I-Premise
% I-Premise
thalidomide I-Premise
vs I-Premise
10 I-Premise
% I-Premise
placebo I-Premise
";" I-Premise
HR I-Premise
= I-Premise
2.13 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
1.41 I-Premise
to I-Premise
3.20 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

The B-Claim
intervention I-Claim
reduced I-Claim
fatigue I-Claim
and I-Claim
improved I-Claim
vitality I-Claim
, I-Claim
aerobic I-Claim
capacity I-Claim
, I-Claim
muscular I-Claim
strength I-Claim
, I-Claim
and I-Claim
physical I-Claim
and I-Claim
functional I-Claim
activity I-Claim
, I-Claim
and I-Claim
emotional I-Claim
wellbeing I-Claim
, I-Claim
but B-Claim
not I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

The O
effects O
, O
safety O
, O
and O
QoL O
were O
determined O
and O
analyzed O
. O

In O
this O
setting O
, O
local B-Claim
control I-Claim
and I-Claim
survival I-Claim
were I-Claim
essentially I-Claim
equal I-Claim
between I-Claim
the I-Claim
surgical I-Claim
and I-Claim
RT I-Claim
arms I-Claim
. I-Claim

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
any I-Premise
outcome I-Premise
between I-Premise
groups I-Premise
. I-Premise

Pre- O
and O
post-assessment O
data O
were O
collected O
via O
online O
questionnaires O
and O
daily O
sleep O
diaries O
. O

Arm O
circumferences O
were O
measured O
before O
and O
the O
1st O
, O
3rd O
, O
and O
6th O
weeks O
of O
the O
treatment O
. O

Treatment O
with O
somatostatin O
analogues O
slowed O
kidney O
growth O
in O
patients O
with O
polycystic O
kidney O
disease O
( O
PKD O
) O
and O
reduced O
liver O
and O
kidney O
volume O
in O
a O
PKD O
rodent O
model O
. O

Depression B-Claim
, I-Claim
anxiety I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
impaired I-Claim
wellbeing I-Claim
are I-Claim
common I-Claim
, I-Claim
important I-Claim
, I-Claim
and I-Claim
closely I-Claim
related I-Claim
in I-Claim
advanced I-Claim
cancer I-Claim
. I-Claim

Two O
participants O
in O
the O
III O
+ O
ISG O
dropped O
out O
, O
compared O
with O
five O
in O
III O
( O
p O
= O
0.39 O
) O
. O

It O
is O
not O
known O
whether O
low-dose O
radioiodine O
( O
1.1 O
GBq O
[ O
30 O
mCi O
] O
) O
is O
as O
effective O
as O
high-dose O
radioiodine O
( O
3.7 O
GBq O
[ O
100 O
mCi O
] O
) O
for O
treating O
patients O
with O
differentiated O
thyroid O
cancer O
or O
whether O
the O
effects O
of O
radioiodine O
( O
especially O
at O
a O
low O
dose O
) O
are O
influenced O
by O
using O
either O
recombinant O
human O
thyrotropin O
( O
thyrotropin O
alfa O
) O
or O
thyroid O
hormone O
withdrawal O
. O

Overall B-Premise
objective I-Premise
response I-Premise
( I-Premise
OR I-Premise
) I-Premise
rates I-Premise
were I-Premise
higher I-Premise
in I-Premise
patients I-Premise
treated I-Premise
with I-Premise
EXE I-Premise
than I-Premise
in I-Premise
those I-Premise
treated I-Premise
with I-Premise
MA I-Premise
( I-Premise
15.0 I-Premise
% I-Premise
v I-Premise
12.4 I-Premise
% I-Premise
) I-Premise
";" I-Premise
a B-Premise
similar I-Premise
trend I-Premise
was I-Premise
noted I-Premise
in I-Premise
patients I-Premise
with I-Premise
visceral I-Premise
metastases I-Premise
( I-Premise
13.5 I-Premise
% I-Premise
v I-Premise
10.5 I-Premise
% I-Premise
) I-Premise
. I-Premise

Patients B-Premise
on I-Premise
DPPE/DOX I-Premise
arm I-Premise
were I-Premise
significantly I-Premise
worse I-Premise
in I-Premise
terms I-Premise
of I-Premise
average I-Premise
and I-Premise
median I-Premise
pain I-Premise
change I-Premise
scores I-Premise
. I-Premise

HRQOL O
questionnaires O
, O
using O
a O
validated O
instrument O
, O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Head O
and O
Neck O
( O
FACT-H O
& O
amp O
";" O
N O
) O
, O
version O
2 O
, O
were O
completed O
by O
patients O
before O
the O
start O
of O
treatment O
. O

In O
445 O
randomly O
assigned O
and O
treated O
patients O
( O
DCF O
= O
221 O
";" O
CF O
= O
224 O
) O
, O
TTP O
was O
longer O
with O
DCF O
versus O
CF O
( O
32 O
% O
risk O
reduction O
";" O
log-rank O
P O
< O
.001 O
) O
. O

After B-Premise
RT I-Premise
, I-Premise
QOL I-Premise
function I-Premise
scores I-Premise
improved I-Premise
( I-Premise
p I-Premise
< I-Premise
.003 I-Premise
) I-Premise
proportionally I-Premise
with I-Premise
improved I-Premise
nutritional I-Premise
intake I-Premise
and I-Premise
status I-Premise
in I-Premise
group I-Premise
1/group I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
.05 I-Premise
) I-Premise
and I-Premise
worsened I-Premise
in I-Premise
group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
.05 I-Premise
) I-Premise
";" I-Premise
at B-Premise
3 I-Premise
months I-Premise
, I-Premise
patients I-Premise
in I-Premise
group I-Premise
1 I-Premise
maintained I-Premise
or I-Premise
improved I-Premise
overall I-Premise
QOL I-Premise
, I-Premise
whereas I-Premise
patients I-Premise
in I-Premise
groups I-Premise
2 I-Premise
and I-Premise
3 I-Premise
maintained I-Premise
or I-Premise
worsened I-Premise
overall I-Premise
QOL I-Premise
. I-Premise

Patients O
were O
interviewed O
by O
telephone O
before O
treatment O
( O
baseline O
) O
, O
midtreatment O
, O
within O
1 O
month O
post-treatment O
, O
and O
at O
12 O
, O
18 O
, O
and O
24 O
months O
postbaseline O
by O
using O
questionnaires O
from O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
, O
a O
breast O
systemic O
adverse O
effects O
scale O
( O
EORTC O
BR23 O
) O
, O
and O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
( O
HADS O
) O
. O

Four O
hundred O
twenty O
previously O
untreated O
patients O
with O
measurable O
disease O
were O
randomized O
to O
receive O
a O
2-hour O
infusion O
of O
LV O
( O
200 O
mg/m O
( O
2 O
) O
/d O
) O
followed O
by O
a O
5FU O
bolus O
( O
400 O
mg/m O
( O
2 O
) O
/d O
) O
and O
22-hour O
infusion O
( O
600 O
mg/m O
( O
2 O
) O
/d O
) O
for O
2 O
consecutive O
days O
every O
2 O
weeks O
, O
either O
alone O
or O
together O
with O
oxaliplatin O
85 O
mg/m O
( O
2 O
) O
as O
a O
2-hour O
infusion O
on O
day O
1 O
. O

After O
anterior O
resection O
for O
cancer O
, O
patients O
were O
allocated O
to O
either O
J-pouch O
or O
CP-anal O
anastomoses O
. O

QoL B-Premise
was I-Premise
better I-Premise
preserved I-Premise
in I-Premise
rhTSH I-Premise
Group I-Premise
than I-Premise
in I-Premise
T4-WD I-Premise
and I-Premise
T3-WD I-Premise
Groups I-Premise
( I-Premise
p I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

The B-Premise
difference I-Premise
in I-Premise
PFS I-Premise
between I-Premise
three I-Premise
and I-Premise
four I-Premise
cycles I-Premise
is I-Premise
-1.0 I-Premise
% I-Premise
( I-Premise
80 I-Premise
% I-Premise
confidence I-Premise
limit I-Premise
[ I-Premise
CL I-Premise
] I-Premise
, I-Premise
-3.8 I-Premise
% I-Premise
, I-Premise
+1.8 I-Premise
% I-Premise
) I-Premise
. I-Premise

For B-Premise
astrocytoma I-Premise
grade I-Premise
III I-Premise
the I-Premise
median I-Premise
survival I-Premise
time I-Premise
was I-Premise
10.6 I-Premise
( I-Premise
1.3-92.7 I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
radiotherapy I-Premise
only I-Premise
group I-Premise
and I-Premise
17.3 I-Premise
( I-Premise
0.4-96.9+ I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
estramustine I-Premise
+ I-Premise
radiotherapy I-Premise
group I-Premise
. I-Premise

In O
an O
open O
, O
randomized O
, O
multicenter O
trial O
, O
patients O
were O
randomized O
to O
treatment O
with O
50 O
mg O
bicalutamide O
( O
n O
= O
243 O
) O
once O
daily O
or O
to O
castration O
( O
n O
= O
243 O
) O
, O
either O
orchiectomy O
or O
depot O
injection O
of O
goserelin O
acetate O
every O
28 O
days O
. O

Forty-six B-Premise
patients I-Premise
( I-Premise
88 I-Premise
% I-Premise
) I-Premise
were I-Premise
in I-Premise
disease I-Premise
remission I-Premise
12 I-Premise
months I-Premise
after I-Premise
radiotherapy I-Premise
. I-Premise

To O
test O
the O
ability O
of O
the O
cytoprotectant O
, O
amifostine O
, O
to O
reduce O
chemoradiotherapy-induced O
esophagitis O
and O
evaluate O
its O
influence O
on O
quality O
of O
life O
( O
QOL O
) O
and O
swallowing O
symptoms O
. O

Eighty-three O
patients O
discontinued O
, O
65 O
due O
to O
disease O
progression O
and O
16 O
because O
of O
AEs O
";" O
two O
patients O
withdrew O
consent O
. O

The B-Premise
dyspnoea I-Premise
palliation I-Premise
rate I-Premise
was I-Premise
lower I-Premise
in I-Premise
the I-Premise
C3 I-Premise
arm I-Premise
at I-Premise
18 I-Premise
and I-Premise
26 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
finding I-Premise
was I-Premise
inconsistent I-Premise
across I-Premise
different I-Premise
methods I-Premise
of I-Premise
analysis I-Premise
. I-Premise

The B-Premise
addition I-Premise
of I-Premise
RT I-Premise
to I-Premise
surgery I-Premise
resulted I-Premise
in I-Premise
more I-Premise
frequent I-Premise
urination I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
early I-Premise
report I-Premise
of I-Premise
more I-Premise
bowel I-Premise
dysfunction I-Premise
, O
although B-Premise
bowel I-Premise
function I-Premise
differences I-Premise
disappeared I-Premise
over I-Premise
the I-Premise
5-year I-Premise
period I-Premise
. I-Premise

The B-Premise
mean I-Premise
reduction I-Premise
in I-Premise
AK I-Premise
count I-Premise
was I-Premise
59.2 I-Premise
% I-Premise
for I-Premise
ALA-PDT I-Premise
and I-Premise
41.4 I-Premise
% I-Premise
for I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
p I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

Anti-aromatase B-Claim
therapy I-Claim
is I-Claim
important I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
in I-Claim
postmenopausal I-Claim
women I-Claim
but O
they O
have O
effects O
on O
the O
bone O
mineral O
density O
( O
BMD O
) O
and O
osteoporosis O
. O

The B-Claim
role I-Claim
of I-Claim
three-drug I-Claim
combinations I-Claim
remains I-Claim
questionable I-Claim
in I-Claim
this I-Claim
subset I-Claim
of I-Claim
patients I-Claim
. I-Claim

Improvement B-Premise
was I-Premise
noted I-Premise
in I-Premise
physical I-Premise
capacity I-Premise
: I-Premise
estimated I-Premise
mean I-Premise
difference I-Premise
between I-Premise
groups I-Premise
for I-Premise
maximum I-Premise
oxygen I-Premise
consumption I-Premise
was I-Premise
0.16 I-Premise
l/min I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.1 I-Premise
to I-Premise
0.2 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
and I-Premise
for I-Premise
muscular I-Premise
strength I-Premise
( I-Premise
leg I-Premise
press I-Premise
) I-Premise
was I-Premise
29.7 I-Premise
kg I-Premise
( I-Premise
23.4 I-Premise
to I-Premise
34.9 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

Fatigue O
is O
the O
most O
commonly O
reported O
symptom O
in O
all O
cancer O
patients O
. O

This O
trial O
is O
registered O
with O
the O
Netherlands O
Trial O
Register O
, O
NTR O
TC O
2452 O
. O

Functionality B-Premise
was I-Premise
not I-Premise
greatly I-Premise
affected I-Premise
by I-Premise
treatment I-Premise
. I-Premise

The B-Premise
SF-36 I-Premise
MCS I-Premise
and I-Premise
PCS I-Premise
, I-Premise
Health I-Premise
Utilities I-Premise
Index I-Premise
Mark I-Premise
3 I-Premise
, I-Premise
EuroQol I-Premise
5D I-Premise
, I-Premise
and I-Premise
UDI I-Premise
scores I-Premise
were I-Premise
improved I-Premise
significantly I-Premise
in I-Premise
both I-Premise
groups I-Premise
at I-Premise
6 I-Premise
months I-Premise
and I-Premise
afterward I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

The O
primary O
end O
point O
was O
time-to-progression O
( O
TTP O
) O
. O

Subjects O
were O
42 O
consecutive O
men O
from O
a O
prospective O
study O
of O
brachytherapy O
as O
monotherapy O
with O
( O
125 O
) O
I O
for O
intermediate-risk O
localized O
prostate O
cancer O
. O

The B-Premise
group I-Premise
treated I-Premise
with I-Premise
oral I-Premise
Etoposide I-Premise
had I-Premise
a I-Premise
significantly I-Premise
better I-Premise
QOL I-Premise
than I-Premise
the I-Premise
radiotherapy I-Premise
group I-Premise
for I-Premise
the I-Premise
total I-Premise
FLI-C I-Premise
score I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
plus I-Premise
standard I-Premise
error I-Premise
at I-Premise
3-months I-Premise
89 I-Premise
+/- I-Premise
3 I-Premise
vs. I-Premise
76 I-Premise
+/- I-Premise
3 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.004 I-Premise
) I-Premise
and I-Premise
for I-Premise
the I-Premise
hardship I-Premise
( I-Premise
11 I-Premise
+/- I-Premise
0.4 I-Premise
vs. I-Premise
9 I-Premise
+/- I-Premise
0.4 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
";" I-Premise
social I-Premise
( I-Premise
10 I-Premise
+/- I-Premise
0.4 I-Premise
vs. I-Premise
8 I-Premise
+/- I-Premise
0.4 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
nausea I-Premise
( I-Premise
9 I-Premise
+/- I-Premise
0.4 I-Premise
vs. I-Premise
8 I-Premise
+/- I-Premise
0.4 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
subscales I-Premise
. I-Premise

Fifty O
GI O
cancer O
patients O
received O
postoperative O
7 O
days O
of O
isocaloric O
and O
isonitrogenous O
TPN O
after O
operation O
. O

It B-Claim
is I-Claim
more I-Claim
likely I-Claim
in I-Claim
full-breasted I-Claim
women I-Claim
and I-Claim
when I-Claim
the I-Claim
radiation I-Claim
is I-Claim
distributed I-Claim
nonhomogeneously I-Claim
in I-Claim
the I-Claim
breast I-Claim
. I-Claim

Forty-five O
patients O
were O
eligible O
, O
of O
whom O
34 O
were O
randomized O
( O
mean O
( O
s.d O
. O
) O
age O
70 O
( O
11·8 O
) O
years O
) O
. O

Research B-Claim
is I-Claim
needed I-Claim
to I-Claim
assess I-Claim
the I-Claim
long I-Claim
term I-Claim
risks I-Claim
and I-Claim
benefits I-Claim
of I-Claim
starting I-Claim
hormone I-Claim
replacement I-Claim
therapy I-Claim
near I-Claim
the I-Claim
menopause I-Claim
, I-Claim
when I-Claim
the I-Claim
effect I-Claim
may I-Claim
be I-Claim
different I-Claim
. I-Claim

A O
dramatic O
rise O
in O
incidence O
, O
an O
aging O
population O
, O
and O
expensive O
palliative O
treatments O
have O
led O
to O
an O
escalating O
burden O
on O
clinicians O
managing O
inoperable O
esophageal O
cancer O
with O
only O
limited O
evidence O
of O
effectiveness O
. O

Time O
to O
disease O
progression O
, O
response O
rate O
, O
adverse O
events O
, O
and O
QOL O
were O
secondary O
end O
points O
. O

Monthly B-Claim
infusion I-Claim
of I-Claim
pamidronate I-Claim
30 I-Claim
mg I-Claim
should I-Claim
be I-Claim
the I-Claim
recommended I-Claim
dose I-Claim
for I-Claim
prevention I-Claim
of I-Claim
bone I-Claim
disease I-Claim
in I-Claim
patients I-Claim
with I-Claim
multiple I-Claim
myeloma I-Claim
. I-Claim

A O
validated O
mucositis O
scoring O
system O
was O
used O
. O

The B-Premise
median I-Premise
PFS I-Premise
was I-Premise
8.8 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
8.1-10.4 I-Premise
months I-Premise
) I-Premise
and I-Premise
11.3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
9.7-12.7 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.247 I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.82 I-Premise
) I-Premise
";" I-Premise
the I-Premise
median I-Premise
OS I-Premise
was I-Premise
25.0 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
18.8-not I-Premise
assessable I-Premise
[ I-Premise
N/A I-Premise
] I-Premise
months I-Premise
) I-Premise
and I-Premise
24.3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
20.3-N/A I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.475 I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.84 I-Premise
) I-Premise
, I-Premise
with I-Premise
PB I-Premise
and I-Premise
PB+G I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Twenty-one O
patients O
received O
BCAA O
granules O
three O
times O
a O
day O
( O
one O
sachet O
after O
each O
meal O
: O
the O
daytime O
group O
) O
, O
and O
16 O
patients O
received O
the O
granules O
twice O
a O
day O
( O
one O
sachet O
after O
breakfast O
, O
and O
two O
sachets O
before O
bedtime O
: O
the O
nocturnal O
group O
) O
. O

At B-Premise
4-month I-Premise
follow-up I-Premise
, I-Premise
intervention I-Premise
patients I-Premise
reported I-Premise
less I-Premise
uncertainty I-Premise
and I-Premise
better I-Premise
communication I-Premise
with I-Premise
spouses I-Premise
than I-Premise
control I-Premise
patients I-Premise
, I-Premise
but B-Premise
they I-Premise
reported I-Premise
no I-Premise
other I-Premise
effects I-Premise
. I-Premise

Nevertheless B-Claim
, I-Claim
both I-Claim
community I-Claim
settings I-Claim
were I-Claim
acceptable I-Claim
to I-Claim
and I-Claim
preferred I-Claim
by I-Claim
patients I-Claim
compared I-Claim
with I-Claim
hospital I-Claim
, I-Claim
were I-Claim
safe I-Claim
, I-Claim
with I-Claim
no I-Claim
detrimental I-Claim
impact I-Claim
on I-Claim
overall I-Claim
health-care I-Claim
costs I-Claim
. I-Claim

To O
determine O
functional O
and O
psychological O
benefits O
of O
a O
12 O
week O
supervised O
group O
exercise O
programme O
during O
treatment O
for O
early O
stage O
breast O
cancer O
, O
with O
six O
month O
follow-up O
. O

The O
proportional O
hazards O
regression O
model O
with O
stratification O
for O
treatment O
, O
and O
the O
logistic O
regression O
model O
adjusting O
for O
treatment O
arm O
were O
used O
for O
univariate O
and O
multivariate O
analyses O
of O
survival O
and O
response O
to O
treatment O
, O
respectively O
. O

Decreasing B-Claim
depression I-Claim
symptoms I-Claim
over I-Claim
the I-Claim
first I-Claim
year I-Claim
were I-Claim
associated I-Claim
with I-Claim
longer I-Claim
subsequent I-Claim
survival I-Claim
for I-Claim
women I-Claim
with I-Claim
MBC I-Claim
in I-Claim
this I-Claim
sample I-Claim
. I-Claim

The O
Pain O
Education O
Program O
was O
tailored O
to O
the O
needs O
of O
the O
individual O
patient O
and O
consisted O
of O
three O
elements O
: O
( O
1 O
) O
educating O
patients O
about O
the O
basic O
principles O
regarding O
pain O
and O
pain O
management O
";" O
( O
2 O
) O
instructing O
patients O
how O
to O
report O
their O
pain O
in O
a O
pain O
diary O
";" O
and O
( O
3 O
) O
instructing O
patients O
how O
to O
communicate O
about O
pain O
and O
how O
to O
contact O
health O
care O
providers O
. O

QoL O
was O
assessed O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
questionnaire O
. O

The B-Premise
KPS I-Premise
score I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
after I-Premise
treatment I-Premise
was I-Premise
improved I-Premise
in I-Premise
13 I-Premise
patients I-Premise
( I-Premise
23.6 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
27 I-Premise
( I-Premise
49.6 I-Premise
% I-Premise
) I-Premise
and I-Premise
declined I-Premise
in I-Premise
15 I-Premise
( I-Premise
27.3 I-Premise
% I-Premise
) I-Premise
, I-Premise
while I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
it I-Premise
was I-Premise
improved I-Premise
in I-Premise
7 I-Premise
( I-Premise
13.2 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
21 I-Premise
( I-Premise
39.6 I-Premise
% I-Premise
) I-Premise
and I-Premise
declined I-Premise
in I-Premise
25 I-Premise
( I-Premise
47.2 I-Premise
% I-Premise
) I-Premise
, I-Premise
the I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
was I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Analyses O
were O
done O
on O
all O
patients O
with O
available O
data O
at O
baseline O
and O
at O
the O
end O
of O
the O
study O
intervention O
. O

We O
conducted O
a O
randomized O
pilot O
study O
in O
patients O
treated O
with O
four O
fractions O
of O
lung O
SBRT O
delivered O
over O
4 O
or O
over O
11 O
days O
. O

Both O
groups O
received O
a O
total O
of O
six O
cycles O
. O

All B-Premise
procedures I-Premise
were I-Premise
well I-Premise
tolerated I-Premise
by I-Premise
the I-Premise
patients I-Premise
. I-Premise

The B-Premise
estimated I-Premise
median I-Premise
overall I-Premise
survival I-Premise
times I-Premise
for I-Premise
RS I-Premise
+ I-Premise
WBRT I-Premise
and I-Premise
S I-Premise
+ I-Premise
WBRT I-Premise
patients I-Premise
were I-Premise
6.2 I-Premise
and I-Premise
2.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
0.53 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
0.20-1.43 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.20 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
effect I-Premise
of I-Premise
change I-Premise
in I-Premise
CES-D I-Premise
over I-Premise
the I-Premise
first I-Premise
year I-Premise
on I-Premise
survival I-Premise
out I-Premise
to I-Premise
14 I-Premise
years I-Premise
( I-Premise
P I-Premise
= I-Premise
.007 I-Premise
) I-Premise
but B-Premise
no I-Premise
significant I-Premise
interaction I-Premise
between I-Premise
treatment I-Premise
condition I-Premise
and I-Premise
CES-D I-Premise
change I-Premise
on I-Premise
survival I-Premise
. I-Premise

One O
hundred O
thirty-two O
anemic O
cancer O
patients O
receiving O
cyclic O
, O
cisplatin-containing O
, O
myelosuppressive O
chemotherapy O
were O
evaluated O
. O

Randomized O
controlled O
trial O
. O

Global B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
not I-Premise
statistically I-Premise
different I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

The B-Premise
global I-Premise
QL I-Premise
scores I-Premise
were I-Premise
better I-Premise
for I-Premise
PVI I-Premise
5-FU I-Premise
+ I-Premise
MMC I-Premise
arm I-Premise
at I-Premise
24 I-Premise
weeks I-Premise
, I-Premise
but B-Premise
the I-Premise
remaining I-Premise
QL I-Premise
data I-Premise
showed I-Premise
no I-Premise
differences I-Premise
. I-Premise

SNB O
had O
sensitivity O
94.5 O
% O
, O
false-negative O
rate O
5.5 O
% O
, O
and O
negative O
predictive O
value O
98 O
% O
. O

Two O
hundred O
forty-six O
of O
302 O
patients O
randomly O
assigned O
provided O
complete O
data O
at O
6 O
weeks O
. O

No B-Claim
difference I-Claim
in I-Claim
QOL I-Claim
was I-Claim
observed I-Claim
. I-Claim

The O
primary O
end-point O
of O
the O
study O
was O
the O
incidence O
of O
Radiation O
Therapy O
Oncology O
Group O
grade O
3 O
mucositis O
. O

The B-Premise
nutrition I-Premise
intervention I-Premise
group I-Premise
had I-Premise
a I-Premise
higher I-Premise
mean I-Premise
protein I-Premise
intake I-Premise
( I-Premise
1.1 I-Premise
to I-Premise
1.3 I-Premise
g/kg/day I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
standard I-Premise
practice I-Premise
group I-Premise
( I-Premise
1.0 I-Premise
to I-Premise
1.1 I-Premise
g/kg/day I-Premise
) I-Premise
( I-Premise
P=0.001 I-Premise
) I-Premise
. I-Premise

With B-Premise
the I-Premise
exceptions I-Premise
of I-Premise
increased I-Premise
granulocytopenia I-Premise
on I-Premise
the I-Premise
low-dose I-Premise
paclitaxel I-Premise
regimen I-Premise
and I-Premise
increased I-Premise
myalgias I-Premise
, I-Premise
neurotoxicity I-Premise
, I-Premise
and I-Premise
, I-Premise
possibly I-Premise
, I-Premise
increased I-Premise
treatment-related I-Premise
cardiac I-Premise
events I-Premise
with I-Premise
high-dose I-Premise
paclitaxel I-Premise
, I-Premise
toxicity I-Premise
was I-Premise
similar I-Premise
across I-Premise
all I-Premise
three I-Premise
arms I-Premise
. I-Premise

The O
sample O
size O
was O
defined O
to O
have O
an O
80 O
% O
power O
to O
detect O
a O
35 O
% O
RR O
for O
each O
experimental O
treatment O
, O
and O
to O
show O
a O
difference O
of O
at O
least O
4 O
% O
in O
RR O
with O
the O
standard O
treatment O
if O
the O
TRUE O
difference O
is O
15 O
% O
or O
more O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
combined O
intrapleural O
therapy O
with O
bevacizumab O
and O
cisplatin O
, O
an O
antineoplastic O
agent O
, O
in O
controlling O
MPE O
. O

The B-Premise
estimated I-Premise
cost I-Premise
of I-Premise
radiotherapy I-Premise
, I-Premise
including I-Premise
retreatments I-Premise
and I-Premise
nonmedical I-Premise
costs I-Premise
, I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
lower I-Premise
for I-Premise
the I-Premise
single-fraction I-Premise
schedule I-Premise
than I-Premise
for I-Premise
the I-Premise
multiple-fraction I-Premise
schedule I-Premise
( I-Premise
$ I-Premise
2438 I-Premise
versus I-Premise
$ I-Premise
3311 I-Premise
, I-Premise
difference I-Premise
= I-Premise
$ I-Premise
873 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
on I-Premise
the I-Premise
difference I-Premise
= I-Premise
$ I-Premise
449 I-Premise
to I-Premise
$ I-Premise
1297 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

One O
hundred O
fifty-three O
patients O
were O
randomly O
assigned O
to O
PLD O
( O
n O
= O
76 O
) O
or O
GEM O
( O
n O
= O
77 O
) O
. O

No B-Premise
adverse I-Premise
events I-Premise
or I-Premise
skeletal I-Premise
complications I-Premise
occurred I-Premise
during I-Premise
the I-Premise
supervised I-Premise
exercise I-Premise
sessions I-Premise
. I-Premise

Patients O
( O
n O
= O
110 O
) O
with O
stage O
II O
, O
III O
, O
or O
IV O
breast O
cancer O
scheduled O
to O
receive O
high O
dose O
chemotherapy O
and O
autologous O
hematopoietic O
stem O
cell O
transplantation O
were O
randomized O
to O
either O
CCSP O
treatment O
or O
control O
group O
. O

Patients O
were O
randomly O
assigned O
to O
a O
sunitinib O
starting O
dose O
of O
37.5 O
mg/d O
in O
the O
morning O
( O
AM O
) O
or O
evening O
( O
PM O
) O
. O

There B-Claim
were I-Claim
no I-Claim
unexpected I-Claim
hematological I-Claim
or I-Claim
non-hematological I-Claim
toxicities I-Claim
. I-Claim

In O
this O
study O
, O
the O
authors O
tested O
the O
effectiveness O
of O
a O
brief O
behaviorally O
oriented O
intervention O
in O
reducing O
CRF O
and O
improving O
physical O
function O
and O
associated O
distress O
in O
individuals O
who O
were O
receiving O
chemotherapy O
. O

Records O
of O
nutritional O
assessments O
, O
inflammatory O
status O
, O
and O
postoperative O
complications O
were O
compared O
between O
the O
two O
groups O
. O

The O
primary O
end O
points O
for O
QOL O
analysis O
were O
time O
to O
deterioration O
of O
three O
common O
lung O
cancer O
symptoms O
: O
cough O
, O
dyspnea O
, O
and O
pain O
. O

In B-Premise
this I-Premise
updated I-Premise
final I-Premise
analysis I-Premise
of I-Premise
all I-Premise
patients I-Premise
randomly I-Premise
assigned I-Premise
with I-Premise
strata I-Premise
( I-Premise
n I-Premise
= I-Premise
291 I-Premise
) I-Premise
, I-Premise
lapatinib I-Premise
plus I-Premise
trastuzumab I-Premise
continued I-Premise
to I-Premise
show I-Premise
superiority I-Premise
to I-Premise
lapatinib I-Premise
monotherapy I-Premise
in I-Premise
PFS I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.74 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.58 I-Premise
to I-Premise
0.94 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.011 I-Premise
) I-Premise
and I-Premise
offered I-Premise
significant I-Premise
OS I-Premise
benefit I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.74 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.57 I-Premise
to I-Premise
0.97 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.026 I-Premise
) I-Premise
. I-Premise

Skin O
care O
, O
30-min O
manual O
lymphatic O
drainage O
, O
1-h O
pneumatic O
compression O
therapy O
, O
application O
of O
a O
short-stretch O
bandage O
or O
K-tape O
for O
each O
group O
, O
and O
a O
20-min O
physical O
therapy O
exercise O
were O
given O
during O
every O
treatment O
session O
. O

The B-Premise
median I-Premise
OS I-Premise
was I-Premise
24 I-Premise
months I-Premise
for I-Premise
the I-Premise
HDCT I-Premise
arm I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
21 I-Premise
to I-Premise
35 I-Premise
months I-Premise
) I-Premise
and I-Premise
28 I-Premise
months I-Premise
for I-Premise
ST I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
22 I-Premise
to I-Premise
33 I-Premise
months I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.9 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.6 I-Premise
to I-Premise
1.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.43 I-Premise
) I-Premise
. I-Premise

No B-Premise
statistical I-Premise
significance I-Premise
was I-Premise
found I-Premise
in I-Premise
the I-Premise
FACT-G I-Premise
scores I-Premise
and I-Premise
FACT-B I-Premise
scores I-Premise
among I-Premise
different I-Premise
groups I-Premise
at I-Premise
baseline I-Premise
, I-Premise
week I-Premise
4 I-Premise
, I-Premise
week I-Premise
8 I-Premise
and I-Premise
week I-Premise
12 I-Premise
after I-Premise
NHT I-Premise
. I-Premise

In B-Premise
70 I-Premise
evaluable I-Premise
study I-Premise
subjects I-Premise
, I-Premise
the I-Premise
curative I-Premise
efficacy I-Premise
in I-Premise
the I-Premise
bevacizumab I-Premise
group I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
found I-Premise
in I-Premise
the I-Premise
cisplatin I-Premise
group I-Premise
( I-Premise
83.33 I-Premise
vs. I-Premise
50.00 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

A O
prospective O
randomized O
clinical O
study O
on O
the O
treatment O
of O
patients O
with O
resectable O
and O
unresectable O
pancreatic O
cancer O
was O
conducted O
at O
the O
Department O
of O
Oncology O
of O
Kaunas O
University O
of O
Medicine O
Hospital O
, O
and O
in O
this O
study O
, O
quality O
of O
life O
was O
analyzed O
. O

The O
usual O
care O
group O
received O
a O
booklet O
with O
information O
about O
fatigue O
and O
its O
management O
. O

The O
immediate O
total O
( O
ie O
, O
> O
90 O
% O
) O
lung O
expansion O
was O
observed O
in O
27 O
patients O
( O
45 O
% O
) O
and O
was O
more O
frequent O
in O
the O
VATS O
group O
( O
60 O
% O
vs O
30 O
% O
, O
respectively O
";" O
p O
= O
0.027 O
) O
. O

Both O
cross-sectional O
single-time O
and O
change O
from O
baseline O
assessments O
were O
run O
at O
day O
2 O
, O
week O
2 O
, O
month O
2 O
, O
and O
month O
18 O
postoperatively O
in O
an O
intention-to-treat O
analysis O
using O
Wilcoxon O
rank-sum O
tests O
. O

However O
, O
the O
survival O
and O
quality-of-life O
( O
QOL O
) O
benefits O
of O
paclitaxel O
used O
as O
a O
single O
agent O
compared O
with O
supportive O
care O
alone O
have O
not O
been O
assessed O
in O
a O
randomized O
clinical O
trial O
. O

Local B-Premise
recurrence I-Premise
was I-Premise
2/74 I-Premise
( I-Premise
stage I-Premise
III I-Premise
";" I-Premise
2.7 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
and I-Premise
1/92 I-Premise
( I-Premise
stage I-Premise
II I-Premise
";" I-Premise
1.1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Patients O
undergoing O
UAE O
were O
randomly O
assigned O
to O
receive O
TAGMs O
or O
PVA O
. O

A O
total O
of O
421 O
patients O
with O
locally O
advanced O
stage O
III O
or O
stage O
IV O
NSCLC O
tumors O
were O
included O
. O

Compared B-Premise
with I-Premise
MA I-Premise
, I-Premise
there I-Premise
were I-Premise
similar I-Premise
or I-Premise
greater I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
, I-Premise
TRSS I-Premise
, I-Premise
and I-Premise
QOL I-Premise
with I-Premise
EXE I-Premise
. I-Premise

Letrozole B-Claim
should I-Claim
be I-Claim
considered I-Claim
for I-Claim
all I-Claim
women I-Claim
completing I-Claim
tamoxifen I-Claim
";" I-Claim
new B-Claim
results I-Claim
from I-Claim
the I-Claim
post-unblinding I-Claim
analysis I-Claim
suggest I-Claim
that I-Claim
letrozole I-Claim
treatment I-Claim
should I-Claim
also I-Claim
be I-Claim
considered I-Claim
for I-Claim
all I-Claim
disease-free I-Claim
women I-Claim
for I-Claim
periods I-Claim
up I-Claim
to I-Claim
5 I-Claim
years I-Claim
following I-Claim
completion I-Claim
of I-Claim
adjuvant I-Claim
tamoxifen I-Claim
. I-Claim

Symptoms B-Claim
were I-Claim
common I-Claim
in I-Claim
both I-Claim
groups I-Claim
. I-Claim

Safety O
was O
also O
assessed O
. O

Patients O
received O
a O
median O
of O
six O
cycles O
in O
both O
arms O
. O

The O
primary O
outcome O
was O
pulmonary O
infection O
within O
the O
first O
2 O
weeks O
after O
surgery O
and O
during O
the O
whole O
stay O
in O
hospital O
. O

The B-Premise
occurrence I-Premise
of I-Premise
adverse I-Premise
reaction I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
was I-Premise
lower I-Premise
than I-Premise
that I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Superior B-Premise
survival I-Premise
was I-Premise
observed I-Premise
with I-Premise
the I-Premise
combined I-Premise
paclitaxel I-Premise
regimens I-Premise
( I-Premise
median I-Premise
survival I-Premise
time I-Premise
, I-Premise
9.9 I-Premise
months I-Premise
";" I-Premise
1-year I-Premise
survival I-Premise
rate I-Premise
, I-Premise
38.9 I-Premise
% I-Premise
) I-Premise
compared I-Premise
with I-Premise
etoposide I-Premise
plus I-Premise
cisplatin I-Premise
( I-Premise
median I-Premise
survival I-Premise
time I-Premise
, I-Premise
7.6 I-Premise
months I-Premise
";" I-Premise
1-year I-Premise
survival I-Premise
rate I-Premise
, I-Premise
31.8 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
. I-Premise
48 I-Premise
) I-Premise
. I-Premise

Discharged O
patients O
were O
followed-up O
in O
the O
outpatient O
clinic O
. O

Several O
guidelines O
on O
the O
treatment O
of O
cancer-related O
fatigue O
recommend O
optimizing O
treatment O
of O
accompanying O
symptoms O
. O

Measurable B-Claim
improvement I-Claim
in I-Claim
a I-Claim
general I-Claim
QOL I-Claim
measure I-Claim
was I-Claim
not I-Claim
demonstrated I-Claim
. I-Claim

Differences O
between O
the O
groups O
over O
time O
were O
assessed O
by O
using O
mixed O
modeling O
. O

The B-Premise
groups I-Premise
that I-Premise
included I-Premise
CBT I-Premise
also I-Premise
showed I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
the I-Premise
perceived I-Premise
burden I-Premise
of I-Premise
hot I-Premise
flashes I-Premise
and I-Premise
night I-Premise
sweats I-Premise
( I-Premise
problem I-Premise
rating I-Premise
scale I-Premise
of I-Premise
the I-Premise
Hot I-Premise
Flush I-Premise
Rating I-Premise
Scale I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.39-0.56 I-Premise
) I-Premise
and I-Premise
an I-Premise
increase I-Premise
in I-Premise
sexual I-Premise
activity I-Premise
( I-Premise
Sexual I-Premise
Activity I-Premise
Questionnaire I-Premise
habit I-Premise
subscale I-Premise
";" I-Premise
P=.027 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.65 I-Premise
) I-Premise
. I-Premise

Treatment O
was O
delivered O
by O
acupuncturists O
once O
a O
week O
for O
6 O
weeks O
through O
needling O
three O
pairs O
of O
acupoints O
. O

Objective B-Premise
response I-Premise
rates I-Premise
were I-Premise
22.8 I-Premise
% I-Premise
( I-Premise
13 I-Premise
of I-Premise
57 I-Premise
) I-Premise
in I-Premise
E I-Premise
and I-Premise
8.9 I-Premise
% I-Premise
( I-Premise
5 I-Premise
of I-Premise
56 I-Premise
) I-Premise
in I-Premise
V I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0388 I-Premise
) I-Premise
. I-Premise

An O
outcome O
of O
noninferiority O
of O
short-term O
androgen O
suppression O
as O
compared O
with O
long-term O
suppression O
required O
a O
hazard O
ratio O
of O
more O
than O
1.35 O
for O
overall O
survival O
, O
with O
a O
one-sided O
alpha O
level O
of O
0.05 O
. O

The B-Claim
possible I-Claim
effectiveness I-Claim
of I-Claim
5-FU+low-dose I-Claim
CDDP I-Claim
for I-Claim
colorectal I-Claim
cancer I-Claim
( I-Claim
CRC I-Claim
) I-Claim
is I-Claim
intriguing I-Claim
. I-Claim

Postoperative B-Claim
adjuvant I-Claim
chemoradiation I-Claim
treatment I-Claim
after I-Claim
curative I-Claim
resection I-Claim
for I-Claim
rectal I-Claim
cancer I-Claim
was I-Claim
needed I-Claim
to I-Claim
reduce I-Claim
recurrence I-Claim
and I-Claim
improve I-Claim
a I-Claim
survival I-Claim
rate I-Claim
. I-Claim

At B-Premise
the I-Premise
doses I-Premise
used I-Premise
, I-Premise
methadone I-Premise
was I-Premise
significantly I-Premise
less I-Premise
expensive I-Premise
( I-Premise
p I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
, I-Premise
while I-Premise
the I-Premise
use I-Premise
and I-Premise
costs I-Premise
of I-Premise
supportive I-Premise
drugs I-Premise
and I-Premise
other I-Premise
analgesics I-Premise
were I-Premise
similar I-Premise
in I-Premise
the I-Premise
three I-Premise
groups I-Premise
. I-Premise

The O
main O
outcome O
measures O
were O
the O
unmet O
supportive O
care O
needs O
, O
health O
service O
utilization O
, O
and O
quality O
of O
life O
at O
1 O
, O
3 O
, O
and O
6 O
months O
postdischarge O
. O

For B-Claim
malignant I-Claim
pleural I-Claim
mesothelioma I-Claim
( I-Claim
MPM I-Claim
) I-Claim
patients I-Claim
with I-Claim
a I-Claim
poor I-Claim
prognosis I-Claim
, I-Claim
maintaining I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
HRQOL I-Claim
) I-Claim
is I-Claim
important I-Claim
. I-Claim

The O
primary O
endpoints O
were O
overall O
survival O
( O
OS O
) O
and O
analysis O
of O
toxicity O
, O
while O
secondary O
endpoints O
included O
response O
rates O
, O
time-to-progression O
( O
TTP O
) O
and O
quality O
of O
life O
( O
QoL O
) O
. O

The B-Premise
hazard I-Premise
ratio I-Premise
was I-Premise
0.63 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
0.52-0.75 I-Premise
";" I-Premise
log-rank I-Premise
, I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

The B-Premise
intervention I-Premise
also I-Premise
improved I-Premise
all I-Premise
other I-Premise
fatigue I-Premise
aspects I-Premise
measured I-Premise
by I-Premise
MFI I-Premise
, I-Premise
including I-Premise
Physical I-Premise
Fatigue I-Premise
and I-Premise
Mental I-Premise
Fatigue I-Premise
( I-Premise
acupuncture I-Premise
effect I-Premise
, I-Premise
-2.36 I-Premise
and I-Premise
-1.94 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
both I-Premise
at I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
anxiety I-Premise
and I-Premise
depression I-Premise
( I-Premise
acupuncture I-Premise
effect I-Premise
, I-Premise
-1.83 I-Premise
and I-Premise
-2.13 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
both I-Premise
at I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
Physical I-Premise
Well-Being I-Premise
effect I-Premise
, I-Premise
3.30 I-Premise
";" I-Premise
Functional I-Premise
Well-Being I-Premise
effect I-Premise
, I-Premise
3.57 I-Premise
";" I-Premise
both I-Premise
at I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
Emotional I-Premise
Well-Being I-Premise
effect I-Premise
, I-Premise
1.93 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.001 I-Premise
";" I-Premise
and I-Premise
Social I-Premise
Functioning I-Premise
Well-Being I-Premise
effect I-Premise
, I-Premise
1.05 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

In O
a O
recent O
randomized O
trial O
, O
stent O
placement O
was O
preferred O
in O
patients O
with O
a O
relatively O
short O
survival O
and O
GJJ O
in O
patients O
with O
a O
longer O
survival O
. O

Compared B-Premise
with I-Premise
each I-Premise
single I-Premise
drug I-Premise
, I-Premise
the I-Premise
combination I-Premise
treatment I-Premise
did I-Premise
not I-Premise
improve I-Premise
survival I-Premise
. I-Premise

Patients O
with O
histologically-proven O
unresectable O
MPM O
, O
not O
pretreated O
with O
chemotherapy O
were O
randomly O
assigned O
to O
receive O
cisplatin O
80 O
mg/m2 O
intravenously O
on O
day O
1 O
, O
with O
or O
without O
preceding O
infusion O
of O
raltitrexed O
3 O
mg/m2 O
. O

In B-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
1 I-Premise
case I-Premise
suffered I-Premise
from I-Premise
chest I-Premise
distress I-Premise
, I-Premise
3 I-Premise
cases I-Premise
suffered I-Premise
from I-Premise
acratia I-Premise
, I-Premise
and I-Premise
4 I-Premise
cases I-Premise
suffered I-Premise
from I-Premise
pyrexia I-Premise
. I-Premise

Comparing B-Claim
the I-Claim
results I-Claim
2 I-Claim
and I-Claim
3 I-Claim
years I-Claim
after I-Claim
radiotherapy I-Claim
, I-Claim
the I-Claim
symptoms I-Claim
of I-Claim
rectal I-Claim
bleeding I-Claim
had I-Claim
improved I-Claim
, I-Claim
erectile I-Claim
function I-Claim
had I-Claim
decreased I-Claim
, I-Claim
and I-Claim
urinary I-Claim
urge I-Claim
incontinence I-Claim
had I-Claim
increased I-Claim
. I-Claim

Control O
subjects O
received O
routine O
hospital O
care O
without O
any O
music O
therapy O
intervention O
. O

Subjects O
completed O
visual O
analog O
scales O
, O
the O
FACIT-Fatigue O
Scale O
and O
the O
Short O
Form-36v2 O
after O
surgery O
and O
again O
3 O
to O
6 O
months O
after O
hospital O
discharge O
. O

At B-Premise
6-month I-Premise
follow-up I-Premise
, I-Premise
AET I-Premise
was I-Premise
still I-Premise
borderline I-Premise
or I-Premise
significantly I-Premise
superior I-Premise
to I-Premise
UC I-Premise
for I-Premise
overall I-Premise
QoL I-Premise
( I-Premise
P I-Premise
= I-Premise
.054 I-Premise
) I-Premise
, I-Premise
happiness I-Premise
( I-Premise
P I-Premise
= I-Premise
.034 I-Premise
) I-Premise
, I-Premise
and I-Premise
depression I-Premise
( I-Premise
P I-Premise
= I-Premise
.009 I-Premise
) I-Premise
without I-Premise
an I-Premise
increased I-Premise
risk I-Premise
of I-Premise
disease I-Premise
recurrence/progression I-Premise
. I-Premise

The O
present O
study O
showed O
that O
ADT O
with O
the O
gonadotropin O
hormone-releasing O
hormone O
( O
GhRH O
) O
antagonist O
degarelix O
is O
non-inferior O
to O
combined O
treatment O
with O
the O
LHRH O
agonist O
goserelin O
and O
bicalutamide O
in O
terms O
of O
reducing O
prostate O
volume O
during O
the O
treatment O
period O
of O
3 O
months O
. O

The B-Premise
median I-Premise
duration I-Premise
of I-Premise
response I-Premise
was I-Premise
8.8 I-Premise
and I-Premise
8.3 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
Study I-Premise
A I-Premise
and I-Premise
Study I-Premise
B I-Premise
. I-Premise

Beyond O
standard O
toxicity O
end O
points O
, O
physician O
dysphagia O
logs O
( O
PDLs O
) O
, O
daily O
patient O
swallowing O
diaries O
, O
and O
QOL O
( O
EORTC O
QLQ-C30/LC-13 O
) O
were O
also O
collected O
. O

This O
study O
examined O
how O
PRO O
feedback O
had O
an O
impact O
on O
patient-physician O
communication O
over O
time O
to O
gain O
a O
better O
understanding O
of O
how O
it O
may O
influence O
patient O
care O
. O

A O
significant O
barrier O
to O
positive O
pain O
management O
is O
patients O
' O
misconceptions O
regarding O
analgesics O
and O
inadequate O
use O
of O
nonpharmacological O
strategies O
as O
pain O
relief O
. O

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
effect I-Premise
of I-Premise
group I-Premise
on I-Premise
women I-Premise
's I-Premise
perceptions I-Premise
of I-Premise
social I-Premise
support I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
being I-Premise
more I-Premise
satisfied I-Premise
with I-Premise
the I-Premise
emotional I-Premise
support I-Premise
they I-Premise
received I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Upon B-Premise
the I-Premise
completion I-Premise
of I-Premise
PMP I-Premise
, I-Premise
pain I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
reduced I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
yet B-Premise
patients I-Premise
in I-Premise
the I-Premise
experimental I-Premise
group I-Premise
showed I-Premise
a I-Premise
significant I-Premise
increase I-Premise
in I-Premise
the I-Premise
use I-Premise
of I-Premise
PRN I-Premise
analgesics I-Premise
and I-Premise
nonpharmacological I-Premise
strategies I-Premise
to I-Premise
relieve I-Premise
pain I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
and I-Premise
significantly I-Premise
reduce I-Premise
barriers I-Premise
to I-Premise
managing I-Premise
their I-Premise
cancer I-Premise
pain I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Vaginal B-Premise
dryness I-Premise
( I-Premise
b I-Premise
= I-Premise
0.064 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.016-0.112 I-Premise
) I-Premise
and I-Premise
sexual I-Premise
problems I-Premise
( I-Premise
b I-Premise
= I-Premise
0.054 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.007-0.102 I-Premise
) I-Premise
increased I-Premise
in I-Premise
women I-Premise
taking I-Premise
anastrozole I-Premise
compared I-Premise
with I-Premise
women I-Premise
taking I-Premise
tamoxifen I-Premise
. I-Premise

The O
exercise O
group O
followed O
a O
progressive O
, O
8-week O
upper-body O
exercise O
program O
consisting O
of O
resistance O
training O
plus O
aerobic O
exercise O
using O
a O
Monark O
Rehab O
Trainer O
arm O
ergometer O
. O

Other O
measurements O
included O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
, O
Functional O
Assessment O
of O
Cancer O
Therapy-General O
quality-of-life O
scale O
, O
and O
expectation O
of O
acupuncture O
effect O
. O

Patients O
received O
LV O
200 O
mg/m O
( O
2 O
) O
( O
2-hour O
infusion O
) O
followed O
by O
FU O
400 O
mg/m O
( O
2 O
) O
( O
bolus O
) O
and O
FU O
600 O
mg/m O
( O
2 O
) O
( O
22-hour O
continuous O
infusion O
) O
on O
days O
1 O
and O
2 O
every O
14 O
days O
( O
LV5FU2 O
";" O
arm O
A O
) O
, O
LV5FU2 O
plus O
cisplatin O
50 O
mg/m O
( O
2 O
) O
( O
1-hour O
infusion O
) O
on O
day O
1 O
or O
2 O
( O
arm O
B O
) O
, O
or O
LV5FU2 O
plus O
irinotecan O
180 O
mg/m O
( O
2 O
) O
( O
2-hour O
infusion O
) O
on O
day O
1 O
( O
arm O
C O
) O
. O

Following O
assessment O
of O
mental O
and O
physical O
well-being O
, O
depression O
, O
anxiety O
, O
exercise O
, O
and O
stress O
reduction O
activity O
before O
chemotherapy O
started O
, O
patients O
were O
randomized O
to O
stress O
management O
training O
( O
SM O
) O
, O
exercise O
( O
EX O
) O
, O
combined O
stress O
management O
and O
exercise O
( O
SMEX O
) O
, O
or O
usual O
care O
only O
( O
UCO O
) O
. O

There O
is O
a O
modest O
dose O
effect O
with O
longer O
time O
to O
progression O
at O
175 O
mg/m2 O
. O

In B-Premise
planned I-Premise
subgroup I-Premise
analyses I-Premise
, I-Premise
a I-Premise
significant I-Premise
interaction I-Premise
was I-Premise
noted I-Premise
( I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
: I-Premise
limited-stage I-Premise
vandetanib I-Premise
patients I-Premise
had I-Premise
longer I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.45 I-Premise
";" I-Premise
one-sided I-Premise
P I-Premise
= I-Premise
.07 I-Premise
) I-Premise
and I-Premise
extensive-stage I-Premise
vandetanib I-Premise
patients I-Premise
shorter I-Premise
survival I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
HR I-Premise
, I-Premise
2.27 I-Premise
";" I-Premise
one-sided I-Premise
P I-Premise
= I-Premise
.996 I-Premise
) I-Premise
. I-Premise

These B-Claim
results I-Claim
suggest I-Claim
that I-Claim
sexual I-Claim
functioning I-Claim
may I-Claim
require I-Claim
focused I-Claim
assessment I-Claim
by I-Claim
providers I-Claim
, I-Claim
beyond I-Claim
broad I-Claim
QOL I-Claim
assessments I-Claim
, I-Claim
and O
that O
attention B-Claim
to I-Claim
Sexual/Relationship I-Claim
Satisfaction I-Claim
may I-Claim
be I-Claim
critical I-Claim
in I-Claim
the I-Claim
development I-Claim
and I-Claim
implementation I-Claim
of I-Claim
interventions I-Claim
for I-Claim
this I-Claim
cohort I-Claim
of I-Claim
patients I-Claim
. I-Claim

A O
total O
of O
120 O
patients O
were O
randomly O
assigned O
to O
receive O
AM O
, O
and O
122 O
, O
to O
receive O
no O
AM O
( O
one O
patient O
was O
ineligible O
) O
";" O
72 O
% O
received O
AM O
per O
protocol O
or O
with O
a O
minor O
deviation O
. O

Some B-Claim
studies I-Claim
have I-Claim
also I-Claim
suggested I-Claim
that I-Claim
gemcitabine I-Claim
is I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
effective I-Claim
in I-Claim
such I-Claim
patients I-Claim
. I-Claim

However B-Premise
, I-Premise
the I-Premise
magnitude I-Premise
of I-Premise
the I-Premise
benefits I-Premise
was I-Premise
small I-Premise
. I-Premise

Most B-Premise
frequent I-Premise
non-hematological I-Premise
toxicities I-Premise
were I-Premise
nausea I-Premise
( I-Premise
76 I-Premise
% I-Premise
) I-Premise
, I-Premise
constipation I-Premise
( I-Premise
68 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
. I-Premise

A B-Premise
slight I-Premise
increase I-Premise
in I-Premise
transfusions I-Premise
was I-Premise
reported I-Premise
in I-Premise
the I-Premise
QW I-Premise
group I-Premise
. I-Premise

CBT-I B-Claim
delivered I-Claim
through I-Claim
an I-Claim
interactive I-Claim
, I-Claim
individually I-Claim
tailored I-Claim
Internet I-Claim
intervention I-Claim
may I-Claim
be I-Claim
a I-Claim
viable I-Claim
treatment I-Claim
option I-Claim
for I-Claim
cancer I-Claim
survivors I-Claim
experiencing I-Claim
insomnia I-Claim
. I-Claim

The B-Premise
mean I-Premise
level I-Premise
of I-Premise
postoperative I-Premise
satisfaction I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
EOF I-Premise
group I-Premise
( I-Premise
82.8 I-Premise
vs. I-Premise
71.7 I-Premise
mm I-Premise
, I-Premise
P I-Premise
B I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Treatment B-Claim
with I-Claim
either I-Claim
paclitaxel I-Claim
or I-Claim
PLD I-Claim
appears I-Claim
to I-Claim
produce I-Claim
significant I-Claim
improvements I-Claim
in I-Claim
pain I-Claim
and I-Claim
swelling I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
, I-Claim
symptomatic I-Claim
, I-Claim
HIV-associated I-Claim
KS I-Claim
treated I-Claim
in I-Claim
the I-Claim
HAART I-Claim
era I-Claim
. I-Claim

HRQOL B-Claim
and I-Claim
AEs I-Claim
were I-Claim
similar I-Claim
with I-Claim
exemestane I-Claim
and I-Claim
anastrozole I-Claim
. I-Claim

Responses O
were O
assessed O
by O
measuring O
changes O
in O
hemoglobin/hematocrit O
, O
transfusion O
requirement O
, O
and O
quality O
of O
life O
. O

A O
measure O
of O
3.7 O
GBq O
of O
radioiodine O
was O
given O
to O
both O
groups O
. O

Survival O
duration O
, O
disease-free O
survival O
, O
quality O
of O
life O
and O
costs O
were O
evaluated O
separately O
. O

We O
assessed O
whether O
minimally O
invasive O
oesophagectomy O
reduces O
morbidity O
compared O
with O
open O
oesophagectomy O
. O

Patients O
were O
stratified O
by O
menopausal O
and O
hormone-receptor O
status O
. O

Quality-of-life B-Premise
scores I-Premise
for I-Premise
physical I-Premise
health I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
and I-Premise
perceived I-Premise
health I-Premise
( I-Premise
P I-Premise
= I-Premise
.043 I-Premise
) I-Premise
decreased I-Premise
at I-Premise
6 I-Premise
months I-Premise
for I-Premise
control I-Premise
group I-Premise
but I-Premise
for I-Premise
not I-Premise
the I-Premise
HBO I-Premise
group I-Premise
. I-Premise

This O
study O
was O
designed O
to O
evaluate O
efficacy O
, O
toxicity O
, O
and O
adverse O
effects O
of O
combination O
of O
chemotherapy O
drugs O
and O
intraperitoneal O
perfusion O
of O
verapamil O
in O
the O
treatment O
of O
malignant O
ascites O
. O

23 O
centres O
in O
the O
United O
Kingdom O
, O
Ireland O
, O
and O
South O
Africa O
. O

To O
determine O
if O
the O
type O
of O
embolic O
material O
used O
for O
uterine O
artery O
embolization O
( O
UAE O
) O
for O
leiomyomas O
has O
an O
impact O
on O
short-term O
recovery O
or O
the O
effectiveness O
of O
embolization O
. O

No B-Premise
differences I-Premise
in I-Premise
overall I-Premise
survival I-Premise
or I-Premise
imatinib I-Premise
resistance I-Premise
were I-Premise
observed I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
. I-Premise

The B-Claim
impact I-Claim
of I-Claim
treatment I-Claim
on I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
HRQoL I-Claim
) I-Claim
is I-Claim
an I-Claim
important I-Claim
consideration I-Claim
in I-Claim
the I-Claim
adjuvant I-Claim
treatment I-Claim
of I-Claim
operable I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Median B-Premise
OS I-Premise
was I-Premise
13.8 I-Premise
months I-Premise
for I-Premise
arm I-Premise
1 I-Premise
versus I-Premise
14.4 I-Premise
months I-Premise
for I-Premise
arm I-Premise
2 I-Premise
( I-Premise
P I-Premise
=.4 I-Premise
) I-Premise
. I-Premise

Assessments O
were O
conducted O
at O
baseline O
, O
immediately O
before O
every O
treatment O
cycle O
, O
at O
the O
end O
of O
treatment O
, O
and O
every O
six O
weeks O
for O
12 O
months O
. O

The O
authors O
conducted O
a O
randomized O
study O
to O
confirm O
the O
effectiveness O
and O
safety O
of O
treatment O
of O
CACS O
utilizing O
megestrol O
acetate O
( O
MA O
) O
plus O
thalidomide O
. O

Dose B-Premise
reductions I-Premise
were I-Premise
required I-Premise
for I-Premise
10 I-Premise
% I-Premise
of I-Premise
patients I-Premise
with I-Premise
rash I-Premise
and I-Premise
4 I-Premise
% I-Premise
of I-Premise
patients I-Premise
with I-Premise
diarrhea I-Premise
. I-Premise

Secondary O
outcomes O
included O
additional O
QOL O
measures O
, O
patient O
satisfaction O
, O
safety O
and O
health O
economics O
. O

In B-Claim
nonrandomized I-Claim
studies I-Claim
involving I-Claim
patients I-Claim
with I-Claim
different I-Claim
tumor I-Claim
types I-Claim
including I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
, I-Claim
ATP I-Claim
infusion I-Claim
appeared I-Claim
to I-Claim
inhibit I-Claim
loss I-Claim
of I-Claim
weight I-Claim
and I-Claim
deterioration I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
and I-Claim
performance I-Claim
status I-Claim
. I-Claim

Differences B-Claim
in I-Claim
chemotherapy I-Claim
scheduling I-Claim
, I-Claim
pre-existing I-Claim
morbidity I-Claim
, I-Claim
and I-Claim
toxicity I-Claim
are I-Claim
important I-Claim
in I-Claim
individualizing I-Claim
therapy I-Claim
. I-Claim

Results B-Premise
from I-Premise
the I-Premise
non-randomised I-Premise
patients I-Premise
did I-Premise
not I-Premise
confirm I-Premise
this I-Premise
effect I-Premise
, I-Premise
however I-Premise
. I-Premise

The B-Premise
Independent I-Premise
Review I-Premise
Committee-assessed I-Premise
PFS I-Premise
hazard I-Premise
ratio I-Premise
was I-Premise
0.72 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.54 I-Premise
to I-Premise
0.94 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.0162 I-Premise
";" I-Premise
median I-Premise
PFS I-Premise
, I-Premise
13.9 I-Premise
v I-Premise
16.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
PFS I-Premise
events I-Premise
in I-Premise
53 I-Premise
% I-Premise
) I-Premise
. I-Premise

General O
practices O
in O
UK O
( O
384 O
) O
, O
Australia O
( O
91 O
) O
, O
and O
New O
Zealand O
( O
24 O
) O
. O

The O
aim O
of O
this O
randomised O
trial O
was O
to O
evaluate O
the O
activity O
and O
toxicity O
of O
a O
biweekly O
regimen O
including O
6S-leucovorin-modulated O
5-fluorouracil O
( O
LFA-5-FU O
) O
, O
combined O
with O
either O
irinotecan O
( O
CPT-11 O
+ O
LFA O
5-FU O
) O
or O
raltitrexed O
( O
Tomudex O
) O
( O
TOM O
+ O
LFA-5-FU O
) O
, O
in O
advanced O
colorectal O
cancer O
patients O
, O
and O
to O
make O
a O
preliminary O
comparison O
of O
both O
these O
experimental O
regimens O
with O
a O
biweekly O
administration O
of O
LFA-5-FU O
modulated O
by O
methotrexate O
( O
MTX O
+ O
LFA-5-FU O
) O
. O

Regimen O
A O
consisted O
of O
PAV O
( O
cisPlatin O
, O
Adriamycin O
, O
VP O
16-213 O
, O
and O
Regimen O
B O
of O
CyMOC O
( O
Cyclophosphamide O
, O
Methotrexate O
, O
Oncovin O
, O
CCNU O
) O
. O

Low-dose B-Claim
CDDP I-Claim
improved I-Claim
the I-Claim
response I-Claim
rate I-Claim
while I-Claim
keeping I-Claim
toxicities I-Claim
within I-Claim
clinically I-Claim
acceptable I-Claim
limits I-Claim
. I-Claim

There B-Premise
was I-Premise
a I-Premise
survival I-Premise
advantage I-Premise
for I-Premise
non-stent-treated I-Premise
patients I-Premise
( I-Premise
log-rank I-Premise
statistic=4.21 I-Premise
, I-Premise
P=0.04 I-Premise
) I-Premise
. I-Premise

Overall B-Premise
response I-Premise
rate I-Premise
was I-Premise
higher I-Premise
with I-Premise
DCF I-Premise
( I-Premise
chi2 I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
the I-Premise
proportion I-Premise
of I-Premise
NK I-Premise
cells I-Premise
, I-Premise
T-cell I-Premise
subgroups I-Premise
CD3+ I-Premise
, I-Premise
CD4+ I-Premise
and I-Premise
CD8+ I-Premise
had I-Premise
a I-Premise
significant I-Premise
change I-Premise
before I-Premise
and I-Premise
after I-Premise
treatment I-Premise
. I-Premise

There B-Claim
is I-Claim
no I-Claim
consensus I-Claim
on I-Claim
an I-Claim
accepted I-Claim
intervention I-Claim
that I-Claim
significantly I-Claim
reduces I-Claim
its I-Claim
severity I-Claim
. I-Claim

The O
treatments O
were O
repeated O
every O
3 O
weeks O
for O
six O
cycles O
";" O
in O
responding O
patients O
, O
an O
additional O
three O
cycles O
of O
single-agent O
carboplatin O
was O
permitted O
. O

One O
group O
was O
treated O
with O
DC/CIK O
immunobiological O
cancer O
therapy O
, O
and O
the O
other O
was O
taken O
as O
a O
control O
group O
. O

The B-Claim
effect I-Claim
appeared I-Claim
to I-Claim
be I-Claim
dose-dependent I-Claim
. I-Claim

Comparing B-Premise
the I-Premise
changes I-Premise
in I-Premise
low-frequency I-Premise
low-intensity I-Premise
electrotherapy I-Premise
with I-Premise
manual I-Premise
lymphatic I-Premise
drainage I-Premise
changes I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
. I-Premise

Intensity O
of O
service O
did O
not O
differ O
between O
the O
2 O
groups O
. O

Four O
hundred O
forty-five O
patients O
randomly O
received O
either O
docetaxel O
75 O
mg/m O
( O
2 O
) O
and O
cisplatin O
75 O
mg/m O
( O
2 O
) O
each O
on O
day O
1 O
plus O
fluorouracil O
750 O
mg/m O
( O
2 O
) O
/d O
continuous O
infusion O
on O
days O
1 O
to O
5 O
every O
3 O
weeks O
( O
DCF O
) O
or O
cisplatin O
100 O
mg/m O
( O
2 O
) O
on O
day O
1 O
plus O
fluorouracil O
1,000 O
mg/m O
( O
2 O
) O
/d O
continuous O
infusion O
on O
days O
1 O
to O
5 O
every O
4 O
weeks O
( O
CF O
) O
. O

This O
resulted O
in O
a O
higher O
need O
to O
remain O
close O
to O
a O
toilet O
and O
, O
as O
a O
consequence O
, O
more O
limitation O
of O
daily O
activities O
because O
of O
bowel O
symptoms O
and O
decreased O
social O
functioning O
. O

Many O
patients O
with O
advanced O
ovarian O
cancer O
will O
develop O
recurrent O
disease O
. O

Zoledronic B-Claim
acid I-Claim
at I-Claim
4 I-Claim
mg I-Claim
given I-Claim
as I-Claim
a I-Claim
15-minute I-Claim
infusion I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
, I-Claim
but O
the B-Claim
8-mg I-Claim
dose I-Claim
was I-Claim
associated I-Claim
with I-Claim
renal I-Claim
function I-Claim
deterioration I-Claim
. I-Claim

Patients O
aged O
70 O
years O
and O
older O
, O
enrolled O
between O
December O
1997 O
and O
November O
2000 O
, O
were O
randomly O
assigned O
to O
receive O
intravenous O
vinorelbine O
( O
30 O
mg/m O
( O
2 O
) O
of O
body O
surface O
area O
) O
, O
gemcitabine O
( O
1200 O
mg/m O
( O
2 O
) O
) O
, O
or O
vinorelbine O
( O
25 O
mg/m O
( O
2 O
) O
) O
plus O
gemcitabine O
( O
1000 O
mg/m O
( O
2 O
) O
) O
. O

OS B-Premise
, I-Premise
PFS I-Premise
, I-Premise
QOL I-Premise
, I-Premise
and I-Premise
RR I-Premise
were I-Premise
comparable I-Premise
between I-Premise
arms I-Premise
. I-Premise

Thus O
, O
an O
alternative O
regimen O
without O
significant O
neurotoxicity O
was O
evaluated O
by O
comparing O
gemcitabine O
plus O
carboplatin O
with O
single-agent O
carboplatin O
in O
platinum-sensitive O
recurrent O
ovarian O
cancer O
patients O
. O

A O
total O
of O
173 O
patients O
( O
82 O
% O
of O
the O
expected O
) O
in O
the O
observation O
arm O
and O
186 O
( O
85 O
% O
of O
expected O
) O
in O
the O
chemotherapy O
arm O
completed O
baseline O
QOL O
assessments O
. O

No B-Premise
significant I-Premise
main I-Premise
effect I-Premise
of I-Premise
the I-Premise
interventions I-Premise
emerged I-Premise
on I-Premise
cancer-specific I-Premise
distress I-Premise
, I-Premise
but B-Premise
EDU I-Premise
prompted I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
this I-Premise
outcome I-Premise
relative I-Premise
to I-Premise
CTL I-Premise
at I-Premise
6 I-Premise
months I-Premise
for I-Premise
patients I-Premise
who I-Premise
felt I-Premise
more I-Premise
prepared I-Premise
for I-Premise
re-entry I-Premise
. I-Premise

We O
evaluated O
thalidomide O
, O
an O
anti-angiogenic O
agent O
, O
when O
combined O
with O
chemotherapy O
and O
as O
maintenance O
treatment O
. O

Survival B-Premise
without I-Premise
performance-status I-Premise
deterioration I-Premise
( I-Premise
p=0.0001 I-Premise
) I-Premise
, I-Premise
without I-Premise
weight I-Premise
loss I-Premise
of I-Premise
more I-Premise
than I-Premise
5 I-Premise
% I-Premise
( I-Premise
p=0.018 I-Premise
) I-Premise
, I-Premise
and I-Premise
pain-free I-Premise
survival I-Premise
( I-Premise
p=0.003 I-Premise
) I-Premise
were I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
patients I-Premise
given I-Premise
irinotecan I-Premise
. I-Premise

N O
, O
N-diethyl-2- O
[ O
-4 O
( O
phenylmethyl O
) O
phenoxy O
] O
ethanamine O
( O
DPPE O
";" O
tesmilifene O
) O
is O
a O
novel O
agent O
that O
augments O
chemotherapy O
cytotoxicity O
in O
vitro O
and O
in O
vivo O
. O

AET B-Claim
significantly I-Claim
improved I-Claim
important I-Claim
patient-rated I-Claim
outcomes I-Claim
and I-Claim
objective I-Claim
physical I-Claim
functioning I-Claim
in I-Claim
lymphoma I-Claim
patients I-Claim
without I-Claim
interfering I-Claim
with I-Claim
medical I-Claim
treatments I-Claim
or I-Claim
response I-Claim
. I-Claim

Fifty-one O
randomly O
assigned O
women O
completed O
the O
study O
. O

Of B-Premise
the I-Premise
36 I-Premise
patients I-Premise
who I-Premise
reported I-Premise
that I-Premise
pain I-Premise
interfered I-Premise
with I-Premise
their I-Premise
normal I-Premise
work I-Premise
or I-Premise
activities I-Premise
at I-Premise
baseline I-Premise
, I-Premise
25 I-Premise
( I-Premise
69 I-Premise
% I-Premise
) I-Premise
improved I-Premise
. I-Premise

The B-Premise
1-year I-Premise
PFS I-Premise
rates I-Premise
were I-Premise
16.7 I-Premise
% I-Premise
with I-Premise
gefitinib I-Premise
and I-Premise
2.8 I-Premise
% I-Premise
with I-Premise
GP I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.198 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.944 I-Premise
to I-Premise
1.520 I-Premise
) I-Premise
. I-Premise

Secondary O
outcome O
measures O
were O
self-reports O
of O
interference O
of O
hot O
flashes O
on O
daily O
activities O
. O

In B-Premise
multivariate I-Premise
analysis I-Premise
, I-Premise
baseline I-Premise
neutrophil I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
baseline I-Premise
platelet I-Premise
counts I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
the I-Premise
difference I-Premise
between I-Premise
white I-Premise
blood I-Premise
cell I-Premise
( I-Premise
WBC I-Premise
) I-Premise
and I-Premise
neutrophil I-Premise
count I-Premise
( I-Premise
P I-Premise
= I-Premise
0.009 I-Premise
) I-Premise
had I-Premise
a I-Premise
significant I-Premise
adverse I-Premise
prognostic I-Premise
value I-Premise
. I-Premise

Improvements B-Premise
in I-Premise
self-esteem I-Premise
observed I-Premise
with I-Premise
RET I-Premise
during I-Premise
breast I-Premise
cancer I-Premise
chemotherapy I-Premise
were I-Premise
maintained I-Premise
at I-Premise
6-month I-Premise
follow-up I-Premise
whereas O
reductions B-Premise
in I-Premise
anxiety I-Premise
not I-Premise
observed I-Premise
with I-Premise
AET I-Premise
during I-Premise
breast I-Premise
cancer I-Premise
chemotherapy I-Premise
emerged I-Premise
at I-Premise
6-month I-Premise
follow-up I-Premise
. I-Premise

A B-Premise
non-significant I-Premise
trend I-Premise
towards I-Premise
delayed I-Premise
time I-Premise
to I-Premise
cough I-Premise
and I-Premise
time I-Premise
to I-Premise
dyspnoea I-Premise
( I-Premise
HR=0.77 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.49-1.21 I-Premise
] I-Premise
and I-Premise
HR=0.75 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.48-1.17 I-Premise
] I-Premise
, I-Premise
respectively I-Premise
) I-Premise
was I-Premise
also I-Premise
observed I-Premise
. I-Premise

Improvements B-Claim
in I-Claim
total I-Claim
quality-of-life I-Claim
change I-Claim
scores I-Claim
demonstrated I-Claim
that I-Claim
at I-Claim
6 I-Claim
months I-Claim
, I-Claim
improvements I-Claim
were I-Claim
more I-Claim
than I-Claim
twice I-Claim
as I-Claim
large I-Claim
and I-Claim
clinically I-Claim
significant I-Claim
in I-Claim
the I-Claim
intervention I-Claim
compared I-Claim
with I-Claim
the I-Claim
control I-Claim
group I-Claim
. I-Claim

Up O
to O
December O
2006 O
, O
eighty-seven O
patients O
of O
stage O
II O
and O
III O
, O
including O
71 O
patients O
of O
middle O
third O
lesions O
and O
16 O
lower O
third O
lesions O
were O
enrolled O
. O

We O
assessed O
HRQOL O
at O
baseline O
and O
at O
every O
3 O
months O
during O
treatment O
until O
progression O
using O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
quality O
of O
life O
questionnaire O
core-30 O
( O
QLQ-C30 O
) O
and O
the O
EORTC O
brain O
cancer O
module O
( O
EORTC O
BN-20 O
) O
. O

Nonsignificant B-Premise
differences I-Premise
between I-Premise
groups I-Premise
were I-Premise
found I-Premise
for I-Premise
all I-Premise
unmet I-Premise
supportive I-Premise
care I-Premise
need I-Premise
and I-Premise
quality-of-life I-Premise
scores I-Premise
, I-Premise
change I-Premise
scores I-Premise
, I-Premise
and I-Premise
trends I-Premise
. I-Premise

The B-Premise
overall I-Premise
progression-free I-Premise
survival I-Premise
rate I-Premise
was I-Premise
53 I-Premise
% I-Premise
at I-Premise
1 I-Premise
year I-Premise
and I-Premise
17 I-Premise
% I-Premise
at I-Premise
3 I-Premise
years I-Premise
. I-Premise

Median B-Premise
TTP I-Premise
was I-Premise
4.5 I-Premise
and I-Premise
4.6 I-Premise
months I-Premise
respectively I-Premise
for I-Premise
weekly I-Premise
VNR/CDDP I-Premise
arm I-Premise
and I-Premise
the I-Premise
day I-Premise
1-8 I-Premise
VNR/CDDP I-Premise
one I-Premise
. I-Premise

The B-Premise
primary I-Premise
outcome I-Premise
measure I-Premise
was I-Premise
achieved I-Premise
in I-Premise
28 I-Premise
% I-Premise
of I-Premise
the I-Premise
immediate I-Premise
treatment I-Premise
group I-Premise
and I-Premise
26 I-Premise
% I-Premise
of I-Premise
patients I-Premise
from I-Premise
the I-Premise
delayed I-Premise
treatment I-Premise
group I-Premise
( I-Premise
27/97 I-Premise
and I-Premise
27/103 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
absolute I-Premise
difference I-Premise
1.6 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
-10.7 I-Premise
% I-Premise
to I-Premise
13.9 I-Premise
% I-Premise
) I-Premise
. I-Premise

Overall B-Premise
the I-Premise
treatment I-Premise
was I-Premise
well I-Premise
tolerated I-Premise
. O

Similar B-Premise
results I-Premise
were I-Premise
found I-Premise
for I-Premise
low-dose I-Premise
radioiodine I-Premise
plus I-Premise
thyrotropin I-Premise
alfa I-Premise
( I-Premise
84.3 I-Premise
% I-Premise
) I-Premise
versus I-Premise
high-dose I-Premise
radioiodine I-Premise
plus I-Premise
thyroid I-Premise
hormone I-Premise
withdrawal I-Premise
( I-Premise
87.6 I-Premise
% I-Premise
) I-Premise
or I-Premise
high-dose I-Premise
radioiodine I-Premise
plus I-Premise
thyrotropin I-Premise
alfa I-Premise
( I-Premise
90.2 I-Premise
% I-Premise
) I-Premise
. I-Premise

This O
study O
is O
registered O
as O
an O
international O
standard O
randomised O
controlled O
trial O
, O
number O
ISRCTN01534787 O
. O

The O
primary O
objective O
was O
to O
demonstrate O
better O
overall O
survival O
( O
OS O
) O
for O
gefitinib O
compared O
with O
GP O
in O
chemotherapy-naive O
NSLAs O
. O

QUARTZ O
was O
threatened O
with O
both O
loss O
of O
funding O
and O
early O
closure O
due O
to O
poor O
accrual O
. O

Recent B-Claim
studies I-Claim
have I-Claim
shown I-Claim
that I-Claim
administering I-Claim
the I-Claim
aromatase I-Claim
inhibitor I-Claim
exemestane I-Claim
after I-Claim
2-3 I-Claim
years I-Claim
of I-Claim
tamoxifen I-Claim
therapy I-Claim
significantly I-Claim
improves I-Claim
disease-free I-Claim
survival I-Claim
in I-Claim
postmenopausal I-Claim
women I-Claim
with I-Claim
primary I-Claim
breast I-Claim
cancer I-Claim
in I-Claim
comparison I-Claim
with I-Claim
standard I-Claim
5-year I-Claim
tamoxifen I-Claim
treatment I-Claim
. I-Claim

Tumour-related O
symptoms O
were O
present O
in O
134 O
( O
71 O
% O
) O
patients O
and O
weight O
loss O
of O
more O
than O
5 O
% O
was O
seen O
in O
15 O
( O
8 O
% O
) O
patients O
. O

To O
examine O
the O
effect O
of O
a O
progressive O
upper-body O
exercise O
program O
on O
lymphedema O
secondary O
to O
breast O
cancer O
treatment O
. O

The B-Claim
incidence I-Claim
and I-Claim
development I-Claim
of I-Claim
cancer I-Claim
are I-Claim
closely I-Claim
related I-Claim
to I-Claim
dysfunction I-Claim
of I-Claim
immune I-Claim
function I-Claim
. I-Claim

The O
objective O
of O
the O
study O
was O
to O
determine O
the O
efficacy O
of O
systematic O
feedback O
from O
standardized O
assessment O
tools O
for O
hospice O
patient-caregiver O
dyads O
in O
improving O
hospice O
outcomes O
compared O
with O
the O
usual O
clinical O
practice O
. O

Progression-free B-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
for I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
( I-Premise
median I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
, I-Premise
4.0 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.4 I-Premise
to I-Premise
4.9 I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
, I-Premise
4.1 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.4 I-Premise
to I-Premise
5.0 I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
5.6 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
4.4 I-Premise
to I-Premise
6.7 I-Premise
] I-Premise
";" I-Premise
P I-Premise
=.029 I-Premise
) I-Premise
. I-Premise

Longitudinal O
data O
were O
available O
for O
166 O
Swedish O
men O
who O
had O
answered O
quality-of-life O
questionnaires O
at O
an O
earlier O
timepoint O
. O

The B-Premise
results I-Premise
from I-Premise
evaluation I-Premise
with I-Premise
QLQ-C30 I-Premise
questionnaire I-Premise
and I-Premise
LC30 I-Premise
scale I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
was I-Premise
also I-Premise
superior I-Premise
to I-Premise
those I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

In O
the O
SUSTENT O
study O
, O
patients O
were O
randomized O
to O
GJJ O
( O
n O
= O
18 O
) O
or O
stent O
placement O
( O
n O
= O
21 O
) O
. O

The B-Premise
two I-Premise
groups I-Premise
were I-Premise
comparable I-Premise
, I-Premise
with I-Premise
low I-Premise
global I-Premise
QOL I-Premise
scores I-Premise
and I-Premise
significant I-Premise
symptom I-Premise
burden I-Premise
, I-Premise
especially I-Premise
pain I-Premise
and I-Premise
fatigue I-Premise
, I-Premise
after I-Premise
thoracotomy I-Premise
. I-Premise

Most B-Premise
participants I-Premise
found I-Premise
writing I-Premise
valuable I-Premise
and I-Premise
did I-Premise
not I-Premise
report I-Premise
any I-Premise
long-term I-Premise
negative I-Premise
effects I-Premise
. I-Premise

Body B-Premise
cell I-Premise
mass I-Premise
was I-Premise
maintained I-Premise
throughout I-Premise
the I-Premise
study I-Premise
in I-Premise
group I-Premise
B I-Premise
, I-Premise
but I-Premise
declined I-Premise
significantly I-Premise
up I-Premise
to I-Premise
weeks I-Premise
4 I-Premise
and I-Premise
8 I-Premise
in I-Premise
group I-Premise
A I-Premise
( I-Premise
intergroup I-Premise
difference I-Premise
: I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
and I-Premise
0.01 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The B-Premise
CP I-Premise
arm I-Premise
produced I-Premise
a I-Premise
significantly I-Premise
higher I-Premise
response I-Premise
rate I-Premise
and I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
but B-Premise
not I-Premise
overall I-Premise
survival I-Premise
( I-Premise
OS I-Premise
) I-Premise
. I-Premise

At B-Premise
12 I-Premise
months I-Premise
, I-Premise
63 I-Premise
% I-Premise
of I-Premise
intervention I-Premise
patients I-Premise
had I-Premise
a I-Premise
50 I-Premise
% I-Premise
or I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
depressive I-Premise
symptoms I-Premise
from I-Premise
baseline I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
Patient I-Premise
Health I-Premise
Questionnaire-9 I-Premise
( I-Premise
PHQ-9 I-Premise
) I-Premise
depression I-Premise
scale I-Premise
compared I-Premise
with I-Premise
50 I-Premise
% I-Premise
of I-Premise
EUC I-Premise
patients I-Premise
( I-Premise
odds I-Premise
ratio I-Premise
[ I-Premise
OR I-Premise
] I-Premise
= I-Premise
1.98 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.16 I-Premise
to I-Premise
3.38 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
. I-Premise

A O
total O
of O
306 O
patients O
with O
localized O
prostate O
cancer O
were O
randomized O
. O

Survival B-Premise
without I-Premise
disease I-Premise
progression I-Premise
or I-Premise
deterioration I-Premise
in I-Premise
global I-Premise
health I-Premise
status I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
allocated I-Premise
to I-Premise
oxaliplatin I-Premise
treatment I-Premise
( I-Premise
P I-Premise
=.004 I-Premise
) I-Premise
. I-Premise

A O
total O
of O
329 O
patients O
from O
10 O
centers O
in O
9 O
countries O
in O
the O
Asia-Pacific O
region O
enrolled O
in O
a O
double-blind O
randomized O
controlled O
trial O
of O
TMX O
120 O
mg/d O
( O
TMX120 O
) O
against O
P O
as O
a O
control O
arm O
with O
an O
intermediate O
dosage O
of O
TMX O
60 O
mg/d O
( O
TMX60 O
) O
to O
assess O
possible O
dose O
response O
. O

Sexual B-Premise
functioning I-Premise
and I-Premise
symptoms I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

This O
international O
, O
randomized O
, O
controlled O
, O
multicenter O
trial O
aimed O
to O
compare O
the O
efficacy O
and O
safety O
of O
recombinant O
human O
TSH O
( O
rhTSH O
) O
to O
prepare O
euthyroid O
patients O
on O
L-thyroxine O
therapy O
( O
euthyroid O
group O
) O
to O
ablate O
remnant O
thyroid O
tissue O
with O
3.7 O
GBq O
( O
100 O
mCi O
) O
131I O
, O
compared O
with O
that O
with O
conventional O
remnant O
ablation O
performed O
in O
the O
hypothyroid O
state O
( O
hypothyroid O
group O
) O
. O

The B-Premise
HR I-Premise
for I-Premise
overall I-Premise
survival I-Premise
was I-Premise
0.96 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.75-1.23 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.7349 I-Premise
) I-Premise
. I-Premise

Functional O
assessment O
of O
cancer O
therapy O
( O
FACT O
) O
questionnaire O
, O
Beck O
depression O
inventory O
, O
positive O
and O
negative O
affect O
scale O
, O
body O
mass O
index O
, O
seven O
day O
recall O
of O
physical O
activity O
, O
12 O
minute O
walk O
test O
, O
and O
assessment O
of O
shoulder O
mobility O
. O

The O
purpose O
of O
this O
study O
was O
to O
test O
the O
efficacy O
of O
a O
comprehensive O
menopausal O
assessment O
( O
CMA O
) O
intervention O
program O
in O
achieving O
relief O
of O
symptoms O
, O
the O
improvement O
in O
quality O
of O
life O
( O
QOL O
) O
, O
and O
sexual O
functioning O
in O
breast O
cancer O
survivors O
. O

This O
study O
examined O
whether O
changes O
in O
self-efficacy O
explain O
the O
effects O
of O
a O
mailed O
print O
intervention O
on O
long-term O
dietary O
practices O
of O
breast O
and O
prostate O
cancer O
survivors O
. O

Of O
558 O
women O
randomly O
assigned O
to O
treatment O
, O
418 O
completed O
the O
6-month O
assessment O
and O
399 O
completed O
the O
12-month O
assessment O
. O

Secondary O
outcome O
measures O
included O
treatment-associated O
morbidity O
, O
mortality O
, O
survival O
, O
and O
cost-effectiveness O
. O

Patients O
without O
prior O
chemotherapy O
for O
metastatic O
disease O
were O
randomly O
assigned O
to O
standard O
combination O
therapy O
with O
doxorubicin O
and O
paclitaxel O
( O
AT O
) O
or O
double O
HDCT O
with O
cyclophosphamide O
, O
mitoxantrone O
, O
and O
etoposide O
followed O
by O
peripheral-blood O
stem-cell O
transplantation O
. O

The B-Premise
5-year I-Premise
biochemical I-Premise
+/- I-Premise
clinical I-Premise
relapse-free I-Premise
and I-Premise
overall I-Premise
survival I-Premise
was I-Premise
55.9 I-Premise
% I-Premise
and I-Premise
85.3 I-Premise
% I-Premise
respectively I-Premise
for I-Premise
all I-Premise
patients I-Premise
, I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
two I-Premise
schedules I-Premise
. I-Premise

The O
140 O
patients O
included O
were O
in O
a O
good O
clinical O
condition O
with O
a O
median O
age O
of O
55 O
years O
( O
range O
22-87 O
) O
. O

Administration O
of O
ESAs O
on O
a O
synchronous O
schedule O
with O
chemotherapy O
administration O
could O
benefit O
patients O
by O
reducing O
clinic O
visits O
and O
potentially O
enhancing O
on-time O
chemotherapy O
delivery O
. O

This B-Claim
translational I-Claim
intervention I-Claim
trial I-Claim
, I-Claim
delivered I-Claim
either I-Claim
FtF I-Claim
or I-Claim
Tel I-Claim
, I-Claim
supports I-Claim
exercise I-Claim
as I-Claim
a I-Claim
form I-Claim
of I-Claim
adjuvant I-Claim
breast I-Claim
cancer I-Claim
therapy I-Claim
that I-Claim
can I-Claim
prevent I-Claim
declines I-Claim
in I-Claim
fitness I-Claim
and I-Claim
function I-Claim
during I-Claim
treatment I-Claim
and I-Claim
optimise I-Claim
recovery I-Claim
post-treatment I-Claim
. I-Claim

Outcomes O
were O
compared O
between O
groups O
using O
analysis O
of O
covariance O
adjusted O
for O
baseline O
values O
. O

At O
baseline O
, O
groups O
were O
comparable O
for O
age O
( O
mean O
, O
61 O
years O
) O
, O
sex O
( O
54 O
% O
men O
) O
, O
weight O
loss O
( O
32 O
% O
> O
or O
= O
10 O
% O
) O
, O
PS O
( O
13 O
% O
ECOG O
= O
2 O
) O
, O
antineoplastic O
treatment O
( O
50 O
% O
) O
, O
appetite O
( O
mean O
VAS O
score O
, O
31/100 O
mm O
) O
, O
and O
QOL O
( O
mean O
score O
, O
30/100 O
) O
. O

Response B-Claim
proportion I-Claim
and I-Claim
survival I-Claim
did I-Claim
not I-Claim
improve I-Claim
significantly I-Claim
with I-Claim
the I-Claim
addition I-Claim
of I-Claim
13-CRA I-Claim
to I-Claim
IFNalpha2a I-Claim
therapy I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
RCC I-Claim
. I-Claim

This O
analysis O
included O
a O
protocol-specified O
time O
to O
definitive O
deterioration O
( O
TDD O
) O
analysis O
at O
a O
5 O
% O
decrease O
in O
HRQOL O
versus O
baseline O
, O
with O
no O
subsequent O
increase O
above O
this O
threshold O
. O

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
weight I-Premise
changes I-Premise
were I-Premise
more I-Premise
common I-Premise
with I-Premise
MA I-Premise
( I-Premise
17.1 I-Premise
% I-Premise
v I-Premise
7.6 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.001 I-Premise
) I-Premise
. I-Premise

At B-Premise
eight I-Premise
weeks I-Premise
, I-Premise
patients I-Premise
in I-Premise
the I-Premise
thalidomide I-Premise
group I-Premise
had I-Premise
lost I-Premise
0.06 I-Premise
kg I-Premise
in I-Premise
weight I-Premise
and I-Premise
0.5 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
in I-Premise
AMA I-Premise
compared I-Premise
with I-Premise
a I-Premise
loss I-Premise
of I-Premise
3.62 I-Premise
kg I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
-3.57 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-6.8 I-Premise
to I-Premise
-0.3 I-Premise
) I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.034 I-Premise
) I-Premise
and I-Premise
8.4 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
-7.9 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-14.0 I-Premise
to I-Premise
-1.8 I-Premise
) I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.014 I-Premise
) I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

Participants O
, O
identified O
within O
1 O
month O
after O
surgery O
( O
registration O
) O
, O
provided O
demographic O
information O
and O
limited O
measures O
of O
quality O
of O
life O
. O

All O
endometrial O
cancers O
in O
the O
tamoxifen O
group O
were O
stage O
I O
( O
localized O
disease O
) O
";" O
no B-Premise
endometrial I-Premise
cancer I-Premise
deaths I-Premise
have I-Premise
occurred I-Premise
in I-Premise
this I-Premise
group I-Premise
. I-Premise

The O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
, O
where O
available O
, O
the O
EuroQOL O
EQ-5D O
questionnaire O
were O
administered O
every O
8 O
weeks O
from O
baseline O
until O
progression O
and O
then O
every O
3 O
months O
. O

Therefore O
, O
a O
randomized O
double-blind O
placebo-controlled O
multicenter O
trial O
was O
performed O
to O
assess O
the O
efficacy O
of O
long-acting O
octreotide O
for O
the O
treatment O
of O
advanced O
HCC O
. O

We O
evaluated O
the O
effects O
of O
lanreotide O
, O
a O
somatostatin O
analogue O
, O
in O
patients O
with O
polycystic O
liver O
because O
of O
autosomal-dominant O
( O
AD O
) O
PKD O
or O
autosomal-dominant O
polycystic O
liver O
disease O
( O
PCLD O
) O
. O

To O
compare O
the O
effects O
of O
cannabis O
extract O
( O
CE O
) O
, O
delta-9-tetrahydrocannabinol O
( O
THC O
) O
, O
and O
placebo O
( O
PL O
) O
on O
appetite O
and O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
cancer-related O
anorexia-cachexia O
syndrome O
( O
CACS O
) O
. O

At B-Premise
12 I-Premise
months I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
tamoxifen I-Premise
had I-Premise
a I-Premise
significantly I-Premise
higher I-Premise
mean I-Premise
hot I-Premise
flash I-Premise
score I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
with I-Premise
daily I-Premise
hot I-Premise
flashes I-Premise
increasing I-Premise
from I-Premise
baseline I-Premise
by I-Premise
33 I-Premise
% I-Premise
compared I-Premise
with I-Premise
a I-Premise
7 I-Premise
% I-Premise
increase I-Premise
from I-Premise
baseline I-Premise
with I-Premise
exemestane I-Premise
. I-Premise

Fourteen O
breast O
cancer O
survivors O
with O
unilateral O
upper O
extremity O
lymphedema O
were O
randomly O
assigned O
to O
an O
exercise O
( O
n O
= O
7 O
) O
or O
control O
group O
( O
n O
= O
7 O
) O
. O

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
in I-Premise
disease-free I-Premise
survival I-Premise
( I-Premise
DFS I-Premise
) I-Premise
( I-Premise
2-year I-Premise
DFS I-Premise
79.8 I-Premise
% I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
and I-Premise
76.4 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
arm I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.527 I-Premise
) I-Premise
and I-Premise
overall I-Premise
survival I-Premise
( I-Premise
OS I-Premise
) I-Premise
( I-Premise
2-year I-Premise
OS I-Premise
83.1 I-Premise
% I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
and I-Premise
84.3 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
arm I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.925 I-Premise
) I-Premise
. I-Premise

The O
RRs O
were O
: O
34 O
% O
( O
95 O
% O
confidence O
interval O
( O
95 O
% O
, O
CI O
) O
: O
21 O
% O
-48 O
% O
) O
in O
arm O
A O
, O
including O
3 O
complete O
responses O
( O
CRs O
) O
and O
15 O
partial O
responses O
( O
PRs O
) O
, O
24 O
% O
( O
95 O
% O
CI O
: O
14 O
% O
-38 O
% O
) O
in O
arm O
B O
, O
including O
2 O
CRs O
and O
11 O
PRs O
, O
and O
24 O
% O
( O
95 O
% O
CI O
: O
14 O
% O
-38 O
% O
) O
, O
with O
2 O
CRs O
and O
11 O
PRs O
, O
in O
arm O
C. O
After B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
time I-Premise
of I-Premise
62 I-Premise
( I-Premise
range I-Premise
18-108 I-Premise
) I-Premise
weeks I-Premise
, I-Premise
the I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
was I-Premise
38 I-Premise
, I-Premise
25 I-Premise
, I-Premise
and I-Premise
27 I-Premise
weeks I-Premise
for I-Premise
arm I-Premise
A I-Premise
, I-Premise
B I-Premise
, I-Premise
and I-Premise
C I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The O
efficacy O
and O
safety O
of O
an O
alternative O
regimen O
that O
does O
not O
show O
significant O
neurotoxicity O
were O
evaluated O
by O
comparing O
gemcitabine-carboplatin O
with O
carboplatin O
in O
platinum-sensitive O
recurrent O
ovarian O
cancer O
patients O
in O
a O
Gynecologic O
Cancer O
InterGroup O
trial O
of O
the O
Arbeitsgemeinschaft O
Gynakologische O
Onkologie O
Ovarian O
Cancer O
Study O
Group O
, O
the O
National O
Cancer O
Institute O
of O
Canada O
Clinical O
Trials O
Group O
, O
and O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Gynaecological O
Cancer O
Group O
. O

Median O
age O
was O
76 O
years O
( O
range O
, O
70 O
years O
to O
86 O
years O
) O
. O

At B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
3.9 I-Premise
years I-Premise
, I-Premise
the I-Premise
estimated I-Premise
4-year I-Premise
recurrence-free I-Premise
survival I-Premise
rate I-Premise
was I-Premise
67.5 I-Premise
% I-Premise
with I-Premise
the I-Premise
16-week I-Premise
regimen I-Premise
versus I-Premise
62.7 I-Premise
% I-Premise
with I-Premise
CAF I-Premise
( I-Premise
P I-Premise
= I-Premise
.19 I-Premise
, I-Premise
two-sided I-Premise
";" I-Premise
P I-Premise
= I-Premise
.095 I-Premise
, I-Premise
one-sided I-Premise
) I-Premise
. I-Premise

Postoperative O
quality O
of O
life O
( O
QOL O
) O
was O
evaluated O
between O
the O
2 O
methods O
by O
a O
multi-institutional O
prospective O
randomized O
trial O
. O

For B-Premise
the I-Premise
QLQ-C30 I-Premise
subscales I-Premise
emotional I-Premise
function I-Premise
and I-Premise
future I-Premise
perspectives I-Premise
, I-Premise
difference I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
MPT I-Premise
arm I-Premise
from I-Premise
the I-Premise
start I-Premise
of I-Premise
treatment I-Premise
was I-Premise
observed I-Premise
( I-Premise
P=0.018 I-Premise
and I-Premise
P=0.045 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
with I-Premise
no I-Premise
significant I-Premise
'time I-Premise
× I-Premise
arm I-Premise
' I-Premise
interaction I-Premise
, I-Premise
indicating I-Premise
a I-Premise
persistent I-Premise
better I-Premise
patient I-Premise
perspective I-Premise
with I-Premise
MPT I-Premise
treatment I-Premise
. I-Premise

At B-Premise
5 I-Premise
years I-Premise
, I-Premise
the I-Premise
prevalence I-Premise
of I-Premise
new I-Premise
fibroid I-Premise
was I-Premise
60 I-Premise
% I-Premise
in I-Premise
the I-Premise
myomectomy I-Premise
group I-Premise
and I-Premise
7 I-Premise
% I-Premise
in I-Premise
the I-Premise
UAE I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0.008 I-Premise
) I-Premise
. I-Premise

Median B-Premise
PFS I-Premise
and I-Premise
OS I-Premise
were I-Premise
8.2 I-Premise
and I-Premise
19.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
at I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
26.4 I-Premise
months I-Premise
. I-Premise

To O
assess O
the O
safety O
, O
tolerability O
and O
efficacy O
of O
abatacept O
in O
patients O
with O
rheumatoid O
arthritis O
( O
RA O
) O
who O
had O
failed O
anti-tumour O
necrosis O
factor O
( O
TNF O
) O
therapy O
and O
were O
switched O
to O
abatacept O
directly O
or O
after O
completing O
washout O
. O

EORTC O
QLQ-C30 O
scores O
were O
evaluated O
among O
patients O
with O
a O
valid O
baseline O
and O
at O
least O
one O
post-baseline O
HRQoL O
assessment O
. O

Assessments O
included O
review O
of O
measurable O
metastases O
, O
prostate O
dimensions O
, O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
, O
pain O
, O
analgesic O
requirements O
, O
and O
quality O
of O
life O
responses O
. O

on O
day O
1 O
, O
followed O
on O
day O
2 O
by O
LFA O
, O
250 O
mg/m2 O
i.v O
. O

Postoperative B-Premise
BMI I-Premise
significantly I-Premise
deteriorated I-Premise
compared I-Premise
with I-Premise
preoperative I-Premise
BMI I-Premise
in I-Premise
each I-Premise
group I-Premise
. I-Premise

Study O
Type O
-- O
Therapy O
( O
RCT O
) O
Level O
of O
Evidence O
1b O
. O

The O
sample O
of O
patients O
( O
n O
= O
709 O
) O
newly O
admitted O
to O
hospice O
home O
care O
in O
2 O
hospices O
had O
designated O
family O
caregivers O
. O

The O
characteristics O
of O
the O
599 O
patients O
were O
well-balanced O
across O
the O
three O
treatment O
groups O
. O

The B-Premise
treatment I-Premise
of I-Premise
control I-Premise
group I-Premise
led I-Premise
to I-Premise
1 I-Premise
case I-Premise
of I-Premise
complete I-Premise
remission I-Premise
and I-Premise
2 I-Premise
cases I-Premise
of I-Premise
partial I-Premise
remission I-Premise
, I-Premise
making I-Premise
the I-Premise
rate I-Premise
of I-Premise
efficacy I-Premise
( I-Premise
complete I-Premise
+ I-Premise
partial I-Premise
remission I-Premise
) I-Premise
of I-Premise
9.7 I-Premise
% I-Premise
. I-Premise

An O
independent O
data O
monitoring O
committee O
reviewed O
all O
aspects O
of O
the O
trial O
. O

Because O
of O
the O
small O
study O
population O
, O
only O
initial O
hospital O
costs O
would O
have O
been O
statistically O
significant O
if O
the O
Bonferroni O
correction O
for O
multiple O
testing O
had O
been O
applied O
. O

Sertraline B-Claim
did I-Claim
not I-Claim
improve I-Claim
symptoms I-Claim
, I-Claim
wellbeing I-Claim
, I-Claim
or I-Claim
survival I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
who I-Claim
do I-Claim
not I-Claim
have I-Claim
major I-Claim
depression I-Claim
, I-Claim
and I-Claim
should I-Claim
be I-Claim
reserved I-Claim
for I-Claim
those I-Claim
with I-Claim
a I-Claim
proven I-Claim
indication I-Claim
. I-Claim

A O
lack O
of O
preliminary O
randomised O
data O
supporting O
the O
trial O
's O
hypotheses O
was O
thought O
to O
underlie O
the O
poor O
accrual O
, O
so O
, O
with O
no O
knowledge O
of O
the O
data O
, O
the O
independent O
trial O
steering O
committee O
agreed O
to O
the O
unusual O
step O
of O
releasing O
interim O
data O
. O

No B-Premise
consistent I-Premise
influence I-Premise
on I-Premise
QOL I-Premise
was I-Premise
detected I-Premise
. I-Premise

This B-Premise
translated I-Premise
into I-Premise
a I-Premise
lower I-Premise
proportion I-Premise
of I-Premise
patients I-Premise
experiencing I-Premise
moist I-Premise
desquamation I-Premise
during I-Premise
or I-Premise
up I-Premise
to I-Premise
6 I-Premise
weeks I-Premise
after I-Premise
their I-Premise
radiation I-Premise
treatment I-Premise
";" I-Premise
31.2 I-Premise
% I-Premise
with I-Premise
IMRT I-Premise
compared I-Premise
with I-Premise
47.8 I-Premise
% I-Premise
with I-Premise
standard I-Premise
treatment I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

Fifty-two O
patients O
with O
breast O
cancer O
were O
divided O
into O
either O
pilates O
exercise O
( O
group O
1 O
) O
and O
control O
group O
( O
group O
2 O
) O
. O

Patients O
( O
age O
range O
, O
16 O
to O
80 O
years O
) O
had O
tumor O
stage O
T1 O
to O
T3 O
, O
with O
possible O
spread O
to O
nearby O
lymph O
nodes O
but O
without O
metastasis O
. O

Breast B-Premise
IMRT I-Premise
significantly I-Premise
improved I-Premise
the I-Premise
dose I-Premise
distribution I-Premise
compared I-Premise
with I-Premise
standard I-Premise
radiation I-Premise
. I-Premise

Pamidronate B-Claim
treatment I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
efficaciously I-Claim
reduced I-Claim
skeletal I-Claim
morbidity I-Claim
. I-Claim

Patients O
( O
N O
= O
572 O
) O
with O
pretreated O
EGFR-detectable O
advanced O
CRC O
were O
randomly O
assigned O
to O
cetuximab O
and O
best O
supportive O
care O
( O
BSC O
) O
or O
to O
BSC O
alone O
. O

Analysis O
was O
by O
intention O
to O
treat O
. O

This O
study O
was O
registered O
on O
ClinicalTrials.gov O
. O

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
found I-Premise
in I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
measure I-Premise
, I-Premise
the I-Premise
hot I-Premise
flash I-Premise
severity I-Premise
score I-Premise
, I-Premise
although B-Premise
there I-Premise
was I-Premise
a I-Premise
positive I-Premise
trend I-Premise
in I-Premise
the I-Premise
single I-Premise
remedy I-Premise
group I-Premise
during I-Premise
the I-Premise
first I-Premise
3 I-Premise
months I-Premise
of I-Premise
the I-Premise
study I-Premise
( I-Premise
p I-Premise
= I-Premise
0.1 I-Premise
) I-Premise
. I-Premise

Intraperitoneal B-Claim
perfusion I-Claim
of I-Claim
verapamil I-Claim
enhances I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
chemotherapy I-Claim
drugs I-Claim
, I-Claim
prolongs I-Claim
survival I-Claim
, I-Claim
and I-Claim
improves I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

The O
primary O
end O
point O
was O
the O
difference O
in O
total O
liver O
volume O
, O
measured O
by O
computerized O
tomography O
at O
weeks O
0 O
and O
24 O
. O

From O
1997 O
to O
2001 O
, O
294 O
patients O
were O
included O
. O

Improvement B-Premise
in I-Premise
physical I-Premise
functioning I-Premise
correlated I-Premise
positively I-Premise
with I-Premise
weight I-Premise
gain I-Premise
( I-Premise
r I-Premise
= I-Premise
0.56 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

In O
this O
randomized O
phase O
III O
trial O
, O
a O
total O
of O
313 O
Korean O
never-smokers O
with O
stage O
IIIB O
or O
IV O
lung O
adenocarcinoma O
, O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
0 O
to O
2 O
, O
and O
adequate O
organ O
function O
were O
randomly O
assigned O
to O
receive O
either O
gefitinib O
( O
250 O
mg O
daily O
) O
or O
GP O
chemotherapy O
( O
gemcitabine O
1,250 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
";" O
cisplatin O
80 O
mg/m O
( O
2 O
) O
on O
day O
1 O
every O
3 O
weeks O
, O
for O
up O
to O
nine O
courses O
) O
. O

The B-Claim
previously I-Claim
reported I-Claim
survival I-Claim
advantage I-Claim
supporting I-Claim
the I-Claim
use I-Claim
of I-Claim
adjuvant I-Claim
chemotherapy I-Claim
is I-Claim
maintained I-Claim
when I-Claim
adjusted I-Claim
using I-Claim
quality I-Claim
adjusted I-Claim
survival I-Claim
methodology I-Claim
. I-Claim

Patient O
evaluation O
items O
included O
physical O
therapy O
assessment O
, O
limb O
size O
, O
water O
composition O
of O
the O
upper O
extremity O
, O
lymphedema-related O
symptoms O
, O
quality O
of O
life O
, O
and O
patients O
' O
acceptance O
to O
the O
bandage O
or O
tape O
. O

Three O
hundred O
nine O
patients O
were O
analyzed O
per O
protocol O
( O
gefitinib O
arm O
, O
n O
= O
159 O
";" O
GP O
arm O
, O
n O
= O
150 O
) O
. O

Patients O
with O
advanced O
HIV-associated O
KS O
were O
randomly O
assigned O
to O
receive O
paclitaxel O
at O
a O
dose O
of O
100 O
mg/m2 O
intravenously O
( O
iv O
) O
every O
2 O
weeks O
or O
PLD O
at O
a O
dose O
of O
20 O
mg/m2 O
iv O
every O
3 O
weeks O
. O

Bladder B-Premise
toxicity I-Premise
was I-Premise
more I-Premise
frequent I-Premise
at I-Premise
80 I-Premise
Gy I-Premise
than I-Premise
at I-Premise
70 I-Premise
Gy I-Premise
( I-Premise
p I-Premise
= I-Premise
.039 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
survival I-Premise
differences I-Premise
between I-Premise
the I-Premise
244 I-Premise
interferon-alfa-treated I-Premise
patients I-Premise
and I-Premise
248 I-Premise
noninterferon-alfa I-Premise
patients I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1.00 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.81-1.24 I-Premise
) I-Premise
or I-Premise
between I-Premise
the I-Premise
247 I-Premise
interleukin-2 I-Premise
and I-Premise
245 I-Premise
noninterleukin-2-treated I-Premise
patients I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1.07 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.87-1.33 I-Premise
";" I-Premise
log I-Premise
rank I-Premise
, I-Premise
0.99 I-Premise
and I-Premise
0.52 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

A O
total O
of O
198 O
women O
continued O
after O
year O
7 O
. O

Fatigue B-Premise
at I-Premise
T2 I-Premise
was I-Premise
predicted I-Premise
by I-Premise
a I-Premise
significant I-Premise
interaction I-Premise
between I-Premise
self-reported I-Premise
cognitive I-Premise
functioning I-Premise
and I-Premise
CBT I-Premise
. I-Premise

The O
effect O
of O
this O
intervention O
on O
a O
patient O
's O
general O
well-being O
was O
also O
investigated O
. O

Only O
37 O
% O
of O
the O
patients O
completed O
protocol O
treatment O
. O

Baseline O
characteristics O
, O
including O
LCSS O
scores O
, O
were O
well O
balanced O
between O
groups O
. O

Patients B-Premise
carrying I-Premise
a I-Premise
GCLC I-Premise
77 I-Premise
genotype I-Premise
had I-Premise
a I-Premise
worse I-Premise
overall I-Premise
survival I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
( I-Premise
HR I-Premise
) I-Premise
= I-Premise
1.5 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Treatment B-Claim
with I-Claim
PB+G I-Claim
increased I-Claim
the I-Claim
incidence I-Claim
of I-Claim
severe I-Claim
neutropenia I-Claim
and I-Claim
dyspnea I-Claim
, I-Claim
although B-Claim
the I-Claim
regimen I-Claim
generally I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

Compared O
with O
placebo O
, O
prophylactic O
treatment O
with O
bisphosphonates O
reduces O
risk O
of O
skeletal O
events O
in O
patients O
with O
multiple O
myeloma O
. O

The O
study O
was O
conducted O
in O
the O
palliative O
care O
and O
hospice O
ward O
of O
a O
public O
hospital O
in O
Hong O
Kong O
. O

This O
article O
reports O
the O
health-related O
quality-of-life O
( O
HRQL O
) O
outcomes O
from O
CO.17 O
. O

To O
determine O
whether O
patients O
with O
locally O
advanced O
non-small O
cell O
lung O
cancer O
unsuitable O
for O
resection O
or O
radical O
radiotherapy O
, O
and O
with O
minimal O
thoracic O
symptoms O
, O
should O
be O
given O
palliative O
thoracic O
radiotherapy O
immediately O
or O
as O
needed O
to O
treat O
symptoms O
. O

Long-term B-Premise
benefits I-Premise
for I-Premise
older I-Premise
patients I-Premise
were I-Premise
seen I-Premise
in I-Premise
the I-Premise
anger-hostility I-Premise
scale I-Premise
at I-Premise
week I-Premise
27 I-Premise
( I-Premise
92.2 I-Premise
vs. I-Premise
84.2 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.027 I-Premise
) I-Premise
and I-Premise
week I-Premise
52 I-Premise
( I-Premise
96.3 I-Premise
vs. I-Premise
85.9 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
. I-Premise

Patients B-Claim
who I-Claim
performed I-Claim
prophylactic I-Claim
swallowing I-Claim
exercises I-Claim
had I-Claim
improved I-Claim
swallowing I-Claim
function I-Claim
at I-Claim
3 I-Claim
and I-Claim
6 I-Claim
months I-Claim
after I-Claim
CRT I-Claim
but I-Claim
not I-Claim
immediately I-Claim
after I-Claim
CRT I-Claim
or I-Claim
at I-Claim
9 I-Claim
and I-Claim
12 I-Claim
months I-Claim
after I-Claim
CRT I-Claim
. I-Claim

Between O
July O
, O
2001 O
, O
and O
February O
, O
2006 O
, O
189 O
patients O
with O
advanced O
cancer O
were O
randomly O
assigned O
sertraline O
50 O
mg O
( O
n=95 O
) O
, O
or O
placebo O
( O
n=94 O
) O
, O
once O
per O
day O
. O

At B-Premise
3 I-Premise
months I-Premise
, I-Premise
G1 I-Premise
patients I-Premise
maintained/improved I-Premise
function I-Premise
, I-Premise
symptoms I-Premise
, I-Premise
and I-Premise
single-item I-Premise
scores I-Premise
( I-Premise
P I-Premise
< I-Premise
.02 I-Premise
) I-Premise
";" I-Premise
in I-Premise
G2 I-Premise
, I-Premise
only I-Premise
few I-Premise
function I-Premise
and I-Premise
symptom I-Premise
scales I-Premise
improved I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
";" I-Premise
in I-Premise
G3 I-Premise
, I-Premise
QoL I-Premise
remained I-Premise
as I-Premise
poor I-Premise
as I-Premise
after I-Premise
radiotherapy I-Premise
. I-Premise

Compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
the I-Premise
death I-Premise
number I-Premise
decreased I-Premise
, I-Premise
the I-Premise
survival I-Premise
rate I-Premise
increased I-Premise
, I-Premise
the I-Premise
life I-Premise
span I-Premise
of I-Premise
dead I-Premise
children I-Premise
was I-Premise
prolonged I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
showing I-Premise
statistical I-Premise
difference I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Perceived O
preparedness O
for O
re-entry O
was O
analyzed O
as O
a O
moderator O
of O
effects O
. O

Maintenance O
therapy O
, O
commenced O
immediately O
after O
the O
completion O
of O
first-line O
chemotherapy O
, O
is O
a O
promising O
strategy O
for O
improving O
treatment O
outcomes O
in O
patients O
with O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

The B-Premise
adherence I-Premise
rate I-Premise
to I-Premise
ALT I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
the I-Premise
adherence I-Premise
to I-Premise
self-management I-Premise
therapy I-Premise
. I-Premise

QOL O
was O
assessed O
with O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
and O
a O
trial-specific O
checklist O
at O
baseline O
and O
at O
weeks O
5 O
and O
9 O
for O
those O
who O
received O
chemotherapy O
and O
at O
follow-up O
months O
3 O
, O
6 O
, O
9 O
, O
12 O
, O
18 O
, O
24 O
, O
30 O
and O
36 O
. O

The B-Claim
efficacy I-Claim
of I-Claim
5-FU I-Claim
, I-Claim
modulated I-Claim
with I-Claim
6S-LV I-Claim
, I-Claim
is I-Claim
moderate I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
carcinoma I-Claim
, I-Claim
similar I-Claim
to I-Claim
cisplatin-containing I-Claim
regimens I-Claim
. I-Claim

Radiotherapy B-Claim
is I-Claim
an I-Claim
effective I-Claim
palliative I-Claim
treatment I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
painful I-Claim
bone I-Claim
metastases I-Claim
. I-Claim

The B-Premise
BPI-SF I-Premise
revealed I-Premise
a I-Premise
decline I-Premise
in I-Premise
pain I-Premise
scores I-Premise
in I-Premise
both I-Premise
arms I-Premise
from I-Premise
the I-Premise
first I-Premise
to I-Premise
fourth I-Premise
assessments I-Premise
. I-Premise

After O
chemotherapy O
those O
in O
the O
treatment O
group O
took O
modified O
FJD O
. O

Postoperative B-Premise
morbidity I-Premise
rate I-Premise
was I-Premise
28.9 I-Premise
percent I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
vs. I-Premise
40 I-Premise
percent I-Premise
in I-Premise
the I-Premise
open I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.18 I-Premise
) I-Premise
. I-Premise

To O
explore O
the O
role O
of O
monochemotherapy O
, O
the O
authors O
evaluated O
5-fluorouracil O
( O
5-FU O
) O
, O
modulated O
by O
6S-leucovorin O
( O
6S-LV O
) O
and O
a O
cisplatin-containing O
regimen O
, O
which O
was O
comprised O
of O
epirubicin O
, O
etoposide O
, O
and O
cisplatin O
with O
the O
addition O
of O
the O
reversal O
agent O
lonidamine O
( O
EEP-L O
) O
. O

There B-Claim
was I-Claim
no I-Claim
statistically I-Claim
significant I-Claim
difference I-Claim
in I-Claim
treatment I-Claim
response I-Claim
when I-Claim
the I-Claim
100 I-Claim
% I-Claim
or I-Claim
75 I-Claim
% I-Claim
clearance I-Claim
rate I-Claim
cutoff I-Claim
was I-Claim
used I-Claim
, I-Claim
but B-Claim
our I-Claim
secondary I-Claim
outcome I-Claim
suggests I-Claim
that I-Claim
two I-Claim
sessions I-Claim
of I-Claim
ALA-PDT I-Claim
is I-Claim
superior I-Claim
to I-Claim
imiquimod I-Claim
5 I-Claim
% I-Claim
cream I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
AKs I-Claim
. I-Claim

Intention-to-treat B-Premise
analyses I-Premise
indicated I-Premise
that I-Premise
AET I-Premise
resulted I-Premise
in I-Premise
a I-Premise
nonsignificant I-Premise
( I-Premise
P I-Premise
= I-Premise
0.16 I-Premise
) I-Premise
improvement I-Premise
in I-Premise
global I-Premise
sleep I-Premise
quality I-Premise
compared I-Premise
with I-Premise
usual I-Premise
care I-Premise
[ I-Premise
mean I-Premise
group I-Premise
difference I-Premise
= I-Premise
-0.64 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
, I-Premise
-1.56 I-Premise
to I-Premise
+0.27 I-Premise
] I-Premise
. I-Premise

A O
phase O
III O
trial O
( O
Cancer O
and O
Leukemia O
Group O
B O
CALGB-49907 O
) O
was O
conducted O
to O
test O
whether O
older O
patients O
with O
early-stage O
breast O
cancer O
would O
have O
equivalent O
relapse-free O
and O
overall O
survival O
with O
capecitabine O
compared O
with O
standard O
chemotherapy O
. O

No B-Premise
group-related I-Premise
negative I-Premise
effects I-Premise
were I-Premise
observed I-Premise
and I-Premise
the I-Premise
global I-Premise
satisfaction I-Premise
levels I-Premise
were I-Premise
very I-Premise
high I-Premise
. I-Premise

The O
aim O
was O
to O
rule O
out O
a O
5 O
% O
decrease O
in O
the O
2-year O
progression-free O
survival O
( O
PFS O
) O
rate O
. O

Hence O
, O
nurse-led B-Claim
telephone I-Claim
follow-up I-Claim
seems I-Claim
an I-Claim
appropriate I-Claim
way I-Claim
to I-Claim
reduce I-Claim
clinic I-Claim
visits I-Claim
and I-Claim
represents I-Claim
an I-Claim
accepted I-Claim
alternative I-Claim
strategy I-Claim
. I-Claim

No B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
was I-Premise
noted I-Premise
in I-Premise
the I-Premise
time I-Premise
to I-Premise
local I-Premise
failure I-Premise
between I-Premise
the I-Premise
surgical I-Premise
and I-Premise
RT I-Premise
arms I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
early I-Premise
alternating I-Premise
chemotherapy I-Premise
rated I-Premise
their I-Premise
tumor I-Premise
symptoms I-Premise
, I-Premise
functional I-Premise
states I-Premise
, I-Premise
fatigue/malaise I-Premise
and I-Premise
restriction I-Premise
of I-Premise
social I-Premise
activity I-Premise
significantly I-Premise
better I-Premise
, I-Premise
reflecting I-Premise
an I-Premise
improved I-Premise
subjective I-Premise
adjustment I-Premise
. I-Premise

In O
contrast O
, O
coping B-Premise
strategies I-Premise
( I-Premise
MAC I-Premise
) I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
groups I-Premise
. I-Premise

Combination B-Premise
treatment I-Premise
in I-Premise
the I-Premise
GemCis I-Premise
arm I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
prolonged I-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
5.3 I-Premise
months I-Premise
v I-Premise
3.1 I-Premise
months I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
= I-Premise
0.75 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.053 I-Premise
) I-Premise
. I-Premise

An O
integrated O
quality-survival O
product O
method O
was O
used O
to O
adjust O
any O
treatment O
effect O
on O
survival O
by O
a O
function O
of O
measured O
QoL O
, O
calculated O
over O
a O
restricted O
24-month-period O
( O
QALM-24 O
) O
. O

Sixty-two O
patients O
with O
recurrent O
or O
metastatic O
NSCLC O
expressing O
Le O
( O
y O
) O
, O
one O
or O
two O
prior O
chemotherapy O
regimens O
, O
and O
PS O
< O
or O
2 O
were O
randomized O
2:1 O
to O
receive O
SGN-15 O
200 O
mg/m2/week O
with O
docetaxel O
35 O
mg/m2/week O
( O
Arm O
A O
) O
or O
docetaxel O
35 O
mg/m2/week O
alone O
( O
Arm O
B O
) O
for O
6 O
of O
8 O
weeks O
. O

This O
study O
aimed O
to O
compare O
quality O
of O
life O
( O
QOL O
) O
, O
functional O
outcome O
, O
body O
image O
, O
and O
cosmesis O
after O
hand-assisted O
laparoscopic O
( O
LRP O
) O
versus O
open O
restorative O
proctocolectomy O
( O
ORP O
) O
. O

By B-Premise
contrast I-Premise
, I-Premise
for I-Premise
patients I-Premise
with I-Premise
ER-positive I-Premise
tumors I-Premise
, I-Premise
addition I-Premise
of I-Premise
CMF I-Premise
provided I-Premise
no I-Premise
benefit I-Premise
in I-Premise
terms I-Premise
of I-Premise
DFS I-Premise
( I-Premise
5-year I-Premise
DFS I-Premise
= I-Premise
84 I-Premise
% I-Premise
for I-Premise
CMF I-Premise
-- I-Premise
> I-Premise
tamoxifen I-Premise
versus I-Premise
85 I-Premise
% I-Premise
for I-Premise
tamoxifen I-Premise
alone I-Premise
";" I-Premise
difference I-Premise
= I-Premise
-1 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-6 I-Premise
% I-Premise
to I-Premise
4 I-Premise
% I-Premise
";" I-Premise
RR I-Premise
= I-Premise
0.99 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.75 I-Premise
to I-Premise
1.30 I-Premise
";" I-Premise
P I-Premise
=.92 I-Premise
) I-Premise
or I-Premise
OS I-Premise
( I-Premise
5-year I-Premise
OS I-Premise
= I-Premise
95 I-Premise
% I-Premise
for I-Premise
CMF I-Premise
-- I-Premise
> I-Premise
tamoxifen I-Premise
versus I-Premise
93 I-Premise
% I-Premise
for I-Premise
tamoxifen I-Premise
alone I-Premise
";" I-Premise
difference I-Premise
= I-Premise
2 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-1 I-Premise
% I-Premise
to I-Premise
5 I-Premise
% I-Premise
";" I-Premise
RR I-Premise
= I-Premise
0.95 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.64 I-Premise
to I-Premise
1.40 I-Premise
";" I-Premise
P I-Premise
=.80 I-Premise
) I-Premise
. I-Premise

BMD O
of O
48 O
patients O
were O
analyzed O
";" O
23 O
belongs O
to O
group O
A O
, O
10 O
to O
group O
B O
and O
15 O
to O
group O
C. O
The O
serum O
bone O
turnover O
proteins O
bone-specific O
alkaline O
phosphatase O
( O
BAP O
) O
and O
carboxyterminal O
crosslinked O
telopeptide O
of O
type O
I O
collagen O
( O
ICTP O
) O
, O
were O
measured O
with O
commercially O
available O
test O
kits O
before O
treatment O
, O
3 O
months O
and O
15 O
months O
after O
treatment O
. O

Treatment B-Premise
effects I-Premise
favored I-Premise
castration I-Premise
for I-Premise
both I-Premise
endpoints I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
, I-Premise
with I-Premise
hazard I-Premise
ratios I-Premise
( I-Premise
bicalutamide I-Premise
: I-Premise
castration I-Premise
) I-Premise
of I-Premise
1.54 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
1.18 I-Premise
to I-Premise
2.00 I-Premise
) I-Premise
for I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
and I-Premise
1.6 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.19 I-Premise
to I-Premise
2.15 I-Premise
) I-Premise
for I-Premise
time I-Premise
to I-Premise
disease I-Premise
progression I-Premise
. I-Premise

HRQL O
primary O
end O
points O
assessed O
by O
the O
EORTC O
QLQ-C30 O
were O
physical O
function O
( O
PF O
) O
and O
global O
health O
status O
( O
GHS O
) O
";" O
mean O
changes O
from O
baseline O
to O
8 O
and O
16 O
weeks O
were O
assessed O
. O

Although B-Premise
there I-Premise
was I-Premise
a I-Premise
tendency I-Premise
for I-Premise
improved I-Premise
survival I-Premise
in I-Premise
grade I-Premise
III I-Premise
, I-Premise
no I-Premise
statistical I-Premise
significant I-Premise
differences I-Premise
were I-Premise
found I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

This O
analysis O
investigated O
the O
treatment O
effects O
on O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
. O

Administration O
of O
the O
vaccine O
was O
begun O
within O
1 O
to O
2 O
months O
postoperatively O
, O
with O
10 O
inoculations O
given O
over O
6 O
months O
. O

In O
the O
MRC O
OV05/EORTC O
55955 O
collaborative O
trial O
, O
we O
aimed O
to O
establish O
the O
benefits O
of O
early O
treatment O
on O
the O
basis O
of O
increased O
CA125 O
concentrations O
compared O
with O
delayed O
treatment O
on O
the O
basis O
of O
clinical O
recurrence O
. O

Interaction B-Premise
effects I-Premise
for I-Premise
mental I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
scores I-Premise
were I-Premise
not I-Premise
significant I-Premise
. I-Premise

Few O
well-designed O
studies O
have O
investigated O
whether O
these O
impairments O
can O
be O
prevented O
. O

This B-Claim
supports I-Claim
the I-Claim
need I-Claim
for I-Claim
an I-Claim
individualized I-Claim
approach I-Claim
to I-Claim
therapy I-Claim
recommendations I-Claim
. I-Claim

Significant B-Premise
improvements I-Premise
in I-Premise
self-reported I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
interference I-Premise
of I-Premise
hot I-Premise
flashes I-Premise
on I-Premise
daily I-Premise
activities I-Premise
, I-Premise
and I-Premise
sleep I-Premise
were I-Premise
observed I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
the I-Premise
hypnosis I-Premise
intervention I-Premise
( I-Premise
P I-Premise
< I-Premise
.005 I-Premise
) I-Premise
in I-Premise
comparison I-Premise
to I-Premise
the I-Premise
no I-Premise
treatment I-Premise
control I-Premise
group I-Premise
. I-Premise

Therefore O
, O
IAD B-Claim
is I-Claim
not I-Claim
a I-Claim
good I-Claim
treatment I-Claim
option I-Claim
for I-Claim
many I-Claim
metastatic I-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Treatment O
arms O
were O
compared O
using O
the O
stratified O
log-rank O
test O
and O
Cox O
proportional O
hazards O
model O
adjusted O
for O
trial O
stratum O
( O
visceral O
metastases O
, O
previous O
hormone O
sensitivity O
) O
, O
age O
, O
sex O
, O
race O
, O
baseline O
global O
health O
status O
score O
and O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
, O
prognostic O
risk O
factors O
, O
and O
treatment O
history O
. O

Other B-Premise
toxicities I-Premise
were I-Premise
mild I-Premise
and I-Premise
generally I-Premise
well I-Premise
tolerated I-Premise
. I-Premise

Supervised O
12 O
week O
group O
exercise O
programme O
in O
addition O
to O
usual O
care O
, O
compared O
with O
usual O
care O
. O

The B-Premise
rates I-Premise
of I-Premise
attrition I-Premise
at I-Premise
these I-Premise
time I-Premise
points I-Premise
were I-Premise
28.1 I-Premise
% I-Premise
, I-Premise
17.7 I-Premise
% I-Premise
, I-Premise
and I-Premise
11.1 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
43.1 I-Premise
% I-Premise
of I-Premise
the I-Premise
participants I-Premise
( I-Premise
66 I-Premise
of I-Premise
153 I-Premise
) I-Premise
completed I-Premise
the I-Premise
entire I-Premise
study I-Premise
. I-Premise

Of O
131 O
patients O
in O
the O
larger O
randomized O
controlled O
study O
, O
we O
report O
data O
on O
54 O
evaluable O
patients O
( O
16 O
older O
adults O
and O
38 O
younger O
adults O
) O
randomized O
to O
the O
intervention O
. O

Four O
hundred O
eighty-two O
patients O
were O
randomly O
assigned O
on O
JBR.10 O
. O

In B-Premise
the I-Premise
UAE I-Premise
group I-Premise
, I-Premise
mean I-Premise
± I-Premise
standard I-Premise
deviation I-Premise
uterine I-Premise
volume I-Premise
was I-Premise
670 I-Premise
± I-Premise
503 I-Premise
, I-Premise
422 I-Premise
± I-Premise
353 I-Premise
, I-Premise
and I-Premise
292 I-Premise
± I-Premise
287 I-Premise
mL I-Premise
at I-Premise
baseline I-Premise
, I-Premise
6 I-Premise
months I-Premise
, I-Premise
and I-Premise
5 I-Premise
years I-Premise
, I-Premise
respectively I-Premise
. I-Premise

After O
stratification O
by O
estrogen O
receptor O
( O
ER O
) O
status O
, O
patients O
were O
randomly O
assigned O
to O
receive O
three O
28-day O
courses O
of O
" O
classical O
" O
adjuvant O
CMF O
chemotherapy O
( O
cyclophosphamide O
at O
100 O
mg/m O
( O
2 O
) O
on O
days O
1-14 O
, O
orally O
";" O
methotrexate O
at O
40 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
, O
intravenously O
";" O
and O
5-fluorouracil O
at O
600 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
, O
intravenously O
) O
followed O
by O
tamoxifen O
( O
20 O
mg/day O
, O
orally O
for O
57 O
months O
) O
( O
CMF O
-- O
> O
tamoxifen O
) O
or O
to O
receive O
tamoxifen O
alone O
( O
20 O
mg/day O
, O
orally O
for O
60 O
months O
) O
. O

Local O
symptoms O
were O
scored O
on O
a O
physician-assessed O
, O
five-point O
categorical O
scale O
and O
summed O
to O
produce O
a O
total O
symptom O
score O
( O
TSS O
) O
. O

Ten B-Premise
patients I-Premise
in I-Premise
the I-Premise
embolization I-Premise
group I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
required I-Premise
repeated I-Premise
embolization I-Premise
or I-Premise
hysterectomy I-Premise
for I-Premise
inadequate I-Premise
symptom I-Premise
control I-Premise
. I-Premise

At O
final O
analysis O
, O
there B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
OS I-Premise
seen I-Premise
between I-Premise
ASA404 I-Premise
( I-Premise
n I-Premise
= I-Premise
649 I-Premise
) I-Premise
and I-Premise
placebo I-Premise
( I-Premise
n I-Premise
= I-Premise
650 I-Premise
) I-Premise
arms I-Premise
: I-Premise
median I-Premise
OS I-Premise
was I-Premise
13.4 I-Premise
and I-Premise
12.7 I-Premise
months I-Premise
respectively I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
1.01 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.85 I-Premise
to I-Premise
1.19 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.535 I-Premise
) I-Premise
. I-Premise

The O
2 O
+ O
2.5 O
dosage O
was O
discontinued O
at O
the O
end O
of O
year O
7 O
. O

Recent O
studies O
suggest O
acupuncture O
may O
be O
effective O
in O
reducing O
vasomotor O
symptoms O
in O
menopausal O
women O
. O

One O
hundred O
seventy-four O
patients O
were O
enrolled O
. O

A O
randomised O
study O
was O
undertaken O
to O
compare O
delivery O
of O
cancer O
treatment O
in O
the O
hospital O
with O
two O
different O
community O
settings O
. O

Health-related O
quality O
of O
life O
( O
HRQoL O
";" O
exploratory O
endpoint O
) O
was O
evaluated O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
( O
QLQ-C30 O
) O
. O

To O
compare O
survival O
in O
patients O
with O
recurrent O
or O
metastatic O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
( O
SCCHN O
) O
treated O
with O
gefitinib O
250 O
or O
500 O
mg/day O
or O
standard O
methotrexate O
. O

The B-Claim
effect I-Claim
of I-Claim
grape I-Claim
juice I-Claim
flavonoids I-Claim
on I-Claim
CINV I-Claim
should I-Claim
be I-Claim
investigated I-Claim
further I-Claim
with I-Claim
a I-Claim
larger I-Claim
sample I-Claim
to I-Claim
determine I-Claim
whether I-Claim
preliminary I-Claim
findings I-Claim
are I-Claim
supported I-Claim
. I-Claim

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
better I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
only I-Premise
in I-Premise
the I-Premise
first I-Premise
year I-Premise
after I-Premise
surgery I-Premise
( I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

A O
total O
of O
420 O
patients O
were O
randomised O
and O
411 O
were O
analysed O
. O

The B-Premise
tumor I-Premise
progression I-Premise
duration I-Premise
in I-Premise
these I-Premise
two I-Premise
groups I-Premise
was I-Premise
6.5 I-Premise
and I-Premise
5.6 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

This O
analysis O
evaluates O
the O
effectiveness O
of O
the O
Improving O
Mood-Promoting O
Access O
to O
Collaborative O
Treatment O
( O
IMPACT O
) O
program O
, O
a O
stepped O
care O
management O
program O
for O
depression O
in O
primary O
care O
patients O
who O
had O
an O
ICD-9 O
cancer O
diagnosis O
. O

Decreases B-Premise
in I-Premise
IPSS I-Premise
were I-Premise
greater I-Premise
in I-Premise
degarelix I-Premise
than I-Premise
in I-Premise
goserelin-treated I-Premise
patients I-Premise
, I-Premise
differences I-Premise
being I-Premise
statistically I-Premise
significant I-Premise
in I-Premise
patients I-Premise
with I-Premise
baseline I-Premise
IPSS I-Premise
> I-Premise
13 I-Premise
( I-Premise
-6.7 I-Premise
± I-Premise
1.8 I-Premise
vs I-Premise
-4.0 I-Premise
± I-Premise
1.0 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
were I-Premise
found I-Premise
for I-Premise
mood I-Premise
( I-Premise
p I-Premise
> I-Premise
.05 I-Premise
) I-Premise
or I-Premise
pain I-Premise
( I-Premise
p I-Premise
> I-Premise
.05 I-Premise
) I-Premise
levels I-Premise
. I-Premise

We O
conducted O
a O
prospective O
, O
multicenter O
, O
randomized O
, O
controlled O
, O
clinical O
trial O
with O
215 O
patients O
followed O
until O
death O
or O
study O
closure O
. O

The O
aim O
of O
this O
study O
was O
to O
assess O
efficacy O
and O
safety O
of O
association O
of O
duloxetine O
and O
rehabilitation O
compared O
with O
rehabilitation O
alone O
in O
men O
with O
SUI O
after O
radical O
retropubic O
prostatectomy O
( O
RRP O
) O
, O
and O
to O
compare O
continence O
rate O
even O
after O
planned O
duloxetine O
suspension O
. O

Promising O
results O
in O
a O
randomized O
phase O
II O
trial O
with O
the O
hypoxic O
cytotoxin O
tirapazamine O
( O
TPZ O
) O
combined O
with O
cisplatin O
( O
CIS O
) O
and O
radiation O
led O
to O
this O
phase O
III O
trial O
. O

In B-Claim
V325 I-Claim
, I-Claim
advanced I-Claim
gastric I-Claim
or I-Claim
gastroesophageal I-Claim
junction I-Claim
cancer I-Claim
patients I-Claim
receiving I-Claim
DCF I-Claim
not I-Claim
only I-Claim
had I-Claim
statistically I-Claim
improved I-Claim
overall I-Claim
survival I-Claim
and I-Claim
time I-Claim
to I-Claim
tumor-progression I-Claim
, I-Claim
but I-Claim
they I-Claim
also I-Claim
had I-Claim
better I-Claim
preservation I-Claim
of I-Claim
QOL I-Claim
compared I-Claim
with I-Claim
patients I-Claim
receiving I-Claim
CF I-Claim
. I-Claim

Capecitabine/docetaxel B-Claim
was I-Claim
a I-Claim
cost-effective I-Claim
treatment I-Claim
in I-Claim
patients I-Claim
with I-Claim
anthracycline-pretreated I-Claim
advanced I-Claim
breast I-Claim
carcinoma I-Claim
, I-Claim
and I-Claim
had I-Claim
an I-Claim
incremental I-Claim
cost-effectiveness I-Claim
ratio I-Claim
that I-Claim
compares I-Claim
very I-Claim
favorably I-Claim
with I-Claim
that I-Claim
of I-Claim
many I-Claim
other I-Claim
oncology I-Claim
therapies I-Claim
. I-Claim

Several O
general O
( O
emotional O
functioning O
, O
role O
functioning O
, O
social O
contact O
) O
as O
well O
as O
head O
and O
neck O
cancer-specific O
( O
dry O
mouth O
, O
opening O
mouth O
, O
sticky O
saliva O
, O
pain O
, O
senses O
) O
QOL O
domains O
were O
better O
preserved O
with O
IMRT O
compared O
to O
3D-CRT O
at O
different O
time O
points O
. O

Patients O
in O
group O
1 O
in O
whom O
gynecomastia O
or O
breast O
pain O
developed O
were O
subsequently O
randomized O
to O
receive O
tamoxifen O
or O
RT O
soon O
after O
symptoms O
started O
. O

Median B-Premise
survival I-Premise
time I-Premise
was I-Premise
53.6 I-Premise
months I-Premise
for I-Premise
women I-Premise
with I-Premise
decreasing I-Premise
CES-D I-Premise
scores I-Premise
over I-Premise
1 I-Premise
year I-Premise
and I-Premise
25.1 I-Premise
months I-Premise
for I-Premise
women I-Premise
with I-Premise
increasing I-Premise
CES-D I-Premise
scores I-Premise
. I-Premise

Between O
April O
2010 O
and O
May O
2011 O
, O
patients O
undergoing O
elective O
LCR O
in O
two O
centres O
were O
randomized O
to O
analgesia O
via O
epidural O
or O
WIC O
. O

Although B-Claim
this I-Claim
trial I-Claim
met I-Claim
the I-Claim
pre-determined I-Claim
criteria I-Claim
for I-Claim
equivalence I-Claim
between I-Claim
the I-Claim
two I-Claim
palliative I-Claim
regimens I-Claim
, I-Claim
significantly B-Claim
more I-Claim
patients I-Claim
achieved I-Claim
complete I-Claim
resolution I-Claim
of I-Claim
symptoms I-Claim
and I-Claim
palliation I-Claim
of I-Claim
chest I-Claim
pain I-Claim
and I-Claim
dyspnoea I-Claim
with I-Claim
the I-Claim
fractionated I-Claim
regimen I-Claim
. I-Claim

Thirty-six O
patients O
in O
Study O
A O
received O
bolus O
6S-LV O
, O
100 O
mg/m2 O
, O
followed O
by O
bolus O
5-FU O
, O
370 O
mg/m2 O
, O
on O
Days O
1-5 O
and O
36 O
others O
in O
Study O
B O
received O
epirubicin O
, O
30 O
mg/m2 O
, O
on O
Days O
1 O
and O
5 O
";" O
etoposide O
, O
100 O
mg/m2 O
, O
on O
Days O
1 O
, O
3 O
, O
and O
5 O
";" O
cisplatin O
, O
30 O
mg/m2 O
, O
on O
Days O
2 O
and O
4 O
";" O
and O
lonidamine O
, O
150 O
mg/day O
. O

Given O
the O
existing O
evidence O
supporting O
the O
importance O
of O
social O
support O
in O
adjustment O
to O
breast O
cancer O
, O
it B-Claim
seems I-Claim
feasible I-Claim
to I-Claim
suggest I-Claim
that I-Claim
EW I-Claim
may I-Claim
be I-Claim
a I-Claim
cost I-Claim
effective I-Claim
accessible I-Claim
treatment I-Claim
that I-Claim
could I-Claim
be I-Claim
incorporated I-Claim
into I-Claim
the I-Claim
ongoing I-Claim
care I-Claim
of I-Claim
women I-Claim
. I-Claim

It O
may O
thus O
be O
possible O
to O
selectively O
modulate O
each O
schedule O
biochemically O
. O

Primary O
analyses O
were O
done O
by O
intention O
to O
treat O
and O
were O
based O
on O
scale O
scores O
at O
4 O
weeks O
and O
8 O
weeks O
. O

Cetuximab B-Claim
offers I-Claim
important I-Claim
HRQL I-Claim
and I-Claim
survival I-Claim
benefits I-Claim
for I-Claim
pretreated I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
, I-Claim
wild-type I-Claim
KRAS I-Claim
CRC I-Claim
. I-Claim

At B-Premise
the I-Premise
post-treatment I-Premise
assessment I-Premise
, I-Premise
IMCP I-Premise
participants I-Premise
demonstrated I-Premise
significantly I-Premise
greater I-Premise
improvement I-Premise
than I-Premise
the I-Premise
control I-Premise
condition I-Premise
for I-Premise
the I-Premise
primary I-Premise
outcomes I-Premise
of I-Premise
spiritual I-Premise
well-being I-Premise
( I-Premise
b I-Premise
= I-Premise
0.39 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
, I-Premise
including I-Premise
both I-Premise
components I-Premise
of I-Premise
spiritual I-Premise
well-being I-Premise
( I-Premise
sense I-Premise
of I-Premise
meaning I-Premise
: I-Premise
b I-Premise
= I-Premise
0.34 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.003 I-Premise
and I-Premise
faith I-Premise
: I-Premise
b I-Premise
= I-Premise
0.42 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
b I-Premise
= I-Premise
0.76 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.013 I-Premise
) I-Premise
. I-Premise

There O
are O
very O
few O
randomized O
controlled O
studies O
on O
exercise O
in O
cancer O
patients O
. O

Additional B-Claim
studies I-Claim
are I-Claim
warranted I-Claim
. I-Claim

The O
investigators O
implemented O
a O
randomized O
controlled O
trial O
and O
enrolled O
a O
sample O
composed O
of O
patients O
with O
ONJ O
, O
where O
the O
predictor O
variable O
was O
HBO O
administered O
at O
2 O
atm O
twice O
a O
day O
for O
40 O
treatments O
as O
an O
adjunct O
to O
conventional O
therapy O
of O
surgery O
and O
antibiotics O
versus O
conventional O
therapy O
alone O
. O

Larger B-Claim
studies I-Claim
should I-Claim
be I-Claim
carried I-Claim
out I-Claim
that I-Claim
also I-Claim
include I-Claim
healthy I-Claim
women I-Claim
who I-Claim
want I-Claim
to I-Claim
avoid I-Claim
hormone I-Claim
replacement I-Claim
therapy I-Claim
. I-Claim

However B-Claim
, I-Claim
exercise I-Claim
is I-Claim
not I-Claim
better I-Claim
than I-Claim
progressive I-Claim
relaxation I-Claim
training I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
fatigue I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim

The O
minimum O
follow-up O
time O
was O
5.2 O
years O
for O
the O
surviving O
patients O
. O

Patients B-Premise
overwhelmingly I-Premise
reported I-Premise
that I-Premise
CCSP I-Premise
was I-Premise
beneficial I-Premise
. I-Premise

They O
were O
followed O
until O
they O
finished O
primary O
treatment O
( O
enrollment O
) O
, O
at O
which O
time O
they O
completed O
a O
mailed O
baseline O
survey O
that O
included O
standardized O
measures O
of O
quality O
of O
life O
( O
including O
standardized O
scales O
of O
physical O
and O
emotional O
functioning O
) O
, O
mood O
, O
symptoms O
, O
and O
sexual O
functioning O
. O

The B-Premise
saving I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
was I-Premise
$ I-Premise
1,396 I-Premise
per I-Premise
patient I-Premise
randomized I-Premise
( I-Premise
$ I-Premise
647 I-Premise
the I-Premise
result I-Premise
of I-Premise
shorter I-Premise
length I-Premise
of I-Premise
hospital I-Premise
stay I-Premise
and I-Premise
$ I-Premise
749 I-Premise
the I-Premise
result I-Premise
of I-Premise
the I-Premise
lower I-Premise
cost I-Premise
of I-Premise
postoperative I-Premise
complications I-Premise
) I-Premise
. I-Premise

Possible O
contributing O
factors O
beyond O
the O
efficacy O
of O
the O
intervention O
were O
the O
inability O
of O
patients O
to O
complete O
an O
8-week O
course O
of O
treatment O
and O
return O
in O
a O
timely O
fashion O
for O
follow-up O
assessment O
, O
and O
because O
the O
patients O
may O
have O
only O
had O
weight O
loss O
possible O
not O
related O
to O
cachexia O
, O
but O
other O
causes O
of O
weight O
loss O
, O
such O
as O
decreased O
appetite O
. O

Lung O
cancer O
is O
one O
of O
the O
most O
common O
cancers O
in O
the O
United O
States O
and O
is O
associated O
with O
high O
levels O
of O
symptoms O
, O
including O
pain O
, O
fatigue O
, O
shortness O
of O
breath O
, O
and O
psychological O
distress O
. O

The B-Premise
average I-Premise
costs I-Premise
of I-Premise
the I-Premise
primary I-Premise
treatment I-Premise
were I-Premise
higher I-Premise
in I-Premise
GM-CSF-treated I-Premise
patients I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
i.e I-Premise
. I-Premise
US I-Premise
$ I-Premise
40782 I-Premise
and I-Premise
US I-Premise
$ I-Premise
34465 I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

The O
trial O
was O
stopped O
for O
futility O
at O
interim O
analysis O
. O

PFS B-Premise
was I-Premise
significantly I-Premise
prolonged I-Premise
in I-Premise
the I-Premise
erlotinib I-Premise
treatment I-Premise
arm I-Premise
, I-Premise
both I-Premise
overall I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
: I-Premise
0.57 I-Premise
";" I-Premise
p=0.0067 I-Premise
) I-Premise
and I-Premise
in I-Premise
patients I-Premise
with I-Premise
EGFR I-Premise
IHC-positive I-Premise
disease I-Premise
( I-Premise
HR=0.50 I-Premise
";" I-Premise
p=0.0057 I-Premise
) I-Premise
. I-Premise

This O
reduction O
in O
hot O
flash O
frequency O
persisted O
for O
up O
to O
6 O
months O
after O
the O
completion O
of O
treatment O
. O

Recombinant O
human O
TSH O
( O
rhTSH O
) O
has O
become O
the O
modality O
of O
choice O
for O
radioiodine O
remnant O
ablation O
( O
RRA O
) O
in O
low-risk O
thyroid O
cancer O
patients O
. O

Secondary O
endpoints O
were O
the O
proportions O
of O
women O
with O
at O
least O
15 O
% O
increase O
in O
arm O
volume O
or O
early O
axillary O
morbidity O
, O
and O
average O
scores O
for O
arm O
symptoms O
, O
dysfunctions O
, O
and O
disabilities O
assessed O
at O
6 O
and O
12 O
months O
by O
patients O
with O
the O
SNAC O
Study-Specific O
Scales O
and O
other O
quality-of-life O
instruments O
. O

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
r-HuEPO-treated I-Premise
group I-Premise
. I-Premise

Treatments O
are O
associated O
with O
morbidity O
. O

These B-Premise
differences I-Premise
were I-Premise
not I-Premise
observed I-Premise
between I-Premise
baseline I-Premise
and I-Premise
T3 I-Premise
and I-Premise
T4 I-Premise
assessments I-Premise
. I-Premise

Nonetheless B-Claim
, I-Claim
it I-Claim
is I-Claim
apparent I-Claim
that I-Claim
these I-Claim
first-generation I-Claim
regimens I-Claim
must I-Claim
be I-Claim
applied I-Claim
judiciously I-Claim
, I-Claim
and O
thus B-Claim
we I-Claim
view I-Claim
efforts I-Claim
at I-Claim
better I-Claim
patient I-Claim
selection I-Claim
and I-Claim
the I-Claim
development I-Claim
of I-Claim
more I-Claim
tolerable I-Claim
therapies I-Claim
as I-Claim
higher I-Claim
priorities I-Claim
than I-Claim
carrying I-Claim
either I-Claim
of I-Claim
these I-Claim
regimens I-Claim
to I-Claim
phase I-Claim
III I-Claim
evaluation I-Claim
in I-Claim
the I-Claim
cooperative I-Claim
group I-Claim
setting I-Claim
. I-Claim

Sleep B-Premise
quality I-Premise
differed I-Premise
over I-Premise
1 I-Premise
years I-Premise
time I-Premise
( I-Premise
F I-Premise
[ I-Premise
4,162 I-Premise
] I-Premise
= I-Premise
7.7 I-Premise
, I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
by I-Premise
group I-Premise
, I-Premise
F I-Premise
[ I-Premise
1,173 I-Premise
] I-Premise
= I-Premise
4.8 I-Premise
, I-Premise
P I-Premise
= I-Premise
.029 I-Premise
";" I-Premise
and I-Premise
over I-Premise
time I-Premise
by I-Premise
group I-Premise
, I-Premise
F I-Premise
[ I-Premise
4,162 I-Premise
] I-Premise
= I-Premise
3.3 I-Premise
, I-Premise
P I-Premise
= I-Premise
.013 I-Premise
) I-Premise
. I-Premise

IMRT B-Claim
results I-Claim
in I-Claim
clinically I-Claim
meaningful I-Claim
and I-Claim
statistically I-Claim
better I-Claim
QOL I-Claim
scores I-Claim
for I-Claim
some I-Claim
domains I-Claim
compared I-Claim
to I-Claim
3D-CRT I-Claim
at I-Claim
several I-Claim
time I-Claim
points I-Claim
with I-Claim
comparable I-Claim
disease I-Claim
outcomes I-Claim
that I-Claim
could I-Claim
support I-Claim
its I-Claim
widespread I-Claim
adoption I-Claim
in I-Claim
routine I-Claim
clinical I-Claim
practice I-Claim
. I-Claim

Side O
effects O
of O
appetite O
increase O
and O
weight O
gain O
at O
higher O
doses O
were O
predicted O
to O
have O
a O
negative O
effect O
on O
quality O
of O
life O
. O

In B-Claim
contrast I-Claim
, I-Claim
if I-Claim
their I-Claim
cancer I-Claim
was I-Claim
ER-positive I-Claim
( I-Claim
i.e. I-Claim
, I-Claim
endocrine-responsive I-Claim
) I-Claim
, I-Claim
they I-Claim
obtained I-Claim
no I-Claim
benefit I-Claim
from I-Claim
the I-Claim
combination I-Claim
treatment I-Claim
compared I-Claim
with I-Claim
tamoxifen I-Claim
alone I-Claim
. I-Claim

Epoetin B-Claim
alfa I-Claim
significantly I-Claim
improved I-Claim
HgB I-Claim
and I-Claim
reduced I-Claim
transfusions I-Claim
in I-Claim
this I-Claim
patient I-Claim
population I-Claim
. I-Claim

Evaluation O
at O
baseline O
, O
after O
8 O
sessions O
, O
and O
1 O
month O
after O
programme O
completion O
, O
included O
evaluations O
using O
the O
STAI O
, O
POMS O
, O
MAC O
, O
EORTC O
QLQ-C30 O
and O
EORTC O
QLQ-BR23 O
breast O
module O
scales O
. O

Serum B-Premise
albumin I-Premise
concentration I-Premise
declined I-Premise
by I-Premise
-1.2 I-Premise
g/L I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI= I-Premise
-2.0 I-Premise
to I-Premise
-0.4 I-Premise
) I-Premise
per I-Premise
4 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
but I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0.0 I-Premise
g/L I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-0.3 I-Premise
to I-Premise
+0.3 I-Premise
) I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
( I-Premise
P I-Premise
=.006 I-Premise
) I-Premise
. I-Premise

For O
patients O
who O
received O
thoracic O
radiotherapy O
, O
the O
median O
time O
to O
start O
was O
15 O
days O
in O
the O
immediate O
treatment O
group O
and O
125 O
days O
in O
the O
delayed O
treatment O
group O
. O

At B-Premise
24-month I-Premise
follow-up I-Premise
, I-Premise
patients I-Premise
in I-Premise
the I-Premise
hysterectomy I-Premise
group I-Premise
were I-Premise
significantly I-Premise
more I-Premise
satisfied I-Premise
than I-Premise
those I-Premise
in I-Premise
the I-Premise
UAE I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

QOL B-Premise
was I-Premise
poorer I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
AC→T I-Premise
at I-Premise
6 I-Premise
months I-Premise
but I-Premise
similar I-Premise
to I-Premise
others I-Premise
by I-Premise
12 I-Premise
months I-Premise
. I-Premise

Dignity O
therapy O
is O
a O
unique O
, O
individualised O
, O
short-term O
psychotherapy O
that O
was O
developed O
for O
patients O
( O
and O
their O
families O
) O
living O
with O
life-threatening O
or O
life-limiting O
illness O
. O

Seventy-two O
women O
( O
median O
age O
, O
60 O
y O
) O
were O
randomized O
in O
five O
hospitals O
. O

Patients O
were O
randomly O
assigned O
to O
paclitaxel O
135 O
mg/m O
( O
2 O
) O
over O
24 O
hours O
plus O
Cis O
50 O
mg/m O
( O
2 O
) O
day O
2 O
every O
3 O
weeks O
( O
PC O
, O
reference O
arm O
) O
";" O
vinorelbine O
30 O
mg/m O
( O
2 O
) O
days O
1 O
and O
8 O
plus O
Cis O
50 O
mg/m O
( O
2 O
) O
day O
1 O
every O
3 O
weeks O
( O
VC O
) O
";" O
gemcitabine O
1,000 O
mg/m O
( O
2 O
) O
day O
1 O
and O
8 O
plus O
Cis O
50 O
mg/m O
( O
2 O
) O
day O
1 O
every O
3 O
weeks O
( O
GC O
) O
";" O
or O
topotecan O
0.75 O
mg/m O
( O
2 O
) O
days O
1 O
, O
2 O
, O
and O
3 O
plus O
Cis O
50 O
mg/m O
( O
2 O
) O
day O
1 O
every O
3 O
weeks O
( O
TC O
) O
. O

The B-Premise
difference I-Premise
in I-Premise
mean I-Premise
volume I-Premise
change I-Premise
between I-Premise
randomisation I-Premise
groups I-Premise
at I-Premise
12 I-Premise
months I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
= I-Premise
0.6 I-Premise
) I-Premise
, I-Premise
-1.3 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-6.1 I-Premise
to I-Premise
3.5 I-Premise
) I-Premise
, I-Premise
nor I-Premise
was I-Premise
there I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
response I-Premise
at I-Premise
6 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.7 I-Premise
) I-Premise
, I-Premise
where I-Premise
mean I-Premise
change I-Premise
in I-Premise
arm I-Premise
volume I-Premise
from I-Premise
baseline I-Premise
in I-Premise
the I-Premise
treatment I-Premise
and I-Premise
placebo I-Premise
groups I-Premise
was I-Premise
-2.3 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-7.9 I-Premise
to I-Premise
3.4 I-Premise
) I-Premise
and I-Premise
-1.1 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-3.9 I-Premise
to I-Premise
1.7 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

However B-Claim
, I-Claim
monitoring I-Claim
the I-Claim
lymphocyte I-Claim
count I-Claim
is I-Claim
advisable I-Claim
. I-Claim

High-dose B-Claim
radiotherapy I-Claim
provided I-Claim
a I-Claim
better I-Claim
5-year I-Claim
biochemical I-Claim
outcome I-Claim
with I-Claim
slightly I-Claim
greater I-Claim
toxicity I-Claim
. I-Claim

Postoperative B-Claim
outcomes I-Claim
of I-Claim
patients I-Claim
undergoing I-Claim
laparoscopic-assisted I-Claim
colectomy I-Claim
( I-Claim
LAC I-Claim
) I-Claim
have I-Claim
shown I-Claim
modest I-Claim
improvements I-Claim
in I-Claim
recovery I-Claim
but I-Claim
only I-Claim
minimal I-Claim
differences I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
compared I-Claim
with I-Claim
open I-Claim
colectomy I-Claim
. I-Claim

Of O
these O
70 O
patients O
, O
46 O
underwent O
pretreatment O
FLIC O
and O
49 O
underwent O
pretreatment O
FACT-L O
. O

Moreover O
, O
adopting B-Premise
a I-Premise
combined I-Premise
aerobic I-Premise
and I-Premise
resistance I-Premise
exercise I-Premise
program I-Premise
after I-Premise
breast I-Premise
cancer I-Premise
chemotherapy I-Premise
was I-Premise
associated I-Premise
with I-Premise
further I-Premise
improvements I-Premise
in I-Premise
patient-rated I-Premise
outcomes I-Premise
. I-Premise

The B-Premise
main I-Premise
cost I-Premise
drivers I-Premise
distinguishing I-Premise
epoetin-alfa I-Premise
from I-Premise
placebo I-Premise
were I-Premise
the I-Premise
costs I-Premise
of I-Premise
drug I-Premise
and I-Premise
patient I-Premise
care I-Premise
due I-Premise
to I-Premise
increased I-Premise
survival I-Premise
. I-Premise

Increased B-Claim
expression I-Claim
of I-Claim
metalloproteinases I-Claim
is I-Claim
associated I-Claim
with I-Claim
poor I-Claim
prognosis I-Claim
in I-Claim
small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
SCLC I-Claim
) I-Claim
. I-Claim

To O
assess O
the O
efficacy O
of O
prophylactic O
swallowing O
exercises O
on O
swallowing O
function O
in O
patients O
undergoing O
chemoradiation O
therapy O
( O
CRT O
) O
for O
head O
and O
neck O
cancer O
. O

Drowsiness B-Premise
, I-Premise
confusion I-Premise
and I-Premise
dry I-Premise
mouth I-Premise
were I-Premise
significantly I-Premise
more I-Premise
intense I-Premise
with I-Premise
amitriptyline I-Premise
than I-Premise
with I-Premise
placebo I-Premise
( I-Premise
P I-Premise
< I-Premise
0.036 I-Premise
, I-Premise
0.003 I-Premise
, I-Premise
and I-Premise
0.034 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

A O
total O
of O
1113 O
men O
were O
registered O
, O
of O
whom O
970 O
were O
randomly O
assigned O
, O
483 O
to O
short-term O
suppression O
and O
487 O
to O
long-term O
suppression O
. O

Distress B-Claim
reduction I-Claim
is I-Claim
highlighted I-Claim
as I-Claim
an I-Claim
important I-Claim
mechanism I-Claim
by I-Claim
which I-Claim
health I-Claim
can I-Claim
be I-Claim
improved I-Claim
. I-Claim

QOL O
evaluations O
were O
available O
for O
199 O
patients O
. O

The B-Claim
addition I-Claim
of I-Claim
gemcitabine I-Claim
to I-Claim
PB I-Claim
was I-Claim
not I-Claim
associated I-Claim
with I-Claim
a I-Claim
statistically I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
ORR I-Claim
. I-Claim

In B-Claim
this I-Claim
, I-Claim
the I-Claim
first I-Claim
report I-Claim
of I-Claim
HRQoL I-Claim
over I-Claim
5 I-Claim
years I-Claim
of I-Claim
initial I-Claim
adjuvant I-Claim
therapy I-Claim
with I-Claim
an I-Claim
aromatase I-Claim
inhibitor I-Claim
, I-Claim
we I-Claim
conclude I-Claim
that I-Claim
anastrozole I-Claim
and I-Claim
tamoxifen I-Claim
had I-Claim
similar I-Claim
impacts I-Claim
on I-Claim
HRQoL I-Claim
, I-Claim
which I-Claim
was I-Claim
maintained I-Claim
or I-Claim
slightly I-Claim
improved I-Claim
during I-Claim
the I-Claim
treatment I-Claim
period I-Claim
for I-Claim
both I-Claim
groups I-Claim
. I-Claim

Secondary O
endpoints O
included O
overall O
survival O
( O
OS O
) O
, O
disease O
control O
rate O
, O
safety O
, O
quality O
of O
life O
( O
QoL O
) O
and O
biomarker O
analyses O
. O

The O
primary O
outcome O
was O
the O
feasibility O
of O
a O
large O
RCT O
, O
and O
all O
outcomes O
for O
a O
definitive O
trial O
were O
tested O
. O

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
FOIS I-Premise
scores I-Premise
between I-Premise
intervention I-Premise
and I-Premise
control I-Premise
patients I-Premise
immediately I-Premise
after I-Premise
CRT I-Premise
( I-Premise
immediately I-Premise
after I-Premise
CRT I-Premise
: I-Premise
intervention I-Premise
group I-Premise
median I-Premise
score I-Premise
, I-Premise
3 I-Premise
[ I-Premise
range I-Premise
, I-Premise
1-7 I-Premise
] I-Premise
, I-Premise
vs I-Premise
median I-Premise
control I-Premise
score I-Premise
, I-Premise
4 I-Premise
[ I-Premise
range I-Premise
, I-Premise
1-6 I-Premise
] I-Premise
( I-Premise
P I-Premise
= I-Premise
.88 I-Premise
) I-Premise
. I-Premise

The O
aims O
of O
the O
present O
prospective O
randomized O
study O
were O
to O
evaluate O
the O
impact O
of O
TSH O
stimulation O
procedure O
( O
hypothyroidism O
vs. O
rhTSH O
) O
on O
quality O
of O
life O
( O
QoL O
) O
of O
thyroid O
cancer O
patients O
undergoing O
RRA O
and O
to O
evaluate O
efficacy O
of O
both O
procedures O
. O

Treatment O
arms O
were O
well O
balanced O
for O
clinicopathologic O
characteristics O
. O

HRQOL B-Claim
evaluated I-Claim
3.2 I-Claim
to I-Claim
6.5 I-Claim
years I-Claim
after I-Claim
treatment I-Claim
showed I-Claim
an I-Claim
advantage I-Claim
for I-Claim
BT I-Claim
in I-Claim
urinary I-Claim
and I-Claim
sexual I-Claim
domains I-Claim
and I-Claim
in I-Claim
patient I-Claim
satisfaction I-Claim
. I-Claim

Thirty-two O
women O
with O
breast O
cancer O
were O
randomly O
assigned O
to O
scapula-oriented O
exercise O
group O
( O
n O
= O
16 O
) O
and O
general O
exercise O
group O
( O
n O
= O
16 O
) O
. O

Treatment O
duration O
was O
8 O
weeks O
. O

In B-Claim
fatigued I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
, I-Claim
nurse-led I-Claim
monitoring I-Claim
and I-Claim
protocolized I-Claim
treatment I-Claim
of I-Claim
physical I-Claim
symptoms I-Claim
is I-Claim
effective I-Claim
in I-Claim
alleviating I-Claim
fatigue I-Claim
. I-Claim

Greater O
levels O
of O
anxiety O
, O
depression O
, O
and O
hostility O
at O
baseline O
were O
related O
to O
nausea O
and O
vomiting O
, O
quality O
of O
life O
, O
and O
perceived O
control O
over O
decision O
making O
. O

Quality O
of O
life O
was O
the O
primary O
outcome O
measure O
, O
together O
with O
anxiety O
and O
depression O
and O
cost-effectiveness O
. O

Data O
were O
collected O
on O
three O
treatment-specific O
symptoms O
( O
diarrhea O
, O
gas O
pain O
, O
and O
body O
image O
) O
, O
on O
physical O
functioning O
, O
and O
on O
emotional O
functioning O
. O

Cycles O
were O
repeated O
as O
rapidly O
as O
possible O
. O

Different B-Claim
treatment I-Claim
modalities I-Claim
consisting I-Claim
of I-Claim
MLD I-Claim
and I-Claim
compression I-Claim
bandage I-Claim
( I-Claim
complex I-Claim
decongestive I-Claim
therapy I-Claim
) I-Claim
or I-Claim
IPC I-Claim
and I-Claim
SLD I-Claim
appear I-Claim
to I-Claim
be I-Claim
effective I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
LE I-Claim
with I-Claim
similar I-Claim
therapeutic I-Claim
efficacy I-Claim
in I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

infusion O
and O
5-FU O
, O
1050 O
mg/m2 O
i.v O
. O

Previous B-Claim
trials I-Claim
have I-Claim
suggested I-Claim
a I-Claim
quality-of-life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
improvement I-Claim
for I-Claim
anemic I-Claim
cancer I-Claim
patients I-Claim
treated I-Claim
with I-Claim
erythropoietin I-Claim
, I-Claim
but I-Claim
few I-Claim
used I-Claim
QOL I-Claim
as I-Claim
the I-Claim
primary I-Claim
outcome I-Claim
. I-Claim

RTOG O
89-01 O
accrued O
75 O
patients O
, O
of O
whom O
73 O
were O
eligible O
and O
analyzable O
. O

Safe O
resistance O
exercise O
prescription O
may O
counteract O
this O
effect O
. O

The B-Premise
survival I-Premise
rates I-Premise
at I-Premise
6 I-Premise
months I-Premise
were I-Premise
28 I-Premise
% I-Premise
and I-Premise
38 I-Premise
% I-Premise
for I-Premise
the I-Premise
FU I-Premise
and I-Premise
FUP I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
, I-Premise
and I-Premise
1-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
9 I-Premise
% I-Premise
and I-Premise
17 I-Premise
% I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
= I-Premise
0.10 I-Premise
) I-Premise
. I-Premise

Patients O
initially O
randomly O
assigned O
to O
the O
sham O
group O
were O
crossed O
over O
to O
TRUE O
acupuncture O
starting O
at O
week O
7 O
. O

The O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
the O
gastric O
module O
STO22 O
were O
administered O
every O
8 O
weeks O
until O
progression O
. O

Bone-cancer O
pain O
is O
a O
common O
and O
refractory O
cancer O
pain O
. O

In O
the O
Asia-Pacific O
region O
and O
elsewhere O
, O
almost O
85 O
% O
of O
patients O
with O
hepatocellular O
carcinoma O
( O
HCC O
) O
are O
inoperable O
at O
diagnosis O
and O
have O
a O
dismal O
prognosis O
. O

Patients O
were O
eligible O
if O
they O
were O
aged O
> O
OR= O
70 O
years O
, O
had O
stage O
IIIB O
( O
with O
pleural O
effusion O
) O
or O
stage O
IV O
NSCLC O
, O
had O
a O
performance O
status O
of O
0/1 O
, O
had O
not O
previously O
received O
chemotherapy O
, O
and O
had O
normal O
organ O
function O
. O

182 O
( O
88 O
% O
) O
of O
208 O
men O
in O
the O
radical O
prostatectomy O
group O
, O
167 O
( O
87 O
% O
) O
of O
192 O
men O
in O
the O
watchful-waiting O
group O
, O
and O
214 O
( O
76 O
% O
) O
of O
281 O
men O
in O
the O
population-based O
control O
group O
answered O
the O
questionnaire O
. O

We O
compared O
efficacy O
of O
gefitinib O
with O
gemcitabine O
and O
cisplatin O
( O
GP O
) O
chemotherapy O
in O
this O
group O
of O
patients O
as O
first-line O
therapy O
. O

Increased O
attention O
has O
focused O
on O
exercise O
as O
a O
quality O
of O
life O
intervention O
for O
breast O
cancer O
survivors O
during O
and O
after O
adjuvant O
therapy O
. O

Patient O
compliance O
with O
respect O
to O
the O
HRQOL O
investigation O
was O
minimum O
74 O
% O
. O

Repeated O
measures O
MANCOVA O
was O
used O
to O
evaluate O
outcomes O
. O

Patients O
( O
n O
= O
429 O
) O
were O
randomly O
assigned O
to O
receive O
doxorubicin O
50 O
mg/m O
( O
2 O
) O
plus O
docetaxel O
75 O
mg/m O
( O
2 O
) O
( O
n O
= O
214 O
) O
or O
doxorubicin O
60 O
mg/m O
( O
2 O
) O
plus O
cyclophosphamide O
600 O
mg/m O
( O
2 O
) O
( O
n O
= O
215 O
) O
on O
day O
1 O
, O
every O
3 O
weeks O
for O
up O
to O
eight O
cycles O
. O

Women O
with O
platinum-pretreated O
epithelial O
ovarian O
cancer O
and O
measurable O
recurrent O
disease O
were O
randomized O
in O
a O
bifactorial O
design O
to O
receive O
either O
175 O
or O
135 O
mg/m2 O
of O
Taxol O
over O
either O
24 O
or O
3 O
hours O
. O

The O
primary O
end-point O
was O
progression-free O
survival O
( O
PFS O
) O
. O

Similarly B-Premise
, I-Premise
no I-Premise
difference I-Premise
in I-Premise
survival I-Premise
was I-Premise
found I-Premise
when I-Premise
the I-Premise
patients I-Premise
who I-Premise
received I-Premise
both I-Premise
the I-Premise
planned I-Premise
first-and I-Premise
second-line I-Premise
treatments I-Premise
were I-Premise
compared I-Premise
or I-Premise
when I-Premise
survival I-Premise
was I-Premise
calculated I-Premise
from I-Premise
the I-Premise
beginning I-Premise
of I-Premise
the I-Premise
second-line I-Premise
therapy I-Premise
. I-Premise

New B-Claim
fibroid I-Claim
formation I-Claim
is I-Claim
significantly I-Claim
higher I-Claim
after I-Claim
myomectomy I-Claim
. I-Claim

One O
hundred O
fifty-nine O
patients O
with O
advanced O
colorectal O
carcinoma O
previously O
untreated O
for O
the O
metastatic O
disease O
( O
34 O
of O
them O
previously O
exposed O
to O
adjuvant O
5-FU O
) O
were O
randomly O
allocated O
to O
receive O
: O
CPT-11 O
, O
200 O
mg/m2 O
i.v O
. O

Complete O
remission O
rates O
before O
random O
assignment O
were O
11 O
% O
for O
those O
receiving O
HDCT O
and O
12 O
% O
for O
those O
receiving O
ST. O
After B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
48 I-Premise
months I-Premise
, I-Premise
79 I-Premise
deaths I-Premise
were I-Premise
observed I-Premise
in I-Premise
the I-Premise
HDCT I-Premise
arm I-Premise
and I-Premise
77 I-Premise
deaths I-Premise
were I-Premise
observed I-Premise
in I-Premise
the I-Premise
ST I-Premise
arm I-Premise
";" I-Premise
seven B-Premise
patients I-Premise
( I-Premise
6 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
HDCT I-Premise
arm I-Premise
died I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
toxicity I-Premise
. I-Premise

Everolimus O
( O
EVE O
) O
+exemestane O
( O
EXE O
";" O
n O
= O
485 O
) O
more O
than O
doubled O
median O
progression-free O
survival O
versus O
placebo O
( O
PBO O
) O
+ O
EXE O
( O
n O
= O
239 O
) O
, O
with O
a O
manageable O
safety O
profile O
and O
no O
deterioration O
in O
health-related O
quality-of-life O
( O
HRQOL O
) O
in O
patients O
with O
hormone-receptor-positive O
( O
HR O
( O
+ O
) O
) O
advanced O
breast O
cancer O
( O
ABC O
) O
who O
recurred O
or O
progressed O
on/after O
nonsteroidal O
aromatase O
inhibitor O
( O
NSAI O
) O
therapy O
. O

Efficacy O
was O
assessed O
after O
the O
completion O
of O
3 O
treatment O
cycles O
";" O
28.9 O
% O
of O
patients O
( O
22 O
of O
76 O
patients O
) O
responded O
( O
no O
CRs O
, O
1 O
PR O
, O
and O
21 O
SDs O
) O
. O

Mean B-Premise
hemoglobin I-Premise
levels I-Premise
were I-Premise
higher I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
placebo I-Premise
group I-Premise
after I-Premise
4 I-Premise
cycles I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise

Patients O
were O
prospectively O
stratified O
on O
the O
basis O
of O
disease O
volume O
. O

Sixty O
consecutive O
radiation O
oncology O
outpatients O
( O
51 O
men O
and O
nine O
women O
";" O
age O
61.9+/-14 O
years O
[ O
mean+/-standard O
deviation O
] O
) O
. O

Forty-five O
patients O
were O
randomized O
to O
postinduction O
RT O
or O
surgery O
. O

Trained B-Premise
versus I-Premise
control I-Premise
patients I-Premise
reported I-Premise
reduced I-Premise
barriers I-Premise
to I-Premise
pain I-Premise
relief I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
lower I-Premise
usual I-Premise
pain I-Premise
( I-Premise
P=.03 I-Premise
) I-Premise
, I-Premise
and I-Premise
greater I-Premise
opioid I-Premise
use I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Three B-Premise
years I-Premise
after I-Premise
radiotherapy I-Premise
, I-Premise
urinary I-Premise
incontinence I-Premise
was I-Premise
reported I-Premise
by I-Premise
35 I-Premise
% I-Premise
of I-Premise
patients I-Premise
, I-Premise
but I-Premise
only I-Premise
6 I-Premise
% I-Premise
required I-Premise
the I-Premise
use I-Premise
of I-Premise
a I-Premise
pad I-Premise
or I-Premise
other I-Premise
protective I-Premise
device I-Premise
. I-Premise

Epoetin B-Claim
alfa I-Claim
administered I-Claim
at I-Claim
40,000 I-Claim
U I-Claim
once I-Claim
weekly I-Claim
( I-Claim
qw I-Claim
) I-Claim
to I-Claim
anemic I-Claim
cancer I-Claim
patients I-Claim
receiving I-Claim
chemotherapy I-Claim
increases I-Claim
hemoglobin I-Claim
levels I-Claim
, I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
, I-Claim
and I-Claim
reduces I-Claim
transfusions I-Claim
. I-Claim

Excess B-Premise
limb I-Premise
size I-Premise
( I-Premise
circumference I-Premise
and I-Premise
water I-Premise
displacement I-Premise
) I-Premise
and I-Premise
excess I-Premise
water I-Premise
composition I-Premise
were I-Premise
reduced I-Premise
significantly I-Premise
in I-Premise
the I-Premise
bandage I-Premise
group I-Premise
";" I-Premise
excess B-Premise
circumference I-Premise
and I-Premise
excess I-Premise
water I-Premise
composition I-Premise
were I-Premise
reduced I-Premise
significantly I-Premise
in I-Premise
the I-Premise
tape I-Premise
group I-Premise
. I-Premise

Demographics O
and O
disease O
state O
were O
similar O
between O
groups O
. O

The B-Premise
2-year I-Premise
risk I-Premise
of I-Premise
progression I-Premise
for I-Premise
PSA I-Premise
nadir I-Premise
≤ I-Premise
0.2 I-Premise
ng/ml I-Premise
, I-Premise
and I-Premise
> I-Premise
0.2 I-Premise
to I-Premise
4 I-Premise
ng/ml I-Premise
in I-Premise
CAD I-Premise
was I-Premise
31 I-Premise
% I-Premise
and I-Premise
70 I-Premise
% I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

In B-Premise
the I-Premise
whole I-Premise
population I-Premise
of I-Premise
patients I-Premise
survival I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
patients I-Premise
with I-Premise
a I-Premise
PS I-Premise
of I-Premise
0-1 I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Repeated O
measurement O
analysis O
was O
performed O
for O
between-group O
analysis O
. O

We O
analysed O
data O
with O
prespecified O
criteria O
for O
clinically O
meaningful O
pain O
progression O
and O
deterioration O
in O
HRQoL O
. O

Evidence O
that O
community O
cancer O
services O
improve O
care O
quality O
and/or O
generate O
cost O
savings O
is O
currently O
limited O
. O

Similar B-Premise
results I-Premise
were I-Premise
observed I-Premise
using I-Premise
the I-Premise
LENT-SOMA I-Premise
scale I-Premise
. I-Premise

The O
findings O
were O
not O
explained O
by O
differences O
in O
adherence O
. O

A B-Premise
small I-Premise
decline I-Premise
in I-Premise
visual I-Premise
analogue I-Premise
scale I-Premise
scores I-Premise
was I-Premise
observed I-Premise
( I-Premise
70.7 I-Premise
vs. I-Premise
68.2 I-Premise
, I-Premise
P=0.026 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
cost I-Premise
per I-Premise
QALY I-Premise
gained I-Premise
with I-Premise
combination I-Premise
therapy I-Premise
was I-Premise
13,558 I-Premise
dollars I-Premise
( I-Premise
standard I-Premise
deviation I-Premise
, I-Premise
6742 I-Premise
dollars I-Premise
) I-Premise
. I-Premise

A O
randomised O
controlled O
trial O
( O
RCT O
) O
demonstrated O
that O
cognitive O
behaviour O
therapy O
( O
CBT O
) O
for O
fatigue O
during O
curative O
cancer O
treatment O
was O
effective O
shortly O
after O
cancer O
treatment O
. O

Patients B-Claim
who I-Claim
underwent I-Claim
gastric I-Claim
tube I-Claim
reconstruction I-Claim
develop I-Claim
less I-Claim
postoperative I-Claim
digestive I-Claim
tract I-Claim
complications I-Claim
, I-Claim
and I-Claim
have I-Claim
a I-Claim
quicker I-Claim
recovery I-Claim
and I-Claim
a I-Claim
better I-Claim
QoL I-Claim
during I-Claim
the I-Claim
follow-up I-Claim
period I-Claim
. I-Claim

Adding B-Claim
docetaxel I-Claim
to I-Claim
CF I-Claim
significantly I-Claim
improved I-Claim
TTP I-Claim
, I-Claim
survival I-Claim
, I-Claim
and I-Claim
response I-Claim
rate I-Claim
in I-Claim
gastric I-Claim
cancer I-Claim
patients I-Claim
, I-Claim
but I-Claim
resulted I-Claim
in I-Claim
some I-Claim
increase I-Claim
in I-Claim
toxicity I-Claim
. I-Claim

Fifty O
eight O
of O
the O
60 O
randomized O
patients O
who O
filled O
the O
QOL O
questionnaire O
at O
least O
at O
one O
time O
point O
were O
included O
in O
the O
analysis O
. O

This O
study O
examined O
( O
i O
) O
whether O
patient-caregiver O
dyads O
( O
i.e. O
, O
pairs O
) O
randomly O
assigned O
to O
a O
brief O
or O
extensive O
dyadic O
intervention O
( O
the O
FOCUS O
Program O
) O
had O
better O
outcomes O
than O
dyads O
randomly O
assigned O
to O
usual O
care O
and O
( O
ii O
) O
whether O
patients O
' O
risk O
for O
distress O
and O
other O
factors O
moderated O
the O
effect O
of O
the O
brief O
or O
extensive O
program O
on O
outcomes O
. O

A B-Premise
trend I-Premise
towards I-Premise
increased I-Premise
myelosuppression I-Premise
and I-Premise
infectious I-Premise
complications I-Premise
with I-Premise
TCF I-Premise
versus I-Premise
TC I-Premise
or I-Premise
ECF I-Premise
was I-Premise
observed I-Premise
. I-Premise

When O
60 O
cases O
of O
non-small O
cell O
lung O
cancer O
patients O
in O
stage O
IIIb O
and O
IV O
reached O
stable O
disease O
after O
treatment O
with O
4 O
cycles O
of O
a O
two-drug O
regimen O
with O
platinum O
, O
they O
were O
randomly O
divided O
into O
two O
groups O
. O

On B-Premise
average I-Premise
, I-Premise
there I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
volumes I-Premise
of I-Premise
tris-acryl I-Premise
microspheres I-Premise
used I-Premise
( I-Premise
9.0 I-Premise
mL I-Premise
vs I-Premise
3.0 I-Premise
mL I-Premise
";" I-Premise
P I-Premise
=.0001 I-Premise
) I-Premise
, I-Premise
whereas O
microcatheter B-Premise
occlusion I-Premise
was I-Premise
more I-Premise
common I-Premise
with I-Premise
PVA I-Premise
( I-Premise
28 I-Premise
% I-Premise
vs I-Premise
4 I-Premise
% I-Premise
, I-Premise
P I-Premise
=.001 I-Premise
) I-Premise
. I-Premise

Exclusion O
criteria O
included O
age O
greater O
than O
70 O
years O
, O
World O
Health O
Organization O
( O
WHO O
) O
performance O
status O
greater O
than O
2 O
, O
prior O
chemotherapy O
for O
metastatic O
disease O
, O
and O
presence O
of O
liver O
metastases O
in O
patients O
younger O
than O
50 O
. O

After O
four O
cycles O
of O
platinum-based O
induction O
therapy O
, O
663 O
patients O
with O
stage O
IIIB O
or O
stage O
IV O
NSCLC O
and O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
of O
0 O
or O
1 O
were O
randomly O
assigned O
( O
in O
a O
2:1 O
ratio O
) O
from O
March O
15 O
, O
2005 O
, O
to O
July O
20 O
, O
2007 O
, O
using O
the O
Pocock O
and O
Simon O
minimisation O
method O
to O
receive O
pemetrexed O
( O
500 O
mg/m O
( O
2 O
) O
every O
21 O
days O
";" O
n=441 O
) O
or O
placebo O
( O
n=222 O
) O
plus O
best O
supportive O
care O
until O
disease O
progression O
. O

Therapy O
for O
polycystic O
liver O
is O
invasive O
, O
expensive O
, O
and O
has O
disappointing O
long-term O
results O
. O

The O
primary O
endpoint O
was O
change O
in O
hemoglobin O
from O
baseline O
to O
Week O
13 O
. O

A O
phase O
III O
randomized O
study O
was O
performed O
to O
establish O
the O
most O
effective O
and O
safest O
treatment O
to O
improve O
the O
key O
symptoms O
in O
advanced O
gynecological O
cancer O
patients O
, O
i.e. O
, O
lean O
body O
mass O
( O
LBM O
) O
, O
resting O
energy O
expenditure O
( O
REE O
) O
, O
fatigue O
, O
and O
QoL O
. O

One-year B-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
0 I-Premise
% I-Premise
with I-Premise
FU I-Premise
versus I-Premise
10 I-Premise
% I-Premise
with I-Premise
FUP I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
= I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

The O
primary O
endpoint O
was O
the O
proportion O
of O
patients O
without O
progression O
at O
2 O
years O
. O

Results B-Premise
showed I-Premise
overall I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
psychosocial I-Premise
stress I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
in I-Premise
both I-Premise
the I-Premise
MBAT I-Premise
and I-Premise
educational I-Premise
support I-Premise
groups I-Premise
immediately I-Premise
post-intervention I-Premise
";" I-Premise
however B-Premise
, I-Premise
participants I-Premise
with I-Premise
high I-Premise
stress I-Premise
levels I-Premise
at I-Premise
baseline I-Premise
had I-Premise
significantly I-Premise
improved I-Premise
overall I-Premise
outcomes I-Premise
only I-Premise
in I-Premise
the I-Premise
MBAT I-Premise
group I-Premise
, I-Premise
both I-Premise
immediately I-Premise
post-intervention I-Premise
and I-Premise
at I-Premise
6 I-Premise
months I-Premise
. I-Premise

Patients O
with O
stage O
IIIB O
or O
IV O
NSCLC O
and O
WHO O
performance O
status O
( O
PS O
) O
0-2 O
were O
randomised O
to O
receive O
three O
( O
C3 O
) O
or O
six O
( O
C6 O
) O
courses O
of O
carboplatin O
( O
area O
under O
the O
curve O
( O
AUC O
) O
4 O
, O
Chatelut O
's O
formula O
, O
equivalent O
to O
Calvert O
's O
AUC O
5 O
) O
on O
day O
1 O
and O
vinorelbine O
25 O
mg O
m O
( O
-2 O
) O
on O
days O
1 O
and O
8 O
of O
a O
3-week O
cycle O
. O

Standard O
National O
Cancer O
Institute O
of O
Canada O
Clinical O
Trials O
Group O
( O
NCIC O
CTG O
) O
approaches O
were O
applied O
as O
the O
primary O
method O
to O
analyze O
the O
QOL O
data O
from O
this O
trial O
. O

Therapy B-Claim
of I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
or I-Claim
gastroesophageal I-Claim
junction I-Claim
cancer I-Claim
should I-Claim
provide I-Claim
symptom I-Claim
relief I-Claim
and I-Claim
improve I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
because I-Claim
most I-Claim
patients I-Claim
are I-Claim
symptomatic I-Claim
at I-Claim
baseline I-Claim
. I-Claim

Among B-Premise
the I-Premise
patients I-Premise
receiving I-Premise
treatment I-Premise
3 I-Premise
times I-Premise
weekly I-Premise
, I-Premise
16 I-Premise
of I-Premise
49 I-Premise
patients I-Premise
( I-Premise
32.7 I-Premise
% I-Premise
) I-Premise
achieved I-Premise
a I-Premise
clinical I-Premise
response I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
third I-Premise
treatment I-Premise
cycle I-Premise
( I-Premise
no I-Premise
CRs I-Premise
, I-Premise
1 I-Premise
PR I-Premise
, I-Premise
and I-Premise
15 I-Premise
SDs I-Premise
) I-Premise
. I-Premise

No B-Premise
differences I-Premise
in I-Premise
pain I-Premise
and I-Premise
symptom I-Premise
intensity I-Premise
were I-Premise
observed I-Premise
. I-Premise

The O
intervention O
targeted O
couples O
' O
communication O
, O
hope O
, O
coping O
, O
uncertainty O
, O
and O
symptom O
management O
. O

However B-Claim
, I-Claim
patient I-Claim
self-assessments I-Claim
suggested I-Claim
a I-Claim
possible I-Claim
advantage I-Claim
to I-Claim
AM I-Claim
that I-Claim
is I-Claim
being I-Claim
explored I-Claim
with I-Claim
modified I-Claim
dosing I-Claim
route I-Claim
strategies I-Claim
. I-Claim

The O
functional O
assessment O
of O
chronic O
illness O
therapy-fatigue O
( O
FACIT-F O
) O
was O
administered O
from O
the O
early O
postoperative O
period O
to O
9 O
months O
. O

Climacteric B-Premise
symptoms I-Premise
remained I-Premise
significantly I-Premise
below I-Premise
baseline I-Premise
values I-Premise
after I-Premise
dosage I-Premise
reduction I-Premise
";" I-Premise
some B-Premise
symptoms I-Premise
recurred I-Premise
after I-Premise
discontinuation I-Premise
of I-Premise
ccHRT I-Premise
. I-Premise

This B-Premise
negative I-Premise
impact I-Premise
tended I-Premise
to I-Premise
last I-Premise
longer I-Premise
in I-Premise
the I-Premise
HDC I-Premise
group I-Premise
, I-Premise
as I-Premise
for I-Premise
most I-Premise
of I-Premise
the I-Premise
QLQ-C30 I-Premise
scales I-Premise
, I-Premise
the I-Premise
QOL I-Premise
scores I-Premise
of I-Premise
HDC I-Premise
patients I-Premise
tend I-Premise
to I-Premise
improve I-Premise
at I-Premise
a I-Premise
slower I-Premise
rate I-Premise
than I-Premise
that I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
standard I-Premise
chemotherapy I-Premise
. I-Premise

In O
contrast O
, O
no B-Premise
significant I-Premise
improvement I-Premise
was I-Premise
observed I-Premise
in I-Premise
Group I-Premise
2 I-Premise
after I-Premise
the I-Premise
exercise I-Premise
program I-Premise
in I-Premise
any I-Premise
of I-Premise
parameters I-Premise
in I-Premise
comparison I-Premise
to I-Premise
the I-Premise
pre-exercise I-Premise
period I-Premise
( I-Premise
P I-Premise
> I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

This O
trial O
was O
conducted O
to O
determine O
whether O
high-dose O
fluorouracil O
( O
FU O
) O
given O
as O
a O
weekly O
24-hour O
infusion O
is O
more O
active O
than O
bolus O
FU O
+ O
leucovorin O
( O
LV O
) O
, O
and O
whether O
high-dose O
infusional O
FU O
can O
be O
modulated O
by O
LV O
. O

We O
aimed O
to O
identify O
the O
effects O
of O
an O
established O
antidepressant O
on O
these O
symptoms O
and O
survival O
in O
patients O
with O
advanced O
cancer O
who O
did O
not O
have O
major O
depression O
as O
assessed O
by O
clinicians O
. O

HDCT B-Claim
was I-Claim
associated I-Claim
with I-Claim
more I-Claim
acute I-Claim
adverse I-Claim
effects I-Claim
. I-Claim

Concerning B-Premise
the I-Premise
eating I-Premise
function I-Premise
, I-Premise
both I-Premise
groups I-Premise
had I-Premise
improvements I-Premise
in I-Premise
dysphagia I-Premise
but I-Premise
there I-Premise
were I-Premise
frequent I-Premise
need I-Premise
for I-Premise
endoscopic I-Premise
intervention I-Premise
. I-Premise

They O
provide O
key O
information O
for O
discussing O
the O
trial O
with O
patients O
and O
strengthen O
the O
argument O
for O
continuing O
QUARTZ O
to O
definitively O
answer O
this O
important O
clinical O
question O
. O

Toxicity O
was O
evaluated O
by O
the O
Common O
Toxicity O
Criteria O
( O
CTC O
) O
. O

All O
patients O
received O
four O
cycles O
of O
cisplatin O
and O
etoposide O
every O
3 O
weeks O
( O
step O
1 O
";" O
PE O
) O
. O

No O
patient O
received O
hormonal O
therapy O
. O

Seventy-five O
patients O
with O
good O
performance O
status O
entered O
the O
trial O
. O

Response B-Premise
rates I-Premise
were I-Premise
26.0 I-Premise
% I-Premise
( I-Premise
FU/LV/bevacizumab I-Premise
) I-Premise
and I-Premise
15.2 I-Premise
% I-Premise
( I-Premise
FU/LV/placebo I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.055 I-Premise
) I-Premise
";" I-Premise
duration B-Premise
of I-Premise
response I-Premise
was I-Premise
9.2 I-Premise
months I-Premise
( I-Premise
FU/LV/bevacizumab I-Premise
) I-Premise
and I-Premise
6.8 I-Premise
months I-Premise
( I-Premise
FU/LV/placebo I-Premise
) I-Premise
";" I-Premise
hazard B-Premise
ratio I-Premise
was I-Premise
0.42 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.088 I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
evaluated I-Premise
6 I-Premise
months I-Premise
after I-Premise
random I-Premise
assignment I-Premise
using I-Premise
the I-Premise
30-item I-Premise
Quality I-Premise
of I-Premise
Life I-Premise
Questionnaire I-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
of I-Premise
randomly I-Premise
assigned I-Premise
patients I-Premise
. I-Premise

Secondary O
end O
points O
evaluated O
were O
as O
follows O
: O
clinical O
efficacy O
";" O
quality O
of O
life O
";" O
safety O
";" O
and O
survival O
. O

The O
major O
outcome O
measure O
was O
a O
bivariate O
construct O
that O
represented O
hot O
flash O
frequency O
and O
hot O
flash O
score O
, O
which O
was O
analyzed O
by O
a O
classic O
sums O
and O
differences O
comparison O
. O

The O
primary O
end O
point O
was O
progression-free O
survival O
( O
PFS O
) O
. O

Attrition O
was O
assessed O
in O
terms O
of O
the O
percent O
of O
participants O
who O
failed O
to O
complete O
these O
assessments O
, O
and O
demographic O
, O
psychiatric O
, O
medical O
, O
and O
study-related O
correlates O
of O
attrition O
were O
examined O
for O
the O
participants O
in O
each O
of O
these O
categories O
. O

More B-Premise
major I-Premise
complications I-Premise
( I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
occurred I-Premise
and I-Premise
more I-Premise
reinterventions I-Premise
were I-Premise
performed I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
after I-Premise
stent I-Premise
placement I-Premise
than I-Premise
after I-Premise
GJJ I-Premise
. I-Premise

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
effectiveness O
of O
a O
pain O
management O
program O
( O
PMP O
) O
on O
pain O
intensity O
, O
use O
of O
PRN O
drugs O
and O
nonpharmacological O
strategies O
as O
pain O
relief O
, O
and O
barriers O
to O
managing O
pain O
in O
cancer O
patients O
. O

The B-Premise
median I-Premise
survival I-Premise
rates I-Premise
for I-Premise
both I-Premise
arms I-Premise
were I-Premise
comparable I-Premise
( I-Premise
AM I-Premise
, I-Premise
17.3 I-Premise
v I-Premise
no I-Premise
AM I-Premise
, I-Premise
17.9 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.87 I-Premise
) I-Premise
. I-Premise

This O
was O
a O
multicenter O
prospective O
trial O
. O

What O
's O
known O
on O
the O
subject O
? O

Radiotherapy O
was O
delivered O
on O
weekdays O
2 O
Gy O
daily O
up O
to O
56 O
Gy O
. O

PSA O
decline O
showed O
no O
predictive O
value O
. O

Analysis B-Premise
of I-Premise
the I-Premise
trial I-Premise
group I-Premise
demonstrated I-Premise
a I-Premise
significant I-Premise
increase I-Premise
from I-Premise
baseline I-Premise
in I-Premise
body I-Premise
weight I-Premise
( I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
appetite I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
grip I-Premise
strength I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
fatigue I-Premise
, I-Premise
Glasgow I-Premise
Prognostic I-Premise
Score I-Premise
( I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
Eastern I-Premise
Cooperative I-Premise
Oncology I-Premise
Group I-Premise
performance I-Premise
status I-Premise
( I-Premise
p I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
, I-Premise
IL-6 I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
tumor I-Premise
necrosis I-Premise
factor-α I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

Patients O
allocated O
to O
the O
control O
group O
received O
standard O
follow-up O
only O
. O

Lymphoma O
patients O
commonly O
experience O
declines O
in O
physical O
functioning O
and O
quality O
of O
life O
( O
QoL O
) O
that O
may O
be O
reversed O
with O
exercise O
training O
. O

After O
interim O
analysis O
of O
48 O
patients O
, O
the O
study O
was O
closed O
for O
futility O
. O

A O
total O
of O
60 O
patients O
were O
enrolled O
: O
41 O
patients O
diagnosed O
with O
resectable O
and O
19 O
patients O
diagnosed O
with O
unresectable O
pancreatic O
cancer O
. O

The B-Premise
corresponding I-Premise
mean I-Premise
amounts I-Premise
of I-Premise
residual I-Premise
contrast-enhancing I-Premise
tumor I-Premise
tissue I-Premise
were I-Premise
29.2 I-Premise
and I-Premise
24.4 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

In O
both O
arms O
, O
radiotherapy O
was O
delivered O
as O
60 O
Gy/30 O
fractions O
to O
the O
tumor O
site O
with O
a O
2 O
to O
3 O
cm O
margin O
. O

One O
hundred O
thirty-seven O
eligible O
patients O
were O
randomized O
to O
treatment O
with O
either O
antimicrobial O
lozenge O
( O
69 O
patients O
) O
or O
placebo O
lozenge O
( O
68 O
patients O
) O
. O

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
failure-free I-Premise
survival I-Premise
, I-Premise
time I-Premise
to I-Premise
locoregional I-Premise
failure I-Premise
, I-Premise
or I-Premise
quality I-Premise
of I-Premise
life I-Premise
as I-Premise
measured I-Premise
by I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Head I-Premise
and I-Premise
Neck I-Premise
. I-Premise

At O
29 O
centers O
in O
the O
United O
Kingdom O
, O
we O
conducted O
a O
randomized O
noninferiority O
trial O
comparing O
low-dose O
and O
high-dose O
radioiodine O
, O
each O
in O
combination O
with O
either O
thyrotropin O
alfa O
or O
thyroid O
hormone O
withdrawal O
before O
ablation O
. O

The B-Claim
use I-Claim
of I-Claim
recombinant I-Claim
human I-Claim
thyrotropin I-Claim
and I-Claim
low-dose I-Claim
( I-Claim
1.1 I-Claim
GBq I-Claim
) I-Claim
postoperative I-Claim
radioiodine I-Claim
ablation I-Claim
may I-Claim
be I-Claim
sufficient I-Claim
for I-Claim
the I-Claim
management I-Claim
of I-Claim
low-risk I-Claim
thyroid I-Claim
cancer I-Claim
. I-Claim

No O
differences O
between O
groups O
were O
observed O
, O
with O
the O
exception O
of O
PCS O
scores O
at O
6-week O
follow-up O
: O
Patients O
in O
the O
UAE O
group O
had O
significantly O
better O
scores O
than O
did O
patients O
in O
the O
hysterectomy O
group O
( O
P O
< O
.001 O
) O
. O

Carboplatin/vinorelbine B-Claim
is I-Claim
well I-Claim
tolerated I-Claim
by I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
extensive-stage I-Claim
NSCLC I-Claim
. I-Claim

Fatigue O
is O
a O
frequent O
problem O
after O
surgical O
treatment O
of O
solid O
tumours O
. O

The O
laser O
group O
received O
LLLT O
( O
Technomed O
Electronics O
Advanced O
Laser O
Therapy O
1000 O
, O
He-Ne O
, O
λ O
= O
632.8 O
nm O
, O
power O
density O
= O
24 O
mW/cm O
( O
2 O
) O
, O
dosage O
= O
3.0 O
J O
at O
each O
point O
, O
total O
dose/session O
= O
36-40 O
J O
, O
spot O
size O
1 O
cm O
( O
2 O
) O
, O
irradiation O
time/point O
125 O
s O
) O
before O
each O
radiation O
session O
, O
while O
the O
placebo O
group O
did O
not O
receive O
laser O
therapy O
. O

Mean B-Premise
depression I-Premise
scores I-Premise
fell I-Premise
from I-Premise
6.7 I-Premise
to I-Premise
3.6 I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
compared I-Premise
with I-Premise
6.1 I-Premise
to I-Premise
5.4 I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1,83 I-Premise
) I-Premise
) I-Premise
= I-Premise
14.7 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
] I-Premise
. I-Premise

The B-Claim
combination I-Claim
of I-Claim
self-directed I-Claim
movement I-Claim
and I-Claim
mindfulness I-Claim
, I-Claim
as I-Claim
tested I-Claim
here I-Claim
, I-Claim
may I-Claim
be I-Claim
a I-Claim
valuable I-Claim
tool I-Claim
for I-Claim
promoting I-Claim
health I-Claim
and I-Claim
well-being I-Claim
in I-Claim
older I-Claim
long-term I-Claim
survivors I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

An O
interim O
analysis O
showed O
futility O
, O
and O
the O
results O
are O
presented O
with O
an O
adjusted O
one-sided O
alpha O
level O
of O
0.0429 O
. O

For B-Premise
willingness-to-pay I-Premise
between I-Premise
$ I-Premise
5000 I-Premise
and I-Premise
$ I-Premise
40 I-Premise
0 I-Premise
per I-Premise
quality-adjusted I-Premise
life I-Premise
year I-Premise
, I-Premise
the I-Premise
single-fraction I-Premise
schedule I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
more I-Premise
cost-effective I-Premise
than I-Premise
the I-Premise
multiple-fraction I-Premise
schedule I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
=.05 I-Premise
) I-Premise
. I-Premise

Patients O
were O
randomly O
assigned O
to O
receive O
: O
docetaxel O
75 O
mg/m2 O
plus O
cisplatin O
75 O
mg/m2 O
, O
every O
3 O
weeks O
( O
DC O
) O
";" O
docetaxel O
75 O
mg/m2 O
and O
carboplatin O
6 O
mg/ml O
min O
, O
every O
3 O
weeks O
( O
DCb O
) O
";" O
or O
vinorelbine O
25 O
mg/m2/week O
plus O
cisplatin O
100 O
mg/m2 O
, O
every O
4 O
weeks O
( O
VC O
) O
. O

This O
study O
was O
initiated O
to O
compare O
up-front O
tandem O
HDCT O
and O
standard O
combination O
therapy O
in O
patients O
with O
metastatic O
breast O
cancer O
. O

However B-Premise
, I-Premise
DPPE I-Premise
is I-Premise
associated I-Premise
with I-Premise
unusual I-Premise
toxicity I-Premise
in I-Premise
the I-Premise
form I-Premise
of I-Premise
hallucinations I-Premise
, I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
which I-Premise
were I-Premise
anticipated I-Premise
to I-Premise
impact I-Premise
on I-Premise
short-term I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
QOL I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
16.9 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
10.5 I-Premise
to I-Premise
21.2 I-Premise
months I-Premise
) I-Premise
in I-Premise
the I-Premise
TEE I-Premise
arm I-Premise
and I-Premise
23.4 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
12.9 I-Premise
to I-Premise
30.6 I-Premise
months I-Premise
) I-Premise
for I-Premise
patients I-Premise
treated I-Premise
with I-Premise
KA/VE I-Premise
. I-Premise

They O
were O
stratified O
by O
sex O
, O
age O
, O
institute O
, O
histology O
, O
and O
degree O
of O
lymph O
node O
dissection O
. O

Pairwise B-Premise
comparisons I-Premise
revealed I-Premise
significant I-Premise
differences I-Premise
between I-Premise
groups I-Premise
at I-Premise
90 I-Premise
days I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
but B-Premise
not I-Premise
at I-Premise
1 I-Premise
year I-Premise
( I-Premise
P I-Premise
= I-Premise
.052 I-Premise
) I-Premise
. I-Premise

cancer O
survivors O
with O
different O
diagnoses O
, O
and O
cancer-related O
physical O
and O
psychosocial O
problems O
. O

There B-Premise
was I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
seen I-Premise
between I-Premise
groups I-Premise
for I-Premise
either I-Premise
activity I-Premise
( I-Premise
adjusted I-Premise
difference I-Premise
=-0.4 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
CI I-Premise
-1.0 I-Premise
to I-Premise
0.2 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.17 I-Premise
) I-Premise
or I-Premise
profile I-Premise
scores I-Premise
( I-Premise
adjusted I-Premise
difference I-Premise
= I-Premise
-0.4 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-0.9 I-Premise
to I-Premise
0.1 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.13 I-Premise
) I-Premise
using I-Premise
this I-Premise
trial I-Premise
design I-Premise
, I-Premise
although B-Claim
post I-Claim
hoc I-Claim
power I-Claim
calculations I-Claim
suggests I-Claim
that I-Claim
65-175 I-Claim
would I-Claim
be I-Claim
needed I-Claim
per I-Claim
group I-Claim
to I-Claim
detect I-Claim
differences I-Claim
of I-Claim
this I-Claim
magnitude I-Claim
with I-Claim
sufficient I-Claim
precision I-Claim
. I-Claim

To O
evaluate O
the O
impact O
of O
letrozole O
compared O
with O
placebo O
after O
adjuvant O
tamoxifen O
on O
quality O
of O
life O
( O
QOL O
) O
in O
the O
MA.17 O
trial O
. O

The B-Premise
nutritional I-Premise
condition I-Premise
in I-Premise
the I-Premise
INT I-Premise
group I-Premise
was I-Premise
nearly I-Premise
the I-Premise
same I-Premise
as I-Premise
that I-Premise
in I-Premise
the I-Premise
RY I-Premise
group I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
time I-Premise
of I-Premise
12 I-Premise
months I-Premise
and I-Premise
382 I-Premise
deaths I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
clear I-Premise
survival I-Premise
benefit I-Premise
when I-Premise
comparing I-Premise
PCV I-Premise
with I-Premise
TMZ I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.91 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.74 I-Premise
to I-Premise
1.11 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.350 I-Premise
) I-Premise
. I-Premise

Epoetin B-Claim
alfa I-Claim
administered I-Claim
at I-Claim
40,000 I-Claim
U I-Claim
qw I-Claim
is I-Claim
effective I-Claim
in I-Claim
improving I-Claim
QOL I-Claim
, I-Claim
maintaining I-Claim
hemoglobin I-Claim
level I-Claim
, I-Claim
and I-Claim
reducing I-Claim
transfusion I-Claim
requirements I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

The O
potential O
predictive O
value O
of O
plasma O
VEGF-A O
is O
consistent O
with O
findings O
in O
HER2-negative O
LR/MBC O
, O
warranting O
prospective O
evaluation O
. O

The O
primary O
outcome O
was O
patient-perceived O
benefits O
, O
using O
the O
emotional O
function O
domain O
of O
the O
EORTC O
quality O
of O
life O
( O
QOL O
) O
QLQC30 O
questionnaire O
evaluated O
after O
12 O
weeks O
. O

A B-Claim
more I-Claim
effective I-Claim
, I-Claim
better I-Claim
tolerated I-Claim
version I-Claim
of I-Claim
this I-Claim
FUP I-Claim
combination I-Claim
is I-Claim
needed I-Claim
. I-Claim

Both B-Premise
epoetin I-Premise
beta I-Premise
regiments I-Premise
were I-Premise
well I-Premise
tolerated I-Premise
and I-Premise
there I-Premise
were I-Premise
no I-Premise
dose-dependent I-Premise
adverse I-Premise
events I-Premise
. I-Premise

In O
a O
phase O
III O
clinical O
trial O
organized O
by O
the O
French O
Federation O
of O
Cancer O
Institutes O
, O
patients O
were O
randomly O
assigned O
to O
receive O
either O
EP O
( O
n O
= O
109 O
";" O
etoposide O
at O
a O
dose O
of O
100 O
mg/m O
( O
2 O
) O
on O
days O
1-3 O
plus O
cisplatin O
at O
100 O
mg/m O
( O
2 O
) O
on O
day O
2 O
) O
or O
PCDE O
( O
n O
= O
117 O
";" O
etoposide O
and O
cisplatin O
given O
as O
in O
EP O
plus O
cyclophosphamide O
at O
400 O
mg/m O
( O
2 O
) O
on O
days O
1-3 O
and O
4'-epidoxorubicin O
at O
40 O
mg/m O
( O
2 O
) O
on O
day O
1 O
) O
every O
4 O
weeks O
. O

More O
patients O
in O
the O
11 O
day O
group O
had O
respiratory O
symptoms O
at O
baseline O
. O

Pancreatic O
cancer O
was O
the O
most O
common O
cause O
of O
GOO O
. O

Men O
with O
metastatic O
prostate O
cancer O
( O
n O
= O
161 O
) O
were O
randomized O
to O
receive O
either O
daily O
prednisone O
alone O
or O
mitoxantrone O
( O
every O
3 O
weeks O
) O
plus O
prednisone O
. O

The O
effectiveness O
of O
a O
Pain O
Education O
Program O
in O
cancer O
patients O
with O
chronic O
pain O
offered O
by O
nurses O
was O
investigated O
in O
a O
randomized O
controlled O
clinical O
trial O
. O

The B-Claim
postoperative I-Claim
clinical I-Claim
superiority I-Claim
of I-Claim
the I-Claim
interposition I-Claim
of I-Claim
jejunum I-Claim
reconstruction I-Claim
( I-Claim
INT I-Claim
) I-Claim
to I-Claim
Roux-en-Y I-Claim
reconstruction I-Claim
( I-Claim
RY I-Claim
) I-Claim
after I-Claim
total I-Claim
gastrectomy I-Claim
has I-Claim
not I-Claim
been I-Claim
clarified I-Claim
. I-Claim

Small B-Claim
sample I-Claim
size I-Claim
precludes I-Claim
definitive I-Claim
answers I-Claim
, I-Claim
but B-Claim
results I-Claim
from I-Claim
this I-Claim
preliminary I-Claim
trial I-Claim
suggest I-Claim
that I-Claim
homeopathy I-Claim
may I-Claim
be I-Claim
of I-Claim
value I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
menopausal I-Claim
symptoms I-Claim
and I-Claim
improving I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
especially I-Claim
in I-Claim
those I-Claim
women I-Claim
not I-Claim
on I-Claim
tamoxifen I-Claim
. I-Claim

After O
initial O
lack O
of O
accrual O
, O
a O
multidisciplinary O
educational O
session O
was O
introduced O
for O
eligible O
patients O
. O

As B-Premise
hypothesized I-Premise
, I-Premise
Bcl-2 I-Premise
levels I-Premise
decreased I-Premise
with I-Premise
CRA/IFN I-Premise
therapy I-Premise
only I-Premise
in I-Premise
Arm I-Premise
B I-Premise
( I-Premise
p I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
. I-Premise

Improvement B-Premise
was I-Premise
also I-Premise
found I-Premise
for I-Premise
5-point I-Premise
decrease I-Premise
in I-Premise
PHQ-9 I-Premise
score I-Premise
among I-Premise
72.2 I-Premise
% I-Premise
of I-Premise
intervention I-Premise
patients I-Premise
compared I-Premise
with I-Premise
59.7 I-Premise
% I-Premise
of I-Premise
EUC I-Premise
patients I-Premise
( I-Premise
OR I-Premise
= I-Premise
1.99 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.14 I-Premise
to I-Premise
3.50 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

PFS B-Premise
was I-Premise
significantly I-Premise
longer I-Premise
for I-Premise
fulvestrant I-Premise
500 I-Premise
mg I-Premise
( I-Premise
n I-Premise
= I-Premise
362 I-Premise
) I-Premise
than I-Premise
250 I-Premise
mg I-Premise
( I-Premise
n I-Premise
= I-Premise
374 I-Premise
) I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
= I-Premise
0.80 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.68 I-Premise
to I-Premise
0.94 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.006 I-Premise
) I-Premise
, I-Premise
corresponding I-Premise
to I-Premise
a I-Premise
20 I-Premise
% I-Premise
reduction I-Premise
in I-Premise
risk I-Premise
of I-Premise
progression I-Premise
. I-Premise

Kaposi O
's O
sarcoma O
is O
currently O
the O
most O
common O
tumor O
in O
Zimbabwe O
. O

To O
determine O
the O
long-term O
outcome O
and O
health-related O
quality O
of O
life O
( O
HRQL O
) O
of O
patients O
with O
endometrial O
carcinoma O
( O
EC O
) O
treated O
with O
or O
without O
pelvic O
radiotherapy O
in O
the O
Post O
Operative O
Radiation O
Therapy O
in O
Endometrial O
Carcinoma O
1 O
( O
PORTEC-1 O
) O
trial O
. O

Three O
patients O
were O
ineligible O
. O

In B-Premise
a I-Premise
multinational I-Premise
trial I-Premise
of I-Premise
anaemic I-Premise
patients I-Premise
with I-Premise
cancer I-Premise
receiving I-Premise
nonplatinum-containing I-Premise
chemotherapy I-Premise
, I-Premise
epoetin-alfa I-Premise
effectively I-Premise
increased I-Premise
haemoglobin I-Premise
levels I-Premise
, I-Premise
reduced I-Premise
red I-Premise
blood I-Premise
cell I-Premise
transfusion I-Premise
requirements I-Premise
, I-Premise
and I-Premise
improved I-Premise
QOL I-Premise
. I-Premise

Third-generation O
aromatase O
inhibitors O
, O
such O
as O
letrozole O
, O
provide O
a O
new O
option O
for O
extended O
adjuvant O
hormonal O
therapy O
after O
5 O
years O
of O
tamoxifen O
. O

Patients O
and O
investigators O
were O
masked O
to O
CA125 O
results O
, O
which O
were O
monitored O
by O
coordinating O
centres O
. O

Docetaxel-carboplatin B-Claim
appears I-Claim
to I-Claim
be I-Claim
similar I-Claim
to I-Claim
paclitaxel-carboplatin I-Claim
in I-Claim
terms I-Claim
of I-Claim
progression-free I-Claim
survival I-Claim
and I-Claim
response I-Claim
, I-Claim
although B-Claim
longer I-Claim
follow-up I-Claim
is I-Claim
required I-Claim
for I-Claim
a I-Claim
definitive I-Claim
statement I-Claim
on I-Claim
survival I-Claim
. I-Claim

For B-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
prostate I-Claim
cancer I-Claim
, I-Claim
treatment I-Claim
is I-Claim
primarily I-Claim
palliative I-Claim
, I-Claim
relying I-Claim
mainly I-Claim
on I-Claim
the I-Claim
suppression I-Claim
of I-Claim
systemic I-Claim
androgen I-Claim
hormone I-Claim
levels I-Claim
. I-Claim

This O
study O
focussed O
on O
the O
QoL O
in O
patients O
after O
oesophagectomy O
for O
cancer O
, O
comparing O
the O
method O
of O
reconstruction O
( O
narrow O
gastric O
tube O
vs O
whole O
stomach O
) O
. O

No B-Premise
discernible I-Premise
important I-Premise
effect I-Premise
on I-Premise
the I-Premise
patients I-Premise
' I-Premise
3-month I-Premise
postoperative I-Premise
course I-Premise
was I-Premise
identified I-Premise
. I-Premise

Patients B-Premise
with I-Premise
wild-type I-Premise
status I-Premise
who I-Premise
received I-Premise
cetuximab I-Premise
experienced I-Premise
improved I-Premise
GHS I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
, I-Premise
whereas I-Premise
patients I-Premise
who I-Premise
received I-Premise
BSC I-Premise
alone I-Premise
deteriorated I-Premise
( I-Premise
3.2 I-Premise
v I-Premise
-7.7 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

The O
day O
before O
the O
nutritional O
interventions O
, O
and O
again O
after O
four O
and O
eight O
weeks O
, O
body O
compartments O
were O
determined O
using O
bioelectrical O
impedance O
analysis O
, O
lymphocyte O
subpopulations O
were O
quantified O
using O
flow O
cytometry O
, O
and O
some O
aspects O
of O
the O
quality O
of O
life O
were O
rated O
using O
four O
linear O
analog O
self-assessment O
( O
LASA O
) O
scales O
. O

This B-Claim
study I-Claim
demonstrates I-Claim
comparable I-Claim
remnant I-Claim
ablation I-Claim
rates I-Claim
in I-Claim
patients I-Claim
prepared I-Claim
for I-Claim
131I I-Claim
remnant I-Claim
ablation I-Claim
with I-Claim
3.7 I-Claim
GBq I-Claim
by I-Claim
either I-Claim
administering I-Claim
rhTSH I-Claim
or I-Claim
withholding I-Claim
thyroid I-Claim
hormone I-Claim
. I-Claim

Stretching B-Claim
is I-Claim
an I-Claim
effective I-Claim
technique I-Claim
for I-Claim
increasing I-Claim
range I-Claim
of I-Claim
motion I-Claim
, I-Claim
hence O
the O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
a O
stretching O
program O
reduced O
acute O
musculoskeletal O
impairments O
in O
patients O
undergoing O
radiotherapy O
for O
breast O
cancer O
. O

At O
9 O
months O
, O
patients O
underwent O
an O
rhTSH O
stimulation O
test O
, O
diagnostic O
( O
131 O
) O
I O
whole O
body O
scan O
( O
dxWBS O
) O
and O
neck O
ultrasonography O
. O

Patients O
receiving O
DPPE O
were O
aggressively O
premedicated O
to O
ameliorate O
toxicity O
. O

In O
Lithuania O
, O
about O
400 O
cases O
of O
pancreatic O
cancer O
are O
diagnosed O
each O
year O
, O
and O
more O
than O
50 O
% O
of O
patients O
are O
diagnosed O
with O
stage O
IV O
disease O
. O

GE O
responses O
: O
1 O
complete O
response O
( O
CR O
, O
1.2 O
% O
) O
, O
6 O
partial O
response O
( O
PR O
, O
7.4 O
% O
) O
, O
and O
33 O
stable O
disease O
( O
SD O
, O
40.7 O
% O
) O
";" O
disease O
control O
rate O
( O
DCR=CR+PR+SD O
, O
49.4 O
% O
) O
. O

Cetuximab B-Premise
preserved I-Premise
GHS I-Premise
at I-Premise
16 I-Premise
weeks I-Premise
( I-Premise
-0.2 I-Premise
v I-Premise
-18.1 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

At B-Premise
1 I-Premise
and I-Premise
4 I-Premise
months I-Premise
, I-Premise
more I-Premise
patients I-Premise
in I-Premise
the I-Premise
4 I-Premise
day I-Premise
group I-Premise
experienced I-Premise
a I-Premise
clinically I-Premise
meaningful I-Premise
worsening I-Premise
in I-Premise
the I-Premise
dyspnea I-Premise
QOL I-Premise
domain I-Premise
compared I-Premise
to I-Premise
the I-Premise
11 I-Premise
day I-Premise
group I-Premise
( I-Premise
44.5 I-Premise
% I-Premise
vs I-Premise
15.4 I-Premise
% I-Premise
, I-Premise
p=0.02 I-Premise
";" I-Premise
38.5 I-Premise
% I-Premise
vs I-Premise
12.0 I-Premise
% I-Premise
, I-Premise
p=0.03 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The B-Premise
differences I-Premise
in I-Premise
tumor I-Premise
response I-Premise
( I-Premise
35.5 I-Premise
and I-Premise
46.5 I-Premise
% I-Premise
for I-Premise
GE I-Premise
and I-Premise
GP I-Premise
, I-Premise
respectively I-Premise
) I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
. I-Premise

The O
primary O
purpose O
of O
this O
study O
was O
to O
compare O
melatonin O
with O
placebo O
for O
appetite O
improvement O
in O
patients O
with O
cancer O
cachexia O
. O

Survival O
was O
the O
primary O
end O
point O
with O
a O
33 O
% O
improvement O
relative O
to O
PC O
considered O
important O
( O
85 O
% O
power O
, O
alpha O
= O
5 O
% O
) O
. O

The O
authors O
of O
this O
report O
conducted O
a O
prospective O
, O
randomized O
phase O
2 O
trial O
to O
evaluate O
the O
effects O
of O
exogenous O
ghrelin O
during O
cisplatin-based O
chemotherapy O
. O

The B-Premise
hazard I-Premise
ratios I-Premise
for I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
were I-Premise
1.36 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.97 I-Premise
to I-Premise
1.90 I-Premise
) I-Premise
for I-Premise
VC I-Premise
, I-Premise
1.39 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.99 I-Premise
to I-Premise
1.96 I-Premise
) I-Premise
for I-Premise
GC I-Premise
, I-Premise
and I-Premise
1.27 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.90 I-Premise
to I-Premise
1.78 I-Premise
) I-Premise
for I-Premise
TC I-Premise
. I-Premise

The O
-1 O
, O
-2 O
, O
and O
3-year O
QOL O
, O
3-year O
survival O
rate O
, O
and O
the O
survival O
life O
of O
dead O
children O
patients O
were O
observed O
. O

To O
compare O
the O
effectiveness O
and O
tolerability O
of O
gemcitabine O
plus O
cisplatin O
with O
single-agent O
gemcitabine O
as O
first-line O
chemotherapy O
for O
locally O
advanced O
or O
metastatic O
pancreatic O
cancer O
. O

Paired O
t O
tests O
were O
performed O
for O
within-group O
analysis O
. O

Trials B-Claim
with I-Claim
late I-Claim
intensification I-Claim
HDCT I-Claim
have I-Claim
failed I-Claim
to I-Claim
show I-Claim
an I-Claim
advantage I-Claim
in I-Claim
overall I-Claim
survival I-Claim
. I-Claim

A B-Premise
higher I-Premise
rate I-Premise
of I-Premise
persistent I-Premise
thyroid I-Premise
remnants I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
rhTSH I-Premise
arm I-Premise
, I-Premise
although B-Premise
in I-Premise
most I-Premise
cases I-Premise
uptake I-Premise
was I-Premise
< I-Premise
0.1 I-Premise
% I-Premise
and I-Premise
of I-Premise
no I-Premise
clinical I-Premise
significance I-Premise
. I-Premise

Quality O
of O
life O
was O
assessed O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
( O
EORTC-C30 O
) O
questionnaire O
. O

Abatacept B-Claim
demonstrated I-Claim
acceptable I-Claim
safety I-Claim
and I-Claim
tolerability I-Claim
and I-Claim
clinically I-Claim
meaningful I-Claim
efficacy I-Claim
over I-Claim
6 I-Claim
months I-Claim
in I-Claim
patients I-Claim
with I-Claim
inadequate I-Claim
response I-Claim
to I-Claim
anti-TNF I-Claim
therapy I-Claim
. I-Claim

This O
study O
sought O
to O
evaluate O
effectiveness O
of O
autologous O
dendritic O
cell O
vaccine O
( O
immunotherapy O
) O
for O
glioblastoma O
multiforme O
( O
GBM O
) O
. O

No B-Premise
differences I-Premise
in I-Premise
QOL I-Premise
between I-Premise
groups I-Premise
2 I-Premise
and I-Premise
3 I-Premise
were I-Premise
found I-Premise
. I-Premise

Gastrointestinal B-Premise
and I-Premise
GU I-Premise
toxicity I-Premise
persisted I-Premise
5 I-Premise
years I-Premise
after I-Premise
RT I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
two I-Premise
dose I-Premise
schedules I-Premise
other I-Premise
than I-Premise
in I-Premise
regard I-Premise
to I-Premise
urgency I-Premise
of I-Premise
defecation I-Premise
. I-Premise

Body O
plethysmography O
was O
used O
when O
available O
. O

Intent-to-treat B-Premise
analysis I-Premise
showed I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
three I-Premise
arms I-Premise
for I-Premise
appetite I-Premise
, I-Premise
QOL I-Premise
, I-Premise
or I-Premise
cannabinoid-related I-Premise
toxicity I-Premise
. I-Premise

Testosterone O
kinetics O
and O
QOL O
were O
also O
evaluated O
. O

Sexual B-Premise
functioning I-Premise
was I-Premise
worse I-Premise
for I-Premise
women I-Premise
who I-Premise
received I-Premise
chemotherapy I-Premise
than I-Premise
for I-Premise
those I-Premise
who I-Premise
did I-Premise
not I-Premise
, I-Premise
regardless I-Premise
of I-Premise
type I-Premise
of I-Premise
surgery I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
Gefitinib I-Premise
group I-Premise
, I-Premise
ORR I-Premise
was I-Premise
17.3 I-Premise
% I-Premise
( I-Premise
4/23 I-Premise
) I-Premise
, I-Premise
DCR I-Premise
was I-Premise
39.1 I-Premise
% I-Premise
( I-Premise
9/23 I-Premise
) I-Premise
, I-Premise
and I-Premise
mPFS I-Premise
was I-Premise
4.4 I-Premise
months I-Premise
. I-Premise

All O
statistical O
tests O
were O
two-sided O
. O

Four O
hundred O
seven O
patients O
were O
eligible O
for O
the O
study O
";" O
395 O
patients O
( O
97 O
% O
) O
participated O
in O
the O
health-related O
quality-of-life O
( O
HRQOL O
) O
study O
. O

Clinic B-Premise
discussions I-Premise
were I-Premise
associated I-Premise
with I-Premise
severity I-Premise
of I-Premise
patient-reported I-Premise
symptoms I-Premise
but I-Premise
not I-Premise
with I-Premise
patient-reported I-Premise
functional I-Premise
concerns I-Premise
. I-Premise

WHO O
performance O
status O
was O
0 O
in O
79 O
( O
42 O
% O
) O
patients O
, O
1 O
in O
77 O
( O
41 O
% O
) O
patients O
, O
and O
2 O
in O
32 O
( O
17 O
% O
) O
patients O
. O

Compared B-Premise
with I-Premise
1-year I-Premise
treatment I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
the I-Premise
2-and I-Premise
3-year I-Premise
psychological I-Premise
functions I-Premise
and I-Premise
the I-Premise
general I-Premise
symptoms I-Premise
scores I-Premise
decreased I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Future O
studies O
can O
provide O
further O
insight O
on O
how O
to O
tailor O
QOL O
interventions O
for O
these O
age O
groups O
. O

Thyroid O
ablation O
was O
assessed O
8 O
months O
after O
radioiodine O
administration O
by O
neck O
ultrasonography O
and O
measurement O
of O
recombinant O
human O
thyrotropin-stimulated O
thyroglobulin O
. O

In B-Premise
patients I-Premise
with I-Premise
low I-Premise
TS I-Premise
, I-Premise
no I-Premise
remarkable I-Premise
difference I-Premise
in I-Premise
overall I-Premise
response I-Premise
to I-Premise
FOLFIRI I-Premise
and I-Premise
FUFA I-Premise
was I-Premise
observed I-Premise
. I-Premise

Bevacizumab B-Claim
, I-Claim
a I-Claim
humanized I-Claim
monoclonal I-Claim
antibody I-Claim
against I-Claim
vascular I-Claim
endothelial I-Claim
growth I-Claim
factor I-Claim
( I-Claim
VEGF I-Claim
) I-Claim
, I-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
be I-Claim
efficient I-Claim
in I-Claim
suppressing I-Claim
the I-Claim
accumulation I-Claim
of I-Claim
pleural I-Claim
fluid I-Claim
. I-Claim

Seven O
days O
of O
diary O
and O
actigraphy O
data O
did O
not O
corroborate O
with O
monthly O
reflections O
( O
PSQI O
) O
. O

This B-Claim
procedure I-Claim
has I-Claim
been I-Claim
performed I-Claim
with I-Claim
the I-Claim
patient I-Claim
in I-Claim
the I-Claim
hypothyroid I-Claim
state I-Claim
to I-Claim
promote I-Claim
endogenous I-Claim
TSH I-Claim
stimulation I-Claim
and I-Claim
is I-Claim
often I-Claim
associated I-Claim
with I-Claim
hypothyroid I-Claim
symptoms I-Claim
and I-Claim
impaired I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

This O
study O
tested O
hyperbaric O
oxygen O
( O
HBO O
) O
as O
an O
adjunct O
to O
surgery O
and O
antibiotics O
in O
the O
treatment O
of O
bisphosphonate-related O
osteonecrosis O
of O
the O
jaw O
( O
ONJ O
) O
and O
evaluated O
its O
effects O
on O
gingival O
healing O
, O
pain O
, O
and O
quality O
of O
life O
. O

Patients O
were O
randomly O
assigned O
to O
receive O
either O
nutrition O
intervention O
( O
n=29 O
) O
( O
nutrition O
counseling O
following O
the O
American O
Dietetic O
Association O
[ O
ADA O
] O
medical O
nutrition O
therapy O
[ O
MNT O
] O
protocol O
for O
radiation O
oncology O
) O
or O
standard O
practice O
( O
n=31 O
) O
( O
general O
nutrition O
talk O
and O
booklet O
) O
. O

Assessments O
at O
baseline O
, O
one O
, O
three O
, O
and O
6 O
months O
included O
barriers O
, O
the O
Brief O
Pain O
Inventory O
, O
opioid O
use O
, O
and O
physician O
and O
nurse O
ratings O
of O
their O
patients O
' O
pain O
. O

The B-Claim
generalizability I-Claim
of I-Claim
palliative I-Claim
care I-Claim
intervention I-Claim
research I-Claim
is I-Claim
often I-Claim
limited I-Claim
by I-Claim
high I-Claim
rates I-Claim
of I-Claim
study I-Claim
attrition I-Claim
. I-Claim

Diarrhea B-Premise
was I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
. I-Premise

With O
the O
exception O
of O
previous O
chemotherapy O
, O
the O
treatment O
groups O
were O
well O
balanced O
, O
both O
regarding O
treatment- O
and O
patient-related O
factors O
. O

To O
determine O
the O
efficacy O
and O
safety O
of O
a O
biweekly O
regimen O
of O
leucovorin O
( O
LV O
) O
plus O
fluorouracil O
( O
FU O
) O
alone O
or O
in O
combination O
with O
cisplatin O
or O
irinotecan O
in O
patients O
with O
previously O
untreated O
metastatic O
gastric O
adenocarcinoma O
and O
to O
select O
the O
best O
arm O
for O
a O
phase O
III O
study O
. O

The B-Premise
night I-Premise
awakenings I-Premise
( I-Premise
Actigraph I-Premise
) I-Premise
pattern I-Premise
was I-Premise
significantly I-Premise
different I-Premise
by I-Premise
group I-Premise
over I-Premise
time I-Premise
( I-Premise
P I-Premise
= I-Premise
.046 I-Premise
) I-Premise
, I-Premise
with I-Premise
no I-Premise
differences I-Premise
between I-Premise
groups I-Premise
at I-Premise
90 I-Premise
days I-Premise
or I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

Moderators O
were O
patient O
preference O
for O
group O
assignment O
, O
marital O
status O
, O
age O
, O
disease O
stage O
, O
and O
chemotherapy O
regimen O
. O

After O
randomization O
, O
L-T4 O
was O
discontinued O
in O
hypothyroid O
( O
hypo O
) O
group O
and O
continued O
in O
rhTSH O
group O
. O

For O
each O
outcome O
, O
separate O
analyses O
of O
covariance O
of O
change O
scores O
between O
baseline O
( O
T1 O
) O
and O
the O
three O
follow-up O
time O
points O
( O
T2 O
, O
T3 O
, O
and O
T4 O
) O
were O
conducted O
, O
controlling O
for O
the O
variable O
's O
corresponding O
baseline O
value O
. O

The O
main O
objective O
of O
the O
study O
was O
to O
determine O
the O
benefits O
of O
psychosocial O
interventions O
for O
cancer O
patients O
who O
received O
RT O
. O

Patients O
and O
clinical O
sites O
were O
informed O
of O
allocation O
to O
early O
treatment O
, O
and O
treatment O
was O
started O
as O
soon O
as O
possible O
within O
28 O
days O
of O
the O
increased O
CA125 O
measurement O
. O

After B-Premise
radiotherapy I-Premise
and I-Premise
at I-Premise
3 I-Premise
months I-Premise
, I-Premise
rates I-Premise
of I-Premise
anorexia I-Premise
, I-Premise
nausea I-Premise
, I-Premise
vomiting I-Premise
, I-Premise
and I-Premise
diarrhea I-Premise
were I-Premise
higher I-Premise
in I-Premise
G3 I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

The O
changes O
in O
the O
BMD O
, O
bone O
turnover O
proteins O
and O
quality-of-life O
( O
QoL O
) O
were O
analyzed O
and O
presented O
here O
. O

Future O
research O
should O
investigate O
ways O
to O
augment O
this O
intervention O
to O
enhance O
its O
benefits O
. O

Follow-up O
assessment O
for O
our O
primary O
end O
point O
was O
96 O
% O
( O
117 O
of O
122 O
) O
at O
postintervention O
and O
90 O
% O
( O
110 O
of O
122 O
) O
at O
6-month O
follow-up O
. O

The B-Claim
superiority I-Claim
of I-Claim
combination I-Claim
therapy I-Claim
over I-Claim
monochemotherapy I-Claim
has I-Claim
not I-Claim
been I-Claim
demonstrated I-Claim
convincingly I-Claim
. I-Claim

Sensitivity O
analysis O
using O
pattern-mixture O
models O
determined O
the O
effect O
of O
study O
discontinuation O
on/before O
week O
24 O
. O

There B-Premise
were I-Premise
no I-Premise
serious I-Premise
events I-Premise
with I-Premise
the I-Premise
1 I-Premise
+ I-Premise
2.5 I-Premise
dosage I-Premise
or I-Premise
after I-Premise
ccHRT I-Premise
discontinuation I-Premise
. I-Premise

Maximum B-Premise
exercise I-Premise
capacity I-Premise
and I-Premise
maximum I-Premise
oxygen I-Premise
consumption I-Premise
were I-Premise
normalized I-Premise
within I-Premise
6 I-Premise
months I-Premise
postoperatively I-Premise
in I-Premise
all I-Premise
groups I-Premise
. I-Premise

The O
FDA O
reviewed O
raw O
data O
in O
electronic O
format O
from O
a O
randomized O
controlled O
clinical O
trial O
comparing O
erlotinib O
with O
placebo O
in O
patients O
with O
locally O
advanced O
or O
metastatic O
NSCLC O
after O
failure O
of O
at O
least O
one O
prior O
chemotherapy O
regimen O
. O

Among B-Premise
the I-Premise
17 I-Premise
participants I-Premise
with I-Premise
depressive I-Premise
symptoms I-Premise
at I-Premise
baseline I-Premise
, I-Premise
both I-Premise
the I-Premise
Onward I-Premise
and I-Premise
the I-Premise
III-only I-Premise
condition I-Premise
showed I-Premise
large I-Premise
reductions I-Premise
in I-Premise
the I-Premise
depression I-Premise
scale I-Premise
of I-Premise
HADS I-Premise
( I-Premise
d I-Premise
= I-Premise
1.27 I-Premise
and I-Premise
0.89 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Investigators O
, O
blinded O
to O
the O
results O
, O
stopped O
the O
trial O
early O
because O
of O
a O
low O
enrollment O
rate O
. O

Twenty-one O
centers O
in O
The O
Netherlands O
. O

Cost B-Premise
savings I-Premise
due I-Premise
to I-Premise
reduced I-Premise
docetaxel I-Premise
dose I-Premise
and I-Premise
hospital I-Premise
use I-Premise
were I-Premise
the I-Premise
major I-Premise
cost I-Premise
offsets I-Premise
with I-Premise
the I-Premise
combination I-Premise
. I-Premise

After B-Claim
1 I-Claim
month I-Claim
of I-Claim
r-HuEPO I-Claim
, I-Claim
there I-Claim
is I-Claim
also I-Claim
a I-Claim
reduction I-Claim
in I-Claim
transfusion I-Claim
requirement I-Claim
. I-Claim

A B-Claim
clinical I-Claim
assessment I-Claim
and I-Claim
intervention I-Claim
program I-Claim
for I-Claim
menopausal I-Claim
symptom I-Claim
management I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
is I-Claim
feasible I-Claim
and I-Claim
acceptable I-Claim
to I-Claim
patients I-Claim
, I-Claim
leading I-Claim
to I-Claim
reduction I-Claim
in I-Claim
symptoms I-Claim
and I-Claim
improvement I-Claim
in I-Claim
sexual I-Claim
functioning I-Claim
. I-Claim

One O
hundred O
ninety-five O
patients O
were O
enrolled O
and O
showed O
baseline O
characteristics O
well O
balanced O
between O
treatment O
arms O
. O

Intravenous O
5-FU O
and O
oral O
doxifluridine O
were O
compared O
with O
respect O
to O
therapeutic O
efficacy O
, O
drug O
toxicity O
, O
and O
quality O
of O
life O
. O

This O
open-label O
study O
was O
designed O
to O
compare O
the O
overall O
survival O
( O
OS O
) O
of O
patients O
randomly O
assigned O
to O
GEM O
alone O
or O
GEM O
plus O
capecitabine O
( O
GEM-CAP O
) O
. O

After B-Premise
2 I-Premise
and I-Premise
3 I-Premise
years I-Premise
, I-Premise
this I-Premise
had I-Premise
decreased I-Premise
to I-Premise
49 I-Premise
% I-Premise
and I-Premise
41 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

Significant B-Premise
deterioration I-Premise
was I-Premise
noted I-Premise
after I-Premise
chemotherapy I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
in I-Premise
QoL I-Premise
scores I-Premise
, I-Premise
appetite I-Premise
, I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
, I-Premise
and I-Premise
global I-Premise
health I-Premise
status I-Premise
. I-Premise

Fortunately O
, O
cognitive-behavioral O
therapy O
for O
insomnia O
( O
CBT-I O
) O
has O
been O
shown O
to O
be O
an O
effective O
treatment O
in O
this O
population O
. O

We O
used O
these O
data O
in O
a O
Cox O
proportional O
hazards O
analysis O
to O
examine O
whether O
decreasing O
depression O
symptoms O
over O
the O
first O
year O
of O
the O
study O
( O
the O
length O
of O
the O
intervention O
) O
would O
be O
associated O
with O
longer O
survival O
. O

The B-Premise
QLQ-C30 I-Premise
subscales I-Premise
pain I-Premise
( I-Premise
P=0.12 I-Premise
) I-Premise
, I-Premise
insomnia I-Premise
( I-Premise
P=0.068 I-Premise
) I-Premise
, I-Premise
appetite I-Premise
loss I-Premise
( I-Premise
P=0.074 I-Premise
) I-Premise
and I-Premise
the I-Premise
QLQ-MY24 I-Premise
item I-Premise
sick I-Premise
( I-Premise
P=0.086 I-Premise
) I-Premise
scored I-Premise
marginally I-Premise
better I-Premise
during I-Premise
thalidomide I-Premise
maintenance I-Premise
. I-Premise

Tamoxifen B-Claim
decreases I-Claim
the I-Claim
incidence I-Claim
of I-Claim
invasive I-Claim
and I-Claim
noninvasive I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
5.5 I-Premise
months I-Premise
v I-Premise
3.1 I-Premise
months I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

In O
addition O
, O
we O
also O
evaluated O
the O
impact O
of O
rhTSH O
( O
rhTSH O
vs. O
conventional O
thyroid O
hormone O
withdrawal O
) O
on O
quality O
of O
life O
( O
QoL O
) O
of O
thyroid O
cancer O
patients O
undergoing O
RI O
ablation O
. O

Results B-Claim
of I-Claim
this I-Claim
randomized I-Claim
study I-Claim
incorporating I-Claim
prospective I-Claim
QOL I-Claim
measurements I-Claim
suggested I-Claim
that I-Claim
in I-Claim
patients I-Claim
with I-Claim
locally I-Claim
advanced I-Claim
NSCLC I-Claim
, I-Claim
analyzing I-Claim
QOL I-Claim
data I-Claim
by I-Claim
either I-Claim
gender I-Claim
or I-Claim
performance I-Claim
status I-Claim
alone I-Claim
may I-Claim
not I-Claim
accurately I-Claim
reflect I-Claim
how I-Claim
these I-Claim
factors I-Claim
depend I-Claim
upon I-Claim
each I-Claim
another I-Claim
. I-Claim

or O
i.v O
. O

Whether B-Claim
such I-Claim
a I-Claim
lozenge I-Claim
would I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
treatment I-Claim
situations I-Claim
where I-Claim
rate I-Claim
of I-Claim
severe I-Claim
mucositis I-Claim
is I-Claim
higher I-Claim
( I-Claim
ie I-Claim
, I-Claim
in I-Claim
patients I-Claim
treated I-Claim
with I-Claim
unconventional I-Claim
fractionation I-Claim
or I-Claim
with I-Claim
concomitant I-Claim
chemotherapy I-Claim
) I-Claim
is I-Claim
unknown I-Claim
. I-Claim

The O
therapeutic O
efficacy O
was O
evaluated O
after O
2 O
cycles O
of O
treatment O
by O
observing O
the O
changes O
of O
short-term O
efficacy O
, O
TCM O
syndrome O
, O
quality O
of O
life O
and O
immune O
function O
, O
as O
well O
as O
the O
adverse O
reaction O
. O

Vaginal B-Claim
brachytherapy I-Claim
provides I-Claim
a I-Claim
better I-Claim
QOL I-Claim
, I-Claim
and I-Claim
should I-Claim
be I-Claim
the I-Claim
preferred I-Claim
treatment I-Claim
from I-Claim
a I-Claim
QOL I-Claim
perspective I-Claim
. I-Claim

Women O
( O
N=13388 O
) O
at O
increased O
risk O
for O
breast O
cancer O
because O
they O
1 O
) O
were O
60 O
years O
of O
age O
or O
older O
, O
2 O
) O
were O
35-59 O
years O
of O
age O
with O
a O
5-year O
predicted O
risk O
for O
breast O
cancer O
of O
at O
least O
1.66 O
% O
, O
or O
3 O
) O
had O
a O
history O
of O
lobular O
carcinoma O
in O
situ O
were O
randomly O
assigned O
to O
receive O
placebo O
( O
n=6707 O
) O
or O
20 O
mg/day O
tamoxifen O
( O
n=6681 O
) O
for O
5 O
years O
. O

Quality B-Premise
of I-Premise
life I-Premise
( I-Premise
QOL I-Premise
) I-Premise
declined I-Premise
significantly I-Premise
over I-Premise
the I-Premise
6 I-Premise
months I-Premise
. I-Premise

Intrusive B-Premise
thoughts I-Premise
also I-Premise
influenced I-Premise
the I-Premise
trajectory I-Premise
of I-Premise
pain I-Premise
, I-Premise
depressive I-Premise
symptoms I-Premise
, I-Premise
negative I-Premise
affect I-Premise
, I-Premise
and I-Premise
physical I-Premise
functioning I-Premise
over I-Premise
time I-Premise
";" I-Premise
women B-Premise
with I-Premise
higher I-Premise
intrusions I-Premise
at I-Premise
baseline I-Premise
started I-Premise
worse I-Premise
and I-Premise
improved I-Premise
over I-Premise
time I-Premise
, I-Premise
whereas I-Premise
those I-Premise
with I-Premise
lower I-Premise
intrusions I-Premise
remained I-Premise
at I-Premise
a I-Premise
constant I-Premise
, I-Premise
lower I-Premise
level I-Premise
over I-Premise
time I-Premise
. I-Premise

Annualized O
percentage O
rates O
for O
cardiovascular O
events O
[ O
corrected O
] O
and O
endometrial O
cancers O
[ O
corrected O
] O
were O
below O
national O
rates O
for O
Finland O
and O
those O
reported O
for O
the O
Women O
's O
Health O
Initiative O
. O

203 O
women O
entered O
the O
study O
";" O
177 O
completed O
the O
six O
month O
follow-up O
. O

In B-Premise
the I-Premise
follow-up I-Premise
in I-Premise
this I-Premise
study I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
recurrences I-Premise
, I-Premise
and I-Premise
the I-Premise
quality I-Premise
of I-Premise
life I-Premise
utilities I-Premise
from I-Premise
EuroQol I-Premise
were I-Premise
almost I-Premise
identical I-Premise
. I-Premise

All O
statistical O
tests O
were O
two-sided O
. O

The B-Premise
AT I-Premise
group I-Premise
without I-Premise
tamoxifen I-Premise
had I-Premise
the I-Premise
lowest I-Premise
rate I-Premise
of I-Premise
amenorrhea I-Premise
. I-Premise

Two-hundred O
seventeen O
of O
425 O
therapeutic O
trial O
patients O
were O
eligible O
and O
registered O
to O
the O
HRQL O
study O
. O

The O
results O
were O
analyzed O
using O
a O
linear O
mixed-effects O
model O
. O

PVI B-Claim
5-FU I-Claim
+ I-Claim
MMC I-Claim
results I-Claim
in I-Claim
failure-free I-Claim
survival I-Claim
and I-Claim
response I-Claim
advantage I-Claim
, I-Claim
tolerable I-Claim
toxicity I-Claim
and I-Claim
better I-Claim
QL I-Claim
when I-Claim
compared I-Claim
to I-Claim
PVI I-Claim
5-FU I-Claim
alone I-Claim
but I-Claim
no I-Claim
overall I-Claim
survival I-Claim
advantage I-Claim
. I-Claim

The O
primary O
efficacy O
data O
have O
been O
reported O
previously O
. O

In B-Claim
minimally I-Claim
symptomatic I-Claim
patients I-Claim
with I-Claim
locally I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
, I-Claim
no I-Claim
persuasive I-Claim
evidence I-Claim
was I-Claim
found I-Claim
to I-Claim
indicate I-Claim
that I-Claim
giving I-Claim
immediate I-Claim
palliative I-Claim
thoracic I-Claim
radiotherapy I-Claim
improves I-Claim
symptom I-Claim
control I-Claim
, I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
or I-Claim
survival I-Claim
when I-Claim
compared I-Claim
with I-Claim
delaying I-Claim
until I-Claim
symptoms I-Claim
require I-Claim
treatment I-Claim
. I-Claim

Progression-free B-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
from I-Premise
date I-Premise
of I-Premise
randomization I-Premise
on I-Premise
step I-Premise
2 I-Premise
was I-Premise
significantly I-Premise
better I-Premise
with I-Premise
topotecan I-Premise
compared I-Premise
with I-Premise
observation I-Premise
( I-Premise
3.6 I-Premise
months I-Premise
v I-Premise
2.3 I-Premise
months I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

By B-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
treatment I-Premise
period I-Premise
, I-Premise
hot I-Premise
flash I-Premise
scores I-Premise
( I-Premise
frequency I-Premise
x I-Premise
average I-Premise
severity I-Premise
) I-Premise
decreased I-Premise
68 I-Premise
% I-Premise
from I-Premise
baseline I-Premise
to I-Premise
end I-Premise
point I-Premise
in I-Premise
the I-Premise
hypnosis I-Premise
arm I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

No B-Premise
between-treatment I-Premise
differences I-Premise
were I-Premise
observed I-Premise
for I-Premise
changes I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
or I-Premise
performance I-Premise
status I-Premise
, I-Premise
but O
patients B-Premise
started I-Premise
on I-Premise
strong I-Premise
opioids I-Premise
had I-Premise
significantly I-Premise
better I-Premise
pain I-Premise
relief I-Premise
than I-Premise
patients I-Premise
treated I-Premise
according I-Premise
to I-Premise
WHO I-Premise
guidelines I-Premise
( I-Premise
P=0.041 I-Premise
) I-Premise
. I-Premise

Results O
of O
the O
pretest O
showed O
that O
many O
patients O
lacked O
knowledge O
about O
pain O
and O
pain O
management O
. O

82 O
postmenopausal O
patients O
with O
histologically O
confirmed O
invasive O
hormone-sensitive O
breast O
cancers O
were O
included O
for O
the O
neoadjuvant O
therapy O
( O
NHT O
) O
. O

Men O
in O
SPCG-4 O
had O
a O
median O
follow-up O
of O
12·2 O
years O
( O
range O
7-17 O
) O
and O
a O
median O
age O
of O
77·0 O
years O
( O
range O
61-88 O
) O
. O

Minimum O
followup O
was O
12 O
months O
. O

Food B-Premise
intake I-Premise
improved I-Premise
more I-Premise
rapidly I-Premise
after I-Premise
stent I-Premise
placement I-Premise
than I-Premise
after I-Premise
GJJ I-Premise
, I-Premise
but B-Premise
long-term I-Premise
relief I-Premise
of I-Premise
obstructive I-Premise
symptoms I-Premise
was I-Premise
better I-Premise
after I-Premise
GJJ I-Premise
. I-Premise

There B-Claim
is I-Claim
substantial I-Claim
deterioration I-Claim
in I-Claim
QOL I-Claim
after I-Claim
curative-intent I-Claim
head-neck I-Claim
irradiation I-Claim
that I-Claim
gradually I-Claim
improves I-Claim
over I-Claim
time I-Claim
. I-Claim

The O
primary O
end-point O
was O
the O
effect O
of O
GM-CSF O
on O
the O
percentage O
of O
complete O
remissions O
( O
CR O
) O
. O

Improvements O
in O
FACT-F O
subscale O
score O
were O
significantly O
( O
P O
< O
0.001 O
) O
correlated O
with O
increases O
in O
Hb O
level O
. O

Patients O
were O
assessed O
each O
week O
during O
and O
up O
to O
6 O
weeks O
after O
radiotherapy O
. O

After B-Claim
validation I-Claim
of I-Claim
our I-Claim
data I-Claim
in I-Claim
a I-Claim
larger I-Claim
group I-Claim
TS I-Claim
determination I-Claim
may I-Claim
have I-Claim
the I-Claim
potential I-Claim
to I-Claim
better I-Claim
help I-Claim
direct I-Claim
systemic I-Claim
treatment I-Claim
in I-Claim
patients I-Claim
with I-Claim
primarily I-Claim
non-resectable I-Claim
mCRC I-Claim
. I-Claim

No B-Premise
differences I-Premise
were I-Premise
observed I-Premise
in I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
subdomain I-Premise
( I-Premise
P=0.40 I-Premise
) I-Premise
between I-Premise
the I-Premise
two I-Premise
regimen I-Premise
. I-Premise

A O
total O
of O
497 O
patients O
with O
previously O
untreated O
metastatic O
colorectal O
cancer O
were O
randomly O
assigned O
to O
receive O
bolus O
FU O
425 O
mg/m2 O
intravenously O
+ O
LV O
20 O
mg/m2 O
on O
days O
1 O
to O
5 O
and O
repeated O
on O
day O
28 O
( O
FU O
+ O
LV O
) O
, O
or O
FU O
2600 O
mg/m2 O
as O
a O
24-hour O
infusion O
alone O
( O
FU24h O
) O
or O
in O
combination O
with O
500 O
mg/m2 O
LV O
( O
FU24h O
+ O
LV O
) O
-all O
given O
weekly O
x6 O
followed O
by O
a O
2-week O
rest O
period O
. O

Patients O
with O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
, O
lymphoblastic O
lymphoma O
( O
LL O
) O
, O
or O
Burkitt O
lymphoma O
( O
BL O
) O
who O
were O
receiving O
frontline O
myelosuppressive O
chemotherapy O
were O
randomized O
to O
receive O
epoetin O
alpha O
or O
no O
epoetin O
during O
the O
first O
6 O
cycles O
of O
their O
planned O
chemotherapy O
. O

" O
Washout O
" O
patients O
discontinued O
anti-TNF O
therapy O
2 O
months O
or O
longer O
pre-screening O
";" O
" O
direct-switch O
100" O
patients O
began O
abatacept O
( O
approximately O
10 O
mg/kg O
) O
at O
their O
next O
scheduled O
anti-TNF O
therapy O
dose O
. O

The O
present O
study O
aimed O
to O
compare O
FUP O
with O
5-FU O
alone O
, O
which O
was O
the O
control O
arm O
in O
former O
Mayo O
Clinic O
trials O
. O

Adverse B-Premise
events I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
immediate I-Premise
treatment I-Premise
group I-Premise
. I-Premise

The B-Premise
weekly I-Premise
VNR/CDDP I-Premise
regimen I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
lower I-Premise
received I-Premise
dose I-Premise
intensity I-Premise
in I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
fashion I-Premise
( I-Premise
9 I-Premise
% I-Premise
versus I-Premise
22 I-Premise
% I-Premise
";" I-Premise
p=0.0001 I-Premise
) I-Premise
and I-Premise
with I-Premise
a I-Premise
lower I-Premise
non-statistically I-Premise
significant I-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
as I-Premise
compared I-Premise
to I-Premise
the I-Premise
day I-Premise
1-8 I-Premise
VNR/CDDP I-Premise
schedule I-Premise
. I-Premise

Overall O
, O
QoL B-Claim
scores I-Claim
were I-Claim
similar I-Claim
in I-Claim
the I-Claim
two I-Claim
treatment I-Claim
groups I-Claim
, I-Claim
but B-Claim
thalidomide I-Claim
was I-Claim
associated I-Claim
with I-Claim
less I-Claim
insomnia I-Claim
and I-Claim
diarrhea I-Claim
and I-Claim
more I-Claim
constipation I-Claim
and I-Claim
peripheral I-Claim
neuropathy I-Claim
. I-Claim

At B-Premise
6 I-Premise
months I-Premise
and I-Premise
2 I-Premise
years I-Premise
, I-Premise
using I-Premise
post-hoc I-Premise
as-observed I-Premise
analyses I-Premise
, I-Premise
the I-Premise
percentage I-Premise
of I-Premise
patients I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
) I-Premise
achieving I-Premise
DAS28 I-Premise
( I-Premise
C-reactive I-Premise
protein I-Premise
) I-Premise
low I-Premise
disease I-Premise
activity I-Premise
score I-Premise
( I-Premise
< I-Premise
or I-Premise
= I-Premise
3.2 I-Premise
) I-Premise
and I-Premise
DAS28 I-Premise
( I-Premise
C-reactive I-Premise
protein I-Premise
) I-Premise
-defined I-Premise
remission I-Premise
( I-Premise
< I-Premise
2.6 I-Premise
) I-Premise
increased I-Premise
from I-Premise
18.3 I-Premise
% I-Premise
( I-Premise
13.0 I-Premise
, I-Premise
23.5 I-Premise
) I-Premise
to I-Premise
32.0 I-Premise
% I-Premise
( I-Premise
24.6 I-Premise
, I-Premise
39.4 I-Premise
) I-Premise
and I-Premise
11.1 I-Premise
% I-Premise
( I-Premise
6.8 I-Premise
, I-Premise
15.3 I-Premise
) I-Premise
to I-Premise
20.3 I-Premise
% I-Premise
( I-Premise
13.9 I-Premise
, I-Premise
26.6 I-Premise
) I-Premise
. I-Premise

Both B-Claim
drugs I-Claim
were I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

Patients O
aged O
> O
65 O
years O
with O
newly O
diagnosed O
MM O
were O
randomized O
to O
receive O
melphalan O
plus O
prednisone O
( O
MP O
) O
or O
MPT O
, O
followed O
by O
thalidomide O
maintenance O
in O
the O
MPT O
arm O
. O

The O
mean O
age O
was O
52.3 O
vs. O
59.5 O
, O
respectively O
. O

Our B-Claim
study I-Claim
indicates I-Claim
that I-Claim
use I-Claim
of I-Claim
rhTSH I-Claim
preserves I-Claim
QoL I-Claim
in I-Claim
patients I-Claim
undergoing I-Claim
RI I-Claim
ablation I-Claim
and I-Claim
affords I-Claim
an I-Claim
ablation I-Claim
success I-Claim
rate I-Claim
comparable I-Claim
to I-Claim
that I-Claim
seen I-Claim
after I-Claim
thyroid I-Claim
hormone I-Claim
withdrawal I-Claim
. I-Claim

We B-Premise
found I-Premise
significant I-Premise
improvements I-Premise
over I-Premise
time I-Premise
in I-Premise
favor I-Premise
of I-Premise
PPT I-Premise
for I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
general I-Premise
fatigue I-Premise
( I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
, I-Premise
with I-Premise
significant I-Premise
group I-Premise
differences I-Premise
at I-Premise
month I-Premise
1 I-Premise
( I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.26 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.007 I-Premise
) I-Premise
and I-Premise
month I-Premise
2 I-Premise
( I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.35 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.005 I-Premise
) I-Premise
. I-Premise

The O
patients O
' O
quality O
of O
life O
was O
scored O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
30-item O
cancer-specific O
and O
25-item O
prostate-specific O
modules O
. O

HDCT B-Claim
did I-Claim
not I-Claim
improve I-Claim
OS I-Claim
in I-Claim
women I-Claim
with I-Claim
MBC I-Claim
when I-Claim
used I-Claim
as I-Claim
consolidation I-Claim
after I-Claim
response I-Claim
to I-Claim
induction I-Claim
chemotherapy I-Claim
. I-Claim

At B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
30 I-Premise
months I-Premise
, I-Premise
letrozole I-Premise
significantly I-Premise
improved I-Premise
disease-free I-Premise
survival I-Premise
( I-Premise
DFS I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
the I-Premise
primary I-Premise
end I-Premise
point I-Premise
, I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
for I-Premise
recurrence I-Premise
or I-Premise
contralateral I-Premise
breast I-Premise
cancer I-Premise
0.58 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
0.45 I-Premise
, I-Premise
0.76 I-Premise
] I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Of O
these O
, O
433 O
are O
known O
to O
be O
dead O
, O
26 O
are O
lost O
to O
follow-up O
and O
11 O
are O
still O
alive O
. O

Overall B-Claim
survival I-Claim
was I-Claim
not I-Claim
statistically I-Claim
significantly I-Claim
improved I-Claim
at I-Claim
this I-Claim
time I-Claim
. I-Claim

Immediate B-Premise
lung I-Premise
expansion I-Premise
did I-Premise
not I-Premise
correlate I-Premise
with I-Premise
radiologic I-Premise
recurrence I-Premise
, I-Premise
clinical I-Premise
recurrence I-Premise
, I-Premise
or I-Premise
complications I-Premise
( I-Premise
p I-Premise
= I-Premise
0.60 I-Premise
, I-Premise
0.15 I-Premise
, I-Premise
and I-Premise
0.20 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

No B-Premise
late I-Premise
arising I-Premise
QOL I-Premise
issues I-Premise
were I-Premise
observed I-Premise
. I-Premise

Patients B-Premise
with I-Premise
PSA I-Premise
nadir I-Premise
≤ I-Premise
0.2 I-Premise
ng/ml I-Premise
, I-Premise
though I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
2-year I-Premise
risk I-Premise
of I-Premise
progression I-Premise
compared I-Premise
to I-Premise
CAD I-Premise
( I-Premise
53 I-Premise
% I-Premise
vs. I-Premise
31 I-Premise
% I-Premise
( I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Median B-Premise
OS I-Premise
was I-Premise
9.45 I-Premise
and I-Premise
10 I-Premise
months I-Premise
respectively I-Premise
for I-Premise
weekly I-Premise
VNR/CDDP I-Premise
arm I-Premise
and I-Premise
the I-Premise
day I-Premise
1-8 I-Premise
VNR/CDDP I-Premise
one I-Premise
without I-Premise
statistically I-Premise
a I-Premise
significant I-Premise
difference I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
p=0.259 I-Premise
) I-Premise
. I-Premise

Symptom O
and O
quality O
of O
life O
( O
QOL O
) O
status O
was O
determined O
with O
use O
of O
questionnaires O
. O

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
subjects I-Premise
revealed I-Premise
by I-Premise
the I-Premise
questionnaire I-Premise
regarding I-Premise
subjective I-Premise
or I-Premise
objective I-Premise
symptoms I-Premise
, I-Premise
or I-Premise
by I-Premise
the I-Premise
SF-8 I-Premise
between I-Premise
the I-Premise
daytime I-Premise
group I-Premise
and I-Premise
the I-Premise
nocturnal I-Premise
group I-Premise
after I-Premise
3 I-Premise
months I-Premise
of I-Premise
treatment I-Premise
. I-Premise

Complete B-Claim
fibroid I-Claim
infarction I-Claim
does I-Claim
not I-Claim
translate I-Claim
into I-Claim
total I-Claim
freedom I-Claim
from I-Claim
a I-Claim
subsequent I-Claim
reintervention I-Claim
. I-Claim

At B-Premise
T3 I-Premise
, I-Premise
no I-Premise
significant I-Premise
difference I-Premise
on I-Premise
fatigue I-Premise
was I-Premise
found I-Premise
between I-Premise
CBT I-Premise
and I-Premise
usual I-Premise
care I-Premise
. I-Premise

Patient-caregiver B-Claim
dyads I-Claim
benefit I-Claim
when I-Claim
viewed I-Claim
as I-Claim
the I-Claim
'unit I-Claim
of I-Claim
care I-Claim
' I-Claim
. I-Claim

The B-Premise
ORR I-Premise
was I-Premise
also I-Premise
higher I-Premise
with I-Premise
AT I-Premise
in I-Premise
patients I-Premise
with I-Premise
visceral I-Premise
involvement I-Premise
( I-Premise
58 I-Premise
% I-Premise
v I-Premise
41 I-Premise
% I-Premise
";" I-Premise
liver I-Premise
, I-Premise
62 I-Premise
% I-Premise
v I-Premise
42 I-Premise
% I-Premise
";" I-Premise
lung I-Premise
, I-Premise
58 I-Premise
% I-Premise
v I-Premise
35 I-Premise
% I-Premise
) I-Premise
, I-Premise
three I-Premise
or I-Premise
more I-Premise
organs I-Premise
involved I-Premise
( I-Premise
59 I-Premise
% I-Premise
v I-Premise
40 I-Premise
% I-Premise
) I-Premise
, I-Premise
or I-Premise
prior I-Premise
adjuvant I-Premise
CT I-Premise
( I-Premise
53 I-Premise
% I-Premise
v I-Premise
41 I-Premise
% I-Premise
) I-Premise
. I-Premise

Median B-Premise
overall I-Premise
survival I-Premise
was I-Premise
43.1 I-Premise
months I-Premise
for I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
versus I-Premise
44.5 I-Premise
months I-Premise
for I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
stratum-adjusted I-Premise
HR I-Premise
= I-Premise
1.01 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.86 I-Premise
to I-Premise
1.18 I-Premise
] I-Premise
";" I-Premise
P I-Premise
= I-Premise
.885 I-Premise
) I-Premise
. I-Premise

The O
30 O
items O
in O
15 O
subscales O
of O
the O
QLQ-C30 O
include O
global O
health O
status O
wherein O
higher O
scores O
( O
range O
, O
0-100 O
) O
indicate O
better O
HRQOL O
. O

Severe B-Premise
rash I-Premise
occurred I-Premise
in I-Premise
9 I-Premise
% I-Premise
and I-Premise
severe I-Premise
diarrhea I-Premise
in I-Premise
6 I-Premise
% I-Premise
of I-Premise
erlotinib-treated I-Premise
patients I-Premise
and I-Premise
each I-Premise
resulted I-Premise
in I-Premise
study I-Premise
discontinuation I-Premise
in I-Premise
1 I-Premise
% I-Premise
of I-Premise
patients I-Premise
. I-Premise

More B-Premise
thrombocytopenia I-Premise
occurred I-Premise
with I-Premise
GCa I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
was I-Premise
not I-Premise
associated I-Premise
with I-Premise
increased I-Premise
hospital I-Premise
admission I-Premise
or I-Premise
fatality I-Premise
. I-Premise

The B-Claim
efficacy I-Claim
and I-Claim
safety I-Claim
of I-Claim
uterine-artery I-Claim
embolization I-Claim
, I-Claim
as I-Claim
compared I-Claim
with I-Claim
standard I-Claim
surgical I-Claim
methods I-Claim
, I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
symptomatic I-Claim
uterine I-Claim
fibroids I-Claim
remain I-Claim
uncertain I-Claim
. I-Claim

No B-Premise
differences I-Premise
in I-Premise
patients I-Premise
' I-Premise
preference I-Premise
for I-Premise
the I-Premise
two I-Premise
treatment I-Premise
periods I-Premise
were I-Premise
found I-Premise
. I-Premise

Survival O
curves O
were O
drawn O
using O
the O
Kaplan-Meier O
method O
and O
analyzed O
by O
the O
Mantel-Haenszel O
test O
. O

A O
total O
of O
217 O
patients O
were O
randomized O
to O
either O
the O
hypofractionated O
( O
108 O
patients O
) O
or O
the O
conventional O
( O
109 O
patients O
) O
dose O
schedule O
, O
with O
planning O
with O
two-dimensional O
( O
2D O
) O
CT O
scan O
planning O
methodology O
in O
the O
majority O
of O
cases O
. O

The B-Premise
TC I-Premise
regimen I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
higher I-Premise
frequency I-Premise
of I-Premise
hematologic I-Premise
toxicity I-Premise
, I-Premise
but B-Premise
a I-Premise
lower I-Premise
frequency I-Premise
of I-Premise
gastrointestinal I-Premise
and I-Premise
neurologic I-Premise
toxicity I-Premise
, I-Premise
than I-Premise
the I-Premise
PT I-Premise
regimen I-Premise
. I-Premise

Primary O
-- O
patients O
alive O
and O
without O
moderate O
or O
severe O
cough O
, O
chest O
pain O
, O
haemoptysis O
, O
or O
dyspnoea O
six O
months O
from O
randomisation O
, O
as O
recorded O
by O
clinicians O
. O

Subgroup O
analyses O
were O
conducted O
to O
identify O
characteristics O
of O
patients O
deriving O
the O
greatest O
clinical O
benefit O
. O

Subjects O
were O
randomized O
to O
a O
control O
or O
intervention O
group O
";" O
the O
intervention O
was O
performance O
of O
a O
seated O
exercise O
program O
using O
home O
videotape O
three O
times O
per O
week O
for O
four O
cycles O
of O
chemotherapy O
. O

Major B-Premise
toxicity I-Premise
was I-Premise
similar I-Premise
across I-Premise
all I-Premise
three I-Premise
groups I-Premise
. I-Premise

Primary O
outcome O
measures O
assessed O
spiritual O
well-being O
and O
quality O
of O
life O
";" O
secondary O
outcomes O
included O
anxiety O
, O
depression O
, O
hopelessness O
, O
symptom O
burden O
, O
and O
symptom-related O
distress O
. O

Three B-Premise
of I-Premise
the I-Premise
quality-of-life I-Premise
domains I-Premise
showed I-Premise
trends I-Premise
toward I-Premise
increases I-Premise
in I-Premise
the I-Premise
exercise I-Premise
group I-Premise
: I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
P I-Premise
=.050 I-Premise
) I-Premise
, I-Premise
general I-Premise
health I-Premise
( I-Premise
P I-Premise
=.048 I-Premise
) I-Premise
, I-Premise
and I-Premise
vitality I-Premise
( I-Premise
P I-Premise
=.023 I-Premise
) I-Premise
. I-Premise

Finally O
, O
cancer O
progression O
time O
and O
toxicity O
reaction O
of O
the O
two O
groups O
were O
evaluated O
. O

Training B-Claim
oncologists I-Claim
in I-Claim
responding I-Claim
to I-Claim
patient-reported I-Claim
functional I-Claim
concerns I-Claim
may I-Claim
increase I-Claim
the I-Claim
impact I-Claim
of I-Claim
this I-Claim
intervention I-Claim
. I-Claim

KP O
, O
toxicity O
, O
and O
SS14 O
lung O
cancer O
specific O
questions O
were O
recorded O
before O
each O
cycle O
of O
treatment O
. O

Analysis O
was O
by O
intention-to-treat O
. O

This B-Premise
trend I-Premise
for I-Premise
OS I-Premise
benefit I-Premise
for I-Premise
GEM-CAP I-Premise
was I-Premise
consistent I-Premise
across I-Premise
different I-Premise
prognostic I-Premise
subgroups I-Premise
according I-Premise
to I-Premise
baseline I-Premise
stratification I-Premise
factors I-Premise
( I-Premise
stage I-Premise
and I-Premise
performance I-Premise
status I-Premise
) I-Premise
and I-Premise
remained I-Premise
after I-Premise
adjusting I-Premise
for I-Premise
these I-Premise
stratification I-Premise
factors I-Premise
( I-Premise
P I-Premise
= I-Premise
.077 I-Premise
) I-Premise
. I-Premise

Further B-Claim
research I-Claim
is I-Claim
necessary I-Claim
to I-Claim
confirm I-Claim
this I-Claim
hypothesis I-Claim
in I-Claim
other I-Claim
samples I-Claim
, I-Claim
and I-Claim
causation I-Claim
can I-Claim
not I-Claim
be I-Claim
assumed I-Claim
based I-Claim
on I-Claim
this I-Claim
analysis I-Claim
. I-Claim

After B-Premise
4 I-Premise
weeks I-Premise
of I-Premise
NHT I-Premise
, I-Premise
negative I-Premise
changes I-Premise
of I-Premise
FACT-B I-Premise
and I-Premise
FACT-G I-Premise
scores I-Premise
were I-Premise
found I-Premise
in I-Premise
group I-Premise
B I-Premise
and I-Premise
C I-Premise
patients I-Premise
, I-Premise
but B-Premise
there I-Premise
were I-Premise
positive I-Premise
changes I-Premise
in I-Premise
group I-Premise
A I-Premise
patients I-Premise
. I-Premise

The B-Premise
3-drug I-Premise
combination I-Premise
, I-Premise
supportive I-Premise
care I-Premise
and I-Premise
radiotherapy I-Premise
groups I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
from I-Premise
each I-Premise
other I-Premise
with I-Premise
respect I-Premise
to I-Premise
the I-Premise
total I-Premise
FLI-C I-Premise
score I-Premise
or I-Premise
its I-Premise
subscales I-Premise
. I-Premise

No B-Premise
adverse I-Premise
effects I-Premise
were I-Premise
noted I-Premise
. I-Premise

The O
effect O
of O
treatment O
was O
measured O
using O
a O
" O
Well-Being O
scale O
" O
, O
with O
the O
difference O
of O
the O
average O
score O
of O
the O
" O
Well-Being O
scale O
" O
on O
day O
10 O
being O
defined O
as O
primary O
and O
that O
on O
day O
5 O
as O
secondary O
endpoint O
. O

Molecular O
markers O
to O
predict O
response O
to O
5-fluorouracil O
( O
FU O
) O
-based O
treatment O
of O
recurrent O
or O
metastasised O
colorectal O
cancer O
( O
mCRC O
) O
are O
not O
established O
. O

Couples O
were O
randomized O
to O
attend O
four O
sessions O
of O
counseling O
together O
or O
to O
have O
the O
man O
attend O
alone O
. O

Patients O
aged O
65 O
years O
or O
more O
were O
eligible O
provided O
that O
their O
cancers O
were O
considered O
to O
be O
at O
low O
risk O
of O
local O
recurrence O
, O
were O
suitable O
for O
breast-conservation O
surgery O
, O
were O
receiving O
endocrine O
therapy O
and O
were O
able O
and O
willing O
to O
give O
informed O
consent O
. O

To O
evaluate O
the O
safety O
and O
efficacy O
of O
abatacept O
during O
2 O
years O
of O
the O
ATTAIN O
( O
Abatacept O
Trial O
in O
Treatment O
of O
Anti-TNF O
INadequate O
responders O
) O
trial O
in O
patients O
with O
rheumatoid O
arthritis O
. O

Outcomes O
were O
reassessed O
6 O
and O
12 O
weeks O
after O
chemotherapy O
started O
. O

At O
baseline O
after O
surgery O
, O
patient O
functioning O
was O
at O
the O
lowest O
level O
, O
and O
it O
increased O
during O
and O
after O
radiotherapy O
to O
reach O
a O
plateau O
after O
12 O
months O
. O

This O
randomised O
non-inferiority O
trial O
was O
designed O
to O
assess O
whether O
radiosurgery O
plus O
adjuvant O
whole O
brain O
radiotherapy O
( O
RS O
+ O
WBRT O
) O
is O
as O
effective O
as O
surgery O
plus O
whole O
brain O
radiotherapy O
( O
S O
+ O
WBRT O
) O
for O
cancer O
patients O
with O
a O
solitary O
brain O
metastasis O
, O
with O
respect O
to O
overall O
survival O
and O
quality O
of O
life O
. O

Both B-Premise
energy I-Premise
and I-Premise
protein I-Premise
intake I-Premise
decreased I-Premise
significantly I-Premise
in I-Premise
group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

The O
two O
principal O
aims O
were O
: O
( O
1 O
) O
to O
improve O
the O
survival O
of O
children O
with O
rhabdomyosarcoma O
";" O
and O
( O
2 O
) O
to O
reduce O
the O
late O
effects O
from O
therapy O
by O
restricting O
the O
indications O
for O
surgery O
and/or O
radiotherapy O
after O
good O
response O
to O
initial O
chemotherapy O
. O

Neither B-Premise
gefitinib I-Premise
250 I-Premise
nor I-Premise
500 I-Premise
mg/day I-Premise
improved I-Premise
overall I-Premise
survival I-Premise
compared I-Premise
with I-Premise
methotrexate I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
1.22 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.95 I-Premise
to I-Premise
1.57 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.12 I-Premise
";" I-Premise
and I-Premise
HR I-Premise
, I-Premise
1.12 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.87 I-Premise
to I-Premise
1.43 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.39 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Based O
on O
these O
differences O
between O
the O
embolic O
agents O
, O
enrollment O
in O
this O
study O
was O
terminated O
. O

In B-Claim
conclusion I-Claim
, I-Claim
this I-Claim
first I-Claim
randomized I-Claim
study I-Claim
did I-Claim
not I-Claim
demonstrate I-Claim
any I-Claim
significant I-Claim
improvement I-Claim
of I-Claim
using I-Claim
estramustine I-Claim
in I-Claim
addition I-Claim
to I-Claim
conventional I-Claim
radiotherapy I-Claim
, I-Claim
however B-Claim
, I-Claim
a I-Claim
trend I-Claim
for I-Claim
a I-Claim
positive I-Claim
response I-Claim
for I-Claim
the I-Claim
estramustine I-Claim
group I-Claim
was I-Claim
found I-Claim
in I-Claim
patients I-Claim
with I-Claim
grade I-Claim
III I-Claim
glioma I-Claim
. I-Claim

Of O
5,187 O
randomly O
assigned O
women O
in O
the O
trial O
, O
3,612 O
( O
69.9 O
% O
) O
participated O
in O
the O
QOL O
substudy O
: O
1,799 O
were O
allocated O
to O
placebo O
and O
1,813 O
were O
allocated O
to O
letrozole O
. O

The B-Premise
combination I-Premise
arm I-Premise
was I-Premise
more I-Premise
effective I-Premise
than I-Premise
arm I-Premise
2 I-Premise
with I-Premise
respect I-Premise
to I-Premise
LBM I-Premise
, I-Premise
REE I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
and I-Premise
global I-Premise
QoL I-Premise
. I-Premise

The B-Premise
carboplatin I-Premise
containing I-Premise
regimen I-Premise
( I-Premise
MVC I-Premise
) I-Premise
has I-Premise
a I-Premise
significant I-Premise
better I-Premise
toxicity I-Premise
profile I-Premise
than I-Premise
the I-Premise
cisplatin I-Premise
containing I-Premise
( I-Premise
MVP I-Premise
) I-Premise
regimen I-Premise
as I-Premise
proven I-Premise
both I-Premise
by I-Premise
the I-Premise
EORTC I-Premise
questionnaires I-Premise
and I-Premise
by I-Premise
the I-Premise
WHO I-Premise
toxicity I-Premise
data I-Premise
reported I-Premise
by I-Premise
physicians I-Premise
. I-Premise

For B-Premise
patients I-Premise
with I-Premise
ER-negative I-Premise
tumors I-Premise
, I-Premise
the I-Premise
addition I-Premise
of I-Premise
CMF I-Premise
statistically I-Premise
significantly I-Premise
improved I-Premise
DFS I-Premise
( I-Premise
5-year I-Premise
DFS I-Premise
= I-Premise
84 I-Premise
% I-Premise
for I-Premise
CMF I-Premise
-- I-Premise
> I-Premise
tamoxifen I-Premise
versus I-Premise
69 I-Premise
% I-Premise
for I-Premise
tamoxifen I-Premise
alone I-Premise
";" I-Premise
difference I-Premise
= I-Premise
15 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
6 I-Premise
% I-Premise
to I-Premise
24 I-Premise
% I-Premise
";" I-Premise
risk I-Premise
ratio I-Premise
[ I-Premise
RR I-Premise
] I-Premise
= I-Premise
0.52 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.34 I-Premise
to I-Premise
0.79 I-Premise
";" I-Premise
P I-Premise
=.003 I-Premise
) I-Premise
and I-Premise
OS I-Premise
( I-Premise
5-year I-Premise
OS I-Premise
= I-Premise
89 I-Premise
% I-Premise
for I-Premise
CMF I-Premise
-- I-Premise
> I-Premise
tamoxifen I-Premise
versus I-Premise
81 I-Premise
% I-Premise
for I-Premise
tamoxifen I-Premise
alone I-Premise
";" I-Premise
difference I-Premise
= I-Premise
8 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0 I-Premise
% I-Premise
to I-Premise
16 I-Premise
% I-Premise
";" I-Premise
RR I-Premise
= I-Premise
0.51 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.30 I-Premise
to I-Premise
0.87 I-Premise
";" I-Premise
P I-Premise
=.01 I-Premise
) I-Premise
. I-Premise

rhTSH-prepared B-Claim
patients I-Claim
maintained I-Claim
a I-Claim
higher I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
received I-Claim
less I-Claim
radiation I-Claim
exposure I-Claim
to I-Claim
the I-Claim
blood I-Claim
. I-Claim

There O
were O
no O
significant O
differences O
in O
preprocedure O
clinical O
and O
pathologic O
variables O
between O
groups O
. O

Main O
exclusion O
criteria O
were O
brain O
or O
bone O
metastases O
. O

From B-Premise
the I-Premise
1-year I-Premise
survival I-Premise
analysis I-Premise
, I-Premise
the I-Premise
hazard I-Premise
ratio I-Premise
for I-Premise
probability I-Premise
of I-Premise
death I-Premise
was I-Premise
1.29 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.96 I-Premise
to I-Premise
1.72 I-Premise
) I-Premise
. I-Premise

The B-Premise
effects I-Premise
of I-Premise
ATP I-Premise
on I-Premise
body I-Premise
weight I-Premise
, I-Premise
muscle I-Premise
strength I-Premise
, I-Premise
and I-Premise
albumin I-Premise
concentration I-Premise
were I-Premise
especially I-Premise
marked I-Premise
in I-Premise
cachectic I-Premise
patients I-Premise
( I-Premise
P I-Premise
=.0002 I-Premise
, I-Premise
P I-Premise
=.0001 I-Premise
, I-Premise
and I-Premise
P I-Premise
= I-Premise
. I-Premise
1 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
ATP I-Premise
versus I-Premise
no I-Premise
ATP I-Premise
) I-Premise
. I-Premise

Analysis O
was O
by O
intent O
to O
treat O
. O

Quality O
of O
life O
was O
measured O
by O
the O
Functional O
Assessment O
of O
Chronic O
Illness O
Therapy O
for O
Palliative O
Care O
( O
score O
range O
, O
0-184 O
) O
. O

There B-Premise
was I-Premise
significant I-Premise
early I-Premise
attrition I-Premise
due I-Premise
to I-Premise
disease I-Premise
progression I-Premise
";" I-Premise
only I-Premise
61.5 I-Premise
% I-Premise
of I-Premise
patients I-Premise
were I-Premise
alive I-Premise
at I-Premise
2 I-Premise
months I-Premise
. I-Premise

Maintenance B-Claim
treatment I-Claim
with I-Claim
erlotinib I-Claim
appears I-Claim
to I-Claim
be I-Claim
a I-Claim
useful I-Claim
option I-Claim
for I-Claim
the I-Claim
management I-Claim
of I-Claim
Asian I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
without I-Claim
progression I-Claim
after I-Claim
first-line I-Claim
chemotherapy I-Claim
. I-Claim

Genotypes B-Claim
of I-Claim
glutathione-related I-Claim
enzymes I-Claim
, I-Claim
especially I-Claim
GCLC I-Claim
, I-Claim
may I-Claim
be I-Claim
used I-Claim
as I-Claim
host I-Claim
factors I-Claim
in I-Claim
predicting I-Claim
patients I-Claim
' I-Claim
survival I-Claim
after I-Claim
platinum-based I-Claim
chemotherapy I-Claim
. I-Claim

Secondary O
endpoints O
were O
quality O
of O
life O
and O
toxicity O
. O

With B-Premise
the I-Premise
Spitzer I-Premise
's I-Premise
questionnaires I-Premise
a I-Premise
trend I-Premise
towards I-Premise
an I-Premise
improved I-Premise
quality I-Premise
of I-Premise
life I-Premise
index I-Premise
was I-Premise
observed I-Premise
during I-Premise
treatment I-Premise
with I-Premise
the I-Premise
carboplatin I-Premise
combination I-Premise
in I-Premise
comparison I-Premise
to I-Premise
the I-Premise
cisplatin I-Premise
combination I-Premise
. I-Premise

The O
objective O
of O
this O
study O
was O
to O
determine O
whether O
a O
family-based O
intervention O
could O
improve O
appraisal O
variables O
( O
appraisal O
of O
illness O
or O
caregiving O
, O
uncertainty O
, O
hopelessness O
) O
, O
coping O
resources O
( O
coping O
strategies O
, O
self-efficacy O
, O
communication O
) O
, O
symptom O
distress O
, O
and O
quality O
of O
life O
in O
men O
with O
prostate O
cancer O
and O
their O
spouses O
. O

Mean B-Premise
time I-Premise
to I-Premise
improvement I-Premise
was I-Premise
39.7 I-Premise
weeks I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
22.4 I-Premise
to I-Premise
57.0 I-Premise
weeks I-Premise
) I-Premise
for I-Premise
HBO-treated I-Premise
patients I-Premise
versus I-Premise
67.9 I-Premise
weeks I-Premise
( I-Premise
95 I-Premise
CI I-Premise
, I-Premise
48.4 I-Premise
to I-Premise
87.5 I-Premise
weeks I-Premise
) I-Premise
for I-Premise
controls I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
, I-Premise
log-rank I-Premise
test I-Premise
) I-Premise
. I-Premise

The B-Claim
16-week I-Claim
regimen I-Claim
should I-Claim
not I-Claim
be I-Claim
used I-Claim
instead I-Claim
of I-Claim
a I-Claim
standard-dose I-Claim
regimen I-Claim
without I-Claim
careful I-Claim
consideration I-Claim
of I-Claim
the I-Claim
16-week I-Claim
regimen I-Claim
's I-Claim
pros I-Claim
and I-Claim
cons I-Claim
, I-Claim
which I-Claim
include I-Claim
its I-Claim
complicated I-Claim
schedule I-Claim
. I-Claim

Eighteen O
patients O
were O
randomized O
to O
GJJ O
and O
21 O
to O
stent O
placement O
. O

The O
objective O
of O
this O
study O
is O
to O
explore O
the O
inflammatory O
modulation O
effect O
of O
glutamine-enriched O
total O
parenteral O
nutrition O
( O
TPN O
) O
by O
investigating O
the O
alterations O
of O
inflammation-related O
cytokines O
in O
gastrointestinal O
( O
GI O
) O
cancer O
patients O
postoperatively O
. O

In O
the O
multivariate O
analysis O
, O
FACIT-TOI O
changes O
were O
only O
affected O
by O
the O
modality O
of O
TSH O
stimulation O
performed O
for O
RRA O
. O

A O
total O
of O
448 O
patients O
were O
enrolled O
over O
a O
period O
of O
3 O
years O
. O

To O
determine O
whether O
palliation O
of O
chest O
symptoms O
from O
a O
10 O
Gy O
single O
fraction O
( O
regimen O
1 O
) O
was O
equivalent O
to O
that O
from O
30 O
Gy O
in O
10 O
fractions O
( O
regimen O
2 O
) O
. O

Two O
university O
hospitals O
in O
Copenhagen O
, O
Denmark O
. O

Further O
investigation O
in O
larger O
numbers O
of O
patients O
is O
warranted O
. O

In O
a O
previous O
phase O
II O
trial O
, O
5-fluorouracil O
( O
5-FU O
) O
plus O
cisplatin O
( O
FUP O
) O
yielded O
a O
26.5 O
% O
response O
rate O
and O
a O
29 O
% O
survival O
rate O
at O
1 O
year O
. O

The B-Premise
median I-Premise
time I-Premise
to I-Premise
development I-Premise
of I-Premise
severe I-Premise
mucositis I-Premise
from I-Premise
the I-Premise
start I-Premise
of I-Premise
radiotherapy I-Premise
was I-Premise
3.61 I-Premise
weeks I-Premise
on I-Premise
BCoG I-Premise
and I-Premise
3.96 I-Premise
weeks I-Premise
on I-Premise
placebo I-Premise
( I-Premise
P I-Premise
=.61 I-Premise
) I-Premise
. I-Premise

Patients O
were O
then O
followed O
for O
6 O
months O
and O
evaluated O
for O
quality O
of O
life O
, O
completion O
of O
adjuvant O
treatment O
, O
and O
depressive O
symptoms O
. O

Patients O
were O
randomly O
assigned O
at O
registration O
to O
amifostine O
( O
AM O
) O
500 O
mg O
IV O
four O
times O
per O
week O
or O
no O
AM O
during O
chemoradiotherapy O
. O

Misoprostol O
is O
a O
synthetic O
prostaglandin O
E1 O
analogue O
, O
with O
properties O
of O
a O
mucosal O
cytoprotectant O
. O

The B-Premise
most I-Premise
frequent I-Premise
toxic I-Premise
effects I-Premise
were I-Premise
grade I-Premise
3/4 I-Premise
diarrhea I-Premise
( I-Premise
arm I-Premise
A I-Premise
: I-Premise
34 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
19 I-Premise
% I-Premise
) I-Premise
, I-Premise
grade I-Premise
3/4 I-Premise
neutropenia I-Premise
( I-Premise
A I-Premise
: I-Premise
5 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
19 I-Premise
% I-Premise
) I-Premise
and I-Premise
grade I-Premise
2/3 I-Premise
alopecia I-Premise
( I-Premise
A I-Premise
: I-Premise
26 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
65 I-Premise
% I-Premise
) I-Premise
. I-Premise

Cancer O
cachexia O
is O
a O
common O
problem O
among O
advanced O
cancer O
patients O
. O

This O
randomized O
controlled O
trial O
involved O
109 O
women O
commencing O
adjuvant O
chemotherapy O
for O
stage O
I O
or O
II O
breast O
cancer O
in O
five O
chemotherapy O
treatment O
centers O
. O

Mean B-Premise
dominant I-Premise
fibroid I-Premise
diameter I-Premise
was I-Premise
7.6 I-Premise
± I-Premise
3.0 I-Premise
, I-Premise
5.8 I-Premise
± I-Premise
2.9 I-Premise
, I-Premise
and I-Premise
5 I-Premise
± I-Premise
2.9 I-Premise
cm I-Premise
at I-Premise
baseline I-Premise
, I-Premise
6 I-Premise
months I-Premise
, I-Premise
and I-Premise
5 I-Premise
years I-Premise
. I-Premise

QoL O
was O
assessed O
by O
the O
Lung O
Cancer O
Symptom O
Scale O
( O
LCSS O
) O
and O
the O
general O
EuroQol O
five-dimensional O
questionnaire O
( O
EQ-5D O
) O
in O
926 O
chemotherapy-naïve O
patients O
with O
stages O
IIIB O
to O
IV O
NSCLC O
. O

It O
is O
equieffective O
as O
oral O
( O
p.o O
. O
) O

Evidence B-Claim
suggests I-Claim
that I-Claim
the I-Claim
re-entry I-Claim
phase I-Claim
( I-Claim
ie I-Claim
, I-Claim
early I-Claim
period I-Claim
after I-Claim
medical I-Claim
treatment I-Claim
completion I-Claim
) I-Claim
presents I-Claim
distinct I-Claim
challenges I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

From O
1994-1999 O
, O
495 O
EKS O
patients O
were O
accrued O
, O
and O
470 O
were O
evaluable O
. O

Psychosocial O
symptoms O
were O
assessed O
with O
the O
use O
of O
a O
self-report O
screening O
instrument O
, O
and O
distressed O
women O
were O
referred O
for O
counseling O
if O
needed O
. O

At O
the O
time O
of O
the O
second O
prespecified O
interim O
analysis O
, O
median O
follow-up O
was O
22·2 O
months O
( O
IQR O
20·2-24·8 O
) O
. O

Men O
who O
wish O
to O
increase O
their O
odds O
of O
retaining O
sexual O
function O
might O
be O
counseled O
to O
choose O
EBRT O
over O
cryoablation O
. O

Assessments O
included O
weight O
, O
symptoms O
by O
the O
Edmonton O
Symptom O
Assessment O
Scale O
, O
and O
quality O
of O
life O
by O
the O
Functional O
Assessment O
of O
Anorexia/Cachexia O
Therapy O
( O
FAACT O
) O
questionnaire O
. O

The O
impact O
of O
the O
addition O
of O
docetaxel O
on O
patients O
' O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
and O
symptoms O
was O
investigated O
. O

At O
the O
last O
follow-up O
date O
, O
26 O
patients O
had O
died O
, O
10 O
of O
their O
disease O
and O
none O
of O
toxicity O
, O
with O
no O
differences O
between O
the O
two O
arms O
. O

Overall O
disease-related O
symptom O
improvement O
was O
assessed O
using O
an O
eight-item O
questionnaire O
. O

There B-Premise
was I-Premise
no I-Premise
episode I-Premise
of I-Premise
arm I-Premise
infection I-Premise
or I-Premise
aggravation I-Premise
in I-Premise
limb I-Premise
volume I-Premise
during I-Premise
the I-Premise
study I-Premise
period I-Premise
. I-Premise

It B-Claim
has I-Claim
been I-Claim
shown I-Claim
that I-Claim
nonpharmacologic I-Claim
interventions I-Claim
are I-Claim
effective I-Claim
management I-Claim
techniques I-Claim
for I-Claim
cancer-related I-Claim
fatigue I-Claim
( I-Claim
CRF I-Claim
) I-Claim
in I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

Eighteen O
patients O
were O
excluded O
due O
to O
misclassification O
, O
leaving O
122 O
patients O
eligible O
for O
evaluation O
. O

Patients O
with O
advanced O
solid O
tumor O
cancers O
( O
n O
= O
153 O
) O
were O
randomized O
to O
eight O
sessions O
of O
either O
the O
MCGP O
or O
SGP O
. O

Laparoscopic B-Claim
resection I-Claim
reduced I-Claim
length I-Claim
of I-Claim
hospital I-Claim
stay I-Claim
, I-Claim
improved I-Claim
first-year I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
slightly I-Claim
increased I-Claim
hospital I-Claim
costs I-Claim
. I-Claim

Surgery O
and O
radiotherapy O
commonly O
cause O
adverse O
musculoskeletal O
problems O
, O
particularly O
loss O
of O
strength O
and O
range O
of O
motion O
, O
in O
the O
upper O
quadrant O
of O
breast O
cancer O
patients O
. O

Median O
adherence O
to O
the O
supervised O
exercise O
program O
was O
92 O
% O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
if O
topical O
misoprostol O
was O
effective O
in O
reducing O
the O
severity O
of O
radiation-induced O
mucositis O
in O
patients O
receiving O
radical O
dose O
radiotherapy O
. O

Sexual O
dysfunction O
represents O
a O
complex O
and O
multifactorial O
construct O
that O
can O
affect O
both O
men O
and O
women O
and O
has O
been O
noted O
to O
often O
deteriorate O
significantly O
after O
treatment O
for O
rectal O
and O
anal O
cancer O
. O

Previously O
untreated O
patients O
with O
SCLC O
with O
extensive O
disease O
or O
limited O
stage O
with O
poor O
prognostic O
factors O
were O
randomly O
assigned O
to O
six O
3-weekly O
cycles O
of O
GC O
or O
PE O
. O

Kruskall-Wallis O
methodology O
was O
used O
to O
compare O
scores O
between O
older O
and O
younger O
adult O
patients O
randomized O
to O
the O
intervention O
. O

Forty-eight O
women O
( O
56 O
+/- O
10 O
years O
) O
, O
with O
a O
12.8 O
% O
lymphedema O
relative O
volume O
, O
participated O
in O
the O
study O
. O

Group B-Premise
CBT I-Premise
significantly I-Premise
reduced I-Premise
HFNS I-Premise
problem I-Premise
rating I-Premise
at I-Premise
9 I-Premise
weeks I-Premise
after I-Premise
randomisation I-Premise
compared I-Premise
with I-Premise
usual I-Premise
care I-Premise
( I-Premise
mean I-Premise
difference I-Premise
-1·67 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-2·43 I-Premise
to I-Premise
-0·91 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0·0001 I-Premise
) I-Premise
and I-Premise
improvements I-Premise
were I-Premise
maintained I-Premise
at I-Premise
26 I-Premise
weeks I-Premise
( I-Premise
mean I-Premise
difference I-Premise
-1·76 I-Premise
, I-Premise
-2·54 I-Premise
to I-Premise
-0·99 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0·0001 I-Premise
) I-Premise
. I-Premise

The O
primary O
end O
point O
was O
overall O
survival O
( O
OS O
) O
. O

Despite B-Claim
considerable I-Claim
improvement I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
, I-Claim
the I-Claim
optimization I-Claim
of I-Claim
efficacy I-Claim
and I-Claim
tolerability I-Claim
remains I-Claim
an I-Claim
important I-Claim
issue I-Claim
. I-Claim

Equivalence B-Claim
for I-Claim
three I-Claim
versus I-Claim
four I-Claim
cycles I-Claim
is I-Claim
claimed I-Claim
because I-Claim
both I-Claim
the I-Claim
upper I-Claim
and I-Claim
lower I-Claim
bounds I-Claim
of I-Claim
the I-Claim
80 I-Claim
% I-Claim
CL I-Claim
are I-Claim
less I-Claim
than I-Claim
5 I-Claim
% I-Claim
. I-Claim

Despite B-Premise
slow I-Premise
initial I-Premise
symptom I-Premise
improvement I-Premise
, I-Premise
GJJ B-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
long-term I-Claim
results I-Claim
and I-Claim
is I-Claim
therefore I-Claim
the I-Claim
treatment I-Claim
of I-Claim
choice I-Claim
in I-Claim
patients I-Claim
with I-Claim
a I-Claim
life I-Claim
expectancy I-Claim
of I-Claim
2 I-Claim
months I-Claim
or I-Claim
longer I-Claim
. I-Claim

Unmarried B-Premise
, I-Premise
younger I-Premise
patients I-Premise
who I-Premise
were I-Premise
receiving I-Premise
nontaxane-based I-Premise
therapies I-Premise
and I-Premise
had I-Premise
more I-Premise
advanced I-Premise
disease I-Premise
stage I-Premise
experienced I-Premise
better I-Premise
outcomes I-Premise
. I-Premise

A O
total O
of O
438 O
patients O
underwent O
randomization O
";" O
data O
could O
be O
analyzed O
for O
421 O
. O

Sentinel B-Premise
nodes I-Premise
were I-Premise
found I-Premise
in I-Premise
95 I-Premise
% I-Premise
of I-Premise
the I-Premise
SNBM I-Premise
group I-Premise
( I-Premise
29 I-Premise
% I-Premise
positive I-Premise
) I-Premise
and I-Premise
93 I-Premise
% I-Premise
of I-Premise
the I-Premise
RAC I-Premise
group I-Premise
( I-Premise
25 I-Premise
% I-Premise
positive I-Premise
) I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
assessed I-Premise
using I-Premise
EQ-5D I-Premise
showed I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
. I-Premise

Exercise O
for O
Health O
was O
a O
randomized O
, O
controlled O
trial O
designed O
to O
evaluate O
two O
modes O
of O
delivering O
( O
face-to-face O
[ O
FtF O
] O
and O
over-the-telephone O
[ O
Tel O
] O
) O
an O
8-month O
translational O
exercise O
intervention O
, O
commencing O
6-weeks O
post-breast O
cancer O
surgery O
( O
PS O
) O
. O

EGFR-mutated B-Claim
patients I-Claim
had I-Claim
better I-Claim
survival I-Claim
than I-Claim
those I-Claim
with I-Claim
EGFR I-Claim
wild-type I-Claim
disease I-Claim
, I-Claim
regardless I-Claim
of I-Claim
the I-Claim
treatment I-Claim
received I-Claim
. I-Claim

The O
finding O
of O
a O
decrease O
in O
contralateral O
breast O
cancer O
incidence O
following O
tamoxifen O
administration O
for O
adjuvant O
therapy O
led O
to O
the O
concept O
that O
the O
drug O
might O
play O
a O
role O
in O
breast O
cancer O
prevention O
. O

A O
total O
of O
168 O
patients O
with O
rectal O
cancer O
were O
randomly O
assigned O
to O
laparoscopic O
( O
n O
= O
83 O
) O
or O
open O
( O
n O
= O
85 O
) O
resection O
. O

Adverse B-Claim
events I-Claim
during I-Claim
temozolomide I-Claim
treatment I-Claim
included I-Claim
thrombocytopenia I-Claim
, I-Claim
nausea I-Claim
, I-Claim
vomiting I-Claim
, I-Claim
anorexia I-Claim
, I-Claim
constipation I-Claim
, I-Claim
alopecia I-Claim
, I-Claim
headache I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
convulsions I-Claim
. I-Claim

Postmenopausal O
women O
aged O
50-69 O
years O
at O
randomisation O
. O

This O
double-blind O
, O
randomised O
, O
phase O
3 O
trial O
was O
undertaken O
at O
37 O
clinics O
in O
Denmark O
, O
Norway O
, O
and O
Sweden O
. O

The B-Premise
scores I-Premise
of I-Premise
TCM I-Premise
efficacy I-Premise
( I-Premise
24.52 I-Premise
+/- I-Premise
8.98 I-Premise
vs I-Premise
29.76 I-Premise
+/- I-Premise
7.09 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
the I-Premise
6-min I-Premise
walking I-Premise
distance I-Premise
( I-Premise
233.4 I-Premise
+/- I-Premise
29.2 I-Premise
m I-Premise
vs I-Premise
205.8 I-Premise
+/- I-Premise
31.9 I-Premise
m I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
were I-Premise
better I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
. I-Premise

The B-Premise
response I-Premise
rates I-Premise
, I-Premise
QOL I-Premise
, I-Premise
and I-Premise
median I-Premise
RD I-Premise
, I-Premise
TTP I-Premise
, I-Premise
and I-Premise
TTF I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
arms I-Premise
. I-Premise

Median B-Claim
overall I-Claim
survival I-Claim
and I-Claim
progression-free I-Claim
survival I-Claim
were I-Claim
more I-Claim
favorable I-Claim
in I-Claim
the I-Claim
combination I-Claim
arm I-Claim
as I-Claim
compared I-Claim
with I-Claim
gemcitabine I-Claim
alone I-Claim
, I-Claim
although B-Premise
the I-Premise
difference I-Premise
did I-Premise
not I-Premise
attain I-Premise
statistical I-Premise
significance I-Premise
. I-Premise

Participants O
were O
assessed O
before O
cancer O
treatment O
( O
T1 O
) O
, O
postintervention O
( O
T2 O
) O
, O
which O
was O
at O
least O
2 O
months O
after O
cancer O
treatment O
, O
and O
after O
1-year O
follow-up O
( O
T3 O
) O
. O

The O
decreased O
risk O
occurred O
in O
women O
aged O
49 O
years O
or O
younger O
( O
44 O
% O
) O
, O
50-59 O
years O
( O
51 O
% O
) O
, O
and O
60 O
years O
or O
older O
( O
55 O
% O
) O
";" O
risk B-Premise
was I-Premise
also I-Premise
reduced I-Premise
in I-Premise
women I-Premise
with I-Premise
a I-Premise
history I-Premise
of I-Premise
lobular I-Premise
carcinoma I-Premise
in I-Premise
situ I-Premise
( I-Premise
56 I-Premise
% I-Premise
) I-Premise
or I-Premise
atypical I-Premise
hyperplasia I-Premise
( I-Premise
86 I-Premise
% I-Premise
) I-Premise
and I-Premise
in I-Premise
those I-Premise
with I-Premise
any I-Premise
category I-Premise
of I-Premise
predicted I-Premise
5-year I-Premise
risk I-Premise
. I-Premise

A B-Premise
second I-Premise
infusion I-Premise
of I-Premise
pamidronate I-Premise
did I-Premise
not I-Premise
decrease I-Premise
resorption I-Premise
further I-Premise
, I-Premise
but B-Premise
maintained I-Premise
the I-Premise
suppression I-Premise
of I-Premise
resorption I-Premise
at I-Premise
similar I-Premise
levels I-Premise
for I-Premise
a I-Premise
further I-Premise
four I-Premise
weeks I-Premise
. I-Premise

The O
study O
included O
the O
assessment O
of O
patient O
quality O
of O
life O
. O

Median B-Premise
time I-Premise
to I-Premise
progression I-Premise
was I-Premise
6.9 I-Premise
( I-Premise
4.6-10.1 I-Premise
) I-Premise
and I-Premise
9.2 I-Premise
( I-Premise
7.9-11.5 I-Premise
) I-Premise
months I-Premise
and I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
17.4 I-Premise
( I-Premise
12.6-23.0+ I-Premise
) I-Premise
and I-Premise
24.7 I-Premise
( I-Premise
16.3-26.4+ I-Premise
) I-Premise
months I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
KP I-Premise
from I-Premise
baseline I-Premise
to I-Premise
pre-cycle I-Premise
3 I-Premise
in I-Premise
both I-Premise
arms I-Premise
, I-Premise
with I-Premise
a I-Premise
trend I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
3w4 I-Premise
regimen I-Premise
for I-Premise
duration I-Premise
and I-Premise
faster I-Premise
onset I-Premise
of I-Premise
improvement I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
community I-Premise
locations I-Premise
in I-Premise
favour I-Premise
of I-Premise
home I-Premise
( I-Premise
+15·2 I-Premise
, I-Premise
1·3 I-Premise
to I-Premise
29·1 I-Premise
, I-Premise
P=0.033 I-Premise
) I-Premise
. I-Premise

Associations O
of O
treatment O
group O
and O
putative O
prognostic O
variables O
with O
survival O
were O
tested O
in O
the O
Cox O
proportional O
hazards O
model O
. O

We O
report O
results O
for O
quality O
of O
life O
for O
men O
in O
the O
Scandinavian O
Prostate O
Cancer O
Group O
Study O
Number O
4 O
( O
SPCG-4 O
) O
after O
a O
median O
follow-up O
of O
more O
than O
12 O
years O
. O

Although B-Premise
the I-Premise
CR/PR I-Premise
and I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
groups I-Premise
had I-Premise
similar I-Premise
times I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
, I-Premise
patients B-Claim
with I-Claim
CR/PR I-Claim
reported I-Claim
better I-Claim
QL I-Claim
, I-Claim
suggesting I-Claim
more I-Claim
beneficial I-Claim
response I-Claim
to I-Claim
second-line I-Claim
endocrine I-Claim
treatment I-Claim
. I-Claim

Patients B-Premise
on I-Premise
Arms I-Premise
A I-Premise
and I-Premise
B I-Premise
had I-Premise
median I-Premise
survivals I-Premise
of I-Premise
31.4 I-Premise
and I-Premise
25.3 I-Premise
weeks I-Premise
, I-Premise
12-month I-Premise
survivals I-Premise
of I-Premise
29 I-Premise
% I-Premise
and I-Premise
24 I-Premise
% I-Premise
, I-Premise
and I-Premise
18-month I-Premise
survivals I-Premise
of I-Premise
18 I-Premise
% I-Premise
and I-Premise
8 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. O

Fatigue B-Premise
scores I-Premise
indicated I-Premise
less I-Premise
increase I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
subscale I-Premise
scores I-Premise
showed I-Premise
less I-Premise
decline I-Premise
for I-Premise
the I-Premise
experimental I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0.008 I-Premise
and I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

1088 O
patients O
underwent O
randomisation O
: O
546 O
were O
assigned O
to O
abiraterone O
plus O
prednisone O
and O
542 O
to O
placebo O
plus O
prednisone O
. O

LLLT B-Claim
was I-Claim
effective I-Claim
in I-Claim
improving I-Claim
the I-Claim
patient I-Claim
's I-Claim
subjective I-Claim
experience I-Claim
of I-Claim
OM I-Claim
and I-Claim
QOL I-Claim
in I-Claim
HNC I-Claim
patients I-Claim
receiving I-Claim
CRT I-Claim
. I-Claim

Breast B-Claim
and I-Claim
colorectal I-Claim
cancer I-Claim
survivors I-Claim
enrolled I-Claim
in I-Claim
a I-Claim
multicenter I-Claim
, I-Claim
telephone-based I-Claim
physical I-Claim
activity I-Claim
intervention I-Claim
increased I-Claim
physical I-Claim
activity I-Claim
and I-Claim
experienced I-Claim
significant I-Claim
improvements I-Claim
in I-Claim
fitness I-Claim
and I-Claim
physical I-Claim
functioning I-Claim
. I-Claim

Patients O
were O
seen O
by O
homeopathic O
providers O
every O
2 O
months O
for O
1 O
year O
. O

Training O
efficacy O
was O
not O
modified O
by O
patient O
characteristics O
. O

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
QoL I-Premise
from I-Premise
baseline I-Premise
( I-Premise
t0 I-Premise
) I-Premise
to I-Premise
t1 I-Premise
( I-Premise
RRA I-Premise
period I-Premise
) I-Premise
in I-Premise
the I-Premise
hypothyroid I-Premise
group I-Premise
with I-Premise
significant I-Premise
differences I-Premise
in I-Premise
FACIT-F I-Premise
TOI I-Premise
( I-Premise
P I-Premise
< I-Premise
10 I-Premise
( I-Premise
-3 I-Premise
) I-Premise
) I-Premise
, I-Premise
FACT-G I-Premise
total I-Premise
score I-Premise
( I-Premise
P I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
and I-Premise
FACIT-F I-Premise
total I-Premise
score I-Premise
( I-Premise
P I-Premise
= I-Premise
0.003 I-Premise
) I-Premise
. I-Premise

All O
patients O
completed O
incontinence O
quality O
of O
life O
( O
I-QoL O
) O
questionnaire O
and O
bladder O
diary O
. O

In O
both O
arms O
, O
chemotherapy O
was O
repeated O
at O
day O
29 O
. O

Between-group B-Premise
differences I-Premise
in I-Premise
the I-Premise
primary I-Premise
outcomes I-Premise
were I-Premise
not I-Premise
significant I-Premise
at I-Premise
12 I-Premise
months I-Premise
, I-Premise
and B-Premise
no I-Premise
significant I-Premise
effects I-Premise
emerged I-Premise
on I-Premise
the I-Premise
secondary I-Premise
end I-Premise
points I-Premise
. I-Premise

The O
Southwest O
Oncology O
Group O
( O
SWOG O
) O
intergroup O
trial O
compared O
radical O
prostatectomy O
( O
RP O
) O
plus O
observation O
versus O
RP O
plus O
adjuvant O
radiation O
therapy O
( O
RT O
) O
. O

This O
was O
followed O
, O
4 O
weeks O
later O
, O
by O
six O
cycles O
of O
temozolomide O
, O
150 O
or O
200 O
mg/m2 O
daily O
for O
5 O
days O
, O
every O
4 O
weeks O
. O

DC/CIK B-Claim
treatment I-Claim
had I-Claim
potential I-Claim
benefit I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
compared I-Claim
with I-Claim
the I-Claim
control I-Claim
group I-Claim
and I-Claim
had I-Claim
no I-Claim
obvious I-Claim
side I-Claim
effects I-Claim
. I-Claim

A O
brief O
training O
in O
the O
SMART O
program O
can O
enhance O
resilience O
and O
quality O
of O
life O
and O
decrease O
stress O
and O
anxiety O
. O

Expression B-Premise
of I-Premise
somatostatin I-Premise
receptors I-Premise
is I-Premise
found I-Premise
in I-Premise
HCCs I-Premise
, I-Premise
but O
the B-Claim
efficacy I-Claim
of I-Claim
the I-Claim
somatostatin I-Claim
analogue I-Claim
octreotide I-Claim
remains I-Claim
controversial I-Claim
. I-Claim

Although B-Claim
the I-Claim
regimens I-Claim
in I-Claim
this I-Claim
study I-Claim
were I-Claim
similar I-Claim
in I-Claim
that I-Claim
they I-Claim
included I-Claim
taxane I-Claim
, I-Claim
the I-Claim
mean I-Claim
utility I-Claim
scores I-Claim
and I-Claim
longitudinal I-Claim
patterns I-Claim
of I-Claim
utility I-Claim
scores I-Claim
were I-Claim
different I-Claim
among I-Claim
regimens I-Claim
. I-Claim

Overall B-Premise
response I-Premise
was I-Premise
54 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
44.1 I-Premise
% I-Premise
-63.9 I-Premise
% I-Premise
) I-Premise
with I-Premise
PVI I-Premise
5-FU I-Premise
+ I-Premise
MMC I-Premise
compared I-Premise
to I-Premise
38 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
28.3 I-Premise
% I-Premise
-47.7 I-Premise
% I-Premise
) I-Premise
for I-Premise
PVI I-Premise
5-FU I-Premise
alone I-Premise
( I-Premise
P I-Premise
= I-Premise
0.024 I-Premise
) I-Premise
. I-Premise

There O
were O
no O
differences O
in O
the O
intraoperative O
time O
and O
hospital O
stay O
. O

However B-Premise
, I-Premise
complete I-Premise
gingival I-Premise
healing I-Premise
occurred I-Premise
in I-Premise
only I-Premise
14 I-Premise
of I-Premise
25 I-Premise
HBO-treated I-Premise
patients I-Premise
( I-Premise
52 I-Premise
% I-Premise
) I-Premise
versus I-Premise
7 I-Premise
of I-Premise
21 I-Premise
controls I-Premise
( I-Premise
33.3 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.203 I-Premise
, I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
test I-Premise
) I-Premise
, I-Premise
and I-Premise
time I-Premise
to I-Premise
healing I-Premise
was I-Premise
59 I-Premise
weeks I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
42.8 I-Premise
% I-Premise
to I-Premise
75.8 I-Premise
% I-Premise
) I-Premise
for I-Premise
HBO-treated I-Premise
patients I-Premise
versus I-Premise
70 I-Premise
weeks I-Premise
( I-Premise
95 I-Premise
CI I-Premise
, I-Premise
52.2 I-Premise
% I-Premise
to I-Premise
88.36 I-Premise
% I-Premise
) I-Premise
for I-Premise
controls I-Premise
( I-Premise
P I-Premise
= I-Premise
.32 I-Premise
, I-Premise
log-rank I-Premise
test I-Premise
) I-Premise
. I-Premise

No B-Premise
difference I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
topotecan I-Premise
and I-Premise
observation I-Premise
was I-Premise
observed I-Premise
at I-Premise
any I-Premise
assessment I-Premise
time I-Premise
or I-Premise
for I-Premise
any I-Premise
of I-Premise
the I-Premise
subscale I-Premise
scores I-Premise
. I-Premise

Patients O
were O
randomly O
assigned O
to O
fulvestrant O
500 O
mg O
( O
500 O
mg O
intramuscularly O
[ O
IM O
] O
on O
day O
0 O
, O
then O
500 O
mg O
IM O
on O
days O
14 O
and O
28 O
and O
every O
28 O
days O
thereafter O
) O
or O
250 O
mg O
every O
28 O
days O
. O

Hot B-Claim
flashes I-Claim
are I-Claim
a I-Claim
significant I-Claim
problem I-Claim
for I-Claim
many I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

Most O
patients O
had O
visceral O
metastases O
, O
43 O
% O
had O
a O
disease-free O
interval O
less O
than O
12 O
months O
, O
and O
85 O
% O
had O
measurable O
disease O
. O

A O
high O
percentage O
of O
patients O
with O
newly O
diagnosed O
early O
stage O
breast O
cancer O
were O
found O
to O
have O
depressive O
symptoms O
prior O
to O
the O
initiation O
of O
adjuvant O
therapy O
. O

All O
structures O
including O
the O
IUS O
and O
EUS O
were O
contoured O
on O
T2-weighted O
MRI O
at O
day O
30 O
, O
and O
doses O
received O
were O
calculated O
from O
identification O
of O
seeds O
on O
CT. O
Spearman O
's O
( O
nonparametric O
) O
rank O
correlation O
coefficient O
( O
ρ O
) O
was O
used O
for O
statistical O
analyses O
. O

Stage O
IV O
breast O
cancer O
therapy O
costs O
were O
collected O
by O
surveying O
UK O
oncologists O
, O
and O
utilities O
for O
associated O
health O
states O
were O
from O
published O
sources O
. O

Thyroid B-Premise
ablation I-Premise
was I-Premise
complete I-Premise
in I-Premise
631 I-Premise
of I-Premise
the I-Premise
684 I-Premise
patients I-Premise
( I-Premise
92 I-Premise
% I-Premise
) I-Premise
. I-Premise

Using O
the O
Phoenix O
definition O
, O
the O
5-year O
biochemical O
relapse O
rate O
was O
32 O
% O
and O
23.5 O
% O
, O
respectively O
( O
p O
= O
.09 O
) O
. O

The B-Premise
response I-Premise
rate I-Premise
was I-Premise
low I-Premise
in I-Premise
both I-Premise
arms I-Premise
, I-Premise
but I-Premise
superior I-Premise
in I-Premise
the I-Premise
FUP I-Premise
arm I-Premise
: I-Premise
12 I-Premise
% I-Premise
versus I-Premise
0 I-Premise
% I-Premise
( I-Premise
intention-to-treat I-Premise
analysis I-Premise
, I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

QOL B-Premise
was I-Premise
preserved I-Premise
longer I-Premise
for I-Premise
patients I-Premise
on I-Premise
DCF I-Premise
than I-Premise
those I-Premise
on I-Premise
CF I-Premise
for I-Premise
all I-Premise
time I-Premise
to I-Premise
deterioration I-Premise
analyses I-Premise
, I-Premise
demonstrating I-Premise
the I-Premise
statistical I-Premise
superiority I-Premise
of I-Premise
DCF I-Premise
compared I-Premise
with I-Premise
CF I-Premise
. I-Premise

The O
Programme O
Etude O
Rein O
Cytokines O
( O
PERCY O
) O
Quattro O
trial O
was O
designed O
to O
evaluate O
both O
cytokines O
for O
their O
survival O
benefit O
to O
intermediate O
prognosis O
patients O
, O
who O
represent O
the O
majority O
of O
candidates O
for O
these O
treatments O
. O

5 O
significance O
level O
. O

The B-Claim
randomized I-Claim
controlled I-Claim
double-blind I-Claim
HECTOR I-Claim
trial I-Claim
showed I-Claim
no I-Claim
survival I-Claim
benefit I-Claim
for I-Claim
HCC I-Claim
patients I-Claim
treated I-Claim
with I-Claim
long-acting I-Claim
octreotide I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
. I-Claim

The B-Premise
total I-Premise
efficiencies I-Premise
of I-Premise
non-squamous I-Premise
cell I-Premise
carcinoma I-Premise
were I-Premise
27.62 I-Premise
% I-Premise
and I-Premise
16.00 I-Premise
% I-Premise
. I-Premise

However O
, O
there B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
bowel I-Premise
function I-Premise
, I-Premise
continence I-Premise
score I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

A O
total O
of O
749 O
patients O
were O
randomized O
and O
697 O
were O
available O
for O
analysis O
. O

Neither B-Claim
FU24h I-Claim
+ I-Claim
LV I-Claim
nor I-Claim
FU24h I-Claim
prolong I-Claim
survival I-Claim
, I-Claim
relative I-Claim
to I-Claim
bolus I-Claim
FU I-Claim
+ I-Claim
LV I-Claim
. I-Claim

Treatment O
was O
stopped O
due O
to O
low O
accrual O
. O

A O
total O
of O
166 O
eligible O
patients O
were O
randomly O
assigned O
to O
receive O
adjuvant O
tamoxifen O
, O
exemestane O
, O
or O
anastrozole O
. O

Data O
were O
analyzed O
with O
generalized O
estimating O
equations O
methodology O
to O
model O
differences O
between O
groups O
over O
time O
. O

Statistical O
significance O
was O
kept O
at O
p O
< O
0.05 O
. O

To O
compare O
the O
outcomes O
of O
uterine O
artery O
embolization O
( O
UAE O
) O
for O
leiomyomas O
with O
use O
of O
tris-acryl O
gelatin O
microspheres O
( O
TAGM O
) O
versus O
spherical O
polyvinyl O
alcohol O
( O
PVA O
) O
particles O
. O

In O
a O
previously O
conducted O
randomized O
trial O
comparing O
LRP O
with O
ORP O
, O
60 O
patients O
were O
prospectively O
evaluated O
. O

Addition B-Claim
of I-Claim
bevacizumab I-Claim
to I-Claim
FU/LV I-Claim
as I-Claim
first-line I-Claim
therapy I-Claim
in I-Claim
CRC I-Claim
patients I-Claim
who I-Claim
were I-Claim
not I-Claim
considered I-Claim
optimal I-Claim
candidates I-Claim
for I-Claim
first-line I-Claim
irinotecan I-Claim
treatment I-Claim
provided I-Claim
clinically I-Claim
significant I-Claim
patient I-Claim
benefit I-Claim
, I-Claim
including I-Claim
statistically I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
progression-free I-Claim
survival I-Claim
. I-Claim

Each O
time O
period O
was O
tested O
repeatedly O
against O
the O
baseline O
";" O
an O
overall O
P O
value O
was O
assigned O
for O
each O
reported O
symptom O
. O

Within B-Premise
the I-Premise
randomised I-Premise
controlled I-Premise
trial I-Premise
, I-Premise
the I-Premise
Barthel I-Premise
Index I-Premise
demonstrated I-Premise
a I-Premise
small I-Premise
but I-Premise
significant I-Premise
fall I-Premise
in I-Premise
functionality I-Premise
with I-Premise
radiotherapy I-Premise
compared I-Premise
with I-Premise
the I-Premise
no I-Premise
radiotherapy I-Premise
arm I-Premise
of I-Premise
the I-Premise
trial I-Premise
. I-Premise

No B-Premise
significant I-Premise
benefits I-Premise
in I-Premise
analgesia I-Premise
were I-Premise
found I-Premise
in I-Premise
the I-Premise
global I-Premise
pain I-Premise
intensity I-Premise
of I-Premise
the I-Premise
previous I-Premise
week I-Premise
of I-Premise
treatment I-Premise
, I-Premise
the I-Premise
least I-Premise
pain I-Premise
intensity I-Premise
or I-Premise
the I-Premise
pain I-Premise
evaluated I-Premise
just I-Premise
after I-Premise
a I-Premise
week I-Premise
of I-Premise
treatment I-Premise
, I-Premise
at I-Premise
the I-Premise
moment I-Premise
of I-Premise
the I-Premise
visit I-Premise
, I-Premise
when I-Premise
amitriptyline I-Premise
was I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
. I-Premise

The O
study O
was O
completed O
by O
the O
actor O
as O
a O
descriptive O
, O
explorative O
study O
on O
the O
impact O
of O
" O
laying O
on O
of O
hands O
" O
. O

The O
setting O
was O
in O
a O
hydrotherapy O
pool O
, O
1.2 O
m O
depth O
, O
and O
a O
temperature O
of O
32-33 O
degrees O
capital O
ES O
, O
Cyrillic O
. O

Median B-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
16 I-Premise
and I-Premise
21 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
C3 I-Premise
and I-Premise
C6 I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P=0.21 I-Premise
, I-Premise
HR I-Premise
0.86 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.68-1.08 I-Premise
) I-Premise
. I-Premise

We B-Claim
found I-Claim
no I-Claim
evidence I-Claim
that I-Claim
the I-Claim
addition I-Claim
of I-Claim
TPZ I-Claim
to I-Claim
chemoradiotherapy I-Claim
, I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
not I-Claim
selected I-Claim
for I-Claim
the I-Claim
presence I-Claim
of I-Claim
hypoxia I-Claim
, I-Claim
improves I-Claim
OS I-Claim
. I-Claim

All O
P O
values O
are O
two-sided O
. O

Health O
outcomes O
were O
examined O
according O
to O
treatment O
received O
: O
mastectomy O
with O
and O
without O
chemotherapy O
, O
and O
lumpectomy O
with O
and O
without O
chemotherapy O
. O

A B-Claim
three-times-per-week I-Claim
dosing I-Claim
schedule I-Claim
was I-Claim
noted I-Claim
to I-Claim
be I-Claim
more I-Claim
effective I-Claim
compared I-Claim
with I-Claim
a I-Claim
once-a-week I-Claim
schedule I-Claim
without I-Claim
any I-Claim
significant I-Claim
difference I-Claim
in I-Claim
toxicity I-Claim
reported I-Claim
. I-Claim

Eighteen B-Premise
months I-Premise
after I-Premise
surgery I-Premise
, I-Premise
any I-Premise
differences I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
patients I-Premise
randomized I-Premise
to I-Premise
LAC I-Premise
or I-Premise
open I-Premise
colectomy I-Premise
favored I-Premise
LAC I-Premise
. I-Premise

Outcomes O
included O
safety O
and O
tolerance O
of O
the O
exercise O
program O
, O
physical O
function O
, O
physical O
activity O
level O
, O
body O
composition O
, O
fatigue O
, O
quality O
of O
life O
and O
psychological O
distress O
. O

Thirty-six O
women O
with O
chronic O
upper O
limb O
breast O
cancer-related O
lymphoedema O
. O

Body O
image O
and O
QOL O
also O
were O
assessed O
preoperatively O
. O

Secondary O
-- O
quality O
of O
life O
, O
adverse O
events O
, O
survival O
. O

Short-term B-Claim
postoperative I-Claim
morbidity I-Claim
was I-Claim
similar I-Claim
in I-Claim
the I-Claim
two I-Claim
groups I-Claim
. I-Claim

A O
phase O
III O
randomized O
multicenter O
trial O
was O
planned O
to O
compare O
GEM O
( O
1,000 O
mg/m O
( O
2 O
) O
on O
days O
1 O
, O
8 O
, O
and O
15 O
every O
28 O
days O
) O
with O
PLD O
( O
40 O
mg/m O
( O
2 O
) O
every O
28 O
days O
) O
in O
ovarian O
cancer O
patients O
who O
experienced O
treatment O
failure O
with O
only O
one O
platinum/paclitaxel O
regimen O
and O
who O
experienced O
recurrence O
or O
progression O
within O
12 O
months O
after O
completion O
of O
primary O
treatment O
. O

However B-Claim
, I-Claim
modifications I-Claim
are I-Claim
needed I-Claim
in I-Claim
future I-Claim
randomized I-Claim
trials I-Claim
to I-Claim
reduce I-Claim
the I-Claim
rate I-Claim
of I-Claim
premature I-Claim
termination I-Claim
and I-Claim
to I-Claim
improve I-Claim
long-term I-Claim
maintenance I-Claim
of I-Claim
gains I-Claim
. I-Claim

Biomarker O
expression O
was O
assessed O
by O
immunohistochemistry O
. O

Similarly B-Premise
, I-Premise
ASES I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
( I-Premise
p=0.001 I-Premise
) I-Premise
improved I-Premise
in I-Premise
both I-Premise
Group I-Premise
I I-Premise
and I-Premise
II I-Premise
without I-Premise
any I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
groups I-Premise
. I-Premise

Pleural O
fluid O
was O
collected O
from O
both O
groups O
prior O
to O
and O
following O
treatment O
. O

This B-Premise
was I-Premise
accompanied I-Premise
by I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
the I-Premise
physical I-Premise
function I-Premise
( I-Premise
31 I-Premise
% I-Premise
erlotinib I-Premise
v I-Premise
19 I-Premise
% I-Premise
placebo I-Premise
, I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
global I-Premise
QOL I-Premise
( I-Premise
35 I-Premise
% I-Premise
v I-Premise
26 I-Premise
% I-Premise
, I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
lymphedema I-Premise
during I-Premise
the I-Premise
study I-Premise
was I-Premise
low I-Premise
for I-Premise
both I-Premise
groups I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
groups I-Premise
. I-Premise

We O
conducted O
a O
two-arm O
, O
wait-list O
control O
, O
randomized O
trial O
of O
a O
complex O
rehabilitation O
intervention O
delivered O
by O
a O
hospice-based O
multidisciplinary O
team O
vs. O
usual O
care O
for O
active O
, O
progressive O
, O
recurrent O
hematological O
and O
breast O
malignancies O
, O
with O
a O
follow-up O
at O
three O
months O
. O

Behavioral B-Claim
change I-Claim
, I-Claim
rather I-Claim
than I-Claim
immunity I-Claim
change I-Claim
, I-Claim
was I-Claim
influential I-Claim
in I-Claim
achieving I-Claim
lower I-Claim
levels I-Claim
of I-Claim
symptomatology I-Claim
and I-Claim
higher I-Claim
functional I-Claim
status I-Claim
. I-Claim

An O
understanding O
of O
the O
patterns O
of O
side-effects O
and O
time O
dimension O
of O
their O
occurrence O
for O
each O
treatment O
is O
important O
for O
full O
patient O
information O
. O

There O
were O
532 O
eligible O
patients O
( O
266 O
marimastat O
and O
266 O
placebo O
) O
. O

We B-Premise
recorded I-Premise
the I-Premise
following I-Premise
pair-wise I-Premise
mean I-Premise
difference I-Premise
in I-Premise
change I-Premise
in I-Premise
IBDQ-B I-Premise
score I-Premise
between I-Premise
groups I-Premise
: I-Premise
nurse I-Premise
versus I-Premise
booklet I-Premise
4·12 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·04-8·19 I-Premise
";" I-Premise
p=0·04 I-Premise
) I-Premise
, I-Premise
gastroenterologist I-Premise
versus I-Premise
booklet I-Premise
5·47 I-Premise
( I-Premise
1·14-9·81 I-Premise
";" I-Premise
p=0·01 I-Premise
) I-Premise
. I-Premise

By B-Premise
contrast I-Premise
, I-Premise
QoL I-Premise
was I-Premise
preserved I-Premise
in I-Premise
the I-Premise
rhTSH I-Premise
group I-Premise
. I-Premise

The B-Premise
most I-Premise
common I-Premise
grade I-Premise
3 I-Premise
treatment-related I-Premise
AEs I-Premise
were I-Premise
asthenia/fatigue I-Premise
( I-Premise
16 I-Premise
% I-Premise
) I-Premise
, I-Premise
diarrhea I-Premise
( I-Premise
11 I-Premise
% I-Premise
) I-Premise
, I-Premise
hypertension I-Premise
( I-Premise
11 I-Premise
% I-Premise
) I-Premise
, I-Premise
hand-foot I-Premise
syndrome I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
anorexia I-Premise
( I-Premise
8 I-Premise
% I-Premise
) I-Premise
. I-Premise

Participants O
drank O
4 O
oz O
. O

Erlotinib B-Claim
was I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
had I-Claim
no I-Claim
negative I-Claim
impact I-Claim
on I-Claim
QoL I-Claim
in I-Claim
this I-Claim
subpopulation I-Claim
. I-Claim

In B-Premise
an I-Premise
intent-to-treat I-Premise
analysis I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
treatments I-Premise
in I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
( I-Premise
HDCT I-Premise
, I-Premise
11.1 I-Premise
months I-Premise
";" I-Premise
AT I-Premise
, I-Premise
10.6 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.67 I-Premise
) I-Premise
, I-Premise
duration I-Premise
of I-Premise
response I-Premise
( I-Premise
HDCT I-Premise
, I-Premise
13.9 I-Premise
months I-Premise
";" I-Premise
AT I-Premise
, I-Premise
14.3 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.98 I-Premise
) I-Premise
, I-Premise
and I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HDCT I-Premise
, I-Premise
26.9 I-Premise
months I-Premise
";" I-Premise
AT I-Premise
, I-Premise
23.4 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.60 I-Premise
) I-Premise
. I-Premise

Numeric B-Premise
rating I-Premise
scale I-Premise
scores I-Premise
for I-Premise
pain I-Premise
intensity I-Premise
in I-Premise
group I-Premise
1 I-Premise
and I-Premise
group I-Premise
2 I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
those I-Premise
in I-Premise
group I-Premise
3 I-Premise
at I-Premise
T I-Premise
( I-Premise
0-12 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
";" I-Premise
T I-Premise
( I-Premise
12-24 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
";" I-Premise
and I-Premise
T I-Premise
( I-Premise
24-48 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

In O
this O
study O
, O
the O
authors O
examined O
personal O
and O
clinical O
factors O
that O
may O
predict O
exercise O
training O
responses O
. O

One B-Premise
patient I-Premise
died I-Premise
of I-Premise
febrile I-Premise
neutropenia I-Premise
during I-Premise
treatment I-Premise
. I-Premise

As O
patients O
with O
pancreas O
and O
periampullary O
cancer O
( O
PPC O
) O
experience O
improved O
survival O
rates O
and O
longevity O
, O
the O
focus O
shifts O
toward O
living O
life O
while O
surviving O
cancer O
. O

The O
intervention O
took O
place O
over O
a O
4-month O
period O
. O

At O
a O
median O
follow-up O
of O
56 O
months O
, O
there O
were O
more O
locoregional O
recurrences O
in O
the O
SLN O
arm O
, O
and O
the O
5-year O
disease-free O
survival O
was O
89.9 O
% O
in O
the O
ALND O
arm O
and O
87.6 O
% O
in O
the O
SLN O
arm O
, O
with O
a O
difference O
of O
2.3 O
% O
( O
95 O
% O
confidence O
interval O
: O
-3.1 O
% O
to O
7.6 O
% O
) O
. O

Patients B-Premise
receiving I-Premise
tamoxifen I-Premise
had I-Premise
significantly I-Premise
more I-Premise
vaginal I-Premise
discharge I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

Patients O
completed O
the O
Lung O
Cancer O
Symptom O
Scale O
( O
LCSS O
) O
at O
baseline O
, O
after O
each O
cycle O
, O
and O
post-discontinuation O
. O

Safety O
and O
efficacy O
( O
American O
College O
of O
Rheumatology O
( O
ACR O
) O
criteria O
responses O
, O
DAS28 O
( O
C-reactive O
protein O
) O
, O
HAQ-DI O
, O
SF-36 O
, O
Medical O
Outcomes O
Study O
Sleep O
Problems O
Index O
, O
fatigue O
VAS O
) O
were O
assessed O
through O
2 O
years O
. O

GJJ O
and O
stent O
placement O
. O

PF B-Premise
change I-Premise
scores I-Premise
were I-Premise
-3.9 I-Premise
for I-Premise
cetuximab I-Premise
and I-Premise
-8.6 I-Premise
for I-Premise
BSC I-Premise
( I-Premise
P I-Premise
= I-Premise
.046 I-Premise
) I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
and I-Premise
were I-Premise
-5.9 I-Premise
and I-Premise
-12.5 I-Premise
for I-Premise
cetuximab I-Premise
and I-Premise
BSC I-Premise
, I-Premise
respectively I-Premise
, I-Premise
( I-Premise
P I-Premise
= I-Premise
.027 I-Premise
) I-Premise
at I-Premise
16 I-Premise
weeks I-Premise
. I-Premise

To O
analyze O
and O
compare O
radiologic O
lung O
expansion O
after O
talc O
pleurodesis O
performed O
either O
by O
videothoracoscopy O
or O
chest O
tube O
and O
correlate O
it O
with O
clinical O
outcome O
. O

Follow-up O
assessments O
were O
at O
2 O
, O
4 O
and O
8 O
weeks O
postdischarge O
. O

Participation B-Claim
in I-Claim
an I-Claim
upper-body I-Claim
exercise I-Claim
program I-Claim
caused I-Claim
no I-Claim
changes I-Claim
in I-Claim
arm I-Claim
circumference I-Claim
or I-Claim
arm I-Claim
volume I-Claim
in I-Claim
women I-Claim
with I-Claim
lymphedema I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
and I-Claim
they I-Claim
may I-Claim
have I-Claim
experienced I-Claim
an I-Claim
increase I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

These O
measures O
were O
assessed O
at O
baseline O
, O
1 O
month O
, O
and O
every O
3 O
months O
until O
death O
or O
study O
completion O
. O

The O
primary O
objective O
was O
to O
compare O
complete O
response O
( O
CR O
) O
rates O
. O

We O
sought O
the O
extent O
to O
which O
arm O
morbidity O
could O
be O
reduced O
by O
using O
sentinel-lymph-node-based O
management O
in O
women O
with O
clinically O
node-negative O
early O
breast O
cancer O
. O

Oral O
morphine O
was O
used O
as O
breakthrough O
pain O
medication O
during O
opioid O
titration O
. O

The O
primary O
outcomes O
were O
survival O
( O
PCV O
v O
TMZ O
) O
and O
12-week O
progression-free O
survival O
( O
PFS O
";" O
TMZ-5 O
v O
TMZ-21 O
) O
. O

We O
did O
a O
multicentre O
, O
open-label O
, O
randomised O
controlled O
trial O
at O
five O
study O
centres O
in O
three O
countries O
between O
June O
1 O
, O
2009 O
, O
and O
March O
31 O
, O
2011 O
. O

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
maintained I-Premise
better I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
three I-Premise
cycles I-Premise
";" I-Premise
no B-Premise
differences I-Premise
were I-Premise
detected I-Premise
between I-Premise
3 I-Premise
and I-Premise
5 I-Premise
days I-Premise
of I-Premise
treatment I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
was I-Premise
4.57 I-Premise
months I-Premise
in I-Premise
E I-Premise
and I-Premise
2.53 I-Premise
months I-Premise
in I-Premise
V I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0287 I-Premise
) I-Premise
, I-Premise
with I-Premise
an I-Premise
80.6 I-Premise
% I-Premise
increase I-Premise
in I-Premise
median I-Premise
PFS I-Premise
for I-Premise
E I-Premise
compared I-Premise
with I-Premise
V. I-Premise
Median B-Premise
survival I-Premise
time I-Premise
was I-Premise
11.67 I-Premise
months I-Premise
in I-Premise
E I-Premise
and I-Premise
9.3 I-Premise
months I-Premise
in I-Premise
V I-Premise
( I-Premise
p I-Premise
= I-Premise
0.6975 I-Premise
) I-Premise
. I-Premise

A B-Claim
multidimensional I-Claim
rehabilitation I-Claim
program I-Claim
has I-Claim
statistically I-Claim
and I-Claim
clinically I-Claim
relevant I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
exercise I-Claim
capacity I-Claim
, I-Claim
and I-Claim
muscle I-Claim
force I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
different I-Claim
diagnoses I-Claim
. I-Claim

The O
primary O
end O
point O
was O
QL O
reported O
by O
the O
patient O
and O
by O
physician O
assessment O
. O

77 O
adult O
patients O
with O
cancer O
receiving O
moderately O
or O
highly O
emetogenic O
chemotherapy O
agents O
. O

Challenges O
with O
capturing O
pain O
data O
were O
identified O
and O
resolved O
. O

Median B-Premise
time I-Premise
to I-Premise
HRQoL I-Premise
deterioration I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
to I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
than I-Premise
in I-Premise
those I-Premise
assigned I-Premise
to I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
FACT-P I-Premise
total I-Premise
score I-Premise
( I-Premise
12·7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
11·1-14·0 I-Premise
] I-Premise
vs I-Premise
8·3 I-Premise
months I-Premise
[ I-Premise
7·4-10·6 I-Premise
] I-Premise
";" I-Premise
HR I-Premise
0·78 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·66-0·92 I-Premise
";" I-Premise
p=0·003 I-Premise
) I-Premise
and I-Premise
by I-Premise
the I-Premise
score I-Premise
on I-Premise
its I-Premise
prostate-cancer-specific I-Premise
subscale I-Premise
( I-Premise
11·1 I-Premise
months I-Premise
[ I-Premise
8·6-13·8 I-Premise
] I-Premise
vs I-Premise
5·8 I-Premise
months I-Premise
[ I-Premise
5·5-8·3 I-Premise
] I-Premise
";" I-Premise
HR I-Premise
0·70 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·60-0·83 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0·0001 I-Premise
) I-Premise
. I-Premise

At B-Premise
study I-Premise
completion I-Premise
, I-Premise
participants I-Premise
in I-Premise
the I-Premise
IG I-Premise
were I-Premise
walking I-Premise
twice I-Premise
as I-Premise
far I-Premise
and I-Premise
were I-Premise
significantly I-Premise
more I-Premise
likely I-Premise
to I-Premise
have I-Premise
continued I-Premise
walking I-Premise
or I-Premise
another I-Premise
form I-Premise
of I-Premise
exercise I-Premise
as I-Premise
compared I-Premise
with I-Premise
the I-Premise
UCG I-Premise
. I-Premise

Tamoxifen B-Premise
reduced I-Premise
the I-Premise
risk I-Premise
of I-Premise
noninvasive I-Premise
breast I-Premise
cancer I-Premise
by I-Premise
50 I-Premise
% I-Premise
( I-Premise
two-sided I-Premise
P I-Premise
< I-Premise
.002 I-Premise
) I-Premise
. I-Premise

Seated B-Claim
exercise I-Claim
may I-Claim
be I-Claim
a I-Claim
feasible I-Claim
exercise I-Claim
program I-Claim
for I-Claim
women I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
for I-Claim
controlling I-Claim
fatigue I-Claim
and I-Claim
improving I-Claim
physical I-Claim
well-being I-Claim
. I-Claim

Median B-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
mean I-Premise
pain I-Premise
intensity I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
to I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
26·7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
19·3-not I-Premise
estimable I-Premise
] I-Premise
) I-Premise
than I-Premise
in I-Premise
those I-Premise
assigned I-Premise
to I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
18·4 I-Premise
months I-Premise
[ I-Premise
14·9-not I-Premise
estimable I-Premise
] I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
0·82 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·67-1·00 I-Premise
";" I-Premise
p=0·0490 I-Premise
) I-Premise
, I-Premise
as I-Premise
was I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
pain I-Premise
interference I-Premise
with I-Premise
daily I-Premise
activities I-Premise
( I-Premise
10·3 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
9·3-13·0 I-Premise
] I-Premise
vs I-Premise
7·4 I-Premise
months I-Premise
[ I-Premise
6·4-8·6 I-Premise
] I-Premise
";" I-Premise
HR I-Premise
0·79 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·67-0·93 I-Premise
";" I-Premise
p=0·005 I-Premise
) I-Premise
. I-Premise

Axillary B-Claim
clearance I-Claim
in I-Claim
early I-Claim
breast I-Claim
cancer I-Claim
aims I-Claim
to I-Claim
improve I-Claim
locoregional I-Claim
control I-Claim
and I-Claim
provide I-Claim
staging I-Claim
information I-Claim
but O
is O
associated O
with O
undesirable O
morbidity O
. O

After B-Premise
RT I-Premise
, I-Premise
> I-Premise
90 I-Premise
% I-Premise
of I-Premise
patients I-Premise
experienced I-Premise
RT I-Premise
toxicity I-Premise
";" I-Premise
this B-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
groups I-Premise
, I-Premise
with I-Premise
a I-Premise
trend I-Premise
for I-Premise
reduced I-Premise
symptomatology I-Premise
in I-Premise
group I-Premise
1 I-Premise
versus I-Premise
group I-Premise
2/group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
.07 I-Premise
) I-Premise
. I-Premise

A O
consecutive O
subsample O
of O
patients O
was O
invited O
to O
complete O
the O
EQ-5D O
surveys O
. O

Prospective O
randomized O
study O
that O
included O
60 O
patients O
( O
45 O
women O
, O
15 O
men O
";" O
mean O
age O
, O
55.2 O
years O
) O
with O
recurrent O
malignant O
pleural O
effusion O
between O
January O
2005 O
and O
January O
2008 O
. O

A O
total O
of O
191 O
women O
were O
enrolled O
, O
stratified O
by O
age O
and O
stress O
level O
, O
and O
randomized O
to O
receive O
either O
an O
8-week O
MBAT O
intervention O
or O
a O
breast O
cancer O
educational O
support O
program O
of O
equal O
time O
and O
duration O
. O

Pain O
training O
and O
control O
interventions O
were O
matched O
for O
materials O
and O
method O
. O

Significance O
testing O
of O
group-by-time O
interactions O
in O
286 O
patients O
who O
completed O
all O
assessments O
was O
used O
to O
evaluate O
intervention O
efficacy O
. O

Treatment-related B-Premise
toxicity I-Premise
was I-Premise
less I-Premise
in I-Premise
the I-Premise
single-agent I-Premise
arm I-Premise
and I-Premise
quality-of-life I-Premise
( I-Premise
QOL I-Premise
) I-Premise
analysis I-Premise
favored I-Premise
the I-Premise
single-agent I-Premise
arm I-Premise
. I-Premise

Mood O
was O
measured O
by O
the O
Center O
for O
Epidemiological O
Studies O
Depression O
Scale O
( O
range O
, O
0-60 O
) O
. O

The O
standard O
doublet O
, O
vinorelbine-cisplatin O
, O
was O
compared O
with O
a O
triplet O
of O
vinorelbine-ifosfamide-cisplatin O
, O
in O
terms O
of O
survival O
, O
in O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

Global B-Premise
QL I-Premise
scores I-Premise
were I-Premise
lower I-Premise
at I-Premise
both I-Premise
1 I-Premise
and I-Premise
6 I-Premise
weeks I-Premise
following I-Premise
treatment I-Premise
for I-Premise
patients I-Premise
treated I-Premise
by I-Premise
SEMSs I-Premise
( I-Premise
mean I-Premise
difference I-Premise
QL I-Premise
index I-Premise
week I-Premise
1=-0.66 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
-0.02 I-Premise
to I-Premise
-1.30 I-Premise
, I-Premise
P=0.04 I-Premise
";" I-Premise
mean I-Premise
difference I-Premise
QL I-Premise
index I-Premise
week I-Premise
6=-1.01 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-0.30 I-Premise
to I-Premise
-1.72 I-Premise
, I-Premise
P=0.006 I-Premise
) I-Premise
. I-Premise

Patients O
with O
untreated O
stage O
IC-IV O
ovarian O
cancer O
received O
six O
cycles O
of O
carboplatin O
area O
under O
the O
curve O
6 O
( O
AUC O
6 O
) O
3 O
weekly O
either O
with O
no O
dose O
modification O
except O
for O
toxicity O
( O
Arm O
A O
) O
or O
with O
dose O
escalations O
in O
cycles O
2-6 O
based O
on O
nadir O
neutrophil O
and O
platelet O
counts O
( O
Arm O
B O
) O
. O

A O
body O
image O
questionnaire O
was O
used O
to O
evaluate O
body O
image O
and O
cosmesis O
. O

The O
study O
groups O
were O
comparable O
with O
respect O
to O
clinical O
characteristics O
. O

Poor B-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
between I-Premise
two I-Premise
groups I-Premise
was I-Premise
observed I-Premise
at I-Premise
1 I-Premise
month I-Premise
( I-Premise
23.9 I-Premise
% I-Premise
vs. I-Premise
13 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
months I-Premise
( I-Premise
15.8 I-Premise
% I-Premise
vs. I-Premise
3.7 I-Premise
% I-Premise
) I-Premise
after I-Premise
chemotherapy I-Premise
. I-Premise

LV5FU2 O
with O
high-dose O
leucovorin O
( O
LV O
) O
, O
weekly O
infusional O
5-fluorouracil O
( O
5FU O
) O
( O
AIO O
schedule O
) O
and O
raltitrexed O
have O
been O
demonstrated O
to O
be O
active O
agents O
in O
first-line O
treatment O
of O
colorectal O
cancer O
. O

If O
replicated O
, O
these O
results O
may O
inform O
clinical O
practice O
. O

The B-Premise
use I-Premise
of I-Premise
IMRT I-Premise
did I-Premise
not I-Premise
correlate I-Premise
with I-Premise
pain I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
, O
but O
the B-Premise
presence I-Premise
of I-Premise
moist I-Premise
desquamation I-Premise
did I-Premise
significantly I-Premise
correlate I-Premise
with I-Premise
pain I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
and I-Premise
a I-Premise
reduced I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
. I-Premise

Breast O
and O
prostate O
cancer O
survivors O
( O
N O
= O
543 O
) O
from O
39 O
US O
states O
and O
two O
Canadian O
provinces O
participated O
in O
the O
FRESH O
START O
intervention O
trial O
. O

Combining B-Claim
bevacizumab I-Claim
with I-Claim
docetaxel I-Claim
and I-Claim
trastuzumab I-Claim
did I-Claim
not I-Claim
significantly I-Claim
improve I-Claim
investigator-assessed I-Claim
PFS I-Claim
. I-Claim

To O
confirm O
its O
concurrent O
validity O
and O
responsiveness O
to O
treatment O
and O
recurrence O
in O
patients O
with O
breast O
cancer O
, O
emotional O
well-being O
was O
assessed O
every O
3 O
months O
for O
2 O
years O
and O
at O
1 O
and O
6 O
months O
after O
recurrence O
in O
1,169 O
patients O
who O
were O
premenopausal O
and O
960 O
patients O
who O
were O
postmenopausal O
. O

Total O
costs O
varied O
between O
treatment O
arms O
but O
these O
findings O
canceled O
out O
when O
SEMSs O
were O
compared O
with O
non-SEMS O
therapies O
( O
95 O
% O
CI O
-845.15-1,332.62 O
) O
. O

The B-Premise
rate I-Premise
of I-Premise
QOL I-Premise
drop-out I-Premise
for I-Premise
any I-Premise
reason I-Premise
was I-Premise
higher I-Premise
for I-Premise
C I-Premise
( I-Premise
53 I-Premise
% I-Premise
) I-Premise
compared I-Premise
to I-Premise
CP I-Premise
( I-Premise
38 I-Premise
% I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Clinical B-Claim
interventions I-Claim
to I-Claim
address I-Claim
common I-Claim
symptoms I-Claim
associated I-Claim
with I-Claim
treatment I-Claim
should I-Claim
be I-Claim
considered I-Claim
to I-Claim
improve I-Claim
physical I-Claim
and I-Claim
emotional I-Claim
functioning I-Claim
at I-Claim
the I-Claim
end I-Claim
of I-Claim
primary I-Claim
treatment I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

This B-Claim
study I-Claim
is I-Claim
the I-Claim
first I-Claim
to I-Claim
show I-Claim
that I-Claim
ORP I-Claim
has I-Claim
a I-Claim
negative I-Claim
impact I-Claim
on I-Claim
body I-Claim
image I-Claim
and I-Claim
cosmesis I-Claim
as I-Claim
compared I-Claim
with I-Claim
LRP I-Claim
. I-Claim

daily O
";" O
loading-dose O
( O
1200 O
mg O
";" O
Day O
1 O
Cycle O
1 O
only O
) O
and O
G O
1000 O
mg/m O
( O
2 O
) O
i.v O
. O

These B-Claim
results I-Claim
provide I-Claim
further I-Claim
support I-Claim
for I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
abiraterone I-Claim
in I-Claim
this I-Claim
population I-Claim
. I-Claim

Therefore O
a O
phase O
III O
trial O
was O
implemented O
to O
confirm O
this O
activity O
. O

Subgroup B-Claim
analyses I-Claim
suggested I-Claim
a I-Claim
dose-dependent I-Claim
treatment I-Claim
effect I-Claim
. I-Claim

Hazard O
ratios O
( O
HRs O
) O
with O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
were O
estimated O
using O
a O
Cox O
proportional O
hazards O
model O
. O

At O
baseline O
and O
three O
follow-up O
points O
, O
101 O
of O
125 O
women O
completed O
a O
depression O
symptom O
measure O
. O

Among B-Premise
patients I-Premise
with I-Premise
limited-stage I-Premise
disease I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
survival I-Premise
difference I-Premise
( I-Premise
HR I-Premise
for I-Premise
death I-Premise
= I-Premise
0.91 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.73 I-Premise
to I-Premise
1.15 I-Premise
) I-Premise
, I-Premise
but B-Premise
among I-Premise
patients I-Premise
with I-Premise
extensive I-Premise
disease I-Premise
, I-Premise
survival I-Premise
was I-Premise
worse I-Premise
in I-Premise
the I-Premise
thalidomide I-Premise
group I-Premise
( I-Premise
HR I-Premise
for I-Premise
death I-Premise
= I-Premise
1.36 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
1.10 I-Premise
to I-Premise
1.68 I-Premise
) I-Premise
. I-Premise

HRQOL B-Premise
and I-Premise
symptom I-Premise
relief I-Premise
were I-Premise
equivalent I-Premise
in I-Premise
the I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

The B-Premise
most I-Premise
common I-Premise
site I-Premise
of I-Premise
systemic I-Premise
recurrence I-Premise
was I-Premise
the I-Premise
liver I-Premise
. I-Premise

In O
this O
randomised O
controlled O
trial O
, O
we O
recruited O
women O
from O
breast O
clinics O
in O
London O
, O
UK O
, O
who O
had O
problematic O
HFNS O
( O
minimum O
ten O
problematic O
episodes O
a O
week O
) O
after O
breast-cancer O
treatment O
. O

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
scores I-Premise
at I-Premise
months I-Premise
9 I-Premise
and I-Premise
12 I-Premise
( I-Premise
P I-Premise
= I-Premise
.24 I-Premise
and I-Premise
P I-Premise
= I-Premise
.93 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Results O
for O
quality O
of O
life O
, O
symptom O
palliation O
, O
and O
tolerability O
are O
presented O
here O
. O

Patients O
with O
multiple O
myeloma O
who O
were O
starting O
antimyeloma O
treatment O
were O
randomly O
assigned O
in O
a O
1:1 O
ratio O
to O
receive O
one O
of O
two O
doses O
of O
pamidronate O
( O
30 O
mg O
or O
90 O
mg O
) O
given O
by O
intravenous O
infusion O
once O
a O
month O
for O
at O
least O
3 O
years O
. O

This O
study O
provides O
prospective O
data O
on O
how O
multiple O
dosing O
regimens O
available O
with O
darbepoetin O
alfa O
can O
be O
synchronized O
with O
chemotherapy O
administered O
across O
a O
range O
of O
dosing O
schedules O
. O

That B-Premise
is I-Premise
, I-Premise
by I-Premise
specifically I-Premise
lowering I-Premise
intervention I-Premise
patients I-Premise
' I-Premise
distress I-Premise
at I-Premise
4 I-Premise
months I-Premise
, I-Premise
their I-Premise
health I-Premise
was I-Premise
improved I-Premise
at I-Premise
12 I-Premise
months I-Premise
( I-Premise
p I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Seventy-eight O
and O
54 O
% O
of O
C3 O
and O
C6 O
patients O
, O
respectively O
, O
completed O
all O
scheduled O
chemotherapy O
courses O
. O

The B-Claim
-3 I-Claim
and I-Claim
5-year I-Claim
survival I-Claim
rates I-Claim
of I-Claim
nonsurgical I-Claim
therapy I-Claim
were I-Claim
comparable I-Claim
to I-Claim
published I-Claim
surgical I-Claim
trials I-Claim
of I-Claim
N2 I-Claim
disease I-Claim
. I-Claim

This B-Claim
randomised I-Claim
trial I-Claim
encountered I-Claim
the I-Claim
accrual I-Claim
difficulties I-Claim
and I-Claim
consequent I-Claim
low I-Claim
statistical I-Claim
power I-Claim
commonly I-Claim
associated I-Claim
with I-Claim
interdisciplinary I-Claim
studies I-Claim
drawing I-Claim
from I-Claim
a I-Claim
small I-Claim
eligible I-Claim
population I-Claim
, I-Claim
but O
can O
contribute O
to O
future O
overviews O
on O
the O
management O
of O
solitary O
brain O
metastases O
. O

Median B-Premise
survival I-Premise
was I-Premise
16.6 I-Premise
months I-Premise
for I-Premise
the I-Premise
FU/LV/bevacizumab I-Premise
group I-Premise
and I-Premise
12.9 I-Premise
months I-Premise
for I-Premise
the I-Premise
FU/LV/placebo I-Premise
group I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.79 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.16 I-Premise
) I-Premise
. I-Premise

Multilevel O
procedures O
were O
used O
to O
compare O
the O
intervention O
groups O
with O
the O
control O
group O
over O
time O
. O

At B-Premise
2 I-Premise
weeks I-Premise
, I-Premise
assignment I-Premise
to I-Premise
TEC I-Premise
was I-Premise
associated I-Premise
with I-Premise
improvement I-Premise
in I-Premise
pain-related I-Premise
impairment I-Premise
( I-Premise
-0.25 I-Premise
points I-Premise
on I-Premise
a I-Premise
5-point I-Premise
scale I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
-0.43 I-Premise
to I-Premise
-0.06 I-Premise
, I-Premise
P=.01 I-Premise
) I-Premise
but B-Premise
not I-Premise
in I-Premise
pain I-Premise
severity I-Premise
( I-Premise
-0.21 I-Premise
points I-Premise
on I-Premise
an I-Premise
11-point I-Premise
scale I-Premise
, I-Premise
-0.60 I-Premise
to I-Premise
0.17 I-Premise
, I-Premise
P=.27 I-Premise
) I-Premise
. I-Premise

Three B-Premise
treatment-related I-Premise
deaths I-Premise
occurred I-Premise
: I-Premise
2 I-Premise
patients I-Premise
in I-Premise
the I-Premise
surgical I-Premise
arms I-Premise
( I-Premise
one I-Premise
late I-Premise
pulmonary I-Premise
toxicity I-Premise
and I-Premise
one I-Premise
pulmonary I-Premise
embolus I-Premise
) I-Premise
, I-Premise
and I-Premise
1 I-Premise
patient I-Premise
in I-Premise
the I-Premise
radiation I-Premise
arm I-Premise
( I-Premise
radiation I-Premise
pneumonitis I-Premise
) I-Premise
. I-Premise

Therapeutic O
protocols O
associated O
with O
appropriate O
and O
effective O
psychological O
and O
social O
support O
systems O
are O
essential O
to O
counteract O
the O
symptoms O
of O
neoplastic O
disease O
in O
incurable O
patients O
. O

Isotretinoin O
at O
a O
dose O
of O
20 O
mg O
for O
patients O
< O
or O
= O
73 O
kg O
, O
30 O
mg O
for O
patients O
greater O
than O
73 O
kg O
, O
or O
placebo O
daily O
for O
24 O
months O
. O

ADAPt-C B-Claim
collaborative I-Claim
care I-Claim
is I-Claim
feasible I-Claim
and I-Claim
results I-Claim
in I-Claim
significant I-Claim
reduction I-Claim
in I-Claim
depressive I-Claim
symptoms I-Claim
, I-Claim
improvement I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
lower I-Claim
pain I-Claim
levels I-Claim
compared I-Claim
with I-Claim
EUC I-Claim
for I-Claim
patients I-Claim
with I-Claim
depressive I-Claim
disorders I-Claim
in I-Claim
a I-Claim
low-income I-Claim
, I-Claim
predominantly I-Claim
Hispanic I-Claim
population I-Claim
in I-Claim
public I-Claim
sector I-Claim
oncology I-Claim
clinics I-Claim
. I-Claim

Four B-Claim
cycles I-Claim
of I-Claim
PE I-Claim
induction I-Claim
therapy I-Claim
followed I-Claim
by I-Claim
four I-Claim
cycles I-Claim
of I-Claim
topotecan I-Claim
improved I-Claim
PFS I-Claim
but I-Claim
failed I-Claim
to I-Claim
improve I-Claim
overall I-Claim
survival I-Claim
or I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
extensive-stage I-Claim
SCLC I-Claim
. I-Claim

The B-Premise
successful I-Premise
ablation I-Premise
rate I-Premise
was I-Premise
91.0 I-Premise
% I-Premise
in I-Premise
T4-WD I-Premise
Group I-Premise
, I-Premise
91.7 I-Premise
% I-Premise
in I-Premise
T3-WD I-Premise
Group I-Premise
, I-Premise
and I-Premise
91.3 I-Premise
% I-Premise
in I-Premise
rhTSH I-Premise
Group I-Premise
, I-Premise
without I-Premise
significant I-Premise
between-preparation I-Premise
differences I-Premise
( I-Premise
p I-Premise
= I-Premise
0.2061 I-Premise
) I-Premise
. I-Premise

The B-Claim
combination I-Claim
of I-Claim
day I-Claim
1-8 I-Claim
VNR I-Claim
plus I-Claim
CDDP I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
is I-Claim
less I-Claim
toxic I-Claim
and I-Claim
better I-Claim
tolerated I-Claim
than I-Claim
the I-Claim
regimen I-Claim
of I-Claim
weekly I-Claim
VNR I-Claim
plus I-Claim
CDDP I-Claim
every I-Claim
4 I-Claim
weeks I-Claim
. I-Claim

Combined B-Claim
cardiorespiratory I-Claim
and I-Claim
resistance I-Claim
training I-Claim
, I-Claim
even I-Claim
of I-Claim
very I-Claim
brief I-Claim
duration I-Claim
, I-Claim
improves I-Claim
the I-Claim
QOL I-Claim
and I-Claim
the I-Claim
overall I-Claim
physical I-Claim
fitness I-Claim
of I-Claim
women I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

We O
therefore O
studied O
the O
effects O
of O
a O
high-fat O
diet O
, O
particularly O
on O
body O
composition O
. O

194 O
women O
representative O
of O
the O
breast O
cancer O
population O
were O
randomised O
to O
the O
FtF O
( O
n O
= O
67 O
) O
, O
Tel O
( O
n O
= O
67 O
) O
and O
UC O
( O
n O
= O
60 O
) O
groups O
. O

This O
study O
tested O
the O
efficacy O
of O
a O
caregiver-assisted O
CST O
protocol O
in O
a O
sample O
of O
patients O
with O
lung O
cancer O
. O

Chemotherapy B-Claim
can I-Claim
profoundly I-Claim
affect I-Claim
patients I-Claim
' I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
, I-Claim
yet O
few O
clinical O
trials O
in O
advanced O
cervical O
cancer O
have O
included O
QOL O
outcomes O
. O

Quality-of-life O
data O
were O
prospectively O
collected O
. O

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
either I-Premise
PFS I-Premise
or I-Premise
OS I-Premise
between I-Premise
IFN1 I-Premise
and I-Premise
IFN5 I-Premise
( I-Premise
median I-Premise
of I-Premise
3.7 I-Premise
months I-Premise
and I-Premise
median I-Premise
of I-Premise
3.4 I-Premise
months I-Premise
PFS I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
median I-Premise
of I-Premise
25.5 I-Premise
months I-Premise
and I-Premise
median I-Premise
of I-Premise
17.5 I-Premise
months I-Premise
OS I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

HRQoL O
was O
assessed O
with O
the O
EORTC O
Core O
QoL O
Questionnaire O
( O
QLQ-C30 O
) O
and O
the O
myeloma-specific O
module O
( O
QLQ-MY24 O
) O
at O
baseline O
and O
at O
predetermined O
intervals O
during O
treatment O
. O

Cognitive O
and O
behavioural O
techniques O
are O
not O
yet O
well O
established O
in O
France O
. O

cryoablation B-Premise
was I-Premise
associated I-Premise
with I-Premise
more I-Premise
acute I-Premise
urinary I-Premise
dysfunction I-Premise
( I-Premise
mean I-Premise
PCI I-Premise
urinary I-Premise
function I-Premise
cryoablation=69.4 I-Premise
";" I-Premise
mean I-Premise
EBRT=90.7 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
which I-Premise
resolved I-Premise
over I-Premise
time I-Premise
. I-Premise

EBRT B-Claim
for I-Claim
endometrial I-Claim
cancer I-Claim
is I-Claim
associated I-Claim
with I-Claim
long-term I-Claim
urinary I-Claim
and I-Claim
bowel I-Claim
symptoms I-Claim
and I-Claim
lower I-Claim
physical I-Claim
and I-Claim
role-physical I-Claim
functioning I-Claim
, I-Claim
even I-Claim
15 I-Claim
years I-Claim
after I-Claim
treatment I-Claim
. I-Claim

We O
then O
compared O
the O
FACT-An O
data O
from O
the O
Internet O
survey O
with O
the O
QOL O
data O
of O
a O
375-patient O
randomized O
, O
double-blind O
clinical O
trial O
evaluating O
epoetin O
alfa O
versus O
placebo O
in O
anemic O
cancer O
patients O
. O

Median O
age O
was O
72 O
years O
( O
range O
, O
70-82 O
years O
) O
. O

Four B-Claim
cycles I-Claim
of I-Claim
standard I-Claim
PE I-Claim
remains I-Claim
an I-Claim
appropriate I-Claim
first-line I-Claim
treatment I-Claim
for I-Claim
extensive-stage I-Claim
SCLC I-Claim
patients I-Claim
with I-Claim
good I-Claim
performance I-Claim
status I-Claim
. I-Claim

The O
primary O
endpoint O
was O
progression-free O
survival O
( O
PFS O
) O
. O

The O
purpose O
of O
this O
2-group O
randomized O
controlled O
pilot O
feasibility O
study O
was O
to O
test O
short-term O
effects O
of O
a O
12-week O
Mindful O
Movement O
Program O
( O
MMP O
) O
intervention O
combining O
mindfulness O
with O
self-directed O
movement O
on O
QOL O
and O
mindfulness O
in O
female O
BCSs O
50 O
years O
or O
older O
and O
at O
12 O
months O
or O
more O
following O
treatment O
. O

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
a O
novel O
mindfulness O
intervention O
called O
mindfulness-based O
art O
therapy O
( O
MBAT O
) O
versus O
standard O
educational O
support O
, O
on O
indices O
of O
stress O
and O
quality O
of O
life O
in O
breast O
cancer O
patients O
with O
high O
stress O
levels O
. O

In B-Premise
both I-Premise
the I-Premise
patients I-Premise
' I-Premise
subjective I-Premise
assessment I-Premise
of I-Premise
their I-Premise
QL I-Premise
and I-Premise
the I-Premise
physicians I-Premise
' I-Premise
perception I-Premise
of I-Premise
the I-Premise
patients I-Premise
' I-Premise
QL I-Premise
, I-Premise
the I-Premise
largest I-Premise
adverse I-Premise
QL I-Premise
effects I-Premise
of I-Premise
Ax I-Premise
were I-Premise
observed I-Premise
from I-Premise
baseline I-Premise
to I-Premise
the I-Premise
first I-Premise
postoperative I-Premise
assessment I-Premise
, I-Premise
but B-Premise
the I-Premise
differences I-Premise
tended I-Premise
to I-Premise
disappear I-Premise
in I-Premise
6 I-Premise
to I-Premise
12 I-Premise
months I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
42 I-Premise
months I-Premise
, I-Premise
median I-Premise
PFS I-Premise
( I-Premise
11 I-Premise
months I-Premise
v I-Premise
9.1 I-Premise
months I-Premise
";" I-Premise
P I-Premise
=.03 I-Premise
) I-Premise
and I-Premise
TFS I-Premise
( I-Premise
15 I-Premise
months I-Premise
v I-Premise
11 I-Premise
months I-Premise
";" I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
were I-Premise
superior I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
fludarabine I-Premise
. I-Premise

It B-Claim
can I-Claim
be I-Claim
concluded I-Claim
that I-Claim
the I-Claim
tailored I-Claim
Pain I-Claim
Education I-Claim
Program I-Claim
is I-Claim
effective I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
in I-Claim
chronic I-Claim
pain I-Claim
. I-Claim

Among B-Premise
all I-Premise
treatment I-Premise
groups I-Premise
, I-Premise
patients I-Premise
who I-Premise
had I-Premise
a I-Premise
mastectomy I-Premise
had I-Premise
the I-Premise
poorest I-Premise
physical I-Premise
functioning I-Premise
at I-Premise
registration I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
at I-Premise
enrollment I-Premise
( I-Premise
P=.05 I-Premise
) I-Premise
. I-Premise

This O
randomized O
controlled O
trial O
tested O
whether O
acupuncture O
reduces O
vasomotor O
symptoms O
and O
produces O
fewer O
adverse O
effects O
than O
venlafaxine O
. O

Gefitinib B-Claim
failed I-Claim
to I-Claim
demonstrate I-Claim
superior I-Claim
OS I-Claim
compared I-Claim
with I-Claim
GP I-Claim
as I-Claim
first-line I-Claim
therapy I-Claim
for I-Claim
NSLAs I-Claim
. I-Claim

Median B-Premise
survival I-Premise
in I-Premise
the I-Premise
C3 I-Premise
group I-Premise
was I-Premise
28 I-Premise
vs I-Premise
32 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
C6 I-Premise
group I-Premise
( I-Premise
P=0.75 I-Premise
, I-Premise
HR I-Premise
1.04 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.82-1.31 I-Premise
) I-Premise
. I-Premise

Patients O
watched O
a O
video O
followed O
by O
about O
20 O
min O
of O
manual-standardized O
training O
with O
an O
oncology O
nurse O
focused O
on O
reviewing O
the O
printed O
material O
and O
adapted O
to O
individual O
concerns O
of O
patients O
. O

These B-Claim
findings I-Claim
demonstrate I-Claim
clinically I-Claim
meaningful I-Claim
, I-Claim
transitory I-Claim
HRQoL I-Claim
decrements I-Claim
with I-Claim
VMP I-Claim
and I-Claim
relatively I-Claim
lower I-Claim
HRQoL I-Claim
vs. I-Claim
MP I-Claim
during I-Claim
early I-Claim
treatment I-Claim
cycles I-Claim
, I-Claim
associated I-Claim
with I-Claim
the I-Claim
expected I-Claim
additional I-Claim
toxicities I-Claim
. I-Claim

281 B-Premise
( I-Premise
85 I-Premise
% I-Premise
) I-Premise
of I-Premise
332 I-Premise
in I-Premise
the I-Premise
combined-treatment I-Premise
group I-Premise
and I-Premise
227 I-Premise
( I-Premise
72 I-Premise
% I-Premise
) I-Premise
of I-Premise
313 I-Premise
in I-Premise
the I-Premise
endocrine-only I-Premise
group I-Premise
had I-Premise
erectile I-Premise
dysfunction I-Premise
( I-Premise
p=0.0002 I-Premise
) I-Premise
. I-Premise

MSBR B-Premise
improved I-Premise
mood I-Premise
, I-Premise
breast- I-Premise
and I-Premise
endocrine-related I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
and I-Premise
well-being I-Premise
more I-Premise
effectively I-Premise
than I-Premise
standard I-Premise
care I-Premise
in I-Premise
women I-Premise
with I-Premise
stage I-Premise
0 I-Premise
to I-Premise
III I-Premise
breast I-Premise
cancer I-Premise
, I-Premise
and I-Premise
these I-Premise
results I-Premise
persisted I-Premise
at I-Premise
three I-Premise
months I-Premise
. I-Premise

Generalised O
estimating O
equation O
modelling O
determined O
time O
( O
baseline O
[ O
5 O
weeks O
PS O
] O
, O
mid-intervention O
[ O
6 O
months O
PS O
] O
, O
post-intervention O
[ O
12 O
months O
PS O
] O
) O
, O
group O
( O
FtF O
, O
Tel O
, O
Usual O
Care O
[ O
UC O
] O
) O
and O
time-by-group O
effects O
. O

The O
immune O
system O
can O
not O
identify O
and O
remove O
malignant O
and O
mutant O
cells O
, O
which O
cause O
tumor O
cells O
to O
escape O
from O
surveillance O
and O
clearance O
of O
the O
immune O
system O
. O

CONNECT B-Claim
has I-Claim
shown I-Claim
promising I-Claim
indications I-Claim
on I-Claim
health I-Claim
system I-Claim
and I-Claim
patient I-Claim
outcomes I-Claim
that I-Claim
warrant I-Claim
a I-Claim
larger I-Claim
study I-Claim
to I-Claim
further I-Claim
investigate I-Claim
the I-Claim
potential I-Claim
of I-Claim
this I-Claim
intervention I-Claim
. I-Claim

The O
proportions O
of O
patients O
having O
assessable O
EORTC O
QLQ-C30 O
and O
EQ-5D O
questionnaires O
at O
baseline O
were O
86.0 O
% O
and O
78.7 O
% O
with O
DCF O
, O
respectively O
, O
and O
89.7 O
% O
and O
92.8 O
% O
with O
CF O
, O
respectively O
. O

In B-Premise
patients I-Premise
in I-Premise
group I-Premise
1 I-Premise
who I-Premise
had I-Premise
gynecomastia I-Premise
or I-Premise
breast I-Premise
pain I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
symptoms I-Premise
was I-Premise
achieved I-Premise
in I-Premise
those I-Premise
receiving I-Premise
tamoxifen I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Between O
May O
2002 O
and O
April O
2004 O
, O
182 O
patients O
with O
advanced O
GIST O
were O
enrolled O
. O

Patient O
HRQoL O
was O
assessed O
using O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Lung O
questionnaire O
, O
in O
terms O
of O
time O
to O
symptom O
progression O
( O
TSP O
) O
, O
time O
to O
deterioration O
( O
TTD O
) O
in O
Trial O
Outcome O
Index O
( O
TOI O
) O
and O
TTD O
. O

To O
perform O
a O
randomized O
trial O
comparing O
70 O
and O
80 O
Gy O
radiotherapy O
for O
prostate O
cancer O
. O

Other O
functional O
assessments O
included O
pulmonary O
and O
eating O
functions O
. O

In O
light O
of O
the O
results O
obtained O
in O
the O
study O
, O
the B-Claim
extensive I-Claim
use I-Claim
of I-Claim
the I-Claim
drug I-Claim
for I-Claim
cancer I-Claim
pain I-Claim
should I-Claim
be I-Claim
questioned I-Claim
. I-Claim

We O
compared O
a O
policy O
of O
three O
vs O
six O
courses O
of O
new-generation O
platinum-based O
combination O
chemotherapy O
with O
regard O
to O
effects O
on O
quality O
of O
life O
( O
QoL O
) O
and O
survival O
. O

Randomisation O
was O
done O
in O
blocks O
of O
12-20 O
participants O
, O
stratifying O
by O
age O
( O
younger O
than O
50 O
years O
, O
50 O
years O
or O
older O
) O
, O
and O
was O
done O
with O
a O
computer-generated O
sequence O
. O

To O
carry O
out O
a O
preliminary O
trial O
evaluating O
the O
effectiveness O
of O
two O
types O
of O
homeopathy O
for O
the O
treatment O
of O
menopausal O
symptoms O
in O
breast O
cancer O
survivors O
. O

We O
report O
on O
the O
quality O
of O
life O
( O
QOL O
) O
outcomes O
for O
this O
trial O
. O

Primary O
outcome O
measures O
assessed O
at O
baseline O
and O
at O
week O
12 O
included O
the O
Connor O
Davidson O
Resilience O
Scale O
, O
Perceived O
Stress O
Scale O
, O
Smith O
Anxiety O
Scale O
, O
and O
Linear O
Analog O
Self O
Assessment O
Scale O
. O

They O
were O
randomly O
divided O
to O
receive O
either O
glutamine-enriched O
TPN O
or O
standard O
TPN O
. O

We O
compared O
fulvestrant O
500 O
mg O
regimen O
with O
the O
approved O
dose O
of O
fulvestrant O
250 O
mg O
per O
month O
for O
treatment O
of O
postmenopausal O
women O
with O
estrogen O
receptor-positive O
advanced O
breast O
cancer O
who O
experienced O
progression O
after O
prior O
endocrine O
therapy O
. O

There O
were O
no O
differences O
between O
treatment O
groups O
in O
dimension O
scores O
at O
baseline O
( O
randomization O
) O
. O

Costs O
and O
benefits O
were O
jointly O
determined O
for O
the O
stage O
IV O
breast O
cancer O
subgroup O
( O
n O
= O
55 O
) O
. O

The O
second O
International O
Society O
of O
Paediatric O
Oncology O
( O
SIOP O
) O
study O
for O
rhabdomyosarcoma O
( O
MMT84 O
) O
had O
several O
goals O
. O

Androgen O
deprivation O
therapy O
( O
ADT O
) O
is O
commonly O
used O
as O
a O
primary O
treatment O
for O
patients O
with O
prostate O
cancer O
( O
PCa O
) O
who O
are O
not O
eligible O
for O
radical O
treatment O
options O
. O

Prospective O
studies O
comparing O
the O
two O
methods O
in O
Asian O
people O
are O
few O
. O

The O
study O
was O
designed O
to O
detect O
a O
15 O
% O
improvement O
";" O
that O
is O
, O
from O
50 O
% O
to O
65 O
% O
in O
median O
progression-free O
survival O
( O
PFS O
) O
in O
favor O
of O
the O
dose-intensified O
regimen O
. O

The B-Premise
estimated I-Premise
difference I-Premise
in I-Premise
total I-Premise
societal I-Premise
costs I-Premise
was I-Premise
larger I-Premise
, I-Premise
also I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
single-fraction I-Premise
schedule I-Premise
, I-Premise
but B-Premise
it I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
$ I-Premise
4700 I-Premise
versus I-Premise
$ I-Premise
6453 I-Premise
, I-Premise
difference I-Premise
= I-Premise
$ I-Premise
1753 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
on I-Premise
the I-Premise
difference I-Premise
= I-Premise
- I-Premise
$ I-Premise
99 I-Premise
to I-Premise
$ I-Premise
3604 I-Premise
";" I-Premise
P I-Premise
=.06 I-Premise
) I-Premise
. I-Premise

In O
total O
, O
182 O
patients O
were O
enrolled O
. O

Percentages O
of O
patients O
completing O
9 O
months O
of O
treatment O
in O
the O
PCV O
, O
TMZ-5 O
, O
and O
TMZ-21 O
arms O
were O
17 O
% O
, O
26 O
% O
, O
and O
13 O
% O
, O
respectively O
. O

PS B-Claim
and I-Claim
other I-Claim
prognostic I-Claim
factors I-Claim
could I-Claim
influence I-Claim
the I-Claim
response I-Claim
rate I-Claim
, I-Claim
which I-Claim
does I-Claim
not I-Claim
appear I-Claim
to I-Claim
be I-Claim
a I-Claim
reliable I-Claim
parameter I-Claim
for I-Claim
evaluating I-Claim
the I-Claim
outcome I-Claim
of I-Claim
chemotherapy I-Claim
trials I-Claim
. I-Claim

QOL B-Premise
improvement I-Premise
rates I-Premise
( I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Head I-Premise
& I-Premise
amp I-Premise
";" I-Premise
Neck I-Premise
total I-Premise
score I-Premise
) I-Premise
were I-Premise
13.4 I-Premise
% I-Premise
, I-Premise
18.0 I-Premise
% I-Premise
, I-Premise
and I-Premise
6.0 I-Premise
% I-Premise
for I-Premise
gefitinib I-Premise
250 I-Premise
mg/day I-Premise
, I-Premise
500 I-Premise
mg/day I-Premise
, I-Premise
and I-Premise
methotrexate I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Improvements O
can O
be O
made O
in O
the O
quality O
of O
cancer O
care O
if O
supportive O
care O
needs O
are O
addressed O
";" O
however O
, O
there O
are O
few O
trials O
of O
supportive O
care O
interventions O
to O
guide O
policy O
and O
practice O
. O

There B-Premise
is I-Premise
no I-Premise
irreversible I-Premise
toxicity I-Premise
with I-Premise
MMC I-Premise
at I-Premise
a I-Premise
cumulative I-Premise
dose I-Premise
of I-Premise
28 I-Premise
mg/m2 I-Premise
. I-Premise

ES B-Premise
scores I-Premise
and I-Premise
CES-D I-Premise
scores I-Premise
were I-Premise
similar I-Premise
in I-Premise
all I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

This O
study O
addressed O
the O
effects O
of O
pilates O
exercise O
, O
as O
a O
new O
approach O
, O
on O
functional O
capacity O
, O
fatigue O
, O
depression O
and O
quality O
of O
life O
in O
breast O
cancer O
patients O
in O
whom O
there O
are O
doubts O
regarding O
the O
efficacy O
and O
usefulness O
of O
the O
exercise O
. O

Women B-Premise
with I-Premise
advanced I-Premise
breast I-Premise
cancer I-Premise
randomized I-Premise
to I-Premise
the I-Premise
seated I-Premise
exercise I-Premise
intervention I-Premise
had I-Premise
a I-Premise
slower I-Premise
decline I-Premise
in I-Premise
total I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
and I-Premise
less I-Premise
increase I-Premise
in I-Premise
fatigue I-Premise
scores I-Premise
starting I-Premise
with I-Premise
the I-Premise
third I-Premise
cycle I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise

Significant B-Premise
effects I-Premise
were I-Premise
seen I-Premise
on I-Premise
vitality I-Premise
( I-Premise
effect I-Premise
size I-Premise
0.55 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.27 I-Premise
to I-Premise
0.82 I-Premise
) I-Premise
, I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
0.37 I-Premise
, I-Premise
0.09 I-Premise
to I-Premise
0.65 I-Premise
) I-Premise
, I-Premise
role I-Premise
physical I-Premise
( I-Premise
0.37 I-Premise
, I-Premise
0.10 I-Premise
to I-Premise
0.64 I-Premise
) I-Premise
, I-Premise
role I-Premise
emotional I-Premise
( I-Premise
0.32 I-Premise
, I-Premise
0.05 I-Premise
to I-Premise
0.59 I-Premise
) I-Premise
, I-Premise
and I-Premise
mental I-Premise
health I-Premise
( I-Premise
0.28 I-Premise
, I-Premise
0.02 I-Premise
to I-Premise
0.56 I-Premise
) I-Premise
scores I-Premise
. I-Premise

PSA O
and O
testosterone O
data O
were O
used O
from O
a O
phase O
III O
trial O
randomizing O
patients O
without O
progression O
and O
PSA O
< O
4 O
ng/ml O
( O
n O
= O
193 O
) O
, O
after O
6 O
months O
induction O
course O
, O
between O
continuous O
( O
CAD O
) O
( O
n O
= O
96 O
) O
and O
intermittent O
( O
IAD O
) O
( O
n O
= O
97 O
) O
ADT O
. O

The B-Claim
addition I-Claim
of I-Claim
isotretinoin I-Claim
to I-Claim
an I-Claim
adjuvant I-Claim
treatment I-Claim
of I-Claim
low-dose I-Claim
IFNalpha I-Claim
in I-Claim
patients I-Claim
with I-Claim
stage I-Claim
IIA I-Claim
and I-Claim
IIB I-Claim
melanoma I-Claim
had I-Claim
no I-Claim
significant I-Claim
effect I-Claim
on I-Claim
disease-free I-Claim
or I-Claim
overall I-Claim
survival I-Claim
and I-Claim
is I-Claim
therefore I-Claim
not I-Claim
recommended I-Claim
. I-Claim

PORTEC-2 O
accrued O
427 O
patients O
between O
2002 O
and O
2006 O
, O
of O
whom O
214 O
were O
randomly O
assigned O
to O
EBRT O
, O
and O
213 O
were O
randomly O
assigned O
to O
VBT O
. O

The O
association O
between O
intervention O
and O
survival O
was O
also O
assessed O
. O

Pain O
intensity O
on O
a O
numeric O
rating O
scale O
, O
percentage O
of O
patients O
with O
each O
degree O
of O
pain O
, O
quality O
of O
life O
, O
adverse O
reactions O
, O
analgesic O
costs O
, O
and O
hospital O
stays O
were O
evaluated O
and O
compared O
among O
the O
three O
groups O
. O

Gynecological O
neoplastic O
disease O
progression O
is O
characterized O
by O
specific O
energy O
metabolism O
alterations O
and O
by O
symptoms O
including O
fatigue O
, O
anorexia O
, O
nausea O
, O
anemia O
, O
and O
immunodepression O
, O
which O
result O
in O
a O
cachexia O
syndrome O
and O
a O
marked O
decrease O
in O
patient O
quality O
of O
life O
( O
QoL O
) O
. O

Secondary O
end-points O
included O
quality O
of O
life O
( O
QOL O
) O
assessed O
using O
the O
EORTC O
QLQ-C30 O
and O
QLQ-LC13 O
questionnaires O
. O

These O
samples O
were O
analyzed O
using O
six O
polymorphic O
DNA O
markers O
that O
encode O
five O
important O
enzymes O
in O
the O
glutathione O
metabolic O
pathway O
. O

Patients O
in O
both O
groups O
had O
similar O
demographic O
and O
clinical O
characteristics O
. O

Changes O
in O
QOL O
during O
chemotherapy O
were O
relatively O
modest O
";" O
fatigue B-Premise
, I-Premise
nausea I-Premise
, I-Premise
and I-Premise
vomiting I-Premise
worsened I-Premise
, I-Premise
but B-Premise
there I-Premise
was I-Premise
a I-Premise
reduction I-Premise
in I-Premise
pain I-Premise
and I-Premise
no I-Premise
change I-Premise
in I-Premise
global I-Premise
QOL I-Premise
. I-Premise

A O
total O
of O
53 O
patients O
completed O
the O
QOL O
and O
functional O
outcome O
questionnaires O
. O

As O
a O
result O
of O
these O
observations O
, O
paclitaxel B-Claim
( I-Claim
135 I-Claim
mg/m I-Claim
( I-Claim
2 I-Claim
) I-Claim
) I-Claim
combined I-Claim
with I-Claim
cisplatin I-Claim
has I-Claim
replaced I-Claim
etoposide I-Claim
plus I-Claim
cisplatin I-Claim
as I-Claim
the I-Claim
reference I-Claim
regimen I-Claim
in I-Claim
our I-Claim
recently I-Claim
completed I-Claim
phase I-Claim
III I-Claim
trial I-Claim
. I-Claim

Proinflammatory O
cytokines O
, O
especially O
tumour O
necrosis O
factor O
alpha O
( O
TNF-alpha O
) O
, O
play O
a O
prominent O
role O
in O
the O
pathogenesis O
of O
cancer O
cachexia O
. O

We O
investigated O
the O
role O
of O
tamoxifen O
and O
radiotherapy O
( O
RT O
) O
for O
the O
prevention O
and O
treatment O
of O
gynecomastia O
and O
breast O
pain O
during O
adjuvant O
bicalutamide O
monotherapy O
after O
radical O
prostatectomy O
( O
RP O
) O
in O
patients O
with O
prostate O
cancer O
. O

All O
statistical O
tests O
were O
two-sided O
. O

Also O
, O
we O
evaluated O
their O
effects O
on O
patient O
hormonal O
status O
, O
quality O
of O
life O
( O
QOL O
) O
, O
sexual O
function O
and O
prostate O
specific O
antigen O
relapse-free O
survival O
. O

Toxicity O
was O
evaluated O
according O
to O
the O
NCI-CTC O
version O
2.0 O
. O

Notably O
, O
ablation O
preparation O
using O
withdrawal O
of O
LT3 O
for O
2 O
weeks O
did O
not O
prevent O
development O
of O
profound O
hypothyroidism O
, O
as O
also O
occurred O
when O
LT4 O
alone O
was O
withdrawn O
for O
4 O
weeks O
. O

This O
study O
is O
the O
first O
large O
prospective O
RCT O
of O
sentinel O
node O
biopsy O
( O
SNB O
) O
compared O
with O
standard O
axillary O
treatment O
( O
level O
I-III O
axillary O
lymph O
node O
dissection O
or O
four O
node O
sampling O
) O
, O
which O
includes O
comprehensive O
and O
repeated O
quality O
of O
life O
( O
QOL O
) O
assessments O
over O
18 O
months O
. O

Efficacy O
of O
RT O
based O
on O
clinical O
, O
radiologic O
, O
and O
prostate-specific O
antigen O
data O
were O
also O
evaluated O
at O
baseline O
and O
after O
RT O
. O

Among B-Premise
responding I-Premise
patients I-Premise
, I-Premise
mean I-Premise
scores I-Premise
generally I-Premise
improved I-Premise
from I-Premise
time I-Premise
of I-Premise
response I-Premise
to I-Premise
end-of-treatment I-Premise
assessment I-Premise
, I-Premise
substantially I-Premise
driven I-Premise
by I-Premise
patients I-Premise
achieving I-Premise
complete I-Premise
response I-Premise
( I-Premise
CR I-Premise
) I-Premise
. I-Premise

A O
total O
of O
166 O
patients O
were O
randomized O
to O
receive O
intravenous O
5-FU O
( O
450 O
mg/m2/day O
) O
or O
oral O
doxifluridine O
( O
900 O
mg/m2/day O
) O
in O
combination O
with O
leucovorin O
( O
20 O
mg/m2/day O
) O
for O
depth O
of O
invasion O
, O
nodal O
status O
, O
metastasis O
( O
TNM O
) O
stage O
II O
and O
III O
patients O
between O
October O
1997 O
and O
February O
1999 O
. O

The B-Claim
study I-Claim
results I-Claim
suggest I-Claim
that I-Claim
K-tape I-Claim
could I-Claim
replace I-Claim
the I-Claim
bandage I-Claim
in I-Claim
DLT I-Claim
, I-Claim
and I-Claim
it I-Claim
could I-Claim
be I-Claim
an I-Claim
alternative I-Claim
choice I-Claim
for I-Claim
the I-Claim
breast-cancer-related I-Claim
lymphedema I-Claim
patient I-Claim
with I-Claim
poor I-Claim
short-stretch I-Claim
bandage I-Claim
compliance I-Claim
after I-Claim
1-month I-Claim
intervention I-Claim
. I-Claim

Pneumocystis O
carinii O
pneumonia O
prophylaxis O
was O
required O
during O
temozolomide O
+ O
radiotherapy O
treatment O
and O
was O
continued O
until O
recovery O
of O
lymphocytopenia O
( O
Common O
Toxicity O
Criteria O
grade O
< O
1 O
) O
. O

One O
hundred O
twenty O
untreated O
patients O
with O
histologically O
confirmed O
HCC O
were O
randomized O
to O
receive O
either O
long-acting O
octreotide O
( O
Sandostation O
LAR O
30 O
mg O
) O
intramuscularly O
every O
4 O
weeks O
or O
placebo O
. O

Epoetin B-Claim
alfa I-Claim
therapy I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

Improvements B-Premise
in I-Premise
the I-Premise
signs I-Premise
and I-Premise
symptoms I-Premise
of I-Premise
rheumatoid I-Premise
arthritis I-Premise
, I-Premise
physical I-Premise
function I-Premise
and I-Premise
health-related I-Premise
quality I-Premise
of I-Premise
life I-Premise
observed I-Premise
after I-Premise
6 I-Premise
months I-Premise
, I-Premise
were I-Premise
maintained I-Premise
throughout I-Premise
the I-Premise
2 I-Premise
years I-Premise
in I-Premise
this I-Premise
population I-Premise
with I-Premise
difficult-to-treat I-Premise
disease I-Premise
. I-Premise

To O
determine O
1-year O
outcomes O
of O
a O
four-component O
behavioral O
therapy O
( O
BT O
) O
sleep O
intervention O
( O
Individualized O
Sleep O
Promotion O
Plan O
[ O
ISPP O
] O
) O
versus O
a O
healthy O
eating O
control O
( O
HEC O
) O
on O
cancer-related O
fatigue O
in O
women O
receiving O
breast O
cancer O
adjuvant O
chemotherapy O
treatment O
( O
CTX O
) O
. O

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
groups I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
eight I-Premise
components I-Premise
of I-Premise
the I-Premise
SF-36 I-Premise
scores I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

After O
initial O
response O
to O
anthracycline- O
or O
taxane-based O
induction O
chemotherapy O
, O
224 O
patients O
were O
randomly O
assigned O
: O
112 O
to O
high-dose O
cyclophosphamide O
, O
mitoxantrone O
, O
and O
carboplatin O
chemotherapy O
and O
ASCT O
( O
HDCT O
) O
, O
and O
112 O
to O
standard O
therapy O
( O
ST O
) O
. O

The O
aim O
of O
this O
multicenter O
randomized O
trial O
was O
to O
assess O
the O
efficacy O
and O
safety O
of O
sentinel O
lymph O
node O
( O
SLN O
) O
biopsy O
compared O
with O
axillary O
lymph O
node O
dissection O
( O
ALND O
) O
. O

Tamoxifen B-Claim
( I-Claim
TMX I-Claim
) I-Claim
is I-Claim
believed I-Claim
to I-Claim
inhibit I-Claim
HCC I-Claim
positive I-Claim
for I-Claim
estrogen I-Claim
receptor I-Claim
( I-Claim
ER I-Claim
) I-Claim
, I-Claim
but I-Claim
most I-Claim
HCCs I-Claim
are I-Claim
ER I-Claim
negative I-Claim
. I-Claim

Given B-Claim
the I-Claim
adverse I-Claim
effect I-Claim
of I-Claim
CRA/IFN/TAX I-Claim
on I-Claim
QOL I-Claim
, I-Claim
the I-Claim
study I-Claim
of I-Claim
other I-Claim
novel I-Claim
agents I-Claim
that I-Claim
target I-Claim
Bcl-2 I-Claim
family I-Claim
proteins I-Claim
is I-Claim
warranted I-Claim
. I-Claim

Pretreatment O
characteristics O
were O
evenly O
distributed O
between O
the O
two O
arms O
. O

More B-Premise
than I-Premise
90 I-Premise
% I-Premise
of I-Premise
patients I-Premise
did I-Premise
not I-Premise
require I-Premise
a I-Premise
dose I-Premise
increase I-Premise
and I-Premise
28.7 I-Premise
% I-Premise
had I-Premise
a I-Premise
dose I-Premise
reduction I-Premise
. I-Premise

One O
thousand O
two O
hundred O
ninety-nine O
patients O
were O
randomly O
assigned O
. O

Severe B-Premise
nonhematologic I-Premise
toxicity I-Premise
was I-Premise
infrequent I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
including I-Premise
grade I-Premise
3/4 I-Premise
cardiac I-Premise
events I-Premise
( I-Premise
AT I-Premise
, I-Premise
3 I-Premise
% I-Premise
";" I-Premise
AC I-Premise
, I-Premise
4 I-Premise
% I-Premise
) I-Premise
. I-Premise

This O
was O
a O
randomized O
, O
double-blind O
, O
parallel-group O
, O
dose-finding O
study O
assessing O
the O
efficacy O
and O
safety O
of O
once-weekly O
epoetin O
beta O
in O
patients O
with O
solid O
tumours O
receiving O
chemotherapy O
. O

During B-Premise
the I-Premise
first I-Premise
year I-Premise
of I-Premise
follow-up I-Premise
, I-Premise
there I-Premise
were I-Premise
13 I-Premise
major I-Premise
adverse I-Premise
events I-Premise
in I-Premise
the I-Premise
embolization I-Premise
group I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
and I-Premise
10 I-Premise
in I-Premise
the I-Premise
surgical I-Premise
group I-Premise
( I-Premise
20 I-Premise
% I-Premise
) I-Premise
( I-Premise
P=0.22 I-Premise
) I-Premise
, I-Premise
mostly I-Premise
related I-Premise
to I-Premise
the I-Premise
intervention I-Premise
. I-Premise

The O
trial O
statistician O
and O
researchers O
collecting O
outcome O
measures O
were O
masked O
to O
group O
allocation O
. O

There B-Premise
was I-Premise
substantial I-Premise
deterioration I-Premise
in I-Premise
QOL I-Premise
scores I-Premise
immediate I-Premise
post-treatment I-Premise
( I-Premise
3-months I-Premise
) I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

Forty-two O
patients O
with O
esophageal O
cancer O
who O
were O
receiving O
cisplatin-based O
neoadjuvant O
chemotherapy O
were O
assigned O
to O
either O
a O
ghrelin O
group O
( O
n O
= O
21 O
) O
or O
a O
placebo O
group O
( O
n O
= O
21 O
) O
. O

Patients O
( O
n O
= O
829 O
) O
completed O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
- O
Breast O
( O
FACT-B+4 O
) O
and O
the O
Spielberger O
State/Trait O
Anxiety O
Inventory O
( O
STAI O
) O
at O
baseline O
( O
pre-surgery O
) O
and O
at O
1 O
, O
3 O
, O
6 O
, O
12 O
, O
and O
18 O
months O
post-surgery O
. O

The O
primary O
objective O
was O
to O
compare O
progression-free O
survival O
( O
PFS O
) O
between O
the O
groups O
. O

There B-Claim
is I-Claim
a I-Claim
need I-Claim
for I-Claim
further I-Claim
studies I-Claim
so I-Claim
that I-Claim
its I-Claim
effect I-Claim
can I-Claim
be I-Claim
confirmed I-Claim
. I-Claim

Energy B-Premise
intake I-Premise
after I-Premise
RT I-Premise
increased I-Premise
in I-Premise
both I-Premise
groups I-Premise
1 I-Premise
and I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Methodology O
was O
similar O
to O
our O
recently O
published O
study O
( O
Gautam O
et O
al O
. O

The O
randomization O
procedure O
allowed O
some O
investigators O
to O
participate O
only O
in O
the O
comparison O
of O
three O
versus O
four O
cycles O
. O

Patients O
with O
stage O
III O
or O
IV O
cancer O
( O
N O
= O
120 O
) O
were O
randomly O
assigned O
to O
seven O
sessions O
of O
either O
IMCP O
or O
therapeutic O
massage O
( O
TM O
) O
. O

Systematic B-Claim
assessment I-Claim
of I-Claim
depression I-Claim
is I-Claim
needed I-Claim
in I-Claim
hospice I-Claim
patients I-Claim
. I-Claim

Assessments O
were O
done O
at O
baseline O
, O
9 O
weeks O
, O
and O
26 O
weeks O
after O
randomisation O
. O

Of O
the O
246 O
patients O
in O
the O
intent-to-treat O
set O
, O
89·4 O
% O
completed O
the O
3-day O
efficacy O
phase O
. O

Health-related O
quality O
of O
life O
( O
HRQOL O
) O
, O
symptoms O
of O
depression O
, O
and O
adverse O
events O
( O
AEs O
) O
were O
compared O
between O
Japanese O
postmenopausal O
patients O
with O
hormone-sensitive O
breast O
cancer O
( O
BC O
) O
who O
received O
adjuvant O
tamoxifen O
, O
exemestane O
, O
or O
anastrozole O
in O
an O
open-labeled O
, O
randomized O
, O
multicenter O
trial O
designated O
as O
the O
National O
Surgical O
Adjuvant O
Study O
of O
Breast O
Cancer O
( O
N-SAS O
BC O
) O
4 O
substudy O
of O
the O
Tamoxifen O
Exemestane O
Adjuvant O
Multinational O
( O
TEAM O
) O
trial O
. O

There B-Premise
were I-Premise
no I-Premise
unexpected I-Premise
serious I-Premise
adverse I-Premise
events I-Premise
. I-Premise

Small B-Premise
( I-Premise
< I-Premise
0.2 I-Premise
standard I-Premise
deviations I-Premise
) I-Premise
but I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
mean I-Premise
change I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
were I-Premise
seen I-Premise
for I-Premise
the I-Premise
SF-36 I-Premise
domains I-Premise
of I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
12 I-Premise
months I-Premise
) I-Premise
, I-Premise
bodily I-Premise
pain I-Premise
( I-Premise
6 I-Premise
months I-Premise
) I-Premise
and I-Premise
vitality I-Premise
( I-Premise
6 I-Premise
and I-Premise
12 I-Premise
months I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
MENQOL I-Premise
vasomotor I-Premise
( I-Premise
6 I-Premise
, I-Premise
12 I-Premise
, I-Premise
and I-Premise
24 I-Premise
months I-Premise
) I-Premise
and I-Premise
sexual I-Premise
domains I-Premise
( I-Premise
12 I-Premise
and I-Premise
24 I-Premise
months I-Premise
) I-Premise
. I-Premise

Planned O
accrual O
was O
30 O
patients O
per O
arm O
to O
detect O
20 O
% O
difference O
of O
toxicities O
based O
on O
95 O
% O
CIs O
. O

We O
prospectively O
compared O
the O
efficacy O
and O
tolerability O
of O
two O
irinotecan O
regimens O
( O
once O
a O
week O
for O
4 O
weeks O
followed O
by O
a O
2-week O
rest O
period O
[ O
weekly O
] O
v O
once O
every O
3 O
weeks O
) O
in O
such O
patients O
. O

During B-Claim
RT I-Claim
, I-Claim
nutritional I-Claim
interventions I-Claim
positively I-Claim
influenced I-Claim
outcomes I-Claim
, I-Claim
and I-Claim
counseling I-Claim
was I-Claim
of I-Claim
similar/higher I-Claim
benefit I-Claim
";" I-Claim
in B-Claim
the I-Claim
medium I-Claim
term I-Claim
, I-Claim
only I-Claim
counseling I-Claim
exerted I-Claim
a I-Claim
significant I-Claim
impact I-Claim
on I-Claim
patient I-Claim
outcomes I-Claim
. I-Claim

A O
multidimensional O
rehabilitation O
program O
for O
cancer O
survivors O
was O
developed O
to O
overcome O
cancer-related O
problems O
and O
to O
improve O
quality O
of O
life O
. O

The O
participants O
who O
dropped O
out O
pretreatment O
reported O
less O
financial O
concerns O
than O
post-treatment O
dropouts O
, O
and O
the O
participants O
who O
dropped O
out O
of O
the O
study O
midtreatment O
had O
poorer O
physical O
health O
than O
treatment O
completers O
. O

To O
compare O
the O
efficacy O
of O
low-frequency O
low-intensity O
electrotherapy O
and O
manual O
lymphatic O
drainage O
in O
the O
treatment O
of O
chronic O
upper O
limb O
breast O
cancer-related O
lymphoedema O
. O

We O
aimed O
to O
assess O
the O
effectiveness O
of O
acupuncture O
for O
cancer-related O
fatigue O
( O
CRF O
) O
in O
patients O
with O
breast O
cancer O
. O

In B-Claim
recurrent I-Claim
low-grade I-Claim
lymphoma I-Claim
, I-Claim
fludarabine I-Claim
improves I-Claim
PFS I-Claim
, I-Claim
TFS I-Claim
, I-Claim
and I-Claim
social I-Claim
function I-Claim
scores I-Claim
in I-Claim
comparison I-Claim
with I-Claim
CVP I-Claim
but I-Claim
does I-Claim
not I-Claim
improve I-Claim
OS I-Claim
. I-Claim

186 O
previously O
untreated O
eligible O
patients O
entered O
the O
study O
. O

Median B-Premise
survival I-Premise
was I-Premise
significantly I-Premise
shorter I-Premise
in I-Premise
the I-Premise
SN I-Premise
group I-Premise
( I-Premise
5.6 I-Premise
months I-Premise
compared I-Premise
with I-Premise
9 I-Premise
months I-Premise
, I-Premise
unadjusted I-Premise
hazard I-Premise
ratio I-Premise
= I-Premise
1.6 I-Premise
) I-Premise
";" I-Premise
however B-Premise
, I-Premise
this I-Premise
difference I-Premise
may I-Premise
be I-Premise
attributable I-Premise
to I-Premise
the I-Premise
coincidental I-Premise
early I-Premise
death I-Premise
of I-Premise
three I-Premise
patients I-Premise
in I-Premise
the I-Premise
SN I-Premise
group I-Premise
. I-Premise

After B-Premise
the I-Premise
exercise I-Premise
program I-Premise
, I-Premise
improvements I-Premise
were I-Premise
observed I-Premise
in I-Premise
Group I-Premise
1 I-Premise
in I-Premise
6-minute I-Premise
walk I-Premise
test I-Premise
, I-Premise
BDI I-Premise
, I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
functional I-Premise
, I-Premise
and I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
BR23 I-Premise
functional I-Premise
scores I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Transient B-Premise
grade I-Premise
4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
18 I-Premise
and I-Premise
2 I-Premise
patients I-Premise
, I-Premise
and I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
thrombosis I-Premise
in I-Premise
7 I-Premise
patients I-Premise
and I-Premise
1 I-Premise
patient I-Premise
in I-Premise
Arm I-Premise
A I-Premise
and I-Premise
Arm I-Premise
B I-Premise
respectively I-Premise
. I-Premise

Dominant O
fibroid O
diameter O
, O
uterine O
volume O
, O
total O
fibroid O
infarction O
( O
complete O
100 O
% O
, O
almost O
complete O
90-99 O
% O
, O
partial O
< O
90 O
% O
) O
, O
and O
new O
fibroid O
formation O
were O
the O
main O
parameters O
assessed O
and O
related O
to O
the O
need O
for O
reintervention O
. O

16 B-Premise
( I-Premise
29 I-Premise
% I-Premise
) I-Premise
patients I-Premise
in I-Premise
the I-Premise
open I-Premise
oesophagectomy I-Premise
group I-Premise
had I-Premise
pulmonary I-Premise
infection I-Premise
in I-Premise
the I-Premise
first I-Premise
2 I-Premise
weeks I-Premise
compared I-Premise
with I-Premise
five I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
minimally I-Premise
invasive I-Premise
group I-Premise
( I-Premise
relative I-Premise
risk I-Premise
[ I-Premise
RR I-Premise
] I-Premise
0·30 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·12-0·76 I-Premise
";" I-Premise
p=0·005 I-Premise
) I-Premise
. I-Premise

It O
is O
recommended O
to O
provide O
pain O
management O
education O
to O
all O
cancer O
patients O
. O

Also O
, O
a B-Premise
significant I-Premise
reduction I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
in I-Premise
incidence I-Premise
of I-Premise
severe I-Premise
OM I-Premise
, I-Premise
need I-Premise
for I-Premise
opioid I-Premise
analgesics I-Premise
, I-Premise
and I-Premise
total I-Premise
parenteral I-Premise
nutrition I-Premise
was I-Premise
observed I-Premise
. I-Premise

The O
primary O
endpoint O
was O
change O
in O
Inflammatory O
Bowel O
Disease O
Questionnaire-Bowel O
subset O
score O
( O
IBDQ-B O
) O
at O
6 O
months O
, O
analysed O
by O
intention O
to O
treat O
. O

Individuals B-Premise
receiving I-Premise
duloxetine I-Premise
as I-Premise
their I-Premise
initial I-Premise
5-week I-Premise
treatment I-Premise
reported I-Premise
a I-Premise
mean I-Premise
decrease I-Premise
in I-Premise
average I-Premise
pain I-Premise
of I-Premise
1.06 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.72-1.40 I-Premise
) I-Premise
vs I-Premise
0.34 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.01-0.66 I-Premise
) I-Premise
among I-Premise
those I-Premise
who I-Premise
received I-Premise
placebo I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.513 I-Premise
) I-Premise
. I-Premise

Women O
in O
the O
writing O
group O
wrote O
for O
20 O
min O
on O
four O
consecutive O
days O
. O

This O
study O
was O
a O
pilot O
randomized O
controlled O
trial O
. O

During B-Premise
follow-up I-Premise
, I-Premise
71 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
showed I-Premise
unaltered I-Premise
or I-Premise
improved I-Premise
lung I-Premise
expansion I-Premise
and I-Premise
9 I-Premise
patients I-Premise
( I-Premise
15 I-Premise
% I-Premise
) I-Premise
needed I-Premise
new I-Premise
pleural I-Premise
procedures I-Premise
( I-Premise
VATS I-Premise
group I-Premise
, I-Premise
5 I-Premise
recurrences I-Premise
";" I-Premise
TS I-Premise
group I-Premise
, I-Premise
4 I-Premise
recurrences I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.999 I-Premise
) I-Premise
. I-Premise

We O
describe O
analyses O
of O
data O
for O
patient-reported O
pain O
and O
functional O
status O
in O
a O
preplanned O
interim O
analysis O
of O
a O
phase O
3 O
trial O
. O

The O
efficacy O
and O
safety O
of O
letrozole O
therapy O
beyond O
5 O
years O
is O
being O
assessed O
in O
a O
re-randomization O
study O
, O
following O
the O
emergence O
of O
new O
data O
suggesting O
that O
clinical O
benefit O
correlates O
with O
the O
duration O
of O
letrozole O
. O

The B-Premise
quality I-Premise
of I-Premise
life I-Premise
improved I-Premise
in I-Premise
control I-Premise
group I-Premise
by I-Premise
13.7 I-Premise
% I-Premise
, I-Premise
while I-Premise
combined I-Premise
treatment I-Premise
group I-Premise
showed I-Premise
improvement I-Premise
of I-Premise
83.5 I-Premise
% I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
vs. I-Premise
control I-Premise
group I-Premise
) I-Premise
. I-Premise

The O
secondary O
end O
points O
were O
morbidity O
, O
QOL O
, O
and O
functional O
outcome O
. O

The O
low O
response O
rate O
is O
partly O
related O
to O
the O
number O
of O
patients O
who O
received O
only O
one O
cycle O
of O
chemotherapy O
. O

To O
facilitate O
the O
transition O
to O
recovery O
, O
we O
conducted O
the O
Moving O
Beyond O
Cancer O
( O
MBC O
) O
trial O
, O
a O
multisite O
, O
randomized O
, O
controlled O
trial O
of O
psychoeducational O
interventions O
for O
breast O
cancer O
patients O
. O

Longitudinal B-Premise
analyses I-Premise
replicated I-Premise
these I-Premise
findings I-Premise
. I-Premise

Participants O
were O
randomised O
to O
follow-up O
care O
as O
usual O
( O
3-monthly O
outpatient O
clinic O
visits O
) O
, O
nurse-led O
telephone O
follow-up O
, O
or O
the O
former O
strategies O
combined O
with O
an O
educational O
group O
programme O
. O

To O
compare O
the O
outcome O
of O
treatment O
of O
mediastinoscopy-verified O
N2 O
non-small-cell O
lung O
cancer O
treated O
with O
induction O
chemotherapy O
followed O
by O
either O
surgery O
or O
radiotherapy O
( O
RT O
) O
, O
with O
both O
options O
followed O
by O
consolidation O
chemotherapy O
. O

Our O
study O
examined O
intrusive O
thoughts O
as O
a O
predictor O
of O
lingering O
symptoms O
in O
breast O
cancer O
survivors O
in O
the O
year O
following O
treatment O
. O

In B-Claim
conclusion I-Claim
, I-Claim
palliative I-Claim
chemotherapy I-Claim
with I-Claim
carboplatin I-Claim
and I-Claim
vinorelbine I-Claim
beyond I-Claim
three I-Claim
courses I-Claim
conveys I-Claim
no I-Claim
survival I-Claim
or I-Claim
consistent I-Claim
QoL I-Claim
benefits I-Claim
in I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Extracellular O
adenosine O
5'-triphosphate O
( O
ATP O
) O
is O
involved O
in O
the O
regulation O
of O
a O
variety O
of O
biologic O
processes O
, O
including O
neurotransmission O
, O
muscle O
contraction O
, O
and O
liver O
glucose O
metabolism O
, O
via O
purinergic O
receptors O
. O

Food B-Premise
intake I-Premise
improved I-Premise
more I-Premise
rapidly I-Premise
after I-Premise
stent I-Premise
placement I-Premise
than I-Premise
after I-Premise
GJJ I-Premise
( I-Premise
GOO I-Premise
Scoring I-Premise
System I-Premise
score I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
: I-Premise
median I-Premise
5 I-Premise
vs I-Premise
8 I-Premise
days I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
but B-Premise
long-term I-Premise
relief I-Premise
was I-Premise
better I-Premise
after I-Premise
GJJ I-Premise
, I-Premise
with I-Premise
more I-Premise
patients I-Premise
living I-Premise
more I-Premise
days I-Premise
with I-Premise
a I-Premise
GOO I-Premise
Scoring I-Premise
System I-Premise
score I-Premise
of I-Premise
2 I-Premise
or I-Premise
more I-Premise
than I-Premise
after I-Premise
stent I-Premise
placement I-Premise
( I-Premise
72 I-Premise
vs I-Premise
50 I-Premise
days I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
= I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Attrition B-Premise
rates I-Premise
did I-Premise
not I-Premise
vary I-Premise
significantly I-Premise
between I-Premise
study I-Premise
arms I-Premise
. I-Premise

The B-Claim
use I-Claim
of I-Claim
spherical I-Claim
PVA I-Claim
particles I-Claim
in I-Claim
the I-Claim
manner I-Claim
described I-Claim
herein I-Claim
results I-Claim
in I-Claim
an I-Claim
unacceptably I-Claim
high I-Claim
rate I-Claim
of I-Claim
failed I-Claim
tumor I-Claim
infarction I-Claim
in I-Claim
UAE I-Claim
. I-Claim

QOL O
was O
assessed O
by O
using O
the O
Edmonton O
Symptom O
Assessment O
Scale O
( O
ESAS O
) O
and O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
( O
FACT O
) O
-Anemia O
questionnaires O
. O

For O
progression O
analysis O
, O
173 O
patients O
' O
data O
were O
available O
. O

Randomized O
, O
controlled O
, O
longitudinal O
trial O
. O

Questionnaire O
return O
rates O
for O
this O
study O
never O
dropped O
below O
80 O
% O
";" O
only O
2 O
% O
of O
the O
patients O
did O
not O
submit O
baseline O
QOL O
assessments O
. O

An O
overall O
intent-to-treat O
analysis O
was O
performed O
. O

The O
aim O
of O
the O
study O
was O
to O
analyze O
the O
effect O
of O
combined O
treatment O
methods O
on O
quality O
of O
life O
in O
patients O
diagnosed O
with O
pancreatic O
cancer O
. O

Adjusted O
linear O
mixed-model O
analyses O
demonstrated O
that O
patient O
preference O
moderated O
QoL O
response O
( O
P= O
.005 O
) O
. O

The O
impact O
of O
psychotherapeutic O
support O
on O
survival O
for O
patients O
with O
gastrointestinal O
cancer O
undergoing O
surgery O
was O
studied O
. O

Patients O
were O
randomized O
in O
a O
2:1 O
ratio O
( O
erlotinib O
, O
n O
= O
488 O
and O
placebo O
, O
n O
= O
243 O
) O
. O

SCLC O
patients O
in O
complete O
or O
partial O
remission O
were O
eligible O
. O

Docetaxel B-Premise
improved I-Premise
progression-free I-Premise
survival I-Premise
, I-Premise
response I-Premise
rate I-Premise
, I-Premise
and I-Premise
disease-related I-Premise
symptoms I-Premise
versus I-Premise
vinorelbine I-Premise
. I-Premise

Between O
April O
28 O
, O
2009 O
, O
and O
June O
23 O
, O
2010 O
, O
patients O
with O
progressive O
, O
metastatic O
castration-resistant O
prostate O
cancer O
were O
enrolled O
into O
a O
multinational O
, O
double-blind O
, O
placebo-controlled O
trial O
. O

Reports O
of O
thrombotic O
events O
in O
other O
epoetin O
trials O
prompted O
an O
unplanned O
safety O
analysis O
after O
70 O
patients O
had O
been O
randomly O
assigned O
( O
33 O
to O
the O
active O
arm O
and O
37 O
to O
the O
placebo O
arm O
) O
. O

In O
contrast O
, O
the O
energy O
needs O
of O
malignant O
tumors O
are O
almost O
entirely O
met O
by O
glucose O
. O

We O
assessed O
whether O
such O
patients O
could O
be O
helped O
if O
a O
practitioner O
followed O
an O
investigative O
and O
management O
algorithm O
, O
and O
whether O
outcomes O
differed O
by O
whether O
a O
nurse O
or O
a O
gastroenterologist O
led O
this O
algorithm-based O
care O
. O

Docetaxel B-Premise
improved I-Premise
overall I-Premise
disease-related I-Premise
symptoms I-Premise
over I-Premise
vinorelbine I-Premise
( I-Premise
odds I-Premise
ratio I-Premise
, I-Premise
1.86 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.09 I-Premise
to I-Premise
3.20 I-Premise
) I-Premise
. I-Premise

The O
baseline O
characteristics O
( O
with O
the O
exception O
of O
site O
of O
metastases O
) O
were O
balanced O
among O
patients O
with O
CR/PR O
, O
SD O
( O
6m O
) O
, O
and O
progressive O
disease O
( O
PD O
) O
. O

However B-Premise
, I-Premise
utilization I-Premise
of I-Premise
ED I-Premise
treatments I-Premise
increased I-Premise
from I-Premise
31 I-Premise
% I-Premise
at I-Premise
the I-Premise
time I-Premise
of I-Premise
study I-Premise
entry I-Premise
to I-Premise
49 I-Premise
% I-Premise
at I-Premise
the I-Premise
6-month I-Premise
follow-up I-Premise
( I-Premise
P I-Premise
= I-Premise
0.003 I-Premise
) I-Premise
. I-Premise

Chemotherapy B-Claim
prolongs I-Claim
survival I-Claim
and I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
for I-Claim
good I-Claim
performance I-Claim
status I-Claim
( I-Claim
PS I-Claim
) I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

Analysis O
was O
by O
intention O
to O
treat O
. O

L-T4 O
was O
initiated O
in O
both O
groups O
after O
thyroidectomy O
. O

Drug O
toxicity O
and O
quality O
of O
life O
were O
observed O
. O

Here O
we O
report O
mature O
HRQoL O
outcomes O
from O
the O
ATAC O
trial O
, O
comparing O
anastrozole O
with O
tamoxifen O
as O
primary O
adjuvant O
therapy O
for O
postmenopausal O
women O
with O
localized O
breast O
cancer O
. O

All O
treatments O
were O
delivered O
on O
days O
1 O
and O
8 O
every O
3 O
weeks O
for O
a O
maximum O
of O
six O
cycles O
. O

Costs O
to O
the O
NHS O
associated O
with O
postoperative O
radiotherapy O
were O
calculated O
to O
be O
of O
the O
order O
of O
2000 O
pounds O
per O
patient O
. O

Forty O
patients O
on O
Arm O
A O
and O
19 O
on O
Arm O
B O
received O
at O
least O
one O
treatment O
. O

or O
12 O
months O
( O
p.o O
. O
) O
. O

Gemcitabine O
( O
G O
) O
is O
standard O
therapy O
for O
pancreatic O
cancer O
. O

Median B-Premise
survival I-Premise
was I-Premise
10 I-Premise
months I-Premise
with I-Premise
GCa I-Premise
and I-Premise
7.6 I-Premise
months I-Premise
with I-Premise
MIC I-Premise
( I-Premise
difference I-Premise
, I-Premise
2.4 I-Premise
months I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.0 I-Premise
to I-Premise
4.0 I-Premise
) I-Premise
, I-Premise
and I-Premise
1-year I-Premise
survival I-Premise
was I-Premise
40 I-Premise
% I-Premise
with I-Premise
GCa I-Premise
and I-Premise
30 I-Premise
% I-Premise
with I-Premise
MIC I-Premise
( I-Premise
difference I-Premise
, I-Premise
10 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3 I-Premise
% I-Premise
to I-Premise
18 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
incremental I-Premise
cost-effectiveness I-Premise
ratio I-Premise
of I-Premise
GJJ I-Premise
compared I-Premise
to I-Premise
stent I-Premise
placement I-Premise
was I-Premise
euro164 I-Premise
per I-Premise
extra I-Premise
day I-Premise
with I-Premise
a I-Premise
gastric I-Premise
outlet I-Premise
obstruction I-Premise
scoring I-Premise
system I-Premise
( I-Premise
GOOSS I-Premise
) I-Premise
> I-Premise
or=2 I-Premise
adjusted I-Premise
for I-Premise
survival I-Premise
. I-Premise

Paclitaxel O
was O
administered O
at O
two O
different O
dose O
levels O
( O
135 O
mg/m O
( O
2 O
) O
and O
250 O
mg/m O
( O
2 O
) O
) O
, O
and O
etoposide O
was O
given O
at O
a O
dose O
of O
100 O
mg/m O
( O
2 O
) O
daily O
on O
days O
1 O
to O
3 O
. O

Analgesic B-Premise
cost I-Premise
and I-Premise
hospital I-Premise
stay I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
treated I-Premise
groups I-Premise
than I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

To O
analyze O
the O
predictive O
value O
of O
PSA O
for O
progression O
and O
the O
role O
of O
testosterone O
for O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
androgen O
deprivation O
therapy O
( O
ADT O
) O
for O
metastatic O
prostate O
cancer O
. O

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
RR I-Premise
, I-Premise
RD I-Premise
, I-Premise
or I-Premise
PFS I-Premise
between I-Premise
arms I-Premise
. I-Premise

Anaemia O
is O
common O
in O
patients O
receiving O
chemotherapy O
, O
causing O
symptoms O
that O
have O
a O
major O
impact O
on O
quality O
of O
life O
( O
QoL O
) O
. O

Median B-Premise
survivals I-Premise
for I-Premise
marimastat I-Premise
and I-Premise
placebo I-Premise
patients I-Premise
were I-Premise
9.3 I-Premise
months I-Premise
and I-Premise
9.7 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
=.90 I-Premise
) I-Premise
. I-Premise

Ablation B-Premise
success I-Premise
rates I-Premise
were I-Premise
85.0 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
receiving I-Premise
low-dose I-Premise
radioiodine I-Premise
versus I-Premise
88.9 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
receiving I-Premise
the I-Premise
high I-Premise
dose I-Premise
and I-Premise
87.1 I-Premise
% I-Premise
in I-Premise
the I-Premise
thyrotropin I-Premise
alfa I-Premise
group I-Premise
versus I-Premise
86.7 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
undergoing I-Premise
thyroid I-Premise
hormone I-Premise
withdrawal I-Premise
. I-Premise

Four O
hundred O
forty-seven O
patients O
were O
randomly O
assigned O
to O
PCV O
( O
224 O
patients O
) O
or O
TMZ O
( O
sub-random O
assignment O
: O
TMZ-5 O
[ O
200 O
mg/m O
( O
2 O
) O
for O
5 O
days O
, O
112 O
patients O
] O
or O
TMZ-21 O
[ O
100 O
mg/m O
( O
2 O
) O
for O
21 O
days O
, O
111 O
patients O
] O
) O
for O
up O
to O
9 O
months O
or O
until O
progression O
. O

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
functional I-Premise
outcome I-Premise
, I-Premise
morbidity I-Premise
, I-Premise
or I-Premise
QOL I-Premise
between I-Premise
LRP I-Premise
and I-Premise
ORP I-Premise
. I-Premise

QOL O
variables O
related O
to O
survival O
were O
baseline O
support O
( O
P O
= O
0.001 O
) O
and O
baseline O
outlook O
( O
P O
= O
0.01 O
) O
. O

We B-Premise
observed I-Premise
a I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
anxiety I-Premise
( I-Premise
STAI I-Premise
, I-Premise
POMS I-Premise
) I-Premise
among I-Premise
group I-Premise
participants I-Premise
, I-Premise
a I-Premise
reduction I-Premise
in I-Premise
anger I-Premise
, I-Premise
depression I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
POMS I-Premise
) I-Premise
, I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
vigor I-Premise
and I-Premise
interpersonal I-Premise
relationships I-Premise
( I-Premise
POMS I-Premise
) I-Premise
, I-Premise
in I-Premise
emotional I-Premise
and I-Premise
role I-Premise
functioning I-Premise
, I-Premise
in I-Premise
health I-Premise
status I-Premise
and I-Premise
fatigue I-Premise
level I-Premise
( I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
) I-Premise
. I-Premise

From O
March O
1995 O
until O
April O
1998 O
, O
812 O
patients O
were O
randomly O
assigned O
to O
receive O
three O
or O
four O
cycles O
: O
of O
these O
, O
681 O
were O
also O
randomly O
assigned O
to O
the O
5-day O
or O
the O
3-day O
schedule O
. O

The B-Premise
75 I-Premise
% I-Premise
AK I-Premise
clearance I-Premise
rate I-Premise
was I-Premise
34.6 I-Premise
% I-Premise
for I-Premise
ALA-PDT I-Premise
and I-Premise
25 I-Premise
% I-Premise
for I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
p I-Premise
= I-Premise
.30 I-Premise
) I-Premise
. I-Premise

They O
had O
also O
received O
morphine O
or O
transdermal O
fentanyl O
patches O
for O
at O
least O
1 O
week O
. O

CAF B-Premise
produced I-Premise
significantly I-Premise
higher I-Premise
grades I-Premise
of I-Premise
leukopenia I-Premise
, I-Premise
granulocytopenia I-Premise
, I-Premise
and I-Premise
thrombocytopenia I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
liver I-Premise
and I-Premise
cardiac I-Premise
toxicity I-Premise
, I-Premise
whereas O
the B-Premise
16-week I-Premise
regimen I-Premise
produced I-Premise
significantly I-Premise
higher I-Premise
grades I-Premise
of I-Premise
anemia I-Premise
, I-Premise
nausea I-Premise
, I-Premise
stomatitis I-Premise
, I-Premise
and I-Premise
weight I-Premise
loss I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
skin I-Premise
and I-Premise
neurotoxicity I-Premise
. I-Premise

Vinorelbine O
was O
given O
intravenously O
on O
days O
1 O
and O
8 O
of O
a O
21-day O
treatment O
cycle O
, O
for O
a O
total O
of O
six O
cycles O
. O

The O
sample O
size O
required O
in O
a O
larger O
definitive O
study O
is O
32 O
subjects O
per O
group O
. O

Significant B-Premise
differences I-Premise
of I-Premise
FACT-B I-Premise
score I-Premise
( I-Premise
p=0.008 I-Premise
) I-Premise
and I-Premise
FACT-G I-Premise
score I-Premise
( I-Premise
p=0.019 I-Premise
) I-Premise
were I-Premise
observed I-Premise
at I-Premise
that I-Premise
time I-Premise
point I-Premise
. I-Premise

The O
primary O
endpoint O
was O
changes O
in O
oral O
calorie O
intake O
, O
and O
the O
secondary O
endpoints O
were O
chemotherapy-related O
adverse O
events O
";" O
appetite O
visual O
analog O
scale O
( O
VAS O
) O
scores O
";" O
changes O
in O
gastrointestinal O
hormones O
and O
nutritional O
status O
, O
including O
rapid O
turnover O
proteins O
, O
and O
quality O
of O
life O
( O
QoL O
) O
estimated O
with O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QoL O
core O
questionnaire O
( O
QLQ-C30 O
) O
. O

Patients O
completed O
measures O
assessing O
pain O
, O
psychological O
distress O
, O
quality O
of O
life O
( O
QOL O
) O
, O
and O
self-efficacy O
for O
symptom O
management O
";" O
caregivers O
completed O
measures O
assessing O
psychological O
distress O
, O
caregiver O
strain O
, O
and O
self-efficacy O
for O
helping O
the O
patient O
manage O
symptoms O
. O

Their O
median O
age O
was O
65 O
years O
, O
30 O
% O
had O
PS O
2 O
and O
76 O
% O
stage O
IV O
disease O
. O

Median B-Premise
time I-Premise
to I-Premise
progress I-Premise
for I-Premise
radiotherapy I-Premise
only I-Premise
and I-Premise
radiotherapy I-Premise
and I-Premise
estramustin I-Premise
group I-Premise
in I-Premise
grade I-Premise
III I-Premise
tumours I-Premise
was I-Premise
6.5 I-Premise
and I-Premise
10.1 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

EORTC O
QLQ-C30 O
was O
administered O
at O
screening O
, O
on O
day O
1 O
of O
each O
cycle O
, O
at O
the O
end-of-treatment O
visit O
, O
and O
every O
8 O
wk O
until O
progression O
. O

Primary O
end-point O
was O
overall O
response O
to O
first-line O
treatment O
among O
TS O
high O
patients O
. O

TS O
levels O
were O
available O
for O
147 O
patients O
( O
87.5 O
% O
) O
. O

carboplatin O
300 O
mg/m2 O
on O
day O
1 O
and O
etoposide O
120 O
mg/m2 O
orally O
on O
days O
1-5 O
every O
4 O
weeks O
for O
a O
maximum O
of O
eight O
courses O
. O

Outcomes O
were O
lymphoedema O
volume O
, O
pain O
, O
heaviness O
and O
tightness O
, O
and O
health-related O
quality O
of O
life O
measured O
with O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
Questionnaire O
for O
Breast O
Cancer O
version O
4 O
( O
FACT-B+4 O
) O
. O

Both O
gemcitabine O
( O
GEM O
) O
and O
fluoropyrimidines O
are O
valuable O
treatment O
for O
advanced O
pancreatic O
cancer O
. O

To O
examine O
health-related O
quality O
of O
life O
, O
we O
investigated O
the O
effect O
of O
adjuvant O
chemotherapy O
regimens O
on O
utility O
scores O
assessed O
by O
the O
EuroQoL-5D O
( O
EQ-5D O
) O
instrument O
in O
a O
randomized O
, O
controlled O
trial O
for O
breast O
cancer O
patients O
after O
surgery O
. O

In B-Premise
a I-Premise
longitudinal I-Premise
analysis I-Premise
of I-Premise
men I-Premise
in I-Premise
SPCG-4 I-Premise
who I-Premise
provided I-Premise
information I-Premise
at I-Premise
two I-Premise
follow-up I-Premise
points I-Premise
9 I-Premise
years I-Premise
apart I-Premise
, I-Premise
38 I-Premise
( I-Premise
45 I-Premise
% I-Premise
) I-Premise
of I-Premise
85 I-Premise
men I-Premise
allocated I-Premise
radical I-Premise
prostatectomy I-Premise
and I-Premise
48 I-Premise
( I-Premise
60 I-Premise
% I-Premise
) I-Premise
of I-Premise
80 I-Premise
men I-Premise
allocated I-Premise
watchful I-Premise
waiting I-Premise
reported I-Premise
an I-Premise
increase I-Premise
in I-Premise
number I-Premise
of I-Premise
physical I-Premise
symptoms I-Premise
";" I-Premise
50 I-Premise
( I-Premise
61 I-Premise
% I-Premise
) I-Premise
of I-Premise
82 I-Premise
and I-Premise
47 I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
of I-Premise
74 I-Premise
men I-Premise
, I-Premise
respectively I-Premise
, I-Premise
reported I-Premise
a I-Premise
reduction I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

Secondary O
endpoints O
included O
toxicity O
, O
response O
to O
treatment O
, O
quality O
of O
life O
, O
and O
overall O
and O
progression-free O
survival O
time O
. O

Response B-Premise
rates I-Premise
were I-Premise
34 I-Premise
% I-Premise
[ I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
20 I-Premise
% I-Premise
to I-Premise
51 I-Premise
% I-Premise
] I-Premise
in I-Premise
arm I-Premise
A I-Premise
and I-Premise
35 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
20 I-Premise
% I-Premise
to I-Premise
53 I-Premise
% I-Premise
) I-Premise
in I-Premise
arm I-Premise
B I-Premise
. I-Premise

Health O
and O
cost O
outcomes O
in O
the O
two O
arms O
were O
compared O
, O
and O
cost-effectiveness O
was O
estimated O
. O

Baseline O
questionnaires O
were O
available O
for O
490 O
( O
86 O
% O
) O
patients O
. O

Multicenter O
, O
randomized O
trial O
. O

Quality O
of O
life O
was O
determined O
at O
the O
time O
of O
randomization O
and O
ablation O
. O

Quality O
of O
life O
was O
scored O
according O
to O
22 O
daily O
activity O
items O
( O
good O
, O
> O
or O
71 O
";" O
fair O
, O
< O
70 O
";" O
poor O
, O
< O
52 O
) O
. O

The O
primary O
outcome O
measures O
were O
the O
activity O
score O
and O
profile O
score O
of O
the O
Measure O
Yourself O
Medical O
Outcome O
Profile O
( O
MYMOP O
) O
. O

